{"meta":{"query_hash":"65026dd2c025","filters":{"venue":"Clinical Lung Cancer"},"cohort_total":186,"direct_labels_cover":1,"predictions_cover":186,"exported":186,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/65026dd2c025","api":"https://metacan.xera.ac/api/v1/cohort?venue=Clinical+Lung+Cancer"},"results":[{"id":"W15310413","doi":"10.25959/23246261","title":"Geology and genesis of the Battle Zone VHMS deposits, Myra Falls district, British Columbia, Canada","year":2001,"lang":"en","type":"dissertation","venue":"Clinical Lung Cancer","topic":"Geological and Geochemical Analysis","field":"Earth and Planetary Sciences","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Battle; Ancient history; Geology; Archaeology; History","score_opus":0.008899666770834739,"score_gpt":0.24442118459462012,"score_spread":0.2355215178237854,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W15310413","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98250836,0.013635807,0.0000019779616,0.00020755836,0.0012588046,0.00014988212,0.00040872252,0.000009186225,0.0018196974],"genre_scores_gemma":[0.9771841,0.0048350706,0.000031200914,0.0003988,0.00024712482,0.000006915804,0.00078495755,0.000004737027,0.016507097],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981221,0.00012733201,0.0006615675,0.00048004847,0.00029701035,0.00031195898],"domain_scores_gemma":[0.99830157,0.0008345864,0.00033373485,0.00021930246,0.00011797865,0.00019284518],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00014651258,0.00015364448,0.00060710235,0.000011222741,0.00015675106,0.000053683965,0.00037178973,0.00033540974,0.009863903],"category_scores_gemma":[0.00035722734,0.00013788586,0.0002146638,0.00028207272,0.00020309434,0.000026770282,0.000029191013,0.0003834127,0.0000040031623],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000020807212,0.00002024186,0.9323464,0.00006912624,0.00012263618,0.000016685677,0.0000052846713,0.0000518882,0.0000020093084,5.3418916e-7,0.009414013,0.0579304],"study_design_scores_gemma":[0.00017113777,0.00003605325,0.9946311,0.000065877815,0.00029741612,0.0000060659145,0.00005186327,0.00034405373,0.000007286127,0.00015181121,0.004046295,0.00019102074],"about_ca_topic_score_codex":0.9912146,"about_ca_topic_score_gemma":0.9997251,"teacher_disagreement_score":0.062284745,"about_ca_system_score_codex":0.000011530782,"about_ca_system_score_gemma":0.00036236504,"threshold_uncertainty_score":0.99104124},"labels":[],"label_agreement":null},{"id":"W1936584852","doi":"10.1016/j.cllc.2015.05.002","title":"Angiotensin-Converting Enzyme and Aldosterone Serum Levels as Prognostic and Predictive Biomarkers for Cediranib in NCIC Clinical Trials Group Study BR.24","year":2015,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Renin-Angiotensin System Studies","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Ottawa; University Health Network; Queen's University; Ottawa Hospital","funders":"Canadian Cancer Society Research Institute","keywords":"Medicine; Internal medicine; Hazard ratio; Lung cancer; Aldosterone; Oncology; Carboplatin; Angiotensin-converting enzyme; Proportional hazards model; Chemotherapy; Gastroenterology; Endocrinology; Confidence interval; Blood pressure; Cisplatin","score_opus":0.2728953668393806,"score_gpt":0.5054766309152686,"score_spread":0.23258126407588803,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1936584852","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97350335,0.01194631,0.00018736353,0.0040394575,0.0026545487,0.007380382,0.0001296631,0.00008797989,0.00007095151],"genre_scores_gemma":[0.9955983,0.000289729,0.00076569594,0.0010443924,0.0016555516,0.00031971274,0.000010667082,0.00007542111,0.00024051486],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99275357,0.0017106964,0.0032190604,0.0012115579,0.0004937647,0.0006113412],"domain_scores_gemma":[0.98986757,0.007749887,0.00076783076,0.00045370165,0.0005128654,0.00064812624],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.015479185,0.00043269596,0.0027016492,0.00016446084,0.00010552947,0.00005328254,0.00012523668,0.00045465218,0.0000123289765],"category_scores_gemma":[0.02625535,0.00033190887,0.0003559366,0.00029444188,0.00052119006,0.00015604749,0.00026645476,0.0005201332,0.000005619547],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0049091736,0.00047416516,0.96726304,0.00010466312,0.0017722142,0.00009794927,0.0011405365,0.0000013761414,0.000073735806,0.0000041485737,0.009209565,0.014949407],"study_design_scores_gemma":[0.02229397,0.0056726597,0.9641881,0.0010483897,0.002083654,0.000046308924,0.001085834,0.0024850469,0.000026473223,0.000071999515,0.0006570929,0.00034049965],"about_ca_topic_score_codex":0.00012788377,"about_ca_topic_score_gemma":0.00023551028,"teacher_disagreement_score":0.022094972,"about_ca_system_score_codex":0.00017646218,"about_ca_system_score_gemma":0.00038532802,"threshold_uncertainty_score":0.9999133},"labels":[],"label_agreement":null},{"id":"W1967197142","doi":"10.3816/clc.2009.n.024","title":"Management and Prognosis in Synchronous Solitary Resected Brain Metastasis from Non–Small-Cell Lung Cancer","year":2009,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cancer Care Ontario","funders":"","keywords":"Medicine; Brain metastasis; Lung cancer; Radiation therapy; Craniotomy; Univariate analysis; Stage (stratigraphy); Metastasis; Surgery; Performance status; Chemotherapy; Internal medicine; Oncology; Cancer; Radiology; Multivariate analysis","score_opus":0.02925830588355858,"score_gpt":0.3787964857123529,"score_spread":0.3495381798287943,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1967197142","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9453515,0.035157237,0.0001460858,0.015792789,0.00035205562,0.002123075,0.00020366203,0.000067010944,0.0008065957],"genre_scores_gemma":[0.9752418,0.009014882,0.0062893643,0.007241192,0.00048016425,0.0005948771,0.00011151677,0.000044557702,0.000981666],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997358,0.00019724054,0.0007960349,0.0008405249,0.0002841577,0.00052399276],"domain_scores_gemma":[0.9985839,0.00040668162,0.00015572019,0.0004373146,0.00006815371,0.0003482329],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005466784,0.00032130402,0.0008090312,0.00012883314,0.000074896794,0.000032162832,0.00013732565,0.00017392788,0.0004907201],"category_scores_gemma":[0.000066095985,0.00026094168,0.00022504792,0.00032072517,0.00010309627,0.00007110853,0.000098887125,0.00042985054,0.0000062773397],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012015784,0.002172727,0.69339746,0.0005613412,0.0019455615,0.0014025703,0.00030803808,0.000093308925,0.00011550813,0.000045261946,0.047423054,0.2513336],"study_design_scores_gemma":[0.009198292,0.000801947,0.97661334,0.0010652953,0.0027273688,0.00000572535,0.00012688765,0.005035385,0.00031412503,0.00012771567,0.0036021483,0.00038173853],"about_ca_topic_score_codex":0.0018437818,"about_ca_topic_score_gemma":0.00089795236,"teacher_disagreement_score":0.28321594,"about_ca_system_score_codex":0.00035251162,"about_ca_system_score_gemma":0.00014934027,"threshold_uncertainty_score":0.99998426},"labels":[],"label_agreement":null},{"id":"W1969531640","doi":"10.1016/j.cllc.2014.04.003","title":"An Individual Patient Data Metaanalysis of Outcomes and Prognostic Factors After Treatment of Oligometastatic Non–Small-Cell Lung Cancer","year":2014,"lang":"en","type":"review","venue":"Clinical Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":438,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre","funders":"","keywords":"Medicine; Recursive partitioning; Radiosurgery; Internal medicine; Oncology; Radiation therapy; Proportional hazards model; Lung cancer; Adenocarcinoma; Multivariate analysis; Primary tumor; Cancer; Metastasis","score_opus":0.12043424535235503,"score_gpt":0.4722635767882877,"score_spread":0.35182933143593265,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1969531640","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.066347055,0.9249544,0.000012755623,0.00006606898,0.00051687984,0.003524399,0.004527113,0.000021243643,0.000030048874],"genre_scores_gemma":[0.05084671,0.9446784,0.00048611398,0.00008762764,0.00021404828,0.0020703152,0.001396612,0.00011288663,0.000107259366],"study_design_codex":"observational","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99433935,0.00042731193,0.0027094393,0.001420321,0.00062717183,0.0004764167],"domain_scores_gemma":[0.9936212,0.0017390016,0.0018032781,0.0020958206,0.00021425435,0.00052648253],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000396697,0.00091195496,0.006811211,0.00032053763,0.000046962192,0.000034825916,0.0004133635,0.00040531266,0.00035961656],"category_scores_gemma":[0.00015032147,0.00053583033,0.0012859209,0.0004136227,0.0002580812,0.00010076422,0.00024865175,0.00030312676,0.0000023111234],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005656088,0.0020451748,0.5994293,0.023202237,0.014480115,0.000024944664,0.00021889922,0.0000032619387,4.6452485e-8,9.932214e-7,0.00027438483,0.3602641],"study_design_scores_gemma":[0.007745948,0.006156313,0.25232923,0.039757058,0.55107224,0.000008477293,0.000110299,0.00063426147,0.000023901432,0.0000039242536,0.14063965,0.0015186693],"about_ca_topic_score_codex":0.0012185052,"about_ca_topic_score_gemma":0.0007550122,"teacher_disagreement_score":0.5365921,"about_ca_system_score_codex":0.0005219288,"about_ca_system_score_gemma":0.0012529406,"threshold_uncertainty_score":0.9997093},"labels":[],"label_agreement":null},{"id":"W1973723712","doi":"10.3816/clc.2008.n.050","title":"Cooperative Group Research Efforts in Lung Cancer 2008: Focus on Advanced-Stage Non–Small-Cell Lung Cancer","year":2008,"lang":"en","type":"review","venue":"Clinical Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Cetuximab; Lung cancer; Medicine; Bevacizumab; Oncology; Epidermal growth factor receptor; Internal medicine; Mesothelioma; Cancer; Targeted therapy; Chemotherapy; Pathology; Colorectal cancer","score_opus":0.10775675957468764,"score_gpt":0.5328252449507797,"score_spread":0.425068485376092,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1973723712","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.001215742,0.9721345,0.000029044366,0.00075112,0.003440877,0.011455697,0.0015568051,0.00012846115,0.009287787],"genre_scores_gemma":[0.0007289666,0.9478148,0.00019136608,0.00084751705,0.0027175108,0.017377641,0.000481227,0.00040361853,0.029437343],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9900637,0.000898912,0.0029552504,0.0027438423,0.0013719953,0.0019662676],"domain_scores_gemma":[0.99348766,0.0020804408,0.000984678,0.0015818132,0.0008481118,0.0010173002],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","research_integrity"],"category_scores_codex":[0.0010965622,0.0014832265,0.0049981624,0.0008147875,0.0005618805,0.00009993226,0.00072500634,0.0014220896,0.002294418],"category_scores_gemma":[0.00031915284,0.0011360935,0.0014013791,0.0021400834,0.00060951395,0.0002496469,0.00033031098,0.004536112,0.000076488206],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0009232778,0.002371684,0.01851212,0.030266646,0.0040577264,0.0016425869,0.00078042404,0.0006300384,0.0000023853029,0.0001578145,0.13191275,0.8087425],"study_design_scores_gemma":[0.0075695845,0.0007904664,0.0013779319,0.06371486,0.0041756965,0.000019978512,0.00006039185,0.0007972227,0.000009992353,0.0000063160887,0.92019975,0.0012778002],"about_ca_topic_score_codex":0.006083619,"about_ca_topic_score_gemma":0.009802066,"teacher_disagreement_score":0.8074647,"about_ca_system_score_codex":0.007847756,"about_ca_system_score_gemma":0.010247075,"threshold_uncertainty_score":0.9998743},"labels":[],"label_agreement":null},{"id":"W1980672928","doi":"10.1016/j.cllc.2012.01.003","title":"Rationale and Design of MARQUEE: A Phase III, Randomized, Double-Blind Study of Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib in Previously Treated Patients With Locally Advanced or Metastatic, Nonsquamous, Non–Small-Cell Lung Cancer","year":2012,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":126,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Royal Victoria Hospital","funders":"Daiichi Sankyo Europe; Daiichi-Sankyo","keywords":"Erlotinib; Medicine; Oncology; Internal medicine; KRAS; Erlotinib Hydrochloride; Placebo; Lung cancer; Clinical endpoint; non-small cell lung cancer (NSCLC); Phases of clinical research; Epidermal growth factor receptor; Population; Clinical trial; Pharmacology; Cancer; Pathology","score_opus":0.06581369968642774,"score_gpt":0.42345110690013255,"score_spread":0.3576374072137048,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1980672928","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9532639,0.0037712934,0.0015550615,0.00008819528,0.00048426495,0.04032757,0.00017398481,0.000038418526,0.00029730864],"genre_scores_gemma":[0.98590857,0.0009790069,0.003020543,0.00010912373,0.00013926512,0.008151788,0.0001566995,0.00009167226,0.0014433573],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99570125,0.0004695381,0.0019593346,0.0006916145,0.0005791004,0.00059918524],"domain_scores_gemma":[0.99504936,0.0023541884,0.0010977911,0.00047148095,0.0006141747,0.00041298423],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011372056,0.0005093708,0.0022618244,0.00023141169,0.000098841374,0.000020856758,0.00016813952,0.00016469779,0.0003738902],"category_scores_gemma":[0.00028130168,0.00034072265,0.00018870183,0.00057078584,0.00032315022,0.0002782445,0.00007420247,0.00037603473,0.0000015689494],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8745722,0.007682243,0.102906376,0.0005627602,0.0026823166,0.000023257615,0.0046856413,0.0038642697,0.000024932096,0.000009721338,0.00036764223,0.0026186397],"study_design_scores_gemma":[0.9717525,0.0045085456,0.006709479,0.0009271642,0.008166714,0.000002389211,0.0009304098,0.006331748,0.0002162838,0.000001033208,0.00006574797,0.00038797027],"about_ca_topic_score_codex":0.0012368596,"about_ca_topic_score_gemma":0.0016831245,"teacher_disagreement_score":0.097180314,"about_ca_system_score_codex":0.00047291094,"about_ca_system_score_gemma":0.0021747863,"threshold_uncertainty_score":0.99990445},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"randomized_trial","genre":"protocol","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"randomized_trial","genre":"protocol","about_ca_system":false,"about_ca_topic":false,"confidence":"medium"}],"label_agreement":"agree"},{"id":"W1981402488","doi":"10.1016/j.cllc.2014.11.008","title":"Correlation of Dosimetric and Clinical Factors With the Development of Esophagitis and Radiation Pneumonitis in Patients With Limited-Stage Small-Cell Lung Carcinoma","year":2014,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Esophagitis; Pneumonitis; Esophagus; Radiation therapy; Chemoradiotherapy; Nuclear medicine; Internal medicine; Gastroenterology; Lung; Cumulative incidence; Stage (stratigraphy); Lung cancer; Incidence (geometry); Radiology; Reflux; Disease","score_opus":0.026204664064820776,"score_gpt":0.3468570903380057,"score_spread":0.3206524262731849,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1981402488","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99653864,0.0018686368,0.0001920344,0.00017775447,0.00009566559,0.00093025214,0.000018089971,0.000009429863,0.0001694938],"genre_scores_gemma":[0.9988374,0.0005576037,0.0002936287,0.00006771795,0.000054917655,0.000035909437,0.000019598723,0.000020359108,0.00011283052],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99809414,0.0002002006,0.0007665309,0.00034457014,0.0003851473,0.00020943901],"domain_scores_gemma":[0.99746054,0.0015530108,0.00038713563,0.00021608235,0.00024673078,0.00013648212],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008046034,0.00015746034,0.00055261503,0.00014541543,0.000065010994,0.0000100150655,0.00007620559,0.00011134642,0.000011797442],"category_scores_gemma":[0.00046118483,0.000091878435,0.00004477462,0.00039022224,0.00038540113,0.00006685725,0.00008269341,0.00036153983,2.4466183e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000677028,0.00019000802,0.9787518,0.0003146252,0.00015342195,0.0000012560432,0.0005132642,0.000013830352,0.0000022468553,0.0000060858874,0.00009195835,0.019284522],"study_design_scores_gemma":[0.005935157,0.0012327161,0.9903173,0.00026320718,0.00022038819,2.4018303e-7,0.000088492474,0.0016252308,0.0000819959,0.0000010400847,0.00012981289,0.000104441795],"about_ca_topic_score_codex":0.00015244237,"about_ca_topic_score_gemma":0.00036957033,"teacher_disagreement_score":0.01918008,"about_ca_system_score_codex":0.0001282832,"about_ca_system_score_gemma":0.00028671732,"threshold_uncertainty_score":0.37466937},"labels":[],"label_agreement":null},{"id":"W1986487287","doi":"10.1016/j.cllc.2012.06.005","title":"Improving Outcomes for High-Risk Patients With Early-Stage Non–Small-Cell Lung Cancer: Insights from Population-Based Data and the Role of Stereotactic Ablative Radiotherapy","year":2012,"lang":"en","type":"review","venue":"Clinical Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cancer Care Ontario","funders":"","keywords":"Medicine; Stage (stratigraphy); Lung cancer; Lymphadenectomy; Lymph node; Population; Randomized controlled trial; Cancer; Dissection (medical); Radiation therapy; Radiology; Oncology; Internal medicine","score_opus":0.03741369225080014,"score_gpt":0.3812306087150883,"score_spread":0.34381691646428814,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1986487287","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.065383665,0.92239875,0.00013623587,0.00007230186,0.0006768477,0.0066587143,0.0046371412,0.000023225484,0.000013113353],"genre_scores_gemma":[0.078403205,0.91612136,0.000907821,0.00022197721,0.000616719,0.0019243079,0.0015446714,0.00014596165,0.00011396367],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99666184,0.0003210598,0.0013289005,0.00095538545,0.0003745561,0.000358264],"domain_scores_gemma":[0.9920294,0.004071508,0.002078163,0.0013875412,0.00020088378,0.00023250279],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003652813,0.00061351137,0.003096089,0.00008557025,0.00014603949,0.000047951835,0.00038980096,0.00035076222,0.000083009036],"category_scores_gemma":[0.00010975036,0.0003117742,0.00043644942,0.0001591998,0.00017579758,0.00015379058,0.00012309331,0.00053294137,7.1563824e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00060890435,0.00035034842,0.74412096,0.004258767,0.0036588567,9.160775e-7,0.000107437605,0.0000039298957,1.645699e-8,0.000010129166,0.00004525696,0.2468345],"study_design_scores_gemma":[0.041866507,0.0009651169,0.77386445,0.018557776,0.07062397,2.2228195e-7,0.000024312008,0.004322872,0.0000035219193,0.000020642761,0.08875437,0.0009962231],"about_ca_topic_score_codex":0.022152932,"about_ca_topic_score_gemma":0.0019594992,"teacher_disagreement_score":0.24583828,"about_ca_system_score_codex":0.0006550667,"about_ca_system_score_gemma":0.00085592695,"threshold_uncertainty_score":0.9999334},"labels":[],"label_agreement":null},{"id":"W1990284259","doi":"10.1016/j.cllc.2011.06.001","title":"Thymidylate Synthase, Dihydropyrimidine Dehydrogenase, Thymidine Phosphorylase, Orotate Phosphoribosyltransferase mRNA Expression in Lung Cancer Metastatic Lymph Node Samples Obtained by Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration – A Pilot Study","year":2011,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Toronto General Hospital","funders":"","keywords":"Dihydropyrimidine dehydrogenase; Thymidylate synthase; Medicine; Adenocarcinoma; Lymph node; Thymidine phosphorylase; Lung cancer; Pathology; Cancer research; Cancer; Internal medicine; Fluorouracil","score_opus":0.07159735492797094,"score_gpt":0.36575314263064884,"score_spread":0.2941557877026779,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1990284259","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9684978,0.022970898,0.00031556786,0.00031038703,0.00140801,0.0045506344,0.0009670493,0.00022493994,0.00075471704],"genre_scores_gemma":[0.98632133,0.007966288,0.0004587195,0.0006905825,0.00050642976,0.0033007325,0.00023480752,0.00016487943,0.00035624584],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9934901,0.0005050466,0.002297953,0.0016250319,0.0009032999,0.0011785744],"domain_scores_gemma":[0.99710244,0.00075225986,0.00045583624,0.00075046095,0.0002798005,0.00065919483],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0009559023,0.0010228683,0.0020616807,0.0002155513,0.0004198824,0.00006821748,0.0003783353,0.00018897695,0.0018088985],"category_scores_gemma":[0.00038248554,0.0008117705,0.00048083952,0.00079282845,0.0003651167,0.00037876525,0.000097393044,0.00072279316,0.000009419886],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02532697,0.013651806,0.9075396,0.000564171,0.0029023218,0.00036884804,0.0038864135,0.00033591993,0.03395031,0.000019772564,0.006126219,0.005327658],"study_design_scores_gemma":[0.091560565,0.020354077,0.65799755,0.0028635943,0.011322569,0.00008024951,0.0018122586,0.0064246235,0.2024953,0.0001947878,0.0013659,0.0035285095],"about_ca_topic_score_codex":0.016144775,"about_ca_topic_score_gemma":0.006171041,"teacher_disagreement_score":0.24954204,"about_ca_system_score_codex":0.0011712275,"about_ca_system_score_gemma":0.0008184008,"threshold_uncertainty_score":0.99943334},"labels":[],"label_agreement":null},{"id":"W1990748811","doi":"10.1016/j.cllc.2012.11.004","title":"Factors Influencing a Specific Pathologic Diagnosis of Non–Small-Cell Lung Carcinoma","year":2013,"lang":"en","type":"review","venue":"Clinical Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University Health Network; University of Ottawa","funders":"","keywords":"Medicine; Lung cancer; Adenocarcinoma; Medical diagnosis; Carcinoma; Internal medicine; Lung; Odds ratio; Biopsy; Not Otherwise Specified; Small-cell carcinoma; Radiology; Large cell; Oncology; Bronchoscopy; Medical record; Cancer; Logistic regression","score_opus":0.1383429499324044,"score_gpt":0.42840635033421465,"score_spread":0.2900634004018102,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1990748811","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.081951044,0.9110871,0.000004582002,0.000065005726,0.0016153405,0.0041149203,0.00023322429,0.000065906206,0.00086290453],"genre_scores_gemma":[0.008309517,0.98557836,0.00021198038,0.00021113438,0.0011179043,0.0036076487,0.00015976417,0.00016639465,0.00063728355],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9945495,0.00028908125,0.0026291392,0.0013582761,0.0004663574,0.0007076158],"domain_scores_gemma":[0.9944974,0.001819392,0.001498955,0.0013425027,0.0002836824,0.0005580458],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00045940673,0.0010018889,0.005409629,0.00024709434,0.0000870394,0.00004466715,0.00045909375,0.0010504839,0.0015053761],"category_scores_gemma":[0.00016124638,0.00063863595,0.0025554453,0.0005021427,0.00024721443,0.000077255965,0.00026120554,0.0011563045,0.000085740656],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000017312217,0.00075200514,0.57446223,0.03623938,0.000840509,0.00015043443,0.00010688013,9.509943e-7,3.147717e-7,0.000005308522,0.022061901,0.36536276],"study_design_scores_gemma":[0.0027278205,0.0009469264,0.0794228,0.056447577,0.017238092,0.000015959467,0.000060913462,0.000019294013,0.00004520064,0.000005273242,0.8420116,0.0010585653],"about_ca_topic_score_codex":0.0003296454,"about_ca_topic_score_gemma":0.000026763486,"teacher_disagreement_score":0.8199497,"about_ca_system_score_codex":0.0014804375,"about_ca_system_score_gemma":0.0013457116,"threshold_uncertainty_score":0.9996065},"labels":[],"label_agreement":null},{"id":"W2003462019","doi":"10.3816/clc.2009.n.026","title":"Initial Treatment Strategies and Outcomes for Multifocal Bronchioloalveolar Carcinoma","year":2009,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Toronto; University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Systemic therapy; Disease; Internal medicine; Hazard ratio; Odds ratio; Medical record; Carcinoma; Adenocarcinoma; Logistic regression; Cancer; Surgery; Oncology; Confidence interval","score_opus":0.058942492165199235,"score_gpt":0.45782650147508064,"score_spread":0.3988840093098814,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2003462019","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98458505,0.005536342,0.000093840055,0.00699715,0.00054368965,0.0013006654,0.000078298,0.000067455236,0.0007975041],"genre_scores_gemma":[0.9941902,0.0012825711,0.0008252557,0.002194548,0.00072628836,0.0003490384,0.000036803536,0.000019112711,0.00037614902],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986224,0.000036479476,0.00045350852,0.00046424914,0.00012477576,0.00029859727],"domain_scores_gemma":[0.99891394,0.0004100468,0.00008907626,0.00026072178,0.00007442947,0.00025176644],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012278261,0.00023595653,0.00064663216,0.000035296223,0.000090096626,0.000047373393,0.000048861322,0.00015523267,0.00007186508],"category_scores_gemma":[0.000059270376,0.00015607376,0.00031681615,0.000045271227,0.000109403925,0.00010226332,0.000014086381,0.00011460796,0.000003807322],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006758629,0.00082908606,0.85706544,0.000065853084,0.0004207246,0.000033492528,0.00012057416,0.000006249365,0.00001695392,0.0007484506,0.002000076,0.13801725],"study_design_scores_gemma":[0.010258375,0.0039181593,0.97579265,0.00010118434,0.00092728797,0.0000065968634,0.000078479075,0.00056598586,0.00021561394,0.00026101538,0.0076928562,0.00018179156],"about_ca_topic_score_codex":0.00016361898,"about_ca_topic_score_gemma":0.00014460633,"teacher_disagreement_score":0.13783546,"about_ca_system_score_codex":0.00031892682,"about_ca_system_score_gemma":0.00037717447,"threshold_uncertainty_score":0.6364503},"labels":[],"label_agreement":null},{"id":"W2004682614","doi":"10.3816/clc.2006.s.005","title":"Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Lung Cancer: Impact of Primary or Secondary Mutations","year":2006,"lang":"en","type":"review","venue":"Clinical Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":78,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Erlotinib; Gefitinib; Medicine; Lung cancer; Epidermal growth factor receptor; T790M; Oncology; Internal medicine; Tyrosine kinase; Erlotinib Hydrochloride; Clinical trial; Cancer; Cancer research; Receptor","score_opus":0.05832898923244735,"score_gpt":0.4730369604921097,"score_spread":0.41470797125966236,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2004682614","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0024429231,0.98468304,0.000010313796,0.00026419436,0.0017871632,0.003520041,0.006006612,0.0000793771,0.0012063622],"genre_scores_gemma":[0.0009416236,0.9893218,0.0003139416,0.00022758146,0.0017795805,0.0015103257,0.0025714394,0.00017905852,0.0031546266],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99465615,0.00033084425,0.0029432732,0.0009771462,0.00044158378,0.0006510146],"domain_scores_gemma":[0.9960984,0.0011970764,0.0013054572,0.00060346903,0.00035443596,0.0004411356],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00032245243,0.0008048758,0.0040829205,0.00046736887,0.0000986707,0.000032070446,0.00025246062,0.0007671128,0.0026565026],"category_scores_gemma":[0.00035727228,0.0005390261,0.0018567111,0.0010668098,0.00031281047,0.00021687576,0.00010358208,0.0012771547,0.000014295081],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00033469094,0.0011141842,0.07084663,0.033028986,0.003041939,0.00013833634,0.00010762268,0.000021695454,0.0000030213564,0.000011768603,0.076144606,0.8152065],"study_design_scores_gemma":[0.011302903,0.0013442895,0.09632686,0.08271405,0.020442763,0.000049422233,0.000020968693,0.00010077759,0.000014665918,0.00001690709,0.7859734,0.001692985],"about_ca_topic_score_codex":0.0044490662,"about_ca_topic_score_gemma":0.00079171197,"teacher_disagreement_score":0.8135135,"about_ca_system_score_codex":0.00429968,"about_ca_system_score_gemma":0.013140637,"threshold_uncertainty_score":0.99970615},"labels":[],"label_agreement":null},{"id":"W2009402840","doi":"10.3816/clc.2008.n.002","title":"Cooperative Group Research Efforts in Lung Cancer: Focus on Early-Stage Non–Small-Cell Lung Cancer","year":2008,"lang":"en","type":"review","venue":"Clinical Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Lung cancer; Bevacizumab; Oncology; Cancer; Radiosurgery; Radiation therapy; Clinical trial; Stage (stratigraphy); Internal medicine; Treatment of lung cancer; Disease; Chemotherapy; Medical physics","score_opus":0.12386232642892689,"score_gpt":0.5015367848429785,"score_spread":0.37767445841405156,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2009402840","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00556915,0.973164,0.0000054382053,0.0010130389,0.0032614605,0.011225723,0.00095372327,0.00011637178,0.0046910592],"genre_scores_gemma":[0.0029367548,0.96119004,0.00006084987,0.0007913763,0.0038574252,0.020414028,0.0002283927,0.00041699814,0.010104146],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.98880786,0.0012079204,0.0031483357,0.0030982583,0.0016333746,0.0021042535],"domain_scores_gemma":[0.99238664,0.002940584,0.0009860516,0.0018621889,0.0006800605,0.0011444538],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","research_integrity"],"category_scores_codex":[0.0016650038,0.001608427,0.006184059,0.0007387146,0.0004354375,0.00013453577,0.00083969213,0.0017063543,0.0018868439],"category_scores_gemma":[0.00026376045,0.0012063121,0.0018229716,0.0018844744,0.00060786156,0.00016930625,0.00046123384,0.005111467,0.000094807],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.001102346,0.0037761116,0.1961204,0.05007898,0.0048718215,0.002987506,0.00067057926,0.00013323482,5.955948e-7,0.00016148394,0.1770262,0.5630707],"study_design_scores_gemma":[0.00798798,0.0014509142,0.008428053,0.118130125,0.0042339014,0.000016983926,0.000023072644,0.0005004674,0.000017332826,0.000004463538,0.8577278,0.001478853],"about_ca_topic_score_codex":0.018022003,"about_ca_topic_score_gemma":0.013697921,"teacher_disagreement_score":0.6807017,"about_ca_system_score_codex":0.010614168,"about_ca_system_score_gemma":0.0075390316,"threshold_uncertainty_score":0.99966633},"labels":[],"label_agreement":null},{"id":"W2010808964","doi":"10.3816/clc.2004.n.030","title":"Clinical Benefit of Zoledronic Acid in Patients with Lung Cancer and OtherSolid Tumors: Analysis Based on History of Skeletal Complications","year":2004,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Bone health and treatments","field":"Medicine","cited_by":63,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Zoledronic acid; Placebo; Internal medicine; Lung cancer; Spinal cord compression; Surgery; Pathologic fracture; Odds ratio; Urology; Pathology; Spinal cord","score_opus":0.027018927406157973,"score_gpt":0.3890881316739154,"score_spread":0.36206920426775746,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2010808964","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9953259,0.002635032,0.00005574543,0.0006922072,0.00014125576,0.000652746,0.00010062934,0.000013634485,0.00038282646],"genre_scores_gemma":[0.9977462,0.00027059222,0.00042010914,0.0012209225,0.000039344246,0.00010564167,0.000047773614,0.000020927075,0.00012846777],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979896,0.0000591694,0.0010438175,0.00040822182,0.0002668861,0.00023228947],"domain_scores_gemma":[0.998503,0.00021723383,0.00044290238,0.00041319433,0.00016678656,0.0002568772],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027489327,0.00015752262,0.0008747631,0.00016575107,0.00002187049,0.0000015456466,0.00007453456,0.0001410476,0.00012316044],"category_scores_gemma":[0.00007238672,0.00012202168,0.00021956713,0.00031988244,0.000306783,0.00003579252,0.00001725565,0.0003073586,0.0000011981829],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010414377,0.0016709231,0.9909067,0.00018742606,0.00055014633,0.0000027666451,0.000046063713,0.0006190649,0.0000010257256,0.000034981495,0.0001249581,0.004814512],"study_design_scores_gemma":[0.011026293,0.00095727027,0.9833836,0.00064510736,0.0013588336,1.3760173e-7,0.0000036341155,0.002332666,0.0000058113515,0.000008514945,0.00017772977,0.00010039297],"about_ca_topic_score_codex":0.0015991055,"about_ca_topic_score_gemma":0.0021293587,"teacher_disagreement_score":0.009984855,"about_ca_system_score_codex":0.00077494764,"about_ca_system_score_gemma":0.0010852364,"threshold_uncertainty_score":0.49758998},"labels":[],"label_agreement":null},{"id":"W2012503365","doi":"10.1016/j.cllc.2011.11.010","title":"Delay Between the Initial Symptoms, the Diagnosis and the Onset of Specific Treatment in Elderly Patients With Lung Cancer","year":2012,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Institute of Cancer Research; Institut National Du Cancer","keywords":"Medicine; Lung cancer; Cancer; Lung; Internal medicine; Surgery; Pediatrics","score_opus":0.0431387002219345,"score_gpt":0.421283475776395,"score_spread":0.3781447755544605,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2012503365","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97400427,0.017140372,0.000008570565,0.0055527934,0.00041881084,0.002142666,0.0002466381,0.0000117574455,0.00047412846],"genre_scores_gemma":[0.99205077,0.004707104,0.000020408132,0.000709003,0.0006621883,0.0016461103,0.000036789505,0.000024876488,0.00014273674],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99843943,0.00023404561,0.0005130881,0.00023928878,0.00026598907,0.00030814015],"domain_scores_gemma":[0.99744207,0.0017307426,0.00021136743,0.00039268704,0.00009878975,0.00012437199],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037637036,0.0001961314,0.00046110438,0.000032033033,0.00016190483,0.000019693554,0.00012311718,0.00008920436,0.00017799556],"category_scores_gemma":[0.000053232747,0.00007263411,0.00012813449,0.0002029599,0.0005769219,0.00008175128,0.000040303086,0.0002501072,0.0000018514147],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005735347,0.00033845686,0.94983464,0.000022919341,0.00092618546,0.0000019797785,0.0014331914,0.000008972368,6.938596e-8,0.0000723011,0.002333269,0.044454448],"study_design_scores_gemma":[0.009213221,0.00043297635,0.978911,0.00023438872,0.0021449192,0.0000013837042,0.00010398737,0.000029522578,0.0000148498075,0.0000180276,0.008798534,0.00009719656],"about_ca_topic_score_codex":0.0017168333,"about_ca_topic_score_gemma":0.0009262611,"teacher_disagreement_score":0.04435725,"about_ca_system_score_codex":0.00029729347,"about_ca_system_score_gemma":0.00026437733,"threshold_uncertainty_score":0.2961933},"labels":[],"label_agreement":null},{"id":"W2015102817","doi":"10.3816/clc.2009.n.044","title":"Cooperative Group Research Endeavors in Small-Cell Lung Cancer: Current and Future Directions","year":2009,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Lung cancer; Etoposide; Clinical trial; Oncology; Radiation therapy; Internal medicine; Clinical Oncology; Chemotherapy; Intensive care medicine; Cancer; Family medicine","score_opus":0.09840935802406386,"score_gpt":0.519429932824909,"score_spread":0.42102057480084515,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2015102817","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.59204054,0.3658638,0.000018139073,0.03126798,0.0022808681,0.0027923812,0.000088361965,0.00012327878,0.005524659],"genre_scores_gemma":[0.57088095,0.4190046,0.00014713945,0.0010746268,0.0052532633,0.0010325838,0.000019521198,0.000047839098,0.0025394878],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99654996,0.00050384365,0.0006750258,0.00086656463,0.00056844595,0.0008361836],"domain_scores_gemma":[0.9977667,0.0007308642,0.00008950057,0.00041674866,0.0005246168,0.00047161913],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016571716,0.00027054566,0.000711962,0.00027201665,0.00031975453,0.000054630535,0.00019883984,0.00021140967,0.0002561687],"category_scores_gemma":[0.00043449836,0.00021436672,0.0001425379,0.0010213341,0.00045846056,0.00011905181,0.00017891121,0.002288332,0.000007053382],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009328255,0.001017924,0.63426095,0.0006691248,0.00025779617,0.000080965685,0.0016996363,0.000013076008,0.00018935185,0.0005545582,0.079352684,0.2809711],"study_design_scores_gemma":[0.0052959756,0.00088067766,0.6517183,0.0013120775,0.00019765916,0.0000052433024,0.0004977786,0.0015882917,0.00012430229,0.00012488611,0.33786157,0.00039325978],"about_ca_topic_score_codex":0.0008711052,"about_ca_topic_score_gemma":0.0037060422,"teacher_disagreement_score":0.28057787,"about_ca_system_score_codex":0.001052441,"about_ca_system_score_gemma":0.000900543,"threshold_uncertainty_score":0.9941791},"labels":[],"label_agreement":null},{"id":"W2019875881","doi":"10.1016/j.cllc.2012.04.003","title":"A Phase I Open-Label Dose-Escalation Study of Intravenous BI 2536 Together With Pemetrexed in Previously Treated Patients With Non–Small-Cell Lung Cancer","year":2012,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; Princess Margaret Cancer Centre; Boehringer Ingelheim (Canada); Juravinski Cancer Centre","funders":"","keywords":"Pemetrexed; Medicine; Rash; Nausea; Neutropenia; Lung cancer; Adverse effect; Pharmacokinetics; Internal medicine; Phases of clinical research; Oncology; Response Evaluation Criteria in Solid Tumors; Pharmacology; Toxicity; Chemotherapy; Cisplatin","score_opus":0.04642812213176898,"score_gpt":0.4313785693585379,"score_spread":0.3849504472267689,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2019875881","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9896256,0.0017422152,0.000050840543,0.00011578663,0.0002732799,0.0069934176,0.00007530844,0.000034713346,0.001088862],"genre_scores_gemma":[0.9960698,0.00023662532,0.0004410938,0.00026283725,0.00019409327,0.0015420646,0.000096785625,0.00008110816,0.0010755967],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975462,0.00015591495,0.00085354544,0.00055086514,0.00038213725,0.0005113221],"domain_scores_gemma":[0.9981916,0.00016109746,0.000466594,0.0004921324,0.00035688747,0.00033170325],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033780382,0.00033816256,0.00087097444,0.00014869243,0.000080424026,0.000027298558,0.00019004005,0.00014890562,0.00029242187],"category_scores_gemma":[0.000037680176,0.00021987615,0.0000563363,0.0006831106,0.000095378804,0.0002579349,0.00007049303,0.00032508723,0.0000034349112],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0047518783,0.03877852,0.9285477,0.00019968038,0.0010732926,0.000014952597,0.004078472,0.00007312602,0.00003440313,0.0000021622507,0.0004354031,0.022010416],"study_design_scores_gemma":[0.11338644,0.0104019195,0.86929166,0.0009247245,0.0041277776,0.0000011196532,0.00044999397,0.00081648334,0.00010761036,9.894527e-7,0.00015613227,0.00033514964],"about_ca_topic_score_codex":0.00451694,"about_ca_topic_score_gemma":0.0045780223,"teacher_disagreement_score":0.10863456,"about_ca_system_score_codex":0.00056868244,"about_ca_system_score_gemma":0.00061401434,"threshold_uncertainty_score":0.8966289},"labels":[],"label_agreement":null},{"id":"W2022281902","doi":"10.1016/j.cllc.2012.05.008","title":"Chemoradiotherapy for Locoregional Recurrence of Non–Small-Cell Lung Cancer After Surgical Resection: A Retrospective Analysis","year":2012,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Ottawa Hospital","funders":"","keywords":"Medicine; Chemoradiotherapy; Lung cancer; Vinorelbine; Retrospective cohort study; Radiation therapy; Stage (stratigraphy); Surgery; Cancer; Chemotherapy; Internal medicine; Oncology; Cisplatin","score_opus":0.036115652001459664,"score_gpt":0.42091615513868225,"score_spread":0.3848005031372226,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2022281902","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95454085,0.037866056,0.0007563726,0.0020821916,0.0016454131,0.0019066216,0.000284036,0.00003912286,0.00087930943],"genre_scores_gemma":[0.9817852,0.009168772,0.0008829823,0.00058208493,0.002953841,0.0029689625,0.000041234216,0.000043714037,0.0015732342],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976076,0.000074507574,0.0007828117,0.0006355894,0.00038518134,0.0005143298],"domain_scores_gemma":[0.99786377,0.00045227117,0.00035119255,0.00049495016,0.00044187525,0.00039594123],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005863832,0.0002839792,0.0011659854,0.00013916648,0.00007075451,0.0000145010235,0.0001260486,0.00026055175,0.001492406],"category_scores_gemma":[0.00005170244,0.00022006228,0.0009884018,0.0007394259,0.00020424678,0.00009988779,0.00003960163,0.00032463396,0.0000029966618],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002675684,0.0011373014,0.9771602,0.000440275,0.0031562268,0.000009761091,0.000219079,0.000028777633,0.000013156615,0.00004297007,0.012726319,0.00239023],"study_design_scores_gemma":[0.0072163795,0.0006608089,0.97152466,0.00054757035,0.0066953492,0.0000053912468,0.000020240745,0.0025770236,0.0010308528,0.000012953082,0.00940367,0.0003051224],"about_ca_topic_score_codex":0.00033266266,"about_ca_topic_score_gemma":0.00032346777,"teacher_disagreement_score":0.028697284,"about_ca_system_score_codex":0.001032581,"about_ca_system_score_gemma":0.00042933793,"threshold_uncertainty_score":0.99942034},"labels":[],"label_agreement":null},{"id":"W2023701460","doi":"10.1016/j.cllc.2012.06.003","title":"Capturing Acute Toxicity Data During Lung Radiotherapy by Using a Patient-Reported Assessment Tool","year":2012,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Effects of Radiation Exposure","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Acute toxicity; Adverse effect; Lung cancer; Toxicity; Radiation therapy; Pulmonary toxicity; Internal medicine; Emergency medicine","score_opus":0.04790550078805125,"score_gpt":0.4507604764749011,"score_spread":0.4028549756868498,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2023701460","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98910046,0.0057056155,0.0014242611,0.000786185,0.0016192294,0.0009704183,0.00011834886,0.00013333093,0.00014217004],"genre_scores_gemma":[0.9909493,0.00062292826,0.004742529,0.0015584057,0.0016213283,0.00004832836,0.00013746698,0.000068951624,0.00025080593],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972427,0.00018229526,0.0009538274,0.0005730654,0.0004932568,0.0005548931],"domain_scores_gemma":[0.9976216,0.00028928765,0.0004512873,0.0011511251,0.00009737973,0.00038933012],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00092825585,0.00025195355,0.0006012165,0.00006108049,0.00013639737,0.00003780235,0.00023753701,0.00023493632,0.00034082876],"category_scores_gemma":[0.00032741454,0.00022345681,0.00015743304,0.00017406943,0.00008324944,0.0005404803,0.00017127354,0.0005844771,0.0000028433965],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022757628,0.00038999823,0.95540774,0.00015750808,0.0012347784,0.00004113111,0.00013590064,0.000057024048,0.02067692,0.000004399307,0.015914053,0.0057529486],"study_design_scores_gemma":[0.008725474,0.00033829716,0.8901474,0.0006441531,0.0024269563,0.00016029805,0.00004747571,0.07898496,0.00527299,0.0000026137664,0.012394203,0.0008551611],"about_ca_topic_score_codex":0.000083949504,"about_ca_topic_score_gemma":0.000005547089,"teacher_disagreement_score":0.07892794,"about_ca_system_score_codex":0.00069037307,"about_ca_system_score_gemma":0.00031014023,"threshold_uncertainty_score":0.91123044},"labels":[],"label_agreement":null},{"id":"W2025470233","doi":"10.1016/j.cllc.2013.12.003","title":"Thymic Epithelial Neoplasms: A 12-Year Canadian Regional Cancer Program Experience","year":2014,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Myasthenia Gravis and Thymoma","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Ottawa; Ottawa Hospital","funders":"Myasthenia Gravis Foundation of America","keywords":"Medicine; Thymic carcinoma; Thymoma; Carboplatin; Internal medicine; Response Evaluation Criteria in Solid Tumors; Cancer; Radiation therapy; Chemotherapy; Etoposide; Cyclophosphamide; Institutional review board; Surgery; Oncology; Progressive disease; Gastroenterology; Cisplatin","score_opus":0.04413688222408164,"score_gpt":0.4155820739704523,"score_spread":0.3714451917463707,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2025470233","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97930205,0.0009614183,0.000027651007,0.0104575055,0.0017108514,0.0009305322,0.00006283771,0.00013830903,0.0064088725],"genre_scores_gemma":[0.98199004,0.0007359223,0.00079685304,0.008129312,0.0031115692,0.00069436576,0.000024727731,0.000054874807,0.004462341],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9978146,0.000095512005,0.0005602722,0.00057793746,0.00034172635,0.00060993637],"domain_scores_gemma":[0.9981374,0.0001608835,0.00013005355,0.00048677018,0.00014661046,0.00093828724],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00037454892,0.00022474836,0.00050547824,0.00007730459,0.00013870766,0.000036887854,0.00022732173,0.0002500869,0.0019858729],"category_scores_gemma":[0.00023456472,0.0001786993,0.0002547667,0.00017431272,0.00031519236,0.00006416192,0.000039820658,0.00047138063,0.00009525055],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005104251,0.00020799074,0.8223798,0.00008320768,0.00015111022,0.000039675186,0.00047372718,0.0000075318426,0.00009356217,0.0016278564,0.043401986,0.13102312],"study_design_scores_gemma":[0.0022635872,0.0004702971,0.3036771,0.00037462675,0.0001429952,0.000019979654,0.00006084402,0.0021844024,0.000049762944,0.00013117895,0.69033325,0.00029195927],"about_ca_topic_score_codex":0.05492916,"about_ca_topic_score_gemma":0.14784059,"teacher_disagreement_score":0.6469313,"about_ca_system_score_codex":0.00024066358,"about_ca_system_score_gemma":0.0011834987,"threshold_uncertainty_score":0.99892646},"labels":[],"label_agreement":null},{"id":"W2027195058","doi":"10.3816/clc.2008.n.013","title":"Cooperative Group Portfolio in Locally Advanced Non–Small-Cell Lung Cancer: Are We Making Progress?","year":2008,"lang":"en","type":"review","venue":"Clinical Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Cetuximab; Pemetrexed; Oncology; Bevacizumab; Lung cancer; Radiation therapy; Internal medicine; Chemotherapy; Targeted therapy; Clinical trial; Cancer; Colorectal cancer; Cisplatin","score_opus":0.06664254998654251,"score_gpt":0.45614729211374083,"score_spread":0.3895047421271983,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2027195058","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0003701137,0.9870103,0.000024541447,0.0008233342,0.0022780795,0.007707722,0.00028909888,0.0001340325,0.0013627943],"genre_scores_gemma":[0.0007284442,0.9826094,0.00046342233,0.001097446,0.00197037,0.010905226,0.0002068701,0.00029443184,0.0017243928],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9927527,0.00035400264,0.0029272013,0.0021449786,0.0006683326,0.0011528047],"domain_scores_gemma":[0.99548924,0.0006835482,0.0017452326,0.001143122,0.00036811622,0.0005707222],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.00040620507,0.0013495842,0.0059717786,0.0003200053,0.00017411473,0.00006767775,0.0005197224,0.0011317158,0.0006014546],"category_scores_gemma":[0.00010143368,0.0010124033,0.0015940168,0.0010567829,0.00038571953,0.00014756861,0.0002778669,0.0021199747,0.000036012112],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029353693,0.0016472902,0.11873719,0.03279131,0.0017297418,0.0019602447,0.00010861927,0.000038826107,4.5384333e-8,0.000017981654,0.030166116,0.8125091],"study_design_scores_gemma":[0.005585688,0.00054534,0.0031806726,0.19119038,0.004914426,0.000057485304,0.000030212963,0.00028072155,0.0000013336962,0.0000019544825,0.7932102,0.001001569],"about_ca_topic_score_codex":0.00017007985,"about_ca_topic_score_gemma":0.0012010162,"teacher_disagreement_score":0.8115075,"about_ca_system_score_codex":0.003904819,"about_ca_system_score_gemma":0.004330608,"threshold_uncertainty_score":0.9999255},"labels":[],"label_agreement":null},{"id":"W2027658502","doi":"10.1016/j.cllc.2011.09.002","title":"Systematic Review of the Cost-Effectiveness of Positron-Emission Tomography in Staging of Non–Small-Cell Lung Cancer and Management of Solitary Pulmonary Nodules","year":2011,"lang":"en","type":"review","venue":"Clinical Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; London Health Sciences Centre","funders":"","keywords":"Medicine; Context (archaeology); Lung cancer; Cost effectiveness; Positron emission tomography; Quality-adjusted life year; Malignancy; Medical physics; Radiology; Internal medicine; Risk analysis (engineering)","score_opus":0.045376102974456,"score_gpt":0.41723505615138823,"score_spread":0.37185895317693224,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2027658502","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0019190054,0.98566085,0.0000070015453,0.000027566308,0.00034106418,0.011399038,0.00022766051,0.000005865183,0.00041192357],"genre_scores_gemma":[0.0051471787,0.992563,0.00010353419,0.000046120404,0.000039078983,0.0019739033,0.000030844065,0.000046173922,0.00005013756],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99536407,0.0006900117,0.0027456128,0.0005770517,0.0003646464,0.0002586011],"domain_scores_gemma":[0.9956296,0.0009187618,0.0021607073,0.00093898666,0.00022929073,0.00012265274],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0016207843,0.00044740428,0.005191986,0.00016984735,0.000022336746,0.000002356474,0.00033926047,0.000243426,0.000039826304],"category_scores_gemma":[0.000052876792,0.00026139637,0.0012351887,0.000542816,0.00022355565,0.000036005575,0.0002245614,0.00035558201,1.6145258e-7],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009356878,0.0006736016,0.070801,0.8806025,0.0022428883,0.000012332984,0.00002288517,0.00000117979,0.0000011328574,0.000019415034,0.00007872588,0.045450784],"study_design_scores_gemma":[0.0010064763,0.00015843863,0.026952293,0.9453193,0.025846625,0.000003403929,0.000012458804,0.000031963395,0.000060102586,0.0000054021784,0.00041469384,0.0001888366],"about_ca_topic_score_codex":0.0006902272,"about_ca_topic_score_gemma":0.000024779405,"teacher_disagreement_score":0.06471682,"about_ca_system_score_codex":0.00033793674,"about_ca_system_score_gemma":0.00038660193,"threshold_uncertainty_score":0.99998385},"labels":[],"label_agreement":null},{"id":"W2028256811","doi":"10.3816/clc.2000.n.008","title":"Pathological Examination and the Reporting of Lung Cancer Specimens","year":2000,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Victoria Hospital; St. Michael's Hospital; University of Calgary; University Health Network","funders":"","keywords":"Medicine; Lung cancer; Pathological; Cancer; Disease; Stage (stratigraphy); Family medicine; Intensive care medicine; Medical physics; Oncology; Internal medicine","score_opus":0.05316461465144902,"score_gpt":0.43871984117835067,"score_spread":0.38555522652690166,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2028256811","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97406566,0.013124868,0.000007038277,0.005045194,0.0003251849,0.0007254106,0.00001659047,0.000030321604,0.0066597154],"genre_scores_gemma":[0.9779811,0.017691001,0.00013572768,0.0011992576,0.0006020386,0.000290513,0.0000067462393,0.00001555816,0.0020780812],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976685,0.00014624395,0.001364206,0.0003798095,0.00024170526,0.00019951507],"domain_scores_gemma":[0.9982755,0.000529887,0.00066558184,0.00030599098,0.00011154332,0.000111489106],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0014140509,0.00013973203,0.0006354122,0.000020911333,0.00007400617,0.000012996375,0.00006134819,0.00012386129,0.0021267238],"category_scores_gemma":[0.0004564668,0.000076820346,0.00019768243,0.000122032674,0.00037216593,0.000041597654,0.000033545926,0.00023726688,0.0000028286745],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00042930507,0.00021228599,0.8659302,0.00013110443,0.00025649308,0.00004926675,0.00021632438,0.00001773847,0.000017749144,0.00024787098,0.0043280977,0.12816358],"study_design_scores_gemma":[0.004341841,0.0001543513,0.9888406,0.00047961733,0.0008499225,0.000016285898,0.000020437084,0.0014210548,0.00014289918,0.000058546066,0.0035782617,0.000096222284],"about_ca_topic_score_codex":0.0002244027,"about_ca_topic_score_gemma":0.000064998436,"teacher_disagreement_score":0.12806736,"about_ca_system_score_codex":0.00017400054,"about_ca_system_score_gemma":0.00013186205,"threshold_uncertainty_score":0.9987855},"labels":[],"label_agreement":null},{"id":"W2029851073","doi":"10.3816/clc.2001.n.003","title":"Radiosurgery and Radiotherapy for Non–Small-Cell Lung Cancer Metastatic to Brain","year":2001,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Radiosurgery; Medicine; Radiation therapy; Lung cancer; Radiology; Medical physics; Oncology","score_opus":0.05299007568572942,"score_gpt":0.42883620036146936,"score_spread":0.3758461246757399,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2029851073","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90611356,0.044097446,0.010662506,0.033408444,0.0014305594,0.0037160774,0.00020624083,0.000074171054,0.00029100565],"genre_scores_gemma":[0.68690443,0.055559028,0.068070814,0.13377877,0.0067819436,0.0070606326,0.00017082322,0.00046761788,0.04120596],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99796927,0.00010383271,0.0006475422,0.00061250466,0.00018617988,0.00048069583],"domain_scores_gemma":[0.99743396,0.0013932828,0.00014405618,0.00038101277,0.00010247363,0.00054521713],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008566483,0.00027359222,0.0008531312,0.0000879354,0.000096369324,0.00003280052,0.000089048335,0.00010384353,0.00064040313],"category_scores_gemma":[0.0002010429,0.00021139024,0.00033583803,0.00022343289,0.00008452344,0.00004860554,0.000030375852,0.00020068046,0.000004213421],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021917813,0.00077873195,0.5337271,0.0007178666,0.0020704176,0.00019686512,0.0002939854,0.00012778337,0.00048513117,0.00006207049,0.269116,0.19023225],"study_design_scores_gemma":[0.03318296,0.002690127,0.22486746,0.0013480189,0.0054646637,0.000114316295,0.00013533839,0.026517706,0.0006476377,0.000103461825,0.7037281,0.001200223],"about_ca_topic_score_codex":0.0002304298,"about_ca_topic_score_gemma":0.00015435238,"teacher_disagreement_score":0.43461207,"about_ca_system_score_codex":0.00021994907,"about_ca_system_score_gemma":0.00034489617,"threshold_uncertainty_score":0.8620244},"labels":[],"label_agreement":null},{"id":"W2030485399","doi":"10.3816/clc.2006.n.030","title":"K-ras Mutations in Non-Small-Cell Lung Carcinoma: A Review","year":2006,"lang":"en","type":"review","venue":"Clinical Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":226,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Lung cancer; Lung; Oncology; Internal medicine; Carcinoma; Small Cell Lung Carcinoma; Cancer research; Mutation; Small-cell carcinoma; Genetics; Gene; Biology","score_opus":0.0674510554685044,"score_gpt":0.47978170261092284,"score_spread":0.41233064714241846,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2030485399","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000047221176,0.9809916,0.000030240399,0.0004576244,0.0010215896,0.00582698,0.0002742499,0.00006338546,0.011287123],"genre_scores_gemma":[0.000058162994,0.9833274,0.00035229855,0.0012527523,0.0009829235,0.003453611,0.0012248061,0.00013687156,0.009211196],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99556065,0.00024452386,0.0023542189,0.000989648,0.00030813587,0.0005428451],"domain_scores_gemma":[0.997268,0.0006374113,0.00073455676,0.00084153854,0.00019315715,0.00032532317],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00049148,0.0006378087,0.0035885598,0.00023592278,0.00008948099,0.00002828257,0.00025987823,0.00055223145,0.00047229006],"category_scores_gemma":[0.00015786482,0.00048489677,0.0014182483,0.0008749522,0.00012276525,0.00006467564,0.000085549545,0.0011198659,0.000121442165],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000012198752,0.0008024215,0.014515432,0.18170092,0.00062454597,0.0003326783,0.00003475775,0.0000031196394,2.7395211e-8,0.000016479,0.11981424,0.68214315],"study_design_scores_gemma":[0.0018626078,0.000093508614,0.002430471,0.11507256,0.021300193,0.000024849362,0.0000056386184,0.000045410805,7.8158095e-8,0.0000060314073,0.8587356,0.0004230519],"about_ca_topic_score_codex":0.0007662735,"about_ca_topic_score_gemma":0.00046145014,"teacher_disagreement_score":0.73892134,"about_ca_system_score_codex":0.0012780969,"about_ca_system_score_gemma":0.003565866,"threshold_uncertainty_score":0.99976027},"labels":[],"label_agreement":null},{"id":"W2034768910","doi":"10.3816/clc.2008.s.001","title":"The Quest for an Efficacious Lung Cancer Vaccine","year":2008,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Immune responses and vaccinations","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Lung cancer; Intensive care medicine; Oncology","score_opus":0.04231791471250364,"score_gpt":0.4178370065675648,"score_spread":0.37551909185506116,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2034768910","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.87828594,0.10363929,0.0005266948,0.00771754,0.0075203925,0.0014312975,0.00021410696,0.00017690985,0.00048782967],"genre_scores_gemma":[0.9582754,0.015389426,0.000041274026,0.000991649,0.00059350196,0.0007213713,0.000068360794,0.00004044397,0.023878621],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99832684,0.00028507208,0.00056017656,0.00035763456,0.000032355125,0.00043795322],"domain_scores_gemma":[0.9976104,0.0015289545,0.00017232267,0.0004404794,0.0002034037,0.000044429857],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00056608074,0.00016677158,0.00032663564,0.00003264497,0.000985584,0.000016744347,0.00035598016,0.0002847619,0.00041936032],"category_scores_gemma":[0.00038866122,0.00011125436,0.00022815207,0.00011099267,0.00014092265,0.00007497008,0.00006381958,0.0003880154,0.000034440964],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004832148,0.00070545205,0.15367481,0.00006665129,0.001464924,0.000006856681,0.0005319625,0.00013078057,0.005201676,0.0034057344,0.73137325,0.09860572],"study_design_scores_gemma":[0.004490646,0.00041237034,0.20684934,0.00005717902,0.000252748,0.000026588403,0.000042145428,0.000733697,0.0011104835,0.00004764555,0.78566724,0.00030993632],"about_ca_topic_score_codex":0.000257726,"about_ca_topic_score_gemma":0.00080699055,"teacher_disagreement_score":0.098295785,"about_ca_system_score_codex":0.000088954475,"about_ca_system_score_gemma":0.00032920856,"threshold_uncertainty_score":0.7580415},"labels":[],"label_agreement":null},{"id":"W2035891246","doi":"10.1016/j.cllc.2013.11.003","title":"Third-Line Chemotherapy in Small-Cell Lung Cancer: An International Analysis","year":2013,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":62,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; University of British Columbia; Ottawa Hospital; University of Ottawa","funders":"","keywords":"Medicine; Chemotherapy; Regimen; Internal medicine; Lung cancer; Chemotherapy regimen; Oncology; Multivariate analysis; Surgery","score_opus":0.055800522048560286,"score_gpt":0.47713408424617715,"score_spread":0.42133356219761686,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2035891246","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.969398,0.006431904,0.00015615416,0.017126188,0.000905522,0.0012754407,0.000052221432,0.0001043966,0.0045501376],"genre_scores_gemma":[0.9577634,0.024078896,0.00075203885,0.005912779,0.002082508,0.0011127065,0.00006187791,0.000060235223,0.008175582],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971186,0.00014205863,0.0009072121,0.00077298924,0.00050217443,0.00055694504],"domain_scores_gemma":[0.997992,0.0003092255,0.00020622993,0.00062380556,0.00047607624,0.0003926854],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000741625,0.00026878854,0.00088659395,0.0003212287,0.00006728342,0.00006242675,0.00044539667,0.00020450578,0.0048415517],"category_scores_gemma":[0.00023865695,0.00021588316,0.00038725336,0.0008939971,0.00021346087,0.00024048312,0.00015130144,0.0007570311,0.00003306089],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00036915185,0.00048782767,0.9646021,0.00013228045,0.0020914339,0.000019099109,0.0002568806,0.00030041303,0.00021405591,0.000020788035,0.015654335,0.015851598],"study_design_scores_gemma":[0.005227463,0.00024604288,0.9201068,0.00022437135,0.00095686316,9.801987e-7,0.00008733952,0.065446764,0.00030202483,0.000049618295,0.007041137,0.00031055257],"about_ca_topic_score_codex":0.0064559868,"about_ca_topic_score_gemma":0.004746887,"teacher_disagreement_score":0.06514635,"about_ca_system_score_codex":0.00080821436,"about_ca_system_score_gemma":0.00053050346,"threshold_uncertainty_score":0.9960682},"labels":[],"label_agreement":null},{"id":"W2037251572","doi":"10.3816/clc.2000.n.004","title":"Clinical Characteristics and the Impact of Surgery and Chemotherapy on Survival of Patients With Advanced and Metastatic Bronchioloalveolar Carcinoma: A Retrospective Study","year":2000,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; Ottawa Regional Cancer Foundation","funders":"","keywords":"Medicine; Chemotherapy; Stage (stratigraphy); Disease; Surgery; Carcinoma; Lung cancer; Retrospective cohort study; Cancer; Internal medicine","score_opus":0.027188047031011336,"score_gpt":0.3904648448775005,"score_spread":0.36327679784648914,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2037251572","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99712455,0.0011808099,8.325484e-7,0.00020634184,0.00009124194,0.0012168838,0.0001253007,0.000006757363,0.00004728623],"genre_scores_gemma":[0.99407357,0.0055416236,0.000035106044,0.00015321828,0.00007909458,0.000060472667,0.0000101946935,0.00002156141,0.00002514762],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981866,0.00027336297,0.00075902924,0.00039825696,0.00022426467,0.0001584906],"domain_scores_gemma":[0.9974867,0.0015964082,0.00033326435,0.0002973375,0.00014405602,0.0001422072],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00079618447,0.00019606478,0.0013062864,0.00003036067,0.00004159866,0.000008365975,0.000039391656,0.000057813733,0.000086676],"category_scores_gemma":[0.00019662434,0.00009869227,0.00017973618,0.000098171244,0.0005909932,0.000039106628,0.000020857693,0.00022157325,2.1553836e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012076533,0.0018380807,0.949101,0.0000719235,0.001245412,0.000005401479,0.0002248725,9.241796e-7,2.4604162e-7,0.0000070862448,0.00008023084,0.035348333],"study_design_scores_gemma":[0.018463159,0.0048921504,0.9753871,0.00020889226,0.00081403635,9.2310694e-7,0.00003585876,0.000071512186,0.0000021117576,0.000014381314,0.00001478116,0.000095093834],"about_ca_topic_score_codex":0.00020914664,"about_ca_topic_score_gemma":0.00002949905,"teacher_disagreement_score":0.035253238,"about_ca_system_score_codex":0.00007862093,"about_ca_system_score_gemma":0.00014871292,"threshold_uncertainty_score":0.4024554},"labels":[],"label_agreement":null},{"id":"W2041593349","doi":"10.3816/clc.2004.s.018","title":"Bronchoalveolar Carcinoma: Current Treatment and Future Trends","year":2004,"lang":"en","type":"review","venue":"Clinical Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Lung cancer; Epidermal growth factor receptor; Carcinoma; Clinical trial; Cancer; Pathology; Oncology; Internal medicine","score_opus":0.07846136581312092,"score_gpt":0.5167491071157707,"score_spread":0.4382877413026498,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2041593349","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00002733665,0.99294025,0.0000028240274,0.0007062923,0.002972672,0.0012274644,0.0004069762,0.0000741962,0.0016420193],"genre_scores_gemma":[0.00003411281,0.98821443,0.00010556586,0.000100200545,0.0054093627,0.0008759023,0.000610846,0.00009271834,0.004556836],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99742067,0.00010568163,0.000995505,0.0008921893,0.00019739705,0.0003885494],"domain_scores_gemma":[0.9983267,0.00014458569,0.00036126864,0.0005863682,0.00007704847,0.0005039987],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0001099405,0.0006325094,0.0024951287,0.00018364648,0.00011946684,0.00003623025,0.00010341884,0.000480174,0.00047918333],"category_scores_gemma":[0.000015651487,0.00039701565,0.0011815302,0.00026210118,0.00014774733,0.000054814907,0.000050359886,0.0005923082,0.000028877876],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000025092566,0.0004526097,0.0021616668,0.008744757,0.0014367132,0.000045941386,0.00006650871,1.2858352e-7,3.667486e-9,0.00007524603,0.0035779981,0.98341334],"study_design_scores_gemma":[0.0031251258,0.00053593924,0.0024332572,0.009889867,0.022949902,0.000049141316,0.0000058748356,0.0000021076314,4.913906e-8,0.000008213608,0.96067077,0.00032975353],"about_ca_topic_score_codex":0.0001098238,"about_ca_topic_score_gemma":0.00004631609,"teacher_disagreement_score":0.9830836,"about_ca_system_score_codex":0.0019216184,"about_ca_system_score_gemma":0.0025065634,"threshold_uncertainty_score":0.9998482},"labels":[],"label_agreement":null},{"id":"W2042273751","doi":"10.3816/clc.2004.n.010","title":"Megavoltage Computed Tomography Imaging: A Potential Tool to Guide and Improve the Delivery of Thoracic Radiation Therapy","year":2004,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Advanced Radiotherapy Techniques","field":"Physics and Astronomy","cited_by":51,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Regional Cancer Foundation","funders":"National Cancer Institute","keywords":"Tomotherapy; Medicine; Contouring; Radiation therapy; Radiology; Radiation treatment planning; Lung cancer; Nuclear medicine; Medical physics; Mediastinum; Image-guided radiation therapy; Computer science","score_opus":0.009551831587050483,"score_gpt":0.3685170852425558,"score_spread":0.3589652536555053,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2042273751","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.648067,0.003213003,0.34617275,0.0010113538,0.00037378105,0.0008711215,0.00006960742,0.00007542355,0.00014595862],"genre_scores_gemma":[0.9846912,0.00040271803,0.013061885,0.0010436762,0.0006267609,0.000095207244,0.000007554536,0.000025655874,0.000045360794],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9989487,0.00005554356,0.0004202396,0.0002784218,0.00012291972,0.00017418593],"domain_scores_gemma":[0.9992811,0.00010297562,0.00017810665,0.00027544235,0.000098053366,0.00006432349],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025966592,0.00013837138,0.00023515952,0.00004553314,0.0000798441,0.000030197367,0.00018214078,0.00003891414,0.000047824815],"category_scores_gemma":[0.0000067085675,0.00009962993,0.00016224768,0.0001766378,0.00013512383,0.000118215205,0.000044608558,0.00017351996,3.948633e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001902979,0.0001256346,0.09791585,0.000010638703,0.0002034309,0.000001116548,0.00016266284,0.0005615818,0.009111608,0.00095142814,0.0013554334,0.8894103],"study_design_scores_gemma":[0.012262724,0.0017762394,0.5970778,0.0006841196,0.00059160154,0.0000053986782,0.00028991996,0.02812697,0.17307812,0.02750245,0.15590446,0.0027002257],"about_ca_topic_score_codex":0.00026322852,"about_ca_topic_score_gemma":0.0000025805182,"teacher_disagreement_score":0.8867101,"about_ca_system_score_codex":0.000036681045,"about_ca_system_score_gemma":0.00009144527,"threshold_uncertainty_score":0.40627906},"labels":[],"label_agreement":null},{"id":"W2046653378","doi":"10.3816/clc.2003.n.003","title":"Phase I/II Trial of the Safety and Efficacy of AE-941 (Neovastat®) in the Treatment of Non–Small-Cell Lung Cancer","year":2003,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Cancer, Hypoxia, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":56,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cancer Care Ontario; Jewish General Hospital; McGill University; Hôpital Charles-Le Moyne","funders":"","keywords":"Medicine; Lung cancer; Adverse effect; Nausea; Internal medicine; Gastroenterology; Vomiting; Toxicity; Phases of clinical research","score_opus":0.02456018373456367,"score_gpt":0.3771726373027213,"score_spread":0.3526124535681577,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2046653378","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9722952,0.024373569,0.000037335612,0.00015130617,0.00140373,0.0010265597,0.00013772807,0.0000015931722,0.0005729616],"genre_scores_gemma":[0.95809036,0.040142328,0.00006869093,0.0001733663,0.00076736696,0.0001006294,0.000009427524,0.000016943555,0.00063090125],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99834687,0.00024395352,0.0007355117,0.00032126094,0.00014689658,0.00020548288],"domain_scores_gemma":[0.99884087,0.00015509201,0.0003546109,0.00050671713,0.000083686515,0.000059007794],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005037292,0.00016804528,0.00048571298,0.000022689735,0.000050206774,0.0000040121236,0.0002090713,0.00016649207,0.000041470008],"category_scores_gemma":[0.00012339142,0.00010069647,0.0003151877,0.0001440242,0.00028340527,0.0000026823911,0.000046326415,0.00011313177,8.326283e-8],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13414541,0.03569693,0.06524471,0.0010562212,0.0025864334,0.000005529491,0.0064594946,0.0013952636,0.35398164,0.00050805905,0.016858116,0.3820622],"study_design_scores_gemma":[0.30206105,0.00903832,0.026633713,0.0002798924,0.0018164805,0.000003589154,0.0002977928,0.0003176638,0.21081024,0.000033206205,0.4481198,0.00058825535],"about_ca_topic_score_codex":0.00029607816,"about_ca_topic_score_gemma":0.00054133637,"teacher_disagreement_score":0.43126166,"about_ca_system_score_codex":0.000028248556,"about_ca_system_score_gemma":0.00046226414,"threshold_uncertainty_score":0.4106283},"labels":[],"label_agreement":null},{"id":"W2055470920","doi":"10.1016/j.cllc.2011.11.002","title":"International Practice Survey on Palliative Lung Radiotherapy: Third International Consensus Workshop on Palliative Radiotherapy and Symptom Control","year":2012,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Western University","funders":"Canadian Association of Radiation Oncology; American Society for Radiation Oncology","keywords":"Medicine; Guideline; Lung cancer; Brachytherapy; Radiation therapy; Palliative care; External beam radiotherapy; Dose fractionation; Family medicine; Medical physics; Oncology; Internal medicine; Nursing","score_opus":0.05587022727743883,"score_gpt":0.45291786156257285,"score_spread":0.397047634285134,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2055470920","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6475801,0.05237523,0.0019953488,0.24093597,0.025450055,0.005825749,0.0017962138,0.00034857946,0.023692789],"genre_scores_gemma":[0.92364764,0.04371776,0.0011434141,0.025835913,0.0037428811,0.0003375186,0.000121802914,0.000073168754,0.0013799195],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970946,0.00050472864,0.00070237566,0.0006403596,0.00064065977,0.0004173005],"domain_scores_gemma":[0.99012196,0.008267995,0.00047433178,0.00035044976,0.00039849797,0.00038676942],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001266089,0.00036453275,0.0006950054,0.00010519302,0.000097872326,0.0000712009,0.00017992804,0.00025212363,0.0007242703],"category_scores_gemma":[0.0014822213,0.0002784821,0.00022709495,0.00013496565,0.00022800031,0.000139992,0.00003142025,0.000621067,0.000017288645],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008096065,0.0016332964,0.89214945,0.000022798282,0.0055039395,0.000028003526,0.00061573734,0.000083253944,0.0000113788465,0.0007666848,0.07954787,0.011541512],"study_design_scores_gemma":[0.0134925665,0.0005888296,0.8906606,0.0006956782,0.00042610226,0.000005318315,0.000069138645,0.0034771787,0.000026169051,0.000010497916,0.09025038,0.00029753425],"about_ca_topic_score_codex":0.00021038244,"about_ca_topic_score_gemma":0.000071071656,"teacher_disagreement_score":0.27606755,"about_ca_system_score_codex":0.0017639771,"about_ca_system_score_gemma":0.00021950509,"threshold_uncertainty_score":0.99996674},"labels":[],"label_agreement":null},{"id":"W2055986320","doi":"10.1016/j.cllc.2014.02.003","title":"Stage III Non–Small-Cell Lung Cancer: Establishing a Benchmark for the Proportion of Patients Suitable for Radical Treatment","year":2014,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Hospital; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Stage (stratigraphy); Lung cancer; Radical surgery; Pleural effusion; Retrospective cohort study; Performance status; Cancer; Surgery; Malignant pleural effusion; Internal medicine; Chemoradiotherapy; Cohort","score_opus":0.030649212629844238,"score_gpt":0.38028487678316336,"score_spread":0.34963566415331915,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2055986320","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9716269,0.006343984,0.0049492125,0.0029702804,0.002297808,0.010372788,0.00085377303,0.00005260269,0.0005326798],"genre_scores_gemma":[0.9808203,0.0038557593,0.0011166304,0.0008387161,0.0013144865,0.008333345,0.00025268647,0.000069012116,0.003399056],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99746966,0.000063864034,0.0009767608,0.0006228814,0.00035275577,0.0005140789],"domain_scores_gemma":[0.99651295,0.001744616,0.0005260481,0.00053689285,0.00042414578,0.00025534676],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008259222,0.0002941157,0.000828145,0.000039729803,0.00021329818,0.00004066192,0.00017938751,0.00021461149,0.00019507388],"category_scores_gemma":[0.00032465818,0.00017810366,0.0005424749,0.00014384557,0.00013753626,0.00010187735,0.00004982644,0.00017940828,8.030559e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017414417,0.002025617,0.9122933,0.001239573,0.00087434176,0.0000012566712,0.00025825616,0.00021714612,0.000024276813,0.00015711613,0.02676709,0.054400552],"study_design_scores_gemma":[0.07115462,0.010123149,0.4987964,0.0022186912,0.012455761,8.857319e-7,0.00016361299,0.07417992,0.0067132344,0.000088223154,0.32324848,0.0008570201],"about_ca_topic_score_codex":0.0013102721,"about_ca_topic_score_gemma":0.0007094874,"teacher_disagreement_score":0.4134969,"about_ca_system_score_codex":0.0009651699,"about_ca_system_score_gemma":0.0007117767,"threshold_uncertainty_score":0.72628564},"labels":[],"label_agreement":null},{"id":"W2057099389","doi":"10.1016/j.cllc.2016.04.002","title":"Weekly nab-Paclitaxel in Combination With Carboplatin as First-Line Therapy in Patients With Advanced Non–Small-Cell Lung Cancer: Analysis of Safety and Efficacy in Patients With Diabetes","year":2016,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Celgene","keywords":"Medicine; Internal medicine; Hazard ratio; Carboplatin; Lung cancer; Neutropenia; Gastroenterology; Paclitaxel; Oncology; Anemia; Urology; Chemotherapy; Confidence interval; Cisplatin","score_opus":0.008273552640896074,"score_gpt":0.3253109315871075,"score_spread":0.3170373789462114,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2057099389","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99590164,0.0008095664,0.00002947283,0.0006449914,0.00007175459,0.0022417998,0.00014906745,0.000015590698,0.00013612525],"genre_scores_gemma":[0.99800116,0.0009312228,0.00020011024,0.00020902428,0.000020914253,0.00030742338,0.00013709001,0.000042322397,0.00015070889],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977329,0.000091380876,0.0008278023,0.0006093713,0.00037579917,0.00036275564],"domain_scores_gemma":[0.9982713,0.00048786952,0.0004226255,0.0003486102,0.00031491622,0.00015469515],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021695861,0.00029765468,0.0009746452,0.00037119136,0.000043828008,0.000010200723,0.000093149,0.00013208482,0.00006460855],"category_scores_gemma":[0.00007055441,0.00016950467,0.00007505378,0.0011434903,0.0001615809,0.00016876639,0.000027972803,0.00022239963,4.0984375e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0067698793,0.0026933635,0.961466,0.000103068065,0.0010172348,0.0000039801043,0.00046058596,0.0012010545,0.0000054867196,0.000005036628,0.0000111025465,0.026263203],"study_design_scores_gemma":[0.06513301,0.003843944,0.92722005,0.0015150158,0.0011466418,2.4225326e-8,0.000029128449,0.00079834077,0.00004183669,0.000003440972,0.00003699732,0.00023157144],"about_ca_topic_score_codex":0.0010099051,"about_ca_topic_score_gemma":0.0076160347,"teacher_disagreement_score":0.058363136,"about_ca_system_score_codex":0.0006031999,"about_ca_system_score_gemma":0.0003747021,"threshold_uncertainty_score":0.69122},"labels":[],"label_agreement":null},{"id":"W2058344766","doi":"10.1016/j.cllc.2014.08.002","title":"Radical-Intent Hypofractionated Radiotherapy for Locally Advanced Non–Small-Cell Lung Cancer: A Systematic Review of the Literature","year":2014,"lang":"en","type":"review","venue":"Clinical Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":82,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; Western University","funders":"","keywords":"Medicine; Lung cancer; Radiation therapy; Context (archaeology); Toxicity; Chemoradiotherapy; Pulmonary toxicity; Internal medicine; Oncology; Esophageal cancer; Confidence interval; Acute toxicity; Chemotherapy; Cancer","score_opus":0.030862219030328153,"score_gpt":0.4264149500923849,"score_spread":0.39555273106205674,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2058344766","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000063008906,0.9713268,0.00022897706,0.0022399544,0.0029338019,0.022619847,0.00048104694,0.000056746045,0.00010649524],"genre_scores_gemma":[0.000008535537,0.9696419,0.00044742328,0.0070796898,0.00119772,0.018500684,0.00020098087,0.0001952327,0.0027278068],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9932423,0.00064830005,0.0037214507,0.0011691578,0.0006502813,0.0005684735],"domain_scores_gemma":[0.991675,0.0023008808,0.0030229567,0.0017647741,0.0008464774,0.00038986426],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00134211,0.0009380504,0.008406254,0.000113753726,0.00012670601,0.000041095158,0.0006938669,0.00079914765,0.00022726903],"category_scores_gemma":[0.00086463586,0.0004978779,0.0042814193,0.0007262361,0.0001982704,0.00007053077,0.000095228694,0.0011758449,0.000005449129],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010771074,0.00045049074,0.00018919927,0.87492317,0.0037567262,0.000008807639,0.000020973053,0.000003905385,3.1277264e-7,0.00001967625,0.03289512,0.08762392],"study_design_scores_gemma":[0.0021189929,0.00023529041,0.000014947912,0.5980982,0.022860868,0.000017301683,0.0000016126252,0.00017320031,0.0000025456568,0.0000018059611,0.37618268,0.00029254387],"about_ca_topic_score_codex":0.000043458956,"about_ca_topic_score_gemma":0.000021793594,"teacher_disagreement_score":0.34328753,"about_ca_system_score_codex":0.0022107551,"about_ca_system_score_gemma":0.0028848522,"threshold_uncertainty_score":0.9997473},"labels":[],"label_agreement":null},{"id":"W2058732484","doi":"10.3816/clc.2000.n.001","title":"Small-Cell Lung Cancer at the Millennium: Radiotherapy Innovations Improve Survival While New Chemotherapy Treatments Remain Unproven","year":2000,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Prophylactic cranial irradiation; Radiation therapy; Lung cancer; Etoposide; Oncology; Chemotherapy; Regimen; Vincristine; Internal medicine; Cyclophosphamide; Surgery","score_opus":0.05962236724209133,"score_gpt":0.42511883145126506,"score_spread":0.3654964642091737,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2058732484","genre_codex":"empirical","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8102472,0.10744637,0.00009769383,0.0582335,0.0027848484,0.0055266614,0.00033907147,0.00026675683,0.015057891],"genre_scores_gemma":[0.052712128,0.28256354,0.0011225296,0.022290342,0.010415389,0.002899168,0.00013725864,0.00040147893,0.62745816],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99625945,0.00022317332,0.0009797582,0.00096962525,0.0006780193,0.00088995864],"domain_scores_gemma":[0.9972907,0.0006517833,0.00025556504,0.0010915459,0.00028785996,0.00042258686],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007917754,0.00048165032,0.0009420161,0.00008090822,0.00042253666,0.000058220052,0.00042806115,0.0002806029,0.010150002],"category_scores_gemma":[0.00010247083,0.00031584373,0.0004183634,0.0007605679,0.00043807307,0.000105282255,0.00010761802,0.0007713468,0.00005092491],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002833733,0.0005606356,0.29653978,0.00023097736,0.0028868157,0.00002342936,0.00082633214,0.00008354761,0.0016549686,0.000021556802,0.47720522,0.217133],"study_design_scores_gemma":[0.023516392,0.0011760006,0.1425774,0.0005594062,0.0011690013,0.000006015019,0.000109624954,0.0020096437,0.0018947705,0.000054869604,0.82612586,0.00080104603],"about_ca_topic_score_codex":0.0032588413,"about_ca_topic_score_gemma":0.0019907702,"teacher_disagreement_score":0.7575351,"about_ca_system_score_codex":0.0021103406,"about_ca_system_score_gemma":0.0016593622,"threshold_uncertainty_score":0.99992937},"labels":[],"label_agreement":null},{"id":"W2061817827","doi":"10.1016/j.cllc.2014.07.005","title":"Gastric Acid Suppression Is Associated With Decreased Erlotinib Efficacy in Non–Small-Cell Lung Cancer","year":2014,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Metastasis and carcinoma case studies","field":"Medicine","cited_by":104,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Alberta Cancer Foundation; University of Alberta","funders":"","keywords":"Erlotinib; Medicine; Internal medicine; Lung cancer; Concomitant; Oncology; Erlotinib Hydrochloride; Population; Adenocarcinoma; Retrospective cohort study; Cancer; Epidermal growth factor receptor","score_opus":0.036809413154444054,"score_gpt":0.3661857580732465,"score_spread":0.3293763449188024,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2061817827","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98842597,0.0061718887,0.000095122065,0.0014165374,0.0005406632,0.0010435364,0.00006480565,0.000059818754,0.0021816844],"genre_scores_gemma":[0.9933684,0.0015119873,0.00023385829,0.0026813734,0.0005916681,0.00026850068,0.000040582945,0.000061540864,0.0012420891],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99703676,0.0002951524,0.0008691319,0.0007374689,0.00045328756,0.0006082184],"domain_scores_gemma":[0.99775404,0.0007139186,0.0003540522,0.00050441205,0.0002574167,0.00041616097],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010136978,0.00034905563,0.0011037756,0.000120010016,0.000114812035,0.000025015608,0.00016926626,0.00023563586,0.00091611786],"category_scores_gemma":[0.00072565343,0.0002449855,0.00027794586,0.00051736,0.00014772578,0.000053758376,0.000104697865,0.00066644413,0.000012805994],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009819812,0.00087000185,0.93516725,0.0002295171,0.000332167,0.0000757685,0.0002051413,0.000027897651,0.0005466178,0.0000034339985,0.048023473,0.013536727],"study_design_scores_gemma":[0.013371457,0.0005558018,0.9723564,0.0018143761,0.0013189232,0.0000055288806,0.000060929666,0.0052284664,0.0015532196,0.0000024925641,0.003367611,0.00036483214],"about_ca_topic_score_codex":0.0004079942,"about_ca_topic_score_gemma":0.0006990157,"teacher_disagreement_score":0.044655863,"about_ca_system_score_codex":0.0002293279,"about_ca_system_score_gemma":0.00039047134,"threshold_uncertainty_score":0.9999972},"labels":[],"label_agreement":null},{"id":"W2062735451","doi":"10.3816/clc.2008.s.004","title":"Early Clinical Trial Experience with Vaccine Therapies in Non–Small-Cell Lung Cancer","year":2008,"lang":"en","type":"review","venue":"Clinical Lung Cancer","topic":"Immunotherapy and Immune Responses","field":"Immunology and Microbiology","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Lung cancer; Clinical trial; Oncology; Cancer vaccine; Intensive care medicine; Internal medicine; Cancer; Immunotherapy","score_opus":0.07412781374028508,"score_gpt":0.43560081853660926,"score_spread":0.36147300479632416,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2062735451","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.069534265,0.91985303,0.000016319475,0.00007834565,0.0066317646,0.0035349315,0.00008497159,0.00008971701,0.00017663243],"genre_scores_gemma":[0.0010555484,0.9845485,0.00004011072,0.00045206895,0.00091331615,0.0028138773,0.00007490404,0.00017429523,0.0099273585],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.990489,0.002839767,0.0039253524,0.0015276682,0.00012861013,0.0010895927],"domain_scores_gemma":[0.99343693,0.0034301067,0.0015756201,0.0013017135,0.00016253236,0.00009310364],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0012871207,0.0010833744,0.005057951,0.000274898,0.00028311854,0.000052426214,0.0013320425,0.002397466,0.0018998695],"category_scores_gemma":[0.00026006522,0.00074008544,0.0016152306,0.0006157434,0.00080978975,0.00016840795,0.00023398691,0.0034602804,0.0001398663],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.053816497,0.0014973672,0.014596199,0.0020060728,0.0033635418,0.00009952246,0.0011690274,0.0000016572181,0.000016318341,0.000007105182,0.010237042,0.91318965],"study_design_scores_gemma":[0.04444859,0.0016205707,0.003897557,0.009684583,0.00096896314,0.00004120703,0.00005134067,0.000002345855,0.000014494592,0.0000010488293,0.9382024,0.00106689],"about_ca_topic_score_codex":0.00074932084,"about_ca_topic_score_gemma":0.00025244156,"teacher_disagreement_score":0.92796534,"about_ca_system_score_codex":0.00027595964,"about_ca_system_score_gemma":0.00240201,"threshold_uncertainty_score":0.99950504},"labels":[],"label_agreement":null},{"id":"W2067441207","doi":"10.3816/clc.2009.n.027","title":"PROCLAIM: A Phase III Study of Pemetrexed, Cisplatin, and Radiation Therapy Followed by Consolidation Pemetrexed Versus Etoposide, Cisplatin, and Radiation Therapy Followed by Consolidation Cytotoxic Chemotherapy of Choice in Locally Advanced Stage III Non–Small-Cell Lung Cancer of Other than Predominantly Squamous Cell Histology","year":2009,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":51,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Eli Lilly (Canada)","funders":"","keywords":"Pemetrexed; Medicine; Cisplatin; Etoposide; Oncology; Radiation therapy; Chemotherapy; Internal medicine","score_opus":0.020026911475967787,"score_gpt":0.37003484257783686,"score_spread":0.35000793110186906,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2067441207","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9664489,0.025855958,0.00016937905,0.00044037262,0.00037064057,0.006352869,0.00018807389,0.000031367028,0.00014243404],"genre_scores_gemma":[0.9796948,0.018409112,0.00015924821,0.00042152984,0.000090315276,0.00071339594,0.00013699278,0.0000683603,0.00030627107],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99593824,0.0003268743,0.0018972971,0.0009266657,0.0004883346,0.00042261125],"domain_scores_gemma":[0.99593794,0.0011257071,0.0018736637,0.00050884485,0.00035031355,0.00020350069],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006434753,0.0005216592,0.0016082169,0.00029024394,0.00009240012,0.000021440504,0.00016665318,0.00037832523,0.0001383172],"category_scores_gemma":[0.00013291341,0.00046473593,0.00019403175,0.0005720536,0.00021051473,0.00023413016,0.000024627177,0.00032077119,2.3607603e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04833825,0.012400098,0.71937627,0.0005440153,0.00087756827,0.000009410599,0.003949638,0.00019810635,0.13282964,0.000008017916,0.0059265937,0.07554243],"study_design_scores_gemma":[0.52033895,0.027741324,0.17522366,0.00071517413,0.0016708218,0.0000022954277,0.00074817805,0.010790754,0.26036352,0.000009304777,0.0013913597,0.0010046466],"about_ca_topic_score_codex":0.002291603,"about_ca_topic_score_gemma":0.0011842675,"teacher_disagreement_score":0.54415256,"about_ca_system_score_codex":0.0005316324,"about_ca_system_score_gemma":0.00051575,"threshold_uncertainty_score":0.9997804},"labels":[],"label_agreement":null},{"id":"W2067890167","doi":"10.1016/j.cllc.2011.06.011","title":"The Prognostic Significance of Lymphovascular Invasion on Biopsy Specimens in Lung Cancer Treated With Definitive Chemoradiotherapy","year":2011,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Charles-Le Moyne","funders":"Institut National de la Santé et de la Recherche Médicale","keywords":"Medicine; Lymphovascular invasion; Hazard ratio; Stage (stratigraphy); Concomitant; Biopsy; Lung cancer; Internal medicine; Proportional hazards model; Confidence interval; Radiation therapy; Chemoradiotherapy; Oncology; Cancer; Surgery; Metastasis","score_opus":0.051474488045064166,"score_gpt":0.3572952222225964,"score_spread":0.30582073417753225,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2067890167","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98253846,0.011852045,0.000014678835,0.00088638853,0.00028729677,0.0020757678,0.000045999448,0.000042187952,0.0022571504],"genre_scores_gemma":[0.9810259,0.01602842,0.00026865077,0.000639169,0.0002376915,0.0014436645,0.000011739121,0.000059915394,0.00028488712],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99769753,0.00015212371,0.0007060486,0.00063631503,0.0003892991,0.00041869114],"domain_scores_gemma":[0.9979613,0.00074756244,0.00031272302,0.00058572844,0.00020578575,0.00018689588],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041301385,0.00031178608,0.0007890453,0.0000768124,0.000086444394,0.00001355424,0.00016867023,0.00016123468,0.00032219366],"category_scores_gemma":[0.00010941647,0.00017592996,0.00024073476,0.00045578834,0.0003971686,0.000052225016,0.000025002157,0.00027934343,0.000005758131],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031813846,0.0012149641,0.98481166,0.00017820438,0.0010279962,0.0001295218,0.00030704183,0.000021812422,0.00011987886,0.00018371538,0.0008783715,0.007945426],"study_design_scores_gemma":[0.008092758,0.0014083469,0.9777394,0.0024309396,0.000853018,0.000007896567,0.000065551,0.00027721332,0.008284707,0.000026402873,0.0005599623,0.0002538349],"about_ca_topic_score_codex":0.0020237865,"about_ca_topic_score_gemma":0.00088538404,"teacher_disagreement_score":0.008164828,"about_ca_system_score_codex":0.00086972985,"about_ca_system_score_gemma":0.00064218615,"threshold_uncertainty_score":0.7174216},"labels":[],"label_agreement":null},{"id":"W2069287882","doi":"10.1016/j.cllc.2011.04.004","title":"Consensus Statement on Palliative Lung Radiotherapy: Third International Consensus Workshop on Palliative Radiotherapy and Symptom Control","year":2011,"lang":"en","type":"review","venue":"Clinical Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Western University","funders":"American Society for Radiation Oncology","keywords":"Medicine; Palliative care; Lung cancer; Context (archaeology); Radiation therapy; Randomized controlled trial; Quality of life (healthcare); Clinical endpoint; Intensive care medicine; Surgery; Oncology; Nursing","score_opus":0.09557749770243658,"score_gpt":0.4709337016063324,"score_spread":0.37535620390389585,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2069287882","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0003228565,0.9821948,0.00005825997,0.0058264853,0.003485459,0.0052175215,0.0010175342,0.00011474514,0.0017623487],"genre_scores_gemma":[0.00042188188,0.98743886,0.00048289256,0.0056167473,0.0019755347,0.0017571085,0.0001602211,0.0001883639,0.0019584023],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9941473,0.00072289177,0.0021690873,0.0016416954,0.00065753114,0.0006614952],"domain_scores_gemma":[0.9909809,0.00581098,0.0014964548,0.00082991977,0.00030410718,0.00057761255],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00082832534,0.0011346921,0.0040195263,0.00024164002,0.00014172103,0.00008201816,0.00030923187,0.00077043165,0.001009669],"category_scores_gemma":[0.00029774127,0.00078382576,0.0011545663,0.00021481492,0.0005388381,0.000025977044,0.00005257804,0.0013723294,0.0000310208],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0046966057,0.002155678,0.026030665,0.005282453,0.032422036,0.00038372108,0.0005530835,0.000021546826,2.0264143e-7,0.001556246,0.1625756,0.76432216],"study_design_scores_gemma":[0.013447992,0.0015656247,0.0035816305,0.042289764,0.0049649323,0.0000106955895,0.000029090112,0.00044194207,8.7006964e-7,0.00002949336,0.93286,0.000777947],"about_ca_topic_score_codex":0.000087286055,"about_ca_topic_score_gemma":0.00005683788,"teacher_disagreement_score":0.7702844,"about_ca_system_score_codex":0.0042052167,"about_ca_system_score_gemma":0.001293889,"threshold_uncertainty_score":0.99990356},"labels":[],"label_agreement":null},{"id":"W2069425136","doi":"10.3816/clc.2009.s.004","title":"Extending Outcomes: Epidermal Growth Factor Receptor–Targeted Monoclonal Antibodies in Non–Small-Cell Lung Cancer","year":2009,"lang":"en","type":"review","venue":"Clinical Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Cetuximab; Epidermal growth factor receptor; Medicine; Monoclonal antibody; Lung cancer; Tyrosine kinase; Cancer research; Targeted therapy; Oncology; Epidermal growth factor; Antibody; Cancer; Internal medicine; Immunology; Receptor","score_opus":0.07954086513988046,"score_gpt":0.4812353200448106,"score_spread":0.40169445490493016,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2069425136","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0023276294,0.98722124,0.000032666772,0.0007342859,0.0032435767,0.003925256,0.00094607874,0.00014187634,0.0014273826],"genre_scores_gemma":[0.0006083347,0.9872359,0.00097466615,0.0011601232,0.0016374041,0.0014140519,0.00060938473,0.00019449375,0.006165627],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99377906,0.00033417964,0.002768036,0.0015193938,0.0005232305,0.0010761012],"domain_scores_gemma":[0.99624664,0.0010813146,0.001072117,0.00073171174,0.0002686332,0.00059960654],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00046014128,0.0011564536,0.0050397697,0.00045941139,0.00018095478,0.00007203683,0.00042849183,0.0009990953,0.0014627445],"category_scores_gemma":[0.00033694127,0.0008455261,0.0018297064,0.0006907925,0.00017132779,0.00018890864,0.00014318428,0.0017652675,0.00006074892],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010724907,0.00091373647,0.30426034,0.020519327,0.0032500455,0.00023893158,0.00024243773,0.000009200224,0.0000018387283,0.000026729209,0.019112552,0.6513176],"study_design_scores_gemma":[0.008235872,0.00043751308,0.1278554,0.06793795,0.02073635,0.000025470803,0.000057330424,0.00031941754,0.000008612682,0.000023592489,0.77208376,0.0022787468],"about_ca_topic_score_codex":0.00085860555,"about_ca_topic_score_gemma":0.0003523396,"teacher_disagreement_score":0.7529712,"about_ca_system_score_codex":0.0023109927,"about_ca_system_score_gemma":0.0030023833,"threshold_uncertainty_score":0.99945},"labels":[],"label_agreement":null},{"id":"W2070730813","doi":"10.3816/clc.2011.n.004","title":"Randomized Phase II Trial of Concurrent Versus Sequential Bortezomib Plus Docetaxel in Advanced Non–Small-Cell Lung Cancer: A California Cancer Consortium Trial","year":2011,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Ubiquitin and proteasome pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":20,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"National Cancer Institute; Takeda Oncology; Genentech; Eli Lilly and Company","keywords":"Medicine; Docetaxel; Lung cancer; Oncology; Randomized controlled trial; Internal medicine; Cancer; Bortezomib; Clinical trial; Multiple myeloma","score_opus":0.0712764897375286,"score_gpt":0.4051115447035378,"score_spread":0.3338350549660092,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2070730813","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97269404,0.011531149,0.00038280568,0.000092412534,0.007963319,0.0051831463,0.0010238297,0.000024585484,0.0011047377],"genre_scores_gemma":[0.98322064,0.0100022275,0.00018121718,0.00023263595,0.002040448,0.0036361907,0.00014705982,0.000061053295,0.00047852637],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9956147,0.000603265,0.001917878,0.00092176045,0.00029639955,0.00064599176],"domain_scores_gemma":[0.99770314,0.00022859253,0.0009649958,0.0005416075,0.00024679693,0.0003148595],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0014573362,0.00045171875,0.0015417733,0.00008001731,0.00010592951,0.000017742783,0.00046141914,0.0005441239,0.00081686955],"category_scores_gemma":[0.0005310108,0.00040195067,0.0008013696,0.0001792285,0.00049020676,0.000012439447,0.00026398306,0.0005210218,0.0000034813447],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9790399,0.0013157056,0.0005016045,0.00017965556,0.0005600818,0.000011009805,0.00020808598,0.00008384581,0.00857735,0.000023663339,0.0011658418,0.00833325],"study_design_scores_gemma":[0.9293767,0.0028913121,0.000013986336,0.00018189757,0.0007470642,5.393046e-7,0.000028627855,0.0021585338,0.05916706,0.00001025515,0.004932637,0.00049135776],"about_ca_topic_score_codex":0.0013144319,"about_ca_topic_score_gemma":0.0010080464,"teacher_disagreement_score":0.050589714,"about_ca_system_score_codex":0.0001703634,"about_ca_system_score_gemma":0.0022430317,"threshold_uncertainty_score":0.99984324},"labels":[],"label_agreement":null},{"id":"W2074144195","doi":"10.1016/j.cllc.2011.03.013","title":"A Phase II Study of Carboplatin and Irinotecan in Extensive Stage Small-Cell Lung Cancer","year":2011,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"Pfizer","keywords":"Medicine; Carboplatin; Irinotecan; Lung cancer; Oncology; Internal medicine; Stage (stratigraphy); Cancer; Chemotherapy; Cisplatin; Colorectal cancer","score_opus":0.1242241102550383,"score_gpt":0.4814820898648671,"score_spread":0.35725797960982886,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2074144195","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9816473,0.013222438,0.0000061612022,0.00033081183,0.00037064054,0.0024705513,0.00007456598,0.00003847776,0.0018390449],"genre_scores_gemma":[0.9931305,0.00347334,0.00012743409,0.00036955604,0.00026204943,0.00059651706,0.0000027165033,0.00004674746,0.0019911153],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997142,0.00019846985,0.0009850296,0.00072316366,0.00042353375,0.0005277655],"domain_scores_gemma":[0.99814385,0.00033244066,0.00028749186,0.00054012885,0.0003718697,0.00032423402],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007112246,0.00028275425,0.0010358456,0.00017801474,0.00009568674,0.000008106694,0.00018503006,0.00015122588,0.00044039896],"category_scores_gemma":[0.00041399166,0.00023154117,0.00012094919,0.00038492476,0.00034914917,0.00007200581,0.00040938373,0.000748437,0.0000010910663],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003313905,0.0071842126,0.95801234,0.0009873284,0.0006849814,0.00028846678,0.01198954,0.000011292119,0.0007678639,0.000013983723,0.0023513595,0.014394732],"study_design_scores_gemma":[0.060726836,0.019390522,0.90311617,0.0015979214,0.0015140971,0.0000043418954,0.0060477494,0.0035640032,0.0023540277,0.00002300625,0.00097146287,0.00068984815],"about_ca_topic_score_codex":0.010841834,"about_ca_topic_score_gemma":0.011097165,"teacher_disagreement_score":0.057412934,"about_ca_system_score_codex":0.00032123114,"about_ca_system_score_gemma":0.00063614425,"threshold_uncertainty_score":0.99574506},"labels":[],"label_agreement":null},{"id":"W2074269068","doi":"10.1016/j.cllc.2013.08.001","title":"A Phase II Trial of Saracatinib, an Inhibitor of src Kinases, in Previously-Treated Advanced Non–Small-Cell Lung Cancer: The Princess Margaret Hospital Phase II Consortium","year":2013,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Montreal General Hospital; University of Toronto; University of Ottawa; McGill University; Ottawa Hospital","funders":"AstraZeneca","keywords":"Medicine; Lung cancer; Internal medicine; Proto-oncogene tyrosine-protein kinase Src; Oncology; Chemotherapy; Cancer; Kinase; Population; Receptor","score_opus":0.02339027935434116,"score_gpt":0.41810573937268414,"score_spread":0.39471546001834296,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2074269068","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.984096,0.0043504303,0.000019093672,0.0014869821,0.0011266038,0.0078368,0.00035284372,0.000050404782,0.0006808487],"genre_scores_gemma":[0.99248457,0.001916663,0.00029244556,0.0004695772,0.0006286303,0.0028999,0.00017356781,0.000062007166,0.0010726184],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99629676,0.00020236026,0.0018441353,0.00072233,0.00040600367,0.00052841153],"domain_scores_gemma":[0.9968902,0.00037915853,0.0010154359,0.0008260576,0.0005295773,0.00035959648],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00045407529,0.00039224626,0.0012097401,0.00011792184,0.00017446316,0.000020177475,0.00032841362,0.0002554953,0.00052787294],"category_scores_gemma":[0.00025738438,0.0002707911,0.0003334868,0.00048624535,0.00040617952,0.0002609597,0.00014639294,0.00048575178,0.000002413402],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08350331,0.14327239,0.37323827,0.0030252852,0.0035980355,0.0001398418,0.009950231,0.00034050463,0.010995537,0.00013389868,0.024221493,0.34758124],"study_design_scores_gemma":[0.83332485,0.07787762,0.03360411,0.0043798853,0.0073709125,0.0000061733163,0.0011843286,0.008644429,0.024871299,0.00006690912,0.007353482,0.0013159736],"about_ca_topic_score_codex":0.0027055868,"about_ca_topic_score_gemma":0.0005779318,"teacher_disagreement_score":0.74982154,"about_ca_system_score_codex":0.00037044592,"about_ca_system_score_gemma":0.0015836046,"threshold_uncertainty_score":0.9999744},"labels":[],"label_agreement":null},{"id":"W2075136921","doi":"10.1016/j.cllc.2011.03.028","title":"Clinical Outcomes of Extensive Stage Small Cell Lung Carcinoma Patients Treated With Consolidative Thoracic Radiotherapy","year":2011,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":57,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Radiation therapy; Stage (stratigraphy); Lung cancer; Lung; Radiology; Carcinoma; Oncology; Small Cell Lung Carcinoma; Internal medicine; Small-cell carcinoma","score_opus":0.09780638833724518,"score_gpt":0.4554487585161819,"score_spread":0.3576423701789367,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2075136921","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99012274,0.0029917024,0.00010699224,0.00020728631,0.00041142732,0.0021414983,0.0002062542,0.00007542071,0.0037366678],"genre_scores_gemma":[0.9895973,0.002753293,0.0016948137,0.0011911975,0.00024817445,0.00020620177,0.000029857823,0.000087141205,0.004192021],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99600947,0.0005178978,0.0014421534,0.000851321,0.0005649801,0.0006141735],"domain_scores_gemma":[0.9953498,0.0013635156,0.0006632529,0.0008167458,0.0013205638,0.00048609692],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000806184,0.0004107059,0.0017620018,0.00012755292,0.000092229435,0.000011426587,0.0002901631,0.0002667388,0.0006296216],"category_scores_gemma":[0.0006665366,0.00026713786,0.00048066754,0.0003235614,0.0012168982,0.0000988873,0.00014209068,0.0008016597,0.000009970966],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0054618237,0.0012418791,0.9827073,0.00039073313,0.0018042875,0.00009952801,0.00075947534,9.900923e-7,0.000015619667,0.000013861494,0.0038485373,0.0036559226],"study_design_scores_gemma":[0.008803625,0.003161622,0.9847345,0.00030769204,0.00085646793,0.0000012574255,0.00019858508,0.00015601679,0.0007549256,0.0000043354944,0.00072110776,0.0002998843],"about_ca_topic_score_codex":0.0007358324,"about_ca_topic_score_gemma":0.00014622667,"teacher_disagreement_score":0.0033560381,"about_ca_system_score_codex":0.00031173945,"about_ca_system_score_gemma":0.0007667902,"threshold_uncertainty_score":0.99997807},"labels":[],"label_agreement":null},{"id":"W2077739793","doi":"10.1016/j.cllc.2013.12.007","title":"Prognostic Factors in the Radical Nonsurgical Treatment of Stage IIIB Non–Small-Cell Lung Cancer","year":2014,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; McMaster University; University of Ottawa","funders":"","keywords":"Medicine; Lung cancer; Hazard ratio; Internal medicine; Stage (stratigraphy); Pleural effusion; Chemotherapy; Radiation therapy; Multivariate analysis; Surgery; Retrospective cohort study; Malignant pleural effusion; Performance status; Confidence interval","score_opus":0.044150929149990054,"score_gpt":0.39864562866470726,"score_spread":0.35449469951471724,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2077739793","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9882742,0.005285835,0.000039184753,0.0023659475,0.0007042639,0.002263982,0.00010656224,0.000034594002,0.00092541595],"genre_scores_gemma":[0.9897849,0.006303795,0.00012882138,0.0007962547,0.00060781935,0.0011683153,0.000043147855,0.00004540037,0.0011215444],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99700767,0.00030372143,0.0010267061,0.0006743848,0.0004589217,0.00052861706],"domain_scores_gemma":[0.99605954,0.0025727148,0.00028318167,0.0006612883,0.000105545,0.0003177253],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004963402,0.00037904165,0.0010861644,0.000085204534,0.00007718267,0.00003259563,0.0001962581,0.00026878528,0.00061455497],"category_scores_gemma":[0.0002152264,0.00021064571,0.0005205433,0.00029685584,0.00027947538,0.00006142768,0.000045331755,0.00035530614,0.0000070544847],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003770587,0.0030248077,0.98683953,0.00031445106,0.00033257244,0.00008112909,0.00054192485,0.00010177871,0.00001871908,0.00007883492,0.0027265574,0.0055626044],"study_design_scores_gemma":[0.009124656,0.0016161752,0.9606032,0.00070478884,0.0016042194,0.0000038217627,0.000072454364,0.0031865016,0.00043813518,0.000006060014,0.022380915,0.00025910183],"about_ca_topic_score_codex":0.0019645067,"about_ca_topic_score_gemma":0.0012721339,"teacher_disagreement_score":0.02623639,"about_ca_system_score_codex":0.0007192952,"about_ca_system_score_gemma":0.00056995853,"threshold_uncertainty_score":0.8589883},"labels":[],"label_agreement":null},{"id":"W2080543333","doi":"10.1016/s1525-7304(11)70721-5","title":"Commentary on “Effectiveness of Radiation Therapy on Non–Small-Cell Lung Cancer”","year":2001,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Lung cancer; Radiation therapy; Oncology; Medical physics; Internal medicine","score_opus":0.033461582897148894,"score_gpt":0.40922601373530704,"score_spread":0.37576443083815814,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2080543333","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9796443,0.008089515,0.000023392735,0.0064741266,0.0014814867,0.0018410626,0.00006493499,0.000041965053,0.0023391962],"genre_scores_gemma":[0.9467188,0.03936687,0.000022300963,0.011702622,0.0010438651,0.00079614855,0.00005670984,0.000045875524,0.00024678998],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981206,0.00022134789,0.00053964264,0.0005196864,0.00030339014,0.0002953186],"domain_scores_gemma":[0.99790084,0.0010865418,0.0002390928,0.00047368108,0.000098454264,0.00020137356],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000492235,0.00025990955,0.00067421026,0.000077364726,0.00007041223,0.000010882798,0.00012058914,0.00017078772,0.00047196567],"category_scores_gemma":[0.000030333382,0.00019642661,0.00031191265,0.00020895273,0.00008079716,0.00004271745,0.000024381408,0.0003208128,0.00001098569],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003982153,0.002299496,0.8839248,0.0003644613,0.0006454117,0.000031870408,0.00008738205,0.00035757638,0.00014358823,0.000024281191,0.042947333,0.065191686],"study_design_scores_gemma":[0.015537645,0.0029594388,0.9476214,0.0023817925,0.00064589584,0.0000012930933,0.000010968996,0.0010278422,0.015637925,0.000018460565,0.013897225,0.00026009174],"about_ca_topic_score_codex":0.0012478906,"about_ca_topic_score_gemma":0.00012944828,"teacher_disagreement_score":0.064931594,"about_ca_system_score_codex":0.000968761,"about_ca_system_score_gemma":0.00024963135,"threshold_uncertainty_score":0.80100447},"labels":[],"label_agreement":null},{"id":"W2084182647","doi":"10.3816/clc.2002.n.021","title":"Promising Developments in Targeted Therapies for non–small-Cell Lung Cancer","year":2002,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Lung cancer; Clinical trial; Targeted therapy; Cancer; Treatment of lung cancer; Radiation therapy; Oncology; Chemotherapy; Angiogenesis; Receptor tyrosine kinase; Bioinformatics; Cancer research; Internal medicine; Receptor; Biology","score_opus":0.053392158803135914,"score_gpt":0.4216195487616121,"score_spread":0.3682273899584762,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2084182647","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9515878,0.031371884,0.00033922642,0.004260522,0.0018897085,0.0044927816,0.00012030896,0.00010761241,0.005830134],"genre_scores_gemma":[0.9707042,0.0038958364,0.0051136795,0.0026460506,0.0006352824,0.0025349734,0.0000664499,0.00006142564,0.0143421255],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981593,0.000039504794,0.0006758286,0.00050279545,0.00017792267,0.00044463383],"domain_scores_gemma":[0.9990136,0.00021465243,0.00017077665,0.00024954244,0.00016238696,0.00018901356],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002145491,0.00023213401,0.00050636457,0.000092820505,0.00011964105,0.000029003966,0.000114342874,0.00017655907,0.00060677435],"category_scores_gemma":[0.00007715344,0.00018650418,0.0001780825,0.00025547403,0.00006604065,0.00008988166,0.000031850264,0.0002512602,0.00000443365],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000273722,0.000783571,0.92261326,0.0005146326,0.0008510476,0.000023648807,0.0023103675,0.000059473623,0.0004248338,0.000020619118,0.027785895,0.044338897],"study_design_scores_gemma":[0.03973868,0.0006822814,0.8204488,0.0030887679,0.003135343,0.0000066100606,0.00046044588,0.031926386,0.00247898,0.0000851315,0.0967133,0.0012352451],"about_ca_topic_score_codex":0.0002109056,"about_ca_topic_score_gemma":0.00037905868,"teacher_disagreement_score":0.10216446,"about_ca_system_score_codex":0.0005861658,"about_ca_system_score_gemma":0.00047973677,"threshold_uncertainty_score":0.760542},"labels":[],"label_agreement":null},{"id":"W2086142513","doi":"10.3816/clc.2001.n.018","title":"Phase I Study of the BLP25 (MUC1 Peptide) Liposomal Vaccine for Active Specific Immunotherapy in Stage IIIB/IV Non–Small-Cell Lung Cancer","year":2001,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Immunotherapy and Immune Responses","field":"Immunology and Microbiology","cited_by":162,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Alberta Cancer Foundation","funders":"","keywords":"Medicine; Immunotherapy; Vaccination; Immunogenicity; Lung cancer; Cancer vaccine; Immunology; Immune system; Peptide vaccine; Internal medicine; MUC1; Cancer; Oncology; Gastroenterology; Antibody","score_opus":0.03284774457342199,"score_gpt":0.3810141725328872,"score_spread":0.34816642795946523,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2086142513","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95276135,0.040146843,0.00008709752,0.00042455117,0.0028502184,0.0033077188,0.00015612198,0.000037777216,0.00022830523],"genre_scores_gemma":[0.9669158,0.01344023,0.000023183766,0.00050410745,0.00023058627,0.0008638757,0.000020389763,0.00008004037,0.017921785],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9962337,0.000801963,0.0014773266,0.0006894694,0.00009145979,0.0007060923],"domain_scores_gemma":[0.9969426,0.0011991579,0.00068719446,0.00092986244,0.00020635691,0.000034870525],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0008893522,0.00043298482,0.0010401342,0.00015118238,0.00029993316,0.00002294258,0.000841558,0.00045182492,0.0019599625],"category_scores_gemma":[0.000090630885,0.0003183754,0.00048575847,0.00044855976,0.00023394938,0.0001427304,0.00014682191,0.00091900944,0.000010937373],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08802296,0.018668983,0.3364715,0.0001860772,0.0034454109,0.000022530212,0.008149855,0.00023821839,0.44663262,0.00004307395,0.012379417,0.08573935],"study_design_scores_gemma":[0.15531586,0.007955039,0.4834191,0.0007862917,0.0006404183,0.000016125095,0.0044823047,0.0003099196,0.10988402,0.000026359312,0.23576413,0.0014004395],"about_ca_topic_score_codex":0.0010518113,"about_ca_topic_score_gemma":0.0009464,"teacher_disagreement_score":0.3367486,"about_ca_system_score_codex":0.00023653854,"about_ca_system_score_gemma":0.00045502264,"threshold_uncertainty_score":0.9999268},"labels":[],"label_agreement":null},{"id":"W2087317626","doi":"10.3816/clc.2007.s.004","title":"Chemotherapy and Antiangiogenic Agents in Non-Small-Cell Lung Cancer","year":2007,"lang":"en","type":"review","venue":"Clinical Lung Cancer","topic":"Angiogenesis and VEGF in Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Bevacizumab; Medicine; Angiogenesis; Lung cancer; Vascular endothelial growth factor; Cancer research; Chemotherapy; Tyrosine kinase; Cancer; Tyrosine-kinase inhibitor; Oncology; Immunology; Internal medicine; Receptor; VEGF receptors","score_opus":0.06866944912664312,"score_gpt":0.4476173586702438,"score_spread":0.3789479095436007,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2087317626","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0061565563,0.99072665,0.00009095619,0.000047365105,0.001181947,0.0011569457,0.00015487487,0.000012708762,0.000472016],"genre_scores_gemma":[0.00045163534,0.9925637,0.00013641929,0.0011511302,0.0023527332,0.00043294684,0.00013874753,0.00015619512,0.002616486],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99660814,0.00014773286,0.0012099715,0.0012116438,0.00018066826,0.00064184057],"domain_scores_gemma":[0.9984467,0.000089273184,0.0004974907,0.0006279111,0.00008431393,0.0002543119],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00068263995,0.0006208317,0.0015531275,0.00012334574,0.00006829508,0.00003766865,0.00047616588,0.0012704867,0.00028378124],"category_scores_gemma":[0.00002729349,0.0005346178,0.001027694,0.00029677898,0.00016727245,0.000004513621,0.00023232735,0.00043616386,0.000007812937],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000075404314,0.00016135225,0.03626146,0.0067566046,0.0008195667,0.000021668857,0.000019278532,0.0000055318756,0.000038088154,0.0000021132596,0.034619156,0.92121977],"study_design_scores_gemma":[0.0010504589,0.00007802996,0.002311771,0.003966827,0.0008148779,0.000004735729,0.0000040313153,0.000061021958,0.0000690645,0.0000010189007,0.99093485,0.0007033261],"about_ca_topic_score_codex":0.00016667202,"about_ca_topic_score_gemma":0.00042197458,"teacher_disagreement_score":0.9563157,"about_ca_system_score_codex":0.00015196527,"about_ca_system_score_gemma":0.0007257683,"threshold_uncertainty_score":0.99971056},"labels":[],"label_agreement":null},{"id":"W2089438932","doi":"10.3816/clc.2010.n.101","title":"A Multicenter Open-Label Study to Assess the Safety of a New Formulation of BLP25 Liposome Vaccine in Patients With Unresectable Stage III Non–Small-Cell Lung Cancer","year":2010,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Immunotherapy and Immune Responses","field":"Immunology and Microbiology","cited_by":64,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; CancerCare Manitoba; Juravinski Cancer Centre; Hôpital Notre-Dame; Alberta Cancer Foundation","funders":"Merck KGaA","keywords":"Medicine; Adverse effect; Internal medicine; Lung cancer; Vaccination; Pneumonia; Influenza vaccine; Erythema; Gastroenterology; Cancer; Stage (stratigraphy); Surgery; Oncology; Immunology","score_opus":0.03536635394876456,"score_gpt":0.3802033103895624,"score_spread":0.3448369564407978,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2089438932","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.993912,0.0013312465,0.000096848315,0.00019986878,0.0009715798,0.0033111414,0.00007465164,0.00000994282,0.00009276629],"genre_scores_gemma":[0.9938962,0.00018372317,0.00010523139,0.00031273946,0.000036891746,0.00016504548,0.000021195987,0.00003058677,0.0052483785],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99777085,0.00036930185,0.0010342661,0.0003759898,0.000088343324,0.0003612728],"domain_scores_gemma":[0.99792653,0.0006720346,0.00048253717,0.00062119734,0.00026044346,0.00003726064],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010110256,0.00022378858,0.0006744485,0.00009770752,0.00011517062,0.000021648177,0.0007547572,0.00024881688,0.00077879004],"category_scores_gemma":[0.00014064039,0.00014351512,0.0000696451,0.00032672557,0.000069589005,0.00018751418,0.00032873588,0.0008077886,0.0000042752054],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0341675,0.004132643,0.9225906,0.00006077714,0.000581496,6.7854614e-7,0.001948036,0.000098476245,0.03167344,0.000013261153,0.00071961124,0.0040134704],"study_design_scores_gemma":[0.046256922,0.0017431587,0.93810874,0.0002664872,0.00019541757,1.8558937e-7,0.0003264631,0.00014099009,0.010706077,0.0000014211502,0.0020313137,0.00022280891],"about_ca_topic_score_codex":0.005418135,"about_ca_topic_score_gemma":0.007909573,"teacher_disagreement_score":0.020967362,"about_ca_system_score_codex":0.000070032984,"about_ca_system_score_gemma":0.00048001634,"threshold_uncertainty_score":0.8527205},"labels":[],"label_agreement":null},{"id":"W2089664277","doi":"10.3816/clc.2008.n.037","title":"An International, Multicenter, Randomized Phase III Study of First-Line Erlotinib Followed by Second-Line Cisplatin/Gemcitabine Versus First-Line Cisplatin/Gemcitabine Followed by Second-Line Erlotinib in Advanced Non–Small-Cell Lung Cancer: Treatment Rationale and Protocol Dynamics of the TORCH Trial","year":2008,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Erlotinib; Gemcitabine; Medicine; Oncology; Internal medicine; Cisplatin; Erlotinib Hydrochloride; Clinical endpoint; Chemotherapy; Progression-free survival; Randomized controlled trial; Epidermal growth factor receptor; Cancer","score_opus":0.035958572531297826,"score_gpt":0.4227494391711765,"score_spread":0.3867908666398787,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2089664277","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8898669,0.00088849827,0.00025685795,0.0011141393,0.0019069589,0.1028988,0.002767869,0.00006297727,0.00023700102],"genre_scores_gemma":[0.9187296,0.0011766739,0.0005744428,0.00020721984,0.00058551255,0.07217179,0.0016057616,0.00013402152,0.004814947],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99283046,0.00045111522,0.0038551057,0.0013525995,0.00086645305,0.0006442476],"domain_scores_gemma":[0.99358565,0.0021775954,0.0019970275,0.00104358,0.0007597099,0.00043643836],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0009786066,0.0008764988,0.002820198,0.00024446938,0.00033553044,0.000039090024,0.00051767135,0.0003355536,0.0013291987],"category_scores_gemma":[0.0006455062,0.0006416494,0.00068429677,0.0006458473,0.00042030524,0.000385058,0.00016581434,0.00061033183,0.0000012895811],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8368415,0.03589637,0.10657898,0.0007270726,0.0043713115,0.000060332837,0.0032451225,0.0038618094,0.0011544791,0.000012826736,0.0032338644,0.0040162858],"study_design_scores_gemma":[0.8818885,0.010282704,0.0022044193,0.0005409341,0.0026474714,0.000004777851,0.00030495948,0.09807473,0.0010989727,0.0000057447655,0.0024084921,0.0005382663],"about_ca_topic_score_codex":0.0017519693,"about_ca_topic_score_gemma":0.024007149,"teacher_disagreement_score":0.104374565,"about_ca_system_score_codex":0.0011127407,"about_ca_system_score_gemma":0.000996462,"threshold_uncertainty_score":0.99960345},"labels":[],"label_agreement":null},{"id":"W2091582167","doi":"10.3816/clc.2003.n.024","title":"A Phase I Study of Pegylated Liposomal Doxorubicin Hydrochloride (Caelyx™) in Combination with Cyclophosphamide and Vincristine as Second-Line Treatment of Patients with Small-Cell Lung Cancer","year":2003,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Humber River Regional Hospital; Credit Valley Hospital; Mount Sinai Hospital; Toronto East General Hospital; University of Toronto; University Health Network; Essar Steel Algoma (Canada); Northeast Cancer Centre; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Doxorubicin Hydrochloride; Lung cancer; Cyclophosphamide; Vincristine; Doxorubicin; Oncology; Internal medicine; Chemotherapy","score_opus":0.028322384938492345,"score_gpt":0.390273185052095,"score_spread":0.3619508001136027,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2091582167","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99134034,0.004293891,0.0000092154305,0.00014282399,0.00013983261,0.0036014772,0.000086049135,0.0000267074,0.00035968964],"genre_scores_gemma":[0.9971901,0.0012312521,0.00010879499,0.00008193419,0.000060285525,0.0005699189,0.00003195665,0.00005411756,0.00067164603],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99711436,0.0002596403,0.0010413697,0.00060462294,0.00055791775,0.00042207414],"domain_scores_gemma":[0.9978274,0.00046234106,0.0004856495,0.000413488,0.0005616394,0.00024944215],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041059792,0.00036162316,0.0011980986,0.0001771797,0.00008241048,0.000009960253,0.000099259596,0.00011360865,0.00017400342],"category_scores_gemma":[0.00021984198,0.0002443314,0.00007643078,0.00056795776,0.00028451462,0.000086765336,0.00004970606,0.00038861195,5.516481e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013901843,0.01862331,0.961099,0.00075139373,0.0010007606,0.00006917252,0.0017513424,0.00010002672,0.00025281357,0.000008122697,0.000088985566,0.0023531846],"study_design_scores_gemma":[0.14248586,0.058073662,0.78575915,0.001124687,0.0017051158,0.0000036366825,0.0008219867,0.0006964252,0.008656423,0.000012966094,0.00026107777,0.0003990279],"about_ca_topic_score_codex":0.004280329,"about_ca_topic_score_gemma":0.00785005,"teacher_disagreement_score":0.1753399,"about_ca_system_score_codex":0.0006075745,"about_ca_system_score_gemma":0.0006872921,"threshold_uncertainty_score":0.99635446},"labels":[],"label_agreement":null},{"id":"W2095154871","doi":"10.3816/clc.2009.n.030","title":"Skeletal Disease Contributes Substantially to Morbidity and Mortality in Patients with Lung Cancer","year":2009,"lang":"en","type":"review","venue":"Clinical Lung Cancer","topic":"Bone health and treatments","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"Novartis Pharmaceuticals Corporation","keywords":"Medicine; Zoledronic acid; Lung cancer; Spinal cord compression; Oncology; Internal medicine; Cancer; Bisphosphonate; Pathologic fracture; Bone metastasis; Surgery; Metastasis; Osteoporosis","score_opus":0.062457770384616175,"score_gpt":0.476516052412353,"score_spread":0.4140582820277368,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2095154871","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.06817359,0.92559236,0.0000042062816,0.00032436833,0.00056855154,0.0043730577,0.00086389796,0.00003745595,0.00006248948],"genre_scores_gemma":[0.011027843,0.98597866,0.00003294744,0.001375499,0.00026186075,0.0006784115,0.00035169645,0.000056610457,0.000236456],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99659127,0.00021093676,0.0012955987,0.0009186486,0.00039460347,0.000588967],"domain_scores_gemma":[0.9975161,0.0002516933,0.00038716558,0.0005347483,0.00018101987,0.0011292883],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00036711758,0.00051177747,0.002773036,0.000118485936,0.00006871295,0.0000242886,0.0001190836,0.00036713926,0.00010159194],"category_scores_gemma":[0.00024154574,0.000346973,0.00031956818,0.00039192787,0.00013449184,0.00006318421,0.00005981391,0.0007275815,0.000005867313],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00046323898,0.00047576003,0.7057012,0.0069485153,0.00045912687,0.000075018026,0.000003783895,4.1545303e-7,7.859529e-10,0.000008349278,0.0014836673,0.28438094],"study_design_scores_gemma":[0.0038999794,0.00023778049,0.8239771,0.019280337,0.004826416,4.494944e-7,2.9713868e-7,0.000012309864,1.19114745e-8,0.0000055176465,0.14748378,0.00027602722],"about_ca_topic_score_codex":0.0010013247,"about_ca_topic_score_gemma":0.0026947698,"teacher_disagreement_score":0.2841049,"about_ca_system_score_codex":0.0006808076,"about_ca_system_score_gemma":0.002324338,"threshold_uncertainty_score":0.99989825},"labels":[],"label_agreement":null},{"id":"W2096532198","doi":"10.1016/j.cllc.2015.01.008","title":"miR Profiling Identifies Cyclin-Dependent Kinase 6 Downregulation as a Potential Mechanism of Acquired Cisplatin Resistance in Non–Small-Cell Lung Carcinoma","year":2015,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"MicroRNA in disease regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":27,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"Canadian Institutes of Health Research; Cancer Research Society; Lung Cancer Research Foundation","keywords":"Cyclin-dependent kinase 6; Cisplatin; Cancer research; microRNA; Cell cycle; Cell growth; Kinase; Cyclin-dependent kinase 4; Lung cancer; Downregulation and upregulation; Viability assay; Cell culture; Cyclin-dependent kinase; Medicine; Biology; Cancer; Cyclin-dependent kinase 2; Cell biology; Oncology; Internal medicine; Chemotherapy; Biochemistry; Genetics; Gene","score_opus":0.019634450979421823,"score_gpt":0.32424580204051145,"score_spread":0.3046113510610896,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2096532198","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99166125,0.0035677992,0.0028564192,0.000094989744,0.0005910167,0.0007844435,0.000046589787,0.000013673062,0.00038379515],"genre_scores_gemma":[0.99688584,0.00008250287,0.0012832796,0.00007145738,0.00039443283,0.00010346575,0.00016457339,0.000036024172,0.0009784178],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99772453,0.00020141971,0.0008927394,0.00060908904,0.0002886318,0.0002836158],"domain_scores_gemma":[0.99857837,0.000035042885,0.00043026247,0.0004991073,0.00028055452,0.0001766474],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00077222544,0.00020772878,0.0003244353,0.00007469121,0.00004350441,0.000027612612,0.00024755354,0.00034172382,0.00003138153],"category_scores_gemma":[0.0002329069,0.0002181305,0.00018216707,0.00013642208,0.000096936106,0.000014657607,0.00017403207,0.00009620345,0.0000051407656],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011748504,0.00021318943,0.0344995,0.0002821357,0.0000660387,0.000024066849,0.000100230434,0.0010327855,0.9612243,0.00014210974,0.0010280787,0.00021267122],"study_design_scores_gemma":[0.005162042,0.00018491653,0.121177524,0.0002732432,0.0002610531,0.0000034318903,0.00016141575,0.010918909,0.8599215,0.0012740674,0.00011961641,0.0005422509],"about_ca_topic_score_codex":0.00009434433,"about_ca_topic_score_gemma":0.0004012209,"teacher_disagreement_score":0.10130281,"about_ca_system_score_codex":0.000113202295,"about_ca_system_score_gemma":0.00042175245,"threshold_uncertainty_score":0.8895104},"labels":[],"label_agreement":null},{"id":"W2097438316","doi":"10.1016/j.cllc.2015.05.008","title":"Classification and Reporting of Late Radiographic Changes After Lung Stereotactic Body Radiotherapy: Proposing a New System","year":2015,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Advanced Radiotherapy Techniques","field":"Physics and Astronomy","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's College Hospital; University of Toronto; Princess Margaret Cancer Centre","funders":"University of Toronto","keywords":"Medicine; Radiation therapy; Radiography; Inter-rater reliability; Lung cancer; Radiology; Radiosurgery; Nuclear medicine; Lung; Rating scale; Oncology; Internal medicine","score_opus":0.05583796595528764,"score_gpt":0.40573532592632416,"score_spread":0.34989735997103655,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2097438316","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9035176,0.015419885,0.077423885,0.0008812855,0.00068966835,0.0012884921,0.000019610381,0.00023267936,0.00052688655],"genre_scores_gemma":[0.98880094,0.00030857694,0.009372025,0.00008593644,0.00090970565,0.00014538741,0.0000048137936,0.0000494518,0.00032317592],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979192,0.00012833084,0.0011506226,0.00039709755,0.00017426306,0.00023047428],"domain_scores_gemma":[0.9975678,0.000103742146,0.0016517319,0.00035569118,0.00012408078,0.00019700394],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00082451676,0.00018737184,0.0005641643,0.00008904186,0.00004566156,0.000039555445,0.00010959898,0.00009394394,0.000033665096],"category_scores_gemma":[0.000039396,0.00015919679,0.0001299063,0.00020894264,0.00012467812,0.00016795084,0.000027372504,0.00023307816,1.6772644e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016485437,0.000045054217,0.9734789,0.00015047392,0.00027446775,0.0000035726753,0.00031262002,0.000008647354,0.0011938971,0.0004571307,0.00064109504,0.02326928],"study_design_scores_gemma":[0.009294473,0.0013286893,0.80088973,0.0058183647,0.0014738333,0.000038224684,0.00072592706,0.1452766,0.0042699696,0.0015070203,0.026993716,0.0023834594],"about_ca_topic_score_codex":0.0001922435,"about_ca_topic_score_gemma":0.0000073331876,"teacher_disagreement_score":0.1725892,"about_ca_system_score_codex":0.00012126854,"about_ca_system_score_gemma":0.00017660826,"threshold_uncertainty_score":0.64918566},"labels":[],"label_agreement":null},{"id":"W2101035251","doi":"10.3816/clc.2006.n.022","title":"Smoking History and Epidermal Growth Factor Receptor Expression as Predictors of Survival Benefit from Erlotinib for Patients with Non–Small-Cell Lung Cancer in the National Cancer Institute of Canada Clinical Trials Group Study BR.21","year":2006,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":161,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Erlotinib; Lung cancer; Epidermal growth factor receptor; Clinical trial; Oncology; Internal medicine; Cancer; Erlotinib Hydrochloride","score_opus":0.05956746420320729,"score_gpt":0.40224162754214093,"score_spread":0.34267416333893364,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2101035251","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98682797,0.0027764188,0.00003798172,0.0003892063,0.0035916085,0.0037146965,0.0024009002,0.000013284705,0.00024790716],"genre_scores_gemma":[0.99587876,0.00039966853,0.0002159465,0.00041451197,0.0013369016,0.0010949073,0.00023627501,0.000044025517,0.00037903653],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9956407,0.00041170148,0.0021204497,0.00066291733,0.00083192106,0.00033229348],"domain_scores_gemma":[0.9948868,0.0028619329,0.0011801077,0.00025120427,0.0006370614,0.00018287155],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015202852,0.00031297738,0.0013049104,0.000086844026,0.00010385062,0.000011871885,0.00020642311,0.00020760132,0.00026306894],"category_scores_gemma":[0.0007881542,0.00020212325,0.00022246591,0.00016896617,0.00021469026,0.00014978641,0.000055459703,0.0003770262,9.396616e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021148873,0.0017037414,0.9826997,0.0001991479,0.0007707365,0.0000031457905,0.0005617815,0.0001534733,0.000053299766,0.00002048473,0.010575544,0.001144092],"study_design_scores_gemma":[0.017522853,0.0007245467,0.9758659,0.0006931812,0.0015185676,1.4034477e-7,0.00014728466,0.00020619262,0.000077657955,0.000016787397,0.003010705,0.0002161592],"about_ca_topic_score_codex":0.30543196,"about_ca_topic_score_gemma":0.33038798,"teacher_disagreement_score":0.024956014,"about_ca_system_score_codex":0.001187712,"about_ca_system_score_gemma":0.0035963673,"threshold_uncertainty_score":0.82423466},"labels":[],"label_agreement":null},{"id":"W2101440707","doi":"10.1016/j.cllc.2015.05.010","title":"A Randomized, Open-Label Phase II Trial of Volasertib as Monotherapy and in Combination With Standard-Dose Pemetrexed Compared With Pemetrexed Monotherapy in Second-Line Treatment for Non–Small-Cell Lung Cancer","year":2015,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":58,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Boehringer Ingelheim (Canada); Regional Municipality of Durham; Centre Hospitalier de l’Université de Montréal; Princess Margaret Cancer Centre; Ottawa Hospital; McGill University Health Centre; Juravinski Cancer Centre","funders":"","keywords":"Pemetrexed; Medicine; Internal medicine; Lung cancer; Oncology; Clinical endpoint; Adverse effect; Hazard ratio; Chemotherapy; Randomized controlled trial; Confidence interval; Cisplatin","score_opus":0.08825096488267198,"score_gpt":0.4698113163662173,"score_spread":0.38156035148354533,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2101440707","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9787045,0.004274023,0.00052566343,0.0013659047,0.00030097095,0.014221906,0.000279909,0.000024823736,0.00030227043],"genre_scores_gemma":[0.9850707,0.002303106,0.0027922662,0.0005311354,0.00015312707,0.00653485,0.0001636237,0.00008372777,0.0023674378],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9972593,0.00021859238,0.0011708931,0.00067342125,0.00031706408,0.00036068526],"domain_scores_gemma":[0.9976923,0.00063787034,0.0005683383,0.00037283349,0.00042720808,0.00030143504],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00095137843,0.00040409382,0.0019887858,0.00025147712,0.00008101853,0.000046784724,0.00014781853,0.00015552167,0.00012899112],"category_scores_gemma":[0.00009110441,0.0002640594,0.00012486715,0.00046652235,0.00020168695,0.00018806856,0.00003196999,0.00019721105,3.0677884e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9455742,0.011340507,0.025462702,0.00015439338,0.0014637868,0.000020637446,0.0026544088,0.00019872753,0.00011834163,0.000021403217,0.00052621786,0.012464663],"study_design_scores_gemma":[0.9473722,0.026370184,0.0007229449,0.0006465221,0.0014669122,0.000001836864,0.0002948113,0.020924488,0.0009861811,0.00006112944,0.00085447874,0.00029831112],"about_ca_topic_score_codex":0.0035480238,"about_ca_topic_score_gemma":0.012677851,"teacher_disagreement_score":0.024739757,"about_ca_system_score_codex":0.0011856154,"about_ca_system_score_gemma":0.0023277514,"threshold_uncertainty_score":0.99998116},"labels":[],"label_agreement":null},{"id":"W2105133481","doi":"10.3816/clc.2009.n.045","title":"Understanding Prognostic Gene Expression Signatures in Lung Cancer","year":2009,"lang":"en","type":"review","venue":"Clinical Lung Cancer","topic":"Gene expression and cancer classification","field":"Biochemistry, Genetics and Molecular Biology","cited_by":55,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Lung cancer; Gene expression profiling; Gene signature; Medicine; Gene expression; DNA microarray; Computational biology; Bioinformatics; Microarray; Oncology; Gene; Biology; Genetics","score_opus":0.14544177085970228,"score_gpt":0.45863562165865673,"score_spread":0.31319385079895445,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2105133481","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00009648263,0.99571127,0.0007782017,0.00011526389,0.0014034548,0.0012646054,0.00007485275,0.000029391029,0.0005264522],"genre_scores_gemma":[0.0015987818,0.99349004,0.00014731883,0.00036833354,0.0017423256,0.00091355335,0.00024122285,0.00008358071,0.0014148446],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99645686,0.00042950347,0.0011537843,0.0011959348,0.00028643289,0.0004774595],"domain_scores_gemma":[0.9982894,0.00012079008,0.0006287703,0.0006706582,0.00007412119,0.00021626151],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00046813794,0.00051580265,0.0011722096,0.00015743797,0.00009905,0.00005422267,0.00052196934,0.0012613789,0.00020313231],"category_scores_gemma":[0.00020827248,0.00041568806,0.0005691048,0.0003427788,0.000105106905,0.0000075981447,0.00016444642,0.0007913588,0.0000031275351],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022957414,0.00041951737,0.005192674,0.009754229,0.00046709357,0.000027885366,0.000041741427,0.00041106873,0.0024623848,0.00008184993,0.30050614,0.68040586],"study_design_scores_gemma":[0.00069004105,0.00009286063,0.00032079272,0.015962154,0.00056002144,0.0000018873737,0.000011918912,0.00015097618,0.00032236523,0.000031514,0.9811321,0.0007233786],"about_ca_topic_score_codex":0.000011574266,"about_ca_topic_score_gemma":0.00007075319,"teacher_disagreement_score":0.680626,"about_ca_system_score_codex":0.00041697657,"about_ca_system_score_gemma":0.0010663108,"threshold_uncertainty_score":0.9998295},"labels":[],"label_agreement":null},{"id":"W2112232053","doi":"10.3816/clc.2010.n.031","title":"Analysis of a Novel Protocol of Combined Induction Chemotherapy and Concurrent Chemoradiation in Unresected Non–Small-Cell Lung Cancer: A Ten-Year Experience With Vinblastine, Cisplatin, and Radiation Therapy","year":2010,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Medicine; Vinblastine; Lung cancer; Retrospective cohort study; Radiation therapy; Internal medicine; Oncology; Pneumonitis; Cisplatin; Univariate analysis; Cohort; Chemotherapy; Chemoradiotherapy; Proportional hazards model; Surgery; Multivariate analysis; Lung","score_opus":0.024639681763455504,"score_gpt":0.38831750593655645,"score_spread":0.36367782417310096,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2112232053","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9823649,0.00029451397,0.00006974216,0.00040583068,0.000118930555,0.016671479,0.00003327548,0.000012892716,0.000028420836],"genre_scores_gemma":[0.97637844,0.0011448977,0.00028135502,0.00011032399,0.000103429185,0.021917174,0.00002281732,0.000020021795,0.000021550995],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985056,0.000034987712,0.0006459732,0.00042593564,0.00022338178,0.00016415249],"domain_scores_gemma":[0.99873954,0.00016324237,0.0005099975,0.00023417338,0.00023078166,0.0001222352],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023467657,0.00018675072,0.00068491156,0.00019431779,0.000030230194,0.000012937027,0.000056825327,0.00015515595,0.000093520925],"category_scores_gemma":[0.000051847976,0.00013716366,0.00008270788,0.0007274484,0.00018338142,0.00008207888,0.000016974742,0.00024951965,4.1076337e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018366082,0.0010277092,0.9696133,0.0002838342,0.00059517095,9.12888e-7,0.0008515974,0.00007547381,0.0049876436,0.000010670236,0.00007742655,0.020639628],"study_design_scores_gemma":[0.021409946,0.0009075192,0.9336032,0.00028890074,0.0006301679,7.1915633e-7,0.000050573664,0.03357025,0.00932983,7.864139e-7,0.000074525575,0.00013354183],"about_ca_topic_score_codex":0.0009701904,"about_ca_topic_score_gemma":0.00094393693,"teacher_disagreement_score":0.036010083,"about_ca_system_score_codex":0.00012689446,"about_ca_system_score_gemma":0.00030213853,"threshold_uncertainty_score":0.5593372},"labels":[],"label_agreement":null},{"id":"W2120295366","doi":"10.3816/clc.2011.n.002","title":"Classification and Toxicities of Vascular Disrupting Agents","year":2011,"lang":"en","type":"review","venue":"Clinical Lung Cancer","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Nausea; Vomiting; Headaches; Adverse effect; Pharmacology; Lung cancer; Anesthesia; Oncology; Surgery","score_opus":0.2931588339410363,"score_gpt":0.555318490067568,"score_spread":0.26215965612653164,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2120295366","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00064770115,0.9958225,0.000003382405,0.000035559966,0.00072705897,0.0007818034,0.000045934165,0.000020410262,0.001915675],"genre_scores_gemma":[0.00029204114,0.9971447,0.00006587601,0.00012343099,0.0006478016,0.00020794303,0.00006760131,0.00003367608,0.0014169343],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984367,0.00013456478,0.00082583976,0.00034758466,0.00009846727,0.00015685009],"domain_scores_gemma":[0.99882287,0.00028840327,0.0004541164,0.00024786656,0.000059866685,0.0001268569],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028455432,0.00021252918,0.0015856219,0.000067183304,0.000028374874,0.0000044865888,0.00007728043,0.00032115,0.00067661644],"category_scores_gemma":[0.0000654808,0.00015500405,0.00051838835,0.00010064423,0.0001962408,0.000025428371,0.000052550397,0.00032240408,0.00000805697],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004058932,0.00016393671,0.010672512,0.014316463,0.0011912424,0.0000054254033,0.000054332515,1.5715619e-8,3.7168613e-7,0.00009049902,0.00363648,0.9698281],"study_design_scores_gemma":[0.00073728873,0.00017629734,0.00625861,0.0073889517,0.0064554457,0.0000052692913,0.000007536611,0.000016818323,4.7982746e-7,0.000009281432,0.97881186,0.00013215099],"about_ca_topic_score_codex":0.0000433632,"about_ca_topic_score_gemma":0.000009904671,"teacher_disagreement_score":0.9751754,"about_ca_system_score_codex":0.00011114702,"about_ca_system_score_gemma":0.00031809876,"threshold_uncertainty_score":0.7408476},"labels":[],"label_agreement":null},{"id":"W2126151458","doi":"10.3816/clc.2009.n.075","title":"Cooperative Group Research Efforts in Thoracic Malignancies 2009: A Review From the 10th Annual International Lung Cancer Congress","year":2009,"lang":"en","type":"review","venue":"Clinical Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Lung cancer; Mesothelioma; Clinical trial; Cancer; Oncology; Vascular endothelial growth factor; Epidermal growth factor receptor; Internal medicine; VEGF receptors; Pathology","score_opus":0.13413378968187842,"score_gpt":0.5875380266209496,"score_spread":0.45340423693907117,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2126151458","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000057937974,0.9819644,0.0000072330895,0.004325073,0.0027640553,0.0056415508,0.003428299,0.000048472866,0.0017629919],"genre_scores_gemma":[0.000044553723,0.9818386,0.00007806245,0.003844972,0.0025287643,0.004073741,0.001260847,0.00008653916,0.0062439493],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99395037,0.0011996499,0.0019690972,0.0011867139,0.0010092144,0.000684965],"domain_scores_gemma":[0.9951223,0.0021862302,0.00061598216,0.00085261685,0.0009243984,0.00029847087],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0020643284,0.0006207341,0.0028458084,0.00018643391,0.00022175164,0.00009480943,0.0006930004,0.00051391695,0.0020249253],"category_scores_gemma":[0.0009040374,0.0003617287,0.0007793186,0.0009954685,0.00046007746,0.00019752089,0.00021870085,0.0021036346,0.000044291006],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012871066,0.00033913637,0.0034581006,0.008178711,0.001891024,0.00020109561,0.00016989194,0.0000025696822,4.9431055e-8,0.00012358114,0.25221124,0.73329586],"study_design_scores_gemma":[0.00086923107,0.00012546495,0.002150752,0.19220752,0.0035873884,0.000011824616,0.0000319895,0.000038768605,1.3610182e-7,0.000015815027,0.8006617,0.00029944637],"about_ca_topic_score_codex":0.0017151298,"about_ca_topic_score_gemma":0.0026380038,"teacher_disagreement_score":0.73299646,"about_ca_system_score_codex":0.0017211677,"about_ca_system_score_gemma":0.003421418,"threshold_uncertainty_score":0.9998835},"labels":[],"label_agreement":null},{"id":"W2130931569","doi":"10.3816/clc.2010.n.016","title":"Clinical Experience of Lobectomy With Pulmonary Artery Reconstruction for Central Non–Small-Cell Lung Cancer","year":2010,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Surgery; Lung cancer; Perioperative; Pneumonectomy; Bronchopleural fistula; Intensive care unit; Survival rate; Anastomosis; Internal medicine","score_opus":0.027873045424958467,"score_gpt":0.39016898960952234,"score_spread":0.3622959441845639,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2130931569","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.989097,0.0017869503,0.00028045903,0.0010750025,0.0046670414,0.0019909577,0.00010103295,0.000053729877,0.00094780937],"genre_scores_gemma":[0.9879721,0.0030714136,0.0033251294,0.0008058462,0.0024457502,0.0015533658,0.000024830948,0.000059262,0.00074234145],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99704725,0.000060594593,0.0012238496,0.0008481322,0.00027238546,0.00054778677],"domain_scores_gemma":[0.9974625,0.0006042024,0.0004974917,0.0006238542,0.00033501792,0.00047690226],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040521496,0.0003088003,0.00093495625,0.000058564296,0.00009370585,0.000020793232,0.00018384757,0.00035861068,0.00062711985],"category_scores_gemma":[0.00010174381,0.00022554467,0.00048647303,0.000184345,0.00048830244,0.00012676757,0.00004925475,0.00064675923,0.0000030437966],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001510448,0.0009951841,0.94140834,0.00050178246,0.00041855674,0.000030138304,0.00014538702,0.000012189363,0.00040114587,0.000018447936,0.0036053488,0.05095302],"study_design_scores_gemma":[0.00903272,0.00113015,0.9711482,0.0014573315,0.0019313302,0.00005729422,0.00013481812,0.0052155727,0.0034803231,0.000019781297,0.0059554796,0.0004369895],"about_ca_topic_score_codex":0.0003624138,"about_ca_topic_score_gemma":0.0009789412,"teacher_disagreement_score":0.050516028,"about_ca_system_score_codex":0.00022651699,"about_ca_system_score_gemma":0.0010673536,"threshold_uncertainty_score":0.9197445},"labels":[],"label_agreement":null},{"id":"W2145963430","doi":"10.1016/j.cllc.2014.04.008","title":"Brain Metastases in Non–Small-Cell Lung Cancer","year":2014,"lang":"en","type":"review","venue":"Clinical Lung Cancer","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; McMaster University; CancerCare Manitoba","funders":"","keywords":"Medicine; Radiosurgery; Lung cancer; Radiation therapy; Intensive care medicine; Brain metastasis; Oncology; Stereotactic radiotherapy; Cancer; Internal medicine; Metastasis","score_opus":0.08575874932576812,"score_gpt":0.4787013213386106,"score_spread":0.3929425720128425,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2145963430","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0001486925,0.99151033,0.00007262461,0.0010478789,0.0017590444,0.0036509736,0.00062482036,0.000064199645,0.0011214437],"genre_scores_gemma":[0.000049777107,0.98495865,0.0006788155,0.0031319312,0.0020877775,0.0022910093,0.00041468427,0.00019021686,0.006197129],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9941099,0.000879672,0.002391619,0.0013768297,0.00042491002,0.000817011],"domain_scores_gemma":[0.99483913,0.0024285105,0.0008747978,0.0011518631,0.000118995,0.000586719],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00200054,0.00091315253,0.0056103296,0.00026341138,0.000071473514,0.000044907043,0.00038301203,0.00074607524,0.002134758],"category_scores_gemma":[0.000462343,0.00063936104,0.0020634658,0.0005706203,0.00017764751,0.00004878802,0.00020208595,0.001541009,0.00010154694],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007420688,0.00064970745,0.004196567,0.039770097,0.001725487,0.0003066425,0.000018791608,0.0000070180963,9.123617e-8,0.00003138106,0.09267303,0.86054695],"study_design_scores_gemma":[0.003275808,0.00024623537,0.00040956782,0.032420054,0.0132910255,0.000018259909,0.0000057428747,0.00018385849,8.4084064e-7,0.000005623975,0.9495657,0.00057728577],"about_ca_topic_score_codex":0.0007910454,"about_ca_topic_score_gemma":0.00092057907,"teacher_disagreement_score":0.8599697,"about_ca_system_score_codex":0.00077603717,"about_ca_system_score_gemma":0.0019179668,"threshold_uncertainty_score":0.9996058},"labels":[],"label_agreement":null},{"id":"W2154210596","doi":"10.3816/clc.2008.s.010","title":"Emerging Safety Data for Bevacizumab in Advanced Non–Small-Cell Lung Cancer","year":2008,"lang":"en","type":"review","venue":"Clinical Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Bevacizumab; Medicine; Internal medicine; Oncology; Adverse effect; Lung cancer; Clinical trial; Chemotherapy; Surgery","score_opus":0.10299938257047753,"score_gpt":0.523098341916035,"score_spread":0.42009895934555747,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2154210596","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00006262935,0.983171,0.00030763604,0.00047283113,0.002863341,0.007631918,0.0036785337,0.00008470341,0.0017274417],"genre_scores_gemma":[0.00002270204,0.98066413,0.0019380762,0.00057980855,0.0019146766,0.004391017,0.0036335865,0.00022989188,0.0066260933],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99437934,0.00014757112,0.0024510017,0.0018203877,0.00035844487,0.0008432763],"domain_scores_gemma":[0.99540555,0.0010454571,0.00091062876,0.0019913863,0.00023012952,0.0004168257],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00045188342,0.0008076758,0.0037142348,0.00024042359,0.00021045469,0.000029101657,0.00077631406,0.0006971532,0.00040189884],"category_scores_gemma":[0.000306487,0.0006416485,0.0009937971,0.00061802246,0.0001296289,0.00018993372,0.0003506432,0.001100068,0.000016820577],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002601313,0.0004267998,0.0028224522,0.021778256,0.0016039378,0.00008147403,0.000099003904,0.0000435824,1.5190734e-7,0.000008799098,0.035420436,0.937455],"study_design_scores_gemma":[0.006669411,0.00014551607,0.00037966238,0.027928252,0.009801282,0.000017408523,0.000023107354,0.0013319353,3.8130804e-7,0.0000033997435,0.95307237,0.00062730204],"about_ca_topic_score_codex":0.0004216387,"about_ca_topic_score_gemma":0.0010815724,"teacher_disagreement_score":0.93682766,"about_ca_system_score_codex":0.0019521138,"about_ca_system_score_gemma":0.006250614,"threshold_uncertainty_score":0.99960345},"labels":[],"label_agreement":null},{"id":"W2156364905","doi":"10.1016/j.cllc.2011.09.001","title":"Overcoming Molecular Mechanisms of Resistance to First-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors","year":2011,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Gefitinib; Erlotinib; Medicine; Epidermal growth factor receptor; Lung cancer; Tyrosine kinase; Erlotinib Hydrochloride; Cancer research; Pharmacology; Epidermal growth factor; Oncology; Cancer; Internal medicine; Receptor","score_opus":0.0489669299611967,"score_gpt":0.3717236146720273,"score_spread":0.32275668471083063,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2156364905","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9737176,0.0022631339,0.01361353,0.0039327,0.0023359046,0.0015706398,0.00024771952,0.000093399525,0.0022253757],"genre_scores_gemma":[0.9854384,0.00015825954,0.011218752,0.001471695,0.0003951747,0.00016571059,0.00004068321,0.000038841183,0.0010724493],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983759,0.000058838625,0.000669686,0.00040905908,0.00024837282,0.00023817125],"domain_scores_gemma":[0.99885947,0.00008796236,0.00019723072,0.00031614836,0.00026404022,0.00027517413],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017426746,0.00017861486,0.00041961402,0.0000757198,0.00007751701,0.0000089806945,0.00008667011,0.00013679941,0.00061302603],"category_scores_gemma":[0.00032937768,0.00015192536,0.00019586728,0.00022098611,0.00006129294,0.000096770455,0.00004118303,0.00014917519,0.000016384198],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005148459,0.0055010887,0.4204836,0.0020784677,0.0038089415,0.00032049915,0.006830343,0.00012801075,0.32081845,0.03364188,0.17858925,0.022651033],"study_design_scores_gemma":[0.0074265734,0.0016090035,0.11987379,0.001772418,0.0017843441,0.000003989485,0.00012532833,0.00038011797,0.85439515,0.00095057517,0.010889869,0.00078882097],"about_ca_topic_score_codex":0.00020832846,"about_ca_topic_score_gemma":0.00021062237,"teacher_disagreement_score":0.5335767,"about_ca_system_score_codex":0.00023923304,"about_ca_system_score_gemma":0.00021650495,"threshold_uncertainty_score":0.67122054},"labels":[],"label_agreement":null},{"id":"W2171023584","doi":"10.1016/j.cllc.2012.04.005","title":"Prophylactic Cranial Irradiation for Patients With Limited-Stage Small-Cell Lung Cancer With Response to Chemoradiation","year":2012,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; Cancer Care Ontario; University of Alberta","funders":"Saskatchewan Cancer Agency","keywords":"Conventional PCI; Prophylactic cranial irradiation; Medicine; Chemotherapy; Radiation therapy; Lung cancer; Stage (stratigraphy); Internal medicine; Surgery; Oncology; Urology; Myocardial infarction","score_opus":0.038873565552808374,"score_gpt":0.408409128966218,"score_spread":0.36953556341340965,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2171023584","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9872115,0.0016856942,0.0004942245,0.004065009,0.00071964186,0.0052938634,0.00018168181,0.000094542294,0.00025382426],"genre_scores_gemma":[0.9877816,0.0001691781,0.0017092058,0.0016700879,0.0017155465,0.0028415706,0.00005203212,0.000102973456,0.0039578127],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99724936,0.00017663221,0.0005381743,0.00058756245,0.00065485656,0.00079338683],"domain_scores_gemma":[0.99707633,0.00078698056,0.0002878519,0.00045645758,0.0007609024,0.00063145545],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00094141363,0.00031189874,0.00058851164,0.00015051088,0.00019135242,0.00004220931,0.00014783068,0.00016502474,0.00013844299],"category_scores_gemma":[0.0009991229,0.00021744428,0.00012103586,0.00048483838,0.00013009444,0.0002584253,0.0000639479,0.00041034215,0.000011876652],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04475245,0.00072282413,0.9415266,0.0010355043,0.00032535018,0.000003854045,0.00068026397,0.00014027183,0.00020181871,0.000006644031,0.006391891,0.0042125597],"study_design_scores_gemma":[0.012549261,0.0030652091,0.9670151,0.00033066169,0.00087749073,6.872544e-7,0.000052084353,0.0012491008,0.0002803257,0.000001097146,0.01419603,0.00038295102],"about_ca_topic_score_codex":0.00018507618,"about_ca_topic_score_gemma":0.00021419351,"teacher_disagreement_score":0.032203186,"about_ca_system_score_codex":0.0013094731,"about_ca_system_score_gemma":0.0010881047,"threshold_uncertainty_score":0.8867121},"labels":[],"label_agreement":null},{"id":"W2177996735","doi":"10.1016/j.cllc.2015.09.008","title":"A Phase II Trial of Erlotinib and Concurrent Palliative Thoracic Radiation for Patients With Non–Small-Cell Lung Cancer","year":2015,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Clinical Oncology Group; Hamilton Health Sciences; University of Toronto; Juravinski Hospital; McMaster University; Princess Margaret Cancer Centre; Juravinski Cancer Centre","funders":"Hamilton Health Sciences; Roche","keywords":"Medicine; Erlotinib; Lung cancer; Oncology; Internal medicine; Cancer; Radiation therapy; Epidermal growth factor receptor","score_opus":0.06595579759172852,"score_gpt":0.48889927542257866,"score_spread":0.4229434778308501,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2177996735","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9879514,0.003645355,0.0006485632,0.00054705585,0.0012890103,0.0050490918,0.0005222465,0.000023920202,0.00032337167],"genre_scores_gemma":[0.9952449,0.00072306517,0.00059381704,0.00029750727,0.0006389595,0.0015255301,0.00021199536,0.000035078865,0.0007291474],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9984852,0.000054872908,0.0005926471,0.00038936487,0.00024994323,0.00022794043],"domain_scores_gemma":[0.9982661,0.00025728415,0.00043206185,0.00018765927,0.00054753124,0.0003093891],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002456803,0.00019294657,0.00055001763,0.000052454594,0.00008355538,0.000012498358,0.00005817514,0.000116371346,0.000042602405],"category_scores_gemma":[0.00016136092,0.00013626165,0.00012002871,0.00014028496,0.00011434353,0.0000842263,0.000030020812,0.00015042302,5.8528633e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0844521,0.011763461,0.6784089,0.0009653799,0.0019845658,0.0000041012036,0.0035999974,0.000071533614,0.000018275598,0.00006412259,0.017449686,0.20121783],"study_design_scores_gemma":[0.8574388,0.0395612,0.064758256,0.0014142744,0.010467334,4.7141975e-7,0.00027715103,0.010926524,0.00045372482,0.000042650616,0.014066682,0.0005929586],"about_ca_topic_score_codex":0.0001277638,"about_ca_topic_score_gemma":0.000094802635,"teacher_disagreement_score":0.77298665,"about_ca_system_score_codex":0.00027923222,"about_ca_system_score_gemma":0.0011203948,"threshold_uncertainty_score":0.5556589},"labels":[],"label_agreement":null},{"id":"W2189143821","doi":"10.1016/j.cllc.2015.09.007","title":"Thoracic Radiotherapy for Extensive Stage Small-Cell Lung Cancer: A Meta-Analysis","year":2015,"lang":"en","type":"review","venue":"Clinical Lung Cancer","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":96,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre","funders":"","keywords":"Medicine; Radiation therapy; Stage (stratigraphy); Lung cancer; Meta-analysis; Oncology; Radiology; Internal medicine","score_opus":0.4089820723585534,"score_gpt":0.6118290681439336,"score_spread":0.20284699578538018,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2189143821","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000066134526,0.98191863,0.0007987004,0.001476558,0.0011758615,0.01055252,0.0033458043,0.00016259737,0.00056272256],"genre_scores_gemma":[0.0000020665348,0.929442,0.0016976041,0.0015968243,0.0030135612,0.014876536,0.00031397337,0.00031569062,0.048741776],"study_design_codex":"meta_analysis","study_design_gemma":"not_applicable","domain_scores_codex":[0.9909355,0.001097238,0.0029501508,0.002358385,0.0012807935,0.0013779275],"domain_scores_gemma":[0.9896223,0.0032612707,0.0017416107,0.00214643,0.002132885,0.0010954846],"candidate_categories":["metaepi_narrow","metaepi_broad","insufficient_payload"],"consensus_categories":["metaepi_narrow","metaepi_broad"],"category_scores_codex":[0.0039287778,0.0013733391,0.016817637,0.0006601655,0.00022490753,0.00011278554,0.0009109352,0.0010074243,0.0022150874],"category_scores_gemma":[0.0010048059,0.0008971493,0.01379709,0.0019698043,0.00051097677,0.00010414264,0.00033469414,0.0019874296,0.000019726076],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00049682724,0.00027260344,0.00061659823,0.05531236,0.5352566,0.00009063247,0.000109537745,0.00003472038,2.0736032e-7,0.000011842039,0.12823032,0.27956772],"study_design_scores_gemma":[0.0009835765,0.00022655558,0.00001037736,0.0012716445,0.44311044,0.0000023665684,0.000014671262,0.00039031554,5.944228e-7,0.0000035557978,0.55348766,0.0004982825],"about_ca_topic_score_codex":0.0006285594,"about_ca_topic_score_gemma":0.00063360867,"teacher_disagreement_score":0.42525733,"about_ca_system_score_codex":0.0030074345,"about_ca_system_score_gemma":0.0072137425,"threshold_uncertainty_score":0.9999017},"labels":[],"label_agreement":null},{"id":"W2205073074","doi":"10.1016/j.cllc.2015.12.009","title":"Quality of Life After Stereotactic Ablative Radiotherapy for Early-Stage Lung Cancer: A Systematic Review","year":2015,"lang":"en","type":"review","venue":"Clinical Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":65,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cancer Care Ontario","funders":"Vrije Universiteit Amsterdam; Australian Geographic Society; Varian Medical Systems","keywords":"SABR volatility model; Medicine; Lung cancer; Quality of life (healthcare); Radiation therapy; MEDLINE; Guideline; Population; Stage (stratigraphy); Radiosurgery; Intensive care medicine; Internal medicine; Pathology","score_opus":0.15507217596337428,"score_gpt":0.5402312895746902,"score_spread":0.38515911361131594,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2205073074","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000050172755,0.9759851,0.00004176573,0.00048713532,0.0012947606,0.02027905,0.0016745755,0.000055767945,0.00013164234],"genre_scores_gemma":[0.00006824842,0.965789,0.0001769277,0.0020704144,0.00093430834,0.028185375,0.00010136526,0.00018357018,0.0024907927],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9914956,0.001221532,0.004806076,0.0011365396,0.00077908434,0.0005611549],"domain_scores_gemma":[0.9905315,0.002905619,0.0035629214,0.0015252696,0.0007775782,0.00069713255],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0030051419,0.00089264143,0.012984217,0.00012269279,0.000050517396,0.000033620312,0.00036756392,0.00059981743,0.0006736242],"category_scores_gemma":[0.0012926575,0.0005743669,0.0031290618,0.00041601318,0.00019562166,0.00011018524,0.00008035085,0.0006748238,0.000010610276],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00039143936,0.00041810452,0.009668272,0.94111913,0.012692063,0.0000140164075,0.000079820944,3.0101563e-7,5.6501643e-9,0.000020518459,0.013602839,0.021993462],"study_design_scores_gemma":[0.0027462537,0.00043547933,0.00049290975,0.70394886,0.034672625,0.0000028384231,0.000004611423,0.000024984607,7.289491e-8,0.0000026447808,0.25718617,0.0004825355],"about_ca_topic_score_codex":0.0004584473,"about_ca_topic_score_gemma":0.00012674429,"teacher_disagreement_score":0.24358334,"about_ca_system_score_codex":0.0028393911,"about_ca_system_score_gemma":0.0041818265,"threshold_uncertainty_score":0.9996708},"labels":[],"label_agreement":null},{"id":"W2208411064","doi":"10.1016/j.cllc.2015.12.008","title":"Phase II Study of Concurrent Pemetrexed, Cisplatin, and Radiation Therapy for Stage IIIA/B Unresectable Non–Small Cell Lung Cancer","year":2015,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; University of Alberta; Eli Lilly (Canada); Princess Margaret Cancer Centre; Ottawa Hospital; University of Ottawa; Toronto General Hospital; University of Toronto","funders":"Eli Lilly and Company","keywords":"Pemetrexed; Medicine; Cisplatin; Lung cancer; Oncology; Radiation therapy; Stage (stratigraphy); Internal medicine; Chemotherapy; Cancer research","score_opus":0.08506446460470203,"score_gpt":0.46291401741342225,"score_spread":0.37784955280872023,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2208411064","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95827395,0.03484064,0.00009229745,0.0005524313,0.0013450644,0.004336711,0.00026665058,0.000030575837,0.00026169725],"genre_scores_gemma":[0.9855801,0.009787343,0.00010001773,0.00040364877,0.0007082349,0.0018213354,0.00005318996,0.00004761257,0.0014985392],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9977942,0.00009141919,0.000819926,0.00060834765,0.00033884955,0.00034723373],"domain_scores_gemma":[0.99795675,0.00044416066,0.0004165517,0.0003820871,0.00040215146,0.00039828088],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006346329,0.0002733765,0.0008271089,0.00008444012,0.00011114716,0.000022559654,0.00010913737,0.00013868988,0.00020765369],"category_scores_gemma":[0.00011720216,0.00020893436,0.00017134617,0.00020629319,0.00008032097,0.000088463035,0.00006963298,0.00021766245,8.4904286e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027968485,0.011023689,0.86333364,0.00052374374,0.00094293995,0.000010250302,0.0020778454,0.000119984914,0.00009870009,0.000015426249,0.03679997,0.08225698],"study_design_scores_gemma":[0.5054722,0.096014544,0.25313377,0.0017853606,0.0073972843,0.0000034027216,0.0026627046,0.047347855,0.00833514,0.000035450732,0.07635119,0.0014610875],"about_ca_topic_score_codex":0.0012717071,"about_ca_topic_score_gemma":0.00075866963,"teacher_disagreement_score":0.61019987,"about_ca_system_score_codex":0.00045232143,"about_ca_system_score_gemma":0.0007287357,"threshold_uncertainty_score":0.85200965},"labels":[],"label_agreement":null},{"id":"W2217879225","doi":"10.1016/j.cllc.2015.12.011","title":"Patients With Advanced Non–Small Cell Lung Cancer Requiring Inpatient Medical Oncology Consultation: Characteristics, Referral Patterns, and Outcomes","year":2015,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Medicine; Internal medicine; Hazard ratio; Lung cancer; Odds ratio; Proportional hazards model; Confidence interval; Multivariate analysis; Chemotherapy; Population; Performance status; Retrospective cohort study; Oncology","score_opus":0.04075793818615361,"score_gpt":0.4070222253813986,"score_spread":0.366264287195245,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2217879225","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99050915,0.001703407,0.00007519,0.0036820353,0.0019152168,0.0013605069,0.00015301665,0.000058150366,0.0005433543],"genre_scores_gemma":[0.9895492,0.0033931513,0.0005300191,0.004638936,0.0005143395,0.0007538849,0.0001607355,0.00005651757,0.00040317132],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99715143,0.00011198819,0.0009369099,0.0007104538,0.0006374042,0.00045178624],"domain_scores_gemma":[0.9973039,0.00041951393,0.0004306061,0.0003629815,0.00056047813,0.00092254096],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003707869,0.00034019735,0.0009905517,0.000062171915,0.0000816321,0.000027297232,0.00013025885,0.0002933388,0.00027942026],"category_scores_gemma":[0.00038711992,0.00023498319,0.000107986016,0.00011407777,0.0002080433,0.00011414776,0.00013143677,0.0004946474,0.0000072751072],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010626084,0.00090591627,0.9488948,0.00035059362,0.0003722374,0.00007780872,0.00049153384,0.000006840908,6.090927e-7,0.000009522836,0.003537709,0.04428981],"study_design_scores_gemma":[0.020095719,0.001681826,0.9691541,0.0012126875,0.0008414025,0.0000029466314,0.00009551779,0.00060862064,0.000026434323,0.0000025486377,0.0059781894,0.0002999857],"about_ca_topic_score_codex":0.00040721206,"about_ca_topic_score_gemma":0.0007554927,"teacher_disagreement_score":0.043989822,"about_ca_system_score_codex":0.0010780817,"about_ca_system_score_gemma":0.0013827647,"threshold_uncertainty_score":0.95823365},"labels":[],"label_agreement":null},{"id":"W2259127997","doi":"10.1016/j.cllc.2016.01.002","title":"Cetuximab Inhibits T790M-Mediated Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in a Lung Adenocarcinoma Patient-Derived Xenograft Mouse Model","year":2016,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"National Cancer Institute","keywords":"Cetuximab; T790M; Epidermal growth factor receptor; Amphiregulin; Medicine; Erlotinib; Cancer research; Lung cancer; Gefitinib; Tyrosine kinase; Pharmacology; Internal medicine; Cancer; Receptor; Colorectal cancer","score_opus":0.028141009738623202,"score_gpt":0.3555576282809079,"score_spread":0.3274166185422847,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2259127997","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97992134,0.0030867145,0.0005032387,0.011776711,0.00070376624,0.0021370156,0.0014169199,0.00018612052,0.00026819386],"genre_scores_gemma":[0.9890493,0.0006851928,0.0019554417,0.0034538785,0.00052856334,0.00083647313,0.000115167495,0.000116128926,0.00325986],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99602795,0.00017148636,0.0013869493,0.0010625654,0.0005235184,0.00082753925],"domain_scores_gemma":[0.9972815,0.0004972501,0.00030647384,0.00062196894,0.00044709299,0.0008457447],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00022378576,0.00047210619,0.0009330134,0.0002608291,0.00012454232,0.000036517016,0.00019440083,0.0003319023,0.0003621686],"category_scores_gemma":[0.0011443406,0.00033497022,0.00029592108,0.0005658604,0.00019500585,0.00031403027,0.00014391332,0.0004029409,0.000092666945],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0060785143,0.0024295843,0.78718036,0.0005845594,0.0007195442,0.00014927535,0.0021536003,0.000060586044,0.099716544,0.00014288267,0.09051852,0.010266042],"study_design_scores_gemma":[0.0968106,0.0045502377,0.5877466,0.012028889,0.002530837,0.000016368494,0.0004369566,0.004936689,0.27017033,0.00026226896,0.0161389,0.0043712975],"about_ca_topic_score_codex":0.00014780686,"about_ca_topic_score_gemma":0.00055500475,"teacher_disagreement_score":0.19943373,"about_ca_system_score_codex":0.0012601243,"about_ca_system_score_gemma":0.0009806266,"threshold_uncertainty_score":0.99991024},"labels":[],"label_agreement":null},{"id":"W2410584117","doi":"10.1016/j.cllc.2016.05.012","title":"Assessment of Referral and Chemotherapy Treatment Patterns for Elderly Patients With Non–small-Cell Lung Cancer","year":2016,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; McMaster University; CancerCare Manitoba","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Lung cancer; Internal medicine; Referral; Chemotherapy; Cancer; Population; Comorbidity; Cohort; Retrospective cohort study; Malignancy; Oncology; Family medicine","score_opus":0.03130862013876824,"score_gpt":0.4316367468939699,"score_spread":0.4003281267552017,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2410584117","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99247414,0.0006238114,0.0013913374,0.0018270153,0.0003315081,0.0023079778,0.00050748466,0.000024232799,0.000512484],"genre_scores_gemma":[0.9907318,0.002409681,0.0014305124,0.00061475066,0.00026511043,0.0012755204,0.000047477082,0.00004929858,0.0031758787],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986134,0.000025988842,0.00046103302,0.00044884364,0.00017732807,0.00027341265],"domain_scores_gemma":[0.9988143,0.00020958,0.00024229,0.00029658747,0.00023852597,0.00019874123],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008604662,0.00022667383,0.00053288584,0.00004356982,0.000061325445,0.000010922812,0.000059434988,0.0001103563,0.00024908988],"category_scores_gemma":[0.00000926836,0.00011936615,0.000146867,0.00006228871,0.00008429245,0.000064244225,0.000015619702,0.00006954647,4.209339e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004991374,0.0008017036,0.9197968,0.00022099145,0.00094287546,0.0000018196191,0.000121339064,0.000002778555,0.00006897247,0.000015014002,0.0010926817,0.076435864],"study_design_scores_gemma":[0.025850167,0.0034237115,0.96450996,0.00071329984,0.0017520847,4.2976723e-7,0.000023148315,0.00020175453,0.00033588754,0.000007312726,0.003006168,0.0001760577],"about_ca_topic_score_codex":0.00041102522,"about_ca_topic_score_gemma":0.00046458535,"teacher_disagreement_score":0.07625981,"about_ca_system_score_codex":0.0005073068,"about_ca_system_score_gemma":0.0005954219,"threshold_uncertainty_score":0.48676103},"labels":[],"label_agreement":null},{"id":"W2418663364","doi":"10.1016/j.cllc.2016.05.024","title":"Hypofractionated Intensity-Modulated Radiotherapy for Patients With Non–Small-Cell Lung Cancer","year":2016,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Center for Advancing Translational Sciences; National Institutes of Health","keywords":"Medicine; Pneumonitis; Chemoradiotherapy; Interquartile range; Radiation therapy; SABR volatility model; Lung cancer; Confidence interval; Internal medicine; Cumulative incidence; Surgery; Oncology; Lung; Cohort","score_opus":0.021455248222863172,"score_gpt":0.3656664850771735,"score_spread":0.3442112368543103,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2418663364","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98300093,0.0029419682,0.0008201242,0.007960074,0.0018253167,0.0029357353,0.00020313998,0.00011376854,0.00019892989],"genre_scores_gemma":[0.9818316,0.005664886,0.0010378226,0.0047678575,0.0010314179,0.0016784661,0.00007053786,0.00011153206,0.0038058455],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978869,0.000040428295,0.00059830357,0.00073405757,0.00028412516,0.00045620557],"domain_scores_gemma":[0.99764824,0.0005029347,0.00029216372,0.00046137726,0.0007657993,0.00032950836],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018299873,0.0003191019,0.00073819625,0.000072153074,0.00010916154,0.000020596035,0.0001189996,0.00023170156,0.00071477046],"category_scores_gemma":[0.00007729773,0.0001792782,0.00027725924,0.0001913714,0.00012638705,0.00013301538,0.000028323971,0.00020435503,0.000008933453],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034599835,0.0013072898,0.9230409,0.00018285731,0.001434955,0.000009150045,0.000037669786,0.000017815175,0.00016669225,0.0000051988463,0.044397827,0.02593963],"study_design_scores_gemma":[0.03188129,0.0017538967,0.93145615,0.0015919022,0.0017144649,0.0000018882786,0.000006604686,0.0015344376,0.001198753,0.000011876209,0.02842732,0.0004214442],"about_ca_topic_score_codex":0.00027355523,"about_ca_topic_score_gemma":0.00014390219,"teacher_disagreement_score":0.028421309,"about_ca_system_score_codex":0.0012592239,"about_ca_system_score_gemma":0.00050780305,"threshold_uncertainty_score":0.7826235},"labels":[],"label_agreement":null},{"id":"W2460186095","doi":"10.1016/j.cllc.2016.07.002","title":"Postoperative Adjuvant Systemic Therapy in Completely Resected Non–Small-Cell Lung Cancer: A Systematic Review","year":2016,"lang":"en","type":"review","venue":"Clinical Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":110,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; Windsor Regional Hospital; McMaster University; Cancer Care Ontario; Thunder Bay Regional Health Sciences Centre; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Oncology; Lung cancer; Internal medicine; Bevacizumab; Adjuvant therapy; Systematic review; Cochrane Library; Randomized controlled trial; Chemotherapy; Adjuvant; Clinical trial; Meta-analysis; MEDLINE","score_opus":0.09170367555303513,"score_gpt":0.46217389557456495,"score_spread":0.37047022002152985,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2460186095","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00013224168,0.96996313,0.0000062518257,0.0010702332,0.0016202925,0.026031427,0.0006200672,0.000104460676,0.00045189963],"genre_scores_gemma":[0.0002167218,0.96845764,0.000028677343,0.0028334262,0.00084007316,0.025155071,0.00017395985,0.00024200713,0.0020524322],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.98994297,0.0017574021,0.004867793,0.0017821693,0.0007167695,0.00093291135],"domain_scores_gemma":[0.9926024,0.002293961,0.0021283082,0.0018225688,0.0005929762,0.0005598015],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0017034312,0.0013201693,0.012924747,0.0002779834,0.00011340778,0.000057367575,0.00069258566,0.00081401883,0.0007604528],"category_scores_gemma":[0.0004315649,0.00073089567,0.0021509752,0.00083843054,0.00016985879,0.00008734057,0.00017618995,0.0013546472,0.00015020811],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000108014596,0.0005141936,0.002166101,0.89456284,0.002823582,0.00028047536,0.00006924329,4.4127262e-7,5.4653657e-7,0.000008244215,0.017757496,0.08170882],"study_design_scores_gemma":[0.0041098394,0.00061290804,0.0001290034,0.8983176,0.013603595,0.000076648896,0.00000804771,0.000036676574,0.0000012361662,8.7280955e-7,0.08237072,0.0007328818],"about_ca_topic_score_codex":0.0005594283,"about_ca_topic_score_gemma":0.00037008798,"teacher_disagreement_score":0.080975935,"about_ca_system_score_codex":0.0047394647,"about_ca_system_score_gemma":0.004296586,"threshold_uncertainty_score":0.99995494},"labels":[],"label_agreement":null},{"id":"W2461766591","doi":"10.1016/j.cllc.2016.06.007","title":"Overview of Thoracic Oncology Trials in Cooperative Groups Around the Globe","year":2016,"lang":"en","type":"review","venue":"Clinical Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"National Cancer Institute","keywords":"Medicine; Globe; Lung cancer; Oncology; Clinical Oncology; Internal medicine; Medical physics; Cancer; Ophthalmology","score_opus":0.29665332049895055,"score_gpt":0.6364577698399324,"score_spread":0.33980444934098186,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2461766591","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000029832976,0.9888542,0.000024261259,0.0017557673,0.001644941,0.0036684268,0.00043075788,0.00001736675,0.0035744286],"genre_scores_gemma":[0.00007671779,0.99333733,0.00004841517,0.000760522,0.0017510212,0.0013288979,0.00008430455,0.000046854744,0.0025659117],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9934606,0.0024585433,0.0029933914,0.00054423127,0.00024924017,0.00029397092],"domain_scores_gemma":[0.98980623,0.0077598533,0.0014734803,0.0006179892,0.00019776977,0.00014465812],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0036909368,0.0003786033,0.0057101464,0.00010192444,0.0000544083,0.000014387233,0.00025031716,0.00056570687,0.00083706895],"category_scores_gemma":[0.001984872,0.0001634887,0.0013577109,0.00043589086,0.00033665242,0.00005311433,0.00008980723,0.00062698324,0.000049036018],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016123021,0.00031453793,0.00037669484,0.0072274953,0.0019849997,0.00003095907,0.0000540862,3.848505e-7,7.525241e-8,0.0005114629,0.009415378,0.9799227],"study_design_scores_gemma":[0.0013979091,0.0003963082,0.00022008331,0.044466075,0.009158397,0.000013933667,0.000022157508,0.0000028024858,3.5412754e-7,0.000084578016,0.9440744,0.00016301985],"about_ca_topic_score_codex":0.00010506666,"about_ca_topic_score_gemma":0.00024649737,"teacher_disagreement_score":0.9797597,"about_ca_system_score_codex":0.001109216,"about_ca_system_score_gemma":0.004315387,"threshold_uncertainty_score":0.91653174},"labels":[],"label_agreement":null},{"id":"W2465405903","doi":"10.1016/j.cllc.2016.06.006","title":"Immunotherapy Comes of Age in Lung Cancer","year":2016,"lang":"en","type":"review","venue":"Clinical Lung Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":90,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Immunosurveillance; Immunotherapy; Lung cancer; Immunology; Immune system; Immune checkpoint; Cancer; Vaccine therapy; Cytotoxic T cell; Oncology; Cancer research; Internal medicine; Biology","score_opus":0.0805236080097743,"score_gpt":0.49545136780202026,"score_spread":0.41492775979224594,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2465405903","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0001850144,0.99333084,0.0000078144785,0.00044374607,0.0025644114,0.0020400432,0.00027207826,0.00004599279,0.0011100871],"genre_scores_gemma":[0.000059155325,0.9913741,0.00004610166,0.00082726957,0.0011142889,0.0007535897,0.000043242348,0.00013514134,0.005647115],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9953775,0.00033355257,0.002625263,0.0007431286,0.00039818953,0.00052236905],"domain_scores_gemma":[0.99684936,0.0009137174,0.0010619019,0.00090252387,0.000113839385,0.0001586328],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010369869,0.0005820283,0.0042771846,0.00027539095,0.000036728197,0.000015996256,0.00044864605,0.00086246827,0.0033965008],"category_scores_gemma":[0.00009960957,0.0003702657,0.0018724847,0.0005591387,0.00048494077,0.000064018896,0.00007926357,0.0008572994,0.000011968167],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009813677,0.00019471596,0.0082745515,0.017296322,0.0021101136,0.000051146828,0.000042610252,9.597017e-8,0.0000096183985,0.000016051772,0.014113381,0.95691],"study_design_scores_gemma":[0.0038358574,0.00014785724,0.0028271226,0.09228892,0.0009943012,0.0000072533508,0.000003859883,0.000003978669,0.0000035799796,0.0000068071968,0.89947224,0.00040820846],"about_ca_topic_score_codex":0.00047144183,"about_ca_topic_score_gemma":0.00036001662,"teacher_disagreement_score":0.95650184,"about_ca_system_score_codex":0.0009224263,"about_ca_system_score_gemma":0.0020616013,"threshold_uncertainty_score":0.99987495},"labels":[],"label_agreement":null},{"id":"W2475355276","doi":"10.1016/j.cllc.2016.06.009","title":"A Cost-Effectiveness Analysis of Using the JBR.10-Based 15-Gene Expression Signature to Guide Adjuvant Chemotherapy in Early Stage Non–Small-Cell Lung Cancer","year":2016,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ontario Institute for Cancer Research","funders":"National Cancer Institute; Canadian Centre for Applied Research in Cancer Control","keywords":"Medicine; Gene signature; Oncology; Lung cancer; Stage (stratigraphy); Confidence interval; Incremental cost-effectiveness ratio; Internal medicine; Quality-adjusted life year; Clinical trial; Cancer; Cost effectiveness; Gene expression; Gene; Risk analysis (engineering)","score_opus":0.05195019378897891,"score_gpt":0.4344209012641965,"score_spread":0.3824707074752176,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2475355276","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98659503,0.0049686586,0.0029688796,0.0017424979,0.00040485448,0.0028872422,0.00030714445,0.000025742083,0.00009995357],"genre_scores_gemma":[0.9935668,0.0013474112,0.00063500606,0.0018362525,0.00028592563,0.0013129952,0.000015748856,0.0000587033,0.00094114256],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971046,0.00030226135,0.0008909405,0.00080095563,0.0004392821,0.0004619853],"domain_scores_gemma":[0.9969254,0.0012593393,0.00037991695,0.0008342007,0.0003211412,0.00027999075],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0009076836,0.00034540705,0.0011945388,0.00023993119,0.00007096242,0.000019373354,0.00025820124,0.00027489025,0.0011024188],"category_scores_gemma":[0.00012513412,0.00018557992,0.0005627546,0.0009970983,0.00011952925,0.00006500062,0.00007587985,0.00027688386,0.0000031488955],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023146688,0.0007137991,0.94964546,0.00026110647,0.001379396,0.0000325991,0.0002607743,0.0059346533,0.030707885,0.0000016688218,0.0019170571,0.006830933],"study_design_scores_gemma":[0.010942283,0.00039617388,0.82210225,0.0036011531,0.003822019,2.6537194e-7,0.000031456475,0.0074563283,0.14877094,0.0000017696568,0.0025337148,0.0003416464],"about_ca_topic_score_codex":0.0027219248,"about_ca_topic_score_gemma":0.0016087418,"teacher_disagreement_score":0.12754321,"about_ca_system_score_codex":0.0014939032,"about_ca_system_score_gemma":0.00084306544,"threshold_uncertainty_score":0.9998107},"labels":[],"label_agreement":null},{"id":"W2513734563","doi":"10.1016/j.cllc.2016.07.007","title":"Phase 2 Study of Erlotinib in Combination With Linsitinib (OSI-906) or Placebo in Chemotherapy-Naive Patients With Non–Small-Cell Lung Cancer and Activating Epidermal Growth Factor Receptor Mutations","year":2016,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Cancer Centre; Princess Margaret Cancer Centre; University Health Network","funders":"National Cancer Institute; Astellas Foundation for Research on Metabolic Disorders","keywords":"Erlotinib; Medicine; Epidermal growth factor receptor; Lung cancer; Internal medicine; Erlotinib Hydrochloride; Oncology; Placebo; Adverse effect; Pharmacology; Clinical endpoint; Cancer; Randomized controlled trial; Pathology","score_opus":0.026824492551650855,"score_gpt":0.3907059977854347,"score_spread":0.3638815052337838,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2513734563","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99446595,0.00012644164,0.00013960876,0.0009092889,0.00014566748,0.0038986593,0.00015733972,0.000026830354,0.00013021554],"genre_scores_gemma":[0.9975555,0.00019216149,0.00052771467,0.00025312728,0.000092517344,0.00087459054,0.00004174056,0.000055798995,0.0004068799],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979304,0.00012842637,0.0007849442,0.00055335835,0.00029206206,0.00031078205],"domain_scores_gemma":[0.9979573,0.00083540863,0.00046598795,0.00021397183,0.00035756416,0.00016975743],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019985963,0.0002711832,0.00063966785,0.00017694615,0.00007443549,0.000015592095,0.00007868922,0.00011965424,0.0001905864],"category_scores_gemma":[0.00016522004,0.00015671793,0.000046636764,0.0004101931,0.0001328229,0.000226323,0.0000279004,0.0002606211,8.201686e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0068125995,0.006754655,0.9596654,0.00018808283,0.00038053817,0.0000134316715,0.0041124914,0.000020667778,0.00014805587,0.0000039949564,0.00010545687,0.021794615],"study_design_scores_gemma":[0.13317783,0.0049979715,0.85712117,0.0016967386,0.00042719726,8.816765e-7,0.0009629839,0.00045300377,0.0008512052,0.0000033587762,0.000038808248,0.00026886744],"about_ca_topic_score_codex":0.00089904474,"about_ca_topic_score_gemma":0.0018661055,"teacher_disagreement_score":0.12636523,"about_ca_system_score_codex":0.00043882374,"about_ca_system_score_gemma":0.00066241,"threshold_uncertainty_score":0.6390771},"labels":[],"label_agreement":null},{"id":"W2528163604","doi":"10.1016/j.cllc.2016.08.002","title":"Canadian Phase III Randomized Trial of Stereotactic Body Radiotherapy Versus Conventionally Hypofractionated Radiotherapy for Stage I, Medically Inoperable Non–Small-Cell Lung Cancer – Rationale and Protocol Design for the Ontario Clinical Oncology Group (OCOG)-LUSTRE Trial","year":2016,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Dalhousie University; NOSM University; University of British Columbia; Queen's University; Western University; McGill University Health Centre; University of Calgary; CancerCare Manitoba; Windsor Regional Hospital; Centre Hospitalier de l’Université de Montréal; Hôpital Maisonneuve-Rosemont; University of Alberta; University of Saskatchewan; Ontario Clinical Oncology Group; Saint John Regional Hospital; Hôpital Notre-Dame; McMaster University","funders":"Canadian Cancer Society Research Institute","keywords":"Medicine; Stage (stratigraphy); Lung cancer; Radiation therapy; Oncology; Randomized controlled trial; Clinical trial; Internal medicine; Radiology; Medical physics","score_opus":0.08825697473841296,"score_gpt":0.46306231462223635,"score_spread":0.37480533988382336,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2528163604","genre_codex":"protocol","genre_gemma":"protocol","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"protocol","genre_consensus":"protocol","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.16810001,0.0036990368,0.035273254,0.040275134,0.011795176,0.7395096,0.0010004949,0.000082011575,0.0002652893],"genre_scores_gemma":[0.03309916,0.007641753,0.006551718,0.004854279,0.0067722676,0.92623127,0.00017930317,0.00016944298,0.014500784],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99494696,0.00075960683,0.0024435367,0.0008504377,0.00044477027,0.0005547199],"domain_scores_gemma":[0.9783364,0.018868195,0.0011458689,0.00045795608,0.0005703536,0.00062122155],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.004789015,0.00041039073,0.002097285,0.00011587134,0.00027651666,0.00004659541,0.0002482614,0.0005592113,0.0023476735],"category_scores_gemma":[0.0010527086,0.00023494031,0.00094080134,0.00012306338,0.00052322826,0.00017445438,0.000023139753,0.00043386116,7.6155555e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9447825,0.0030622217,0.0027586145,0.00019017824,0.005691384,0.000010079841,0.00012061215,0.000021421018,0.000056035133,0.0001311742,0.022009,0.021166775],"study_design_scores_gemma":[0.8063425,0.012245128,0.00040845206,0.00027986747,0.0022747486,0.0000017866616,0.000012502162,0.004481685,0.000051593473,0.000022351813,0.17364384,0.00023555219],"about_ca_topic_score_codex":0.049340617,"about_ca_topic_score_gemma":0.148108,"teacher_disagreement_score":0.1867217,"about_ca_system_score_codex":0.0034470197,"about_ca_system_score_gemma":0.013646344,"threshold_uncertainty_score":0.9985643},"labels":[],"label_agreement":null},{"id":"W2529324715","doi":"10.1016/j.cllc.2016.09.008","title":"Drug Dose Per Kilogram Lean Body Mass Predicts Hematologic Toxicity From Carboplatin-Doublet Chemotherapy in Advanced Non–Small-Cell Lung Cancer","year":2016,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Nutrition and Health in Aging","field":"Medicine","cited_by":60,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Carboplatin; Gemcitabine; Lean body mass; Lung cancer; Pharmacokinetics; Kilogram; Vinorelbine; Internal medicine; Urology; Pemetrexed; Common Terminology Criteria for Adverse Events; Body surface area; Toxicity; Nuclear medicine; Cancer; Surgery; Chemotherapy; Body weight","score_opus":0.037191301441663764,"score_gpt":0.40611933458511923,"score_spread":0.36892803314345546,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2529324715","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.969504,0.005411099,0.00031832725,0.019717557,0.0017117559,0.0017814653,0.00012219441,0.00018299893,0.0012505781],"genre_scores_gemma":[0.9675111,0.008891774,0.0029395672,0.01625738,0.001273852,0.00058064726,0.000031565854,0.000078788966,0.002435332],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965004,0.00013900558,0.0012797789,0.0009328761,0.00036969603,0.0007782776],"domain_scores_gemma":[0.99756736,0.0007087729,0.0003713724,0.0006049382,0.00018334709,0.0005641877],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006660541,0.00037517375,0.001097553,0.0001189028,0.000102407204,0.000020970401,0.00025938684,0.00039146864,0.0024201325],"category_scores_gemma":[0.00015137185,0.00026925243,0.00025815328,0.00024899564,0.00019580581,0.00011892644,0.00006872208,0.0008232005,0.000029666899],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015162019,0.00057049433,0.96610194,0.00067948655,0.00009830575,0.000062878564,0.00024206837,0.000011508054,0.007771545,0.000030406836,0.015982252,0.006932893],"study_design_scores_gemma":[0.062800914,0.00057386304,0.87512094,0.00932457,0.00049516786,0.000009627682,0.00024318713,0.008282352,0.011958387,0.00093322084,0.028978437,0.0012793631],"about_ca_topic_score_codex":0.00079371576,"about_ca_topic_score_gemma":0.0010256888,"teacher_disagreement_score":0.09098105,"about_ca_system_score_codex":0.0006674521,"about_ca_system_score_gemma":0.000578907,"threshold_uncertainty_score":0.999976},"labels":[],"label_agreement":null},{"id":"W2529738115","doi":"10.1016/j.cllc.2016.09.002","title":"Phase 1/2 Study of the CD56-Targeting Antibody-Drug Conjugate Lorvotuzumab Mertansine (IMGN901) in Combination With Carboplatin/Etoposide in Small-Cell Lung Cancer Patients With Extensive-Stage Disease","year":2016,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":79,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre","funders":"ImmunoGen","keywords":"Carboplatin; Medicine; Etoposide; Internal medicine; Adverse effect; Phases of clinical research; Lung cancer; Gastroenterology; Chemotherapy; Surgery; Cisplatin","score_opus":0.023026111291990812,"score_gpt":0.39652066178710005,"score_spread":0.3734945504951092,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2529738115","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9902647,0.002475627,0.000027110862,0.002097404,0.00033391014,0.0045072143,0.00013546401,0.00003347002,0.00012509066],"genre_scores_gemma":[0.9975053,0.0006538969,0.00003771365,0.00037187786,0.00013023402,0.0005014447,0.000020194382,0.00007237266,0.00070695573],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99609756,0.00043422246,0.0011373189,0.00084447965,0.00085254834,0.0006338887],"domain_scores_gemma":[0.99687755,0.0007436826,0.00057710096,0.00064358866,0.0008656226,0.00029245848],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00070827716,0.00039206358,0.0009843373,0.00017249146,0.000120242265,0.000019041398,0.00028758624,0.00008296882,0.00007751091],"category_scores_gemma":[0.00069962215,0.00020162451,0.00011170338,0.0007249568,0.0004616627,0.0001843372,0.00021453876,0.0005972188,0.000001056108],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008318297,0.004881216,0.9822566,0.0005767235,0.00032465276,0.00011698734,0.0011887129,0.0002361587,0.00042436767,0.000012727487,0.0004483189,0.0012152767],"study_design_scores_gemma":[0.06630426,0.0020326956,0.9237058,0.0035197015,0.00057750754,2.9837196e-7,0.0005338217,0.0024347738,0.00044437934,0.000010578282,0.00008472146,0.00035146586],"about_ca_topic_score_codex":0.0037203794,"about_ca_topic_score_gemma":0.010729178,"teacher_disagreement_score":0.05855076,"about_ca_system_score_codex":0.00091106945,"about_ca_system_score_gemma":0.0011060124,"threshold_uncertainty_score":0.8222009},"labels":[],"label_agreement":null},{"id":"W2532575650","doi":"10.1016/j.cllc.2016.10.006","title":"Predictors and Patterns of Regional Recurrence Following Lung SBRT: A Report From the Elekta Lung Research Group","year":2016,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Lung cancer; Radiation therapy; Lung; Relative risk; Nuclear medicine; Lymph node; Radiology; Internal medicine; Confidence interval","score_opus":0.09110819974574587,"score_gpt":0.4639060050423956,"score_spread":0.37279780529664974,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2532575650","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.969496,0.014820865,0.00012865035,0.013085903,0.0011345869,0.0009088644,0.0001387585,0.00003498568,0.00025139112],"genre_scores_gemma":[0.9856113,0.011570473,0.0000912343,0.00051227614,0.0011832557,0.00034741708,0.00003558063,0.000032816333,0.00061562576],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99682444,0.00028266734,0.00088696217,0.00076969777,0.000816111,0.00042011167],"domain_scores_gemma":[0.99490637,0.0035242783,0.00026328885,0.00081017584,0.00021534752,0.00028053904],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018006583,0.00020016017,0.00056265574,0.00005171022,0.0001383296,0.000023738965,0.00022152378,0.00018200238,0.00027259148],"category_scores_gemma":[0.0007673962,0.000103595674,0.00031184917,0.00018908919,0.000320039,0.00011139747,0.00015142925,0.00042527728,0.00000400829],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026674184,0.0002046924,0.9309228,0.00009169775,0.0007479023,0.0001665495,0.00017978791,1.3885632e-7,0.000053400945,0.000095606985,0.057996143,0.009274533],"study_design_scores_gemma":[0.0028885985,0.00025922223,0.9802471,0.0043119523,0.00065499765,0.000015644933,0.00004714691,0.00009584319,0.00008874645,0.00013095941,0.0111216,0.00013818443],"about_ca_topic_score_codex":0.00096952537,"about_ca_topic_score_gemma":0.00047097926,"teacher_disagreement_score":0.049324296,"about_ca_system_score_codex":0.00050984527,"about_ca_system_score_gemma":0.00037415803,"threshold_uncertainty_score":0.4224509},"labels":[],"label_agreement":null},{"id":"W2532789950","doi":"10.1016/j.cllc.2016.10.007","title":"ALK-Rearranged Non–Small-Cell Lung Cancer Is Associated With a High Rate of Venous Thromboembolism","year":2016,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":100,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Anaplastic lymphoma kinase; Internal medicine; Hazard ratio; Lung cancer; Cohort; Retrospective cohort study; Incidence (geometry); Oncology; Cancer; ROS1; Adenocarcinoma; Confidence interval","score_opus":0.025977953688369745,"score_gpt":0.3429445641154291,"score_spread":0.31696661042705937,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2532789950","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9832453,0.0029326829,0.00014509862,0.0066958517,0.001152851,0.00166187,0.0001935768,0.00010737219,0.0038654131],"genre_scores_gemma":[0.9804498,0.008089689,0.00014024893,0.0058981776,0.00070001435,0.00045151194,0.000017471515,0.00010782448,0.0041452544],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970089,0.00016813033,0.00096077984,0.0007677396,0.0004088,0.0006856071],"domain_scores_gemma":[0.9973498,0.0005333392,0.0006093208,0.0007202332,0.00043393477,0.00035340252],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00080572034,0.00038648694,0.0018502885,0.000104561565,0.00010858912,0.0000213108,0.00028736267,0.0003182881,0.0020171679],"category_scores_gemma":[0.00019474742,0.00024337052,0.0003353927,0.00034664234,0.0002929441,0.00009842693,0.00013395322,0.00035359748,0.000029221155],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016076466,0.009061376,0.5332446,0.0018232412,0.010115889,0.0002802104,0.002021546,0.00007107101,0.010282638,0.0004223935,0.3896441,0.04142525],"study_design_scores_gemma":[0.013841587,0.0015542145,0.9572685,0.005040275,0.0056018177,0.000002179946,0.00006430896,0.00030475442,0.0057562008,0.00010314497,0.009789161,0.0006738927],"about_ca_topic_score_codex":0.0018809116,"about_ca_topic_score_gemma":0.0007269067,"teacher_disagreement_score":0.42402384,"about_ca_system_score_codex":0.0003575433,"about_ca_system_score_gemma":0.000631305,"threshold_uncertainty_score":0.9988951},"labels":[],"label_agreement":null},{"id":"W2544975051","doi":"10.1016/j.cllc.2016.10.008","title":"Radiotherapy With Curative Intent in Patients With Early-stage, Medically Inoperable, Non–Small-cell Lung Cancer: A Systematic Review","year":2016,"lang":"en","type":"review","venue":"Clinical Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Juravinski Cancer Centre; Western University; Queen's University; McMaster University; Regional Municipality of Durham; Kingston General Hospital","funders":"","keywords":"Medicine; Lung cancer; Stage (stratigraphy); Radiation therapy; Adverse effect; Cochrane Library; Radiosurgery; Oncology; Dose fractionation; Internal medicine; Radiology; Meta-analysis","score_opus":0.030766199265703335,"score_gpt":0.40516108301340653,"score_spread":0.3743948837477032,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2544975051","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00026972193,0.97757375,0.000060615173,0.0011065995,0.0005918818,0.019733528,0.00027923172,0.00006172114,0.00032293962],"genre_scores_gemma":[0.000069279144,0.9774083,0.00019911244,0.0029495403,0.0003914537,0.015853146,0.00011154768,0.0002431758,0.0027744558],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99258065,0.0007417567,0.0031631468,0.0015943907,0.0010706015,0.00084946566],"domain_scores_gemma":[0.9942393,0.0010490157,0.0019707743,0.0014103986,0.0006204143,0.0007101465],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009939108,0.0012481818,0.008959458,0.00021385183,0.000085255255,0.000055595377,0.00054770615,0.0005696693,0.0008348733],"category_scores_gemma":[0.00020420896,0.00057948614,0.00087611156,0.0007591522,0.00029365058,0.00013902044,0.00010600511,0.0013329748,0.00002860432],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004001459,0.001222523,0.093083814,0.84271026,0.0051585357,0.00016897688,0.000092633556,9.549123e-7,5.096112e-9,0.000007610999,0.0057017496,0.051452797],"study_design_scores_gemma":[0.008242086,0.0016938426,0.0019028271,0.88591486,0.016192865,0.000006170847,0.00000508315,0.000014639852,1.6460349e-7,3.1258938e-7,0.08529308,0.0007340767],"about_ca_topic_score_codex":0.0004765744,"about_ca_topic_score_gemma":0.00048663636,"teacher_disagreement_score":0.09118099,"about_ca_system_score_codex":0.0039280714,"about_ca_system_score_gemma":0.0040429235,"threshold_uncertainty_score":0.9998957},"labels":[],"label_agreement":null},{"id":"W2563765333","doi":"10.1016/j.cllc.2016.12.015","title":"Real-World EQ5D Health Utility Scores for Patients With Metastatic Lung Cancer by Molecular Alteration and Response to Therapy","year":2016,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":28,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Institut universitaire de cardiologie et de pneumologie de Québec; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Lung cancer; Oncology; Internal medicine; Intensive care medicine","score_opus":0.25702314607183996,"score_gpt":0.5266493956047145,"score_spread":0.2696262495328745,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2563765333","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90011215,0.0055078156,0.01520798,0.072756544,0.0006260102,0.0031527835,0.0025477423,0.000039210125,0.00004978615],"genre_scores_gemma":[0.95767105,0.0030368622,0.0034291071,0.032293923,0.00028759576,0.0019903993,0.00005823214,0.00007796395,0.0011548939],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99480385,0.00072397315,0.0030353335,0.00085533835,0.00011795204,0.00046356113],"domain_scores_gemma":[0.9947565,0.0027202528,0.001480562,0.00047744054,0.00015931856,0.0004058952],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.011633122,0.00022520714,0.0010257151,0.00015837804,0.00018512896,0.00006549524,0.0001763643,0.000077613644,0.0002573043],"category_scores_gemma":[0.0019514547,0.00018944166,0.000105354426,0.00017195064,0.00010719434,0.00029919704,0.000035262277,0.00011080885,0.0000197384],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020534503,0.0001989133,0.8858943,0.00026893744,0.00024863836,2.6625048e-7,0.0004180665,0.000030569194,0.000008110683,0.002628338,0.10060461,0.00764583],"study_design_scores_gemma":[0.0077231135,0.0010007315,0.91051316,0.0005957098,0.00003400743,1.8105915e-7,0.00003116286,0.0035036276,0.0000240711,0.0012179834,0.07474601,0.0006102227],"about_ca_topic_score_codex":0.0021991981,"about_ca_topic_score_gemma":0.0013533699,"teacher_disagreement_score":0.05755889,"about_ca_system_score_codex":0.00088585366,"about_ca_system_score_gemma":0.000694429,"threshold_uncertainty_score":0.7725207},"labels":[],"label_agreement":null},{"id":"W2567886556","doi":"10.1016/j.cllc.2016.12.010","title":"Evolution of Symptom Burden of Advanced Lung Cancer Over a Decade","year":2017,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Cancer survivorship and care","field":"Medicine","cited_by":97,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; Trillium Health Centre; Princess Margaret Cancer Centre; University Health Network","funders":"AstraZeneca","keywords":"Medicine; Lung cancer; Intensive care medicine; Cancer; Oncology; Internal medicine","score_opus":0.026724090379376415,"score_gpt":0.4285317237315859,"score_spread":0.4018076333522095,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2567886556","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97257346,0.019479243,0.000121067,0.0011568633,0.002673843,0.00053784915,0.00014015108,0.000034075474,0.003283444],"genre_scores_gemma":[0.9930521,0.003062213,0.00007292784,0.00020924183,0.0013351011,0.0001187343,0.000006782003,0.00003518339,0.002107669],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979849,0.000059864153,0.0007978851,0.00043053104,0.00042655095,0.0003002553],"domain_scores_gemma":[0.9975532,0.00019830723,0.0007017553,0.0009605324,0.0003771439,0.00020900315],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003825863,0.00018776013,0.0007743596,0.00006410004,0.00011018467,0.000012410468,0.00032890198,0.00026383097,0.0007807857],"category_scores_gemma":[0.00043859685,0.00016428003,0.00038586103,0.000117984055,0.0003764039,0.000148794,0.00013449938,0.00036050507,0.0000023351408],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011861663,0.00010176492,0.95972615,0.0008118362,0.00035362886,0.000006612502,0.00046638056,0.00015738743,0.0024645005,0.0003298349,0.005194359,0.029201396],"study_design_scores_gemma":[0.004276067,0.00024119653,0.9721117,0.0025588125,0.00091542484,0.0000018454542,0.00017202568,0.0034769594,0.0019216458,0.000090221445,0.013962997,0.00027113082],"about_ca_topic_score_codex":0.009996198,"about_ca_topic_score_gemma":0.0039155646,"teacher_disagreement_score":0.028930265,"about_ca_system_score_codex":0.0003841082,"about_ca_system_score_gemma":0.00073718076,"threshold_uncertainty_score":0.99659634},"labels":[],"label_agreement":null},{"id":"W2577702683","doi":"10.1016/j.cllc.2017.01.004","title":"Antiangiogenic Therapy in Advanced Non–small-cell Lung Cancer: A Meta-analysis of Phase III Randomized Trials","year":2017,"lang":"en","type":"review","venue":"Clinical Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Internal medicine; Confidence interval; Hazard ratio; Lung cancer; Odds ratio; Meta-analysis; Randomized controlled trial; Population; Relative risk; Cochrane Library; Oncology; Gastroenterology","score_opus":0.3277469335734769,"score_gpt":0.5966271301539737,"score_spread":0.26888019658049683,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2577702683","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0004240623,0.98308986,0.00013407657,0.00025733165,0.0010667681,0.012626995,0.0015895623,0.000037328966,0.0007740206],"genre_scores_gemma":[0.00069469895,0.9824112,0.00034118007,0.00030234235,0.00052255875,0.010154172,0.00063705957,0.00012532799,0.0048114653],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9891289,0.002015778,0.006398956,0.0013464348,0.000524467,0.0005854663],"domain_scores_gemma":[0.9860362,0.005365551,0.0059942235,0.001827044,0.0004079449,0.00036907897],"candidate_categories":["metaepi_narrow","metaepi_broad","insufficient_payload"],"consensus_categories":["metaepi_broad"],"category_scores_codex":[0.005962613,0.00097593106,0.03568802,0.0009075775,0.00012443251,0.000053476968,0.0005941925,0.0007565282,0.0029096175],"category_scores_gemma":[0.0012152338,0.00058091775,0.025967972,0.0011694571,0.00032457133,0.000109098124,0.00009123266,0.0007422607,0.0000055283235],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01197281,0.0010394929,0.00017533373,0.003963762,0.5216553,0.000045350127,0.00011448515,0.000033570155,0.0000011387328,0.000006139333,0.0010065767,0.459986],"study_design_scores_gemma":[0.17312315,0.00015372834,0.000014409295,0.0023031274,0.6657277,0.0000010694276,0.000005707808,0.0003182592,0.0000036531367,0.0000035240494,0.15798482,0.00036086887],"about_ca_topic_score_codex":0.0015789525,"about_ca_topic_score_gemma":0.0006633847,"teacher_disagreement_score":0.45962512,"about_ca_system_score_codex":0.0005490164,"about_ca_system_score_gemma":0.0042112665,"threshold_uncertainty_score":0.99966425},"labels":[],"label_agreement":null},{"id":"W2581722700","doi":"10.1016/j.cllc.2017.01.007","title":"A Novel Neoadjuvant Therapy for Operable Locally Invasive Non–Small-Cell Lung Cancer. Phase I Study of Neoadjuvant Stereotactic Body Radiotherapy. LINNEARRE I (NCT02433574)","year":2017,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Joseph’s Healthcare Hamilton; Ontario Clinical Oncology Group; McMaster University; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Neoadjuvant therapy; Lung cancer; Radiation therapy; Adverse effect; Radiosurgery; Radiology; Oncology; Surgery; Cancer; Internal medicine","score_opus":0.05903572179777034,"score_gpt":0.4390138701954436,"score_spread":0.37997814839767324,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2581722700","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9626744,0.021418985,0.00063329376,0.0027623477,0.0025429297,0.0092300335,0.00033825546,0.00006494442,0.0003348384],"genre_scores_gemma":[0.9639713,0.02503883,0.00092757103,0.0021476352,0.0017628147,0.004013614,0.000036423407,0.00017646143,0.0019253575],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9956051,0.000115034025,0.0015952968,0.0013270892,0.00054634537,0.0008111045],"domain_scores_gemma":[0.9947294,0.000841407,0.0012078244,0.0019451113,0.0007112075,0.00056506664],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00077116786,0.0006646392,0.0019911034,0.0001161688,0.00052415126,0.00017186988,0.00073592307,0.00033998795,0.000440589],"category_scores_gemma":[0.0002423557,0.00049982057,0.00067899044,0.00015445681,0.0002720395,0.00024667796,0.00015444726,0.0006078685,0.0000045438414],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013720721,0.03449688,0.8483483,0.001685038,0.007921797,0.0002415971,0.002708758,0.00047167347,0.004748388,0.000016264887,0.017539896,0.06810069],"study_design_scores_gemma":[0.48659626,0.05505387,0.34188038,0.008583309,0.010842011,0.000045727327,0.0012502219,0.055959083,0.015895806,0.00002406813,0.021222834,0.0026464253],"about_ca_topic_score_codex":0.004763426,"about_ca_topic_score_gemma":0.0018874208,"teacher_disagreement_score":0.5064679,"about_ca_system_score_codex":0.0009967395,"about_ca_system_score_gemma":0.0025199037,"threshold_uncertainty_score":0.99974537},"labels":[],"label_agreement":null},{"id":"W2589103622","doi":"10.1016/j.cllc.2017.02.001","title":"Immune Checkpoint Inhibitors for Patients With Advanced Non–Small-Cell Lung Cancer: A Systematic Review","year":2017,"lang":"en","type":"review","venue":"Clinical Lung Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":104,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Sunnybrook Health Science Centre; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Pembrolizumab; Atezolizumab; Pemetrexed; Nivolumab; Internal medicine; Oncology; Erlotinib; Lung cancer; Hazard ratio; Docetaxel; Adverse effect; Gefitinib; Chemotherapy; Erlotinib Hydrochloride; Epidermal growth factor receptor; Cancer; Immunotherapy; Confidence interval; Cisplatin","score_opus":0.0542220111495793,"score_gpt":0.43289833144204876,"score_spread":0.37867632029246945,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589103622","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000057136836,0.9681483,0.000024470579,0.00024145957,0.0028197628,0.027932547,0.00044487737,0.000079269485,0.00025220946],"genre_scores_gemma":[0.000014769918,0.9779879,0.0002374036,0.0008437759,0.0009459504,0.015635593,0.00036871084,0.00026935586,0.0036965543],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99257386,0.00027446967,0.0044816164,0.0012988779,0.00058856525,0.00078264205],"domain_scores_gemma":[0.9912592,0.00071549363,0.004835337,0.0021715353,0.0006386427,0.00037977833],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0017614784,0.0011131581,0.009390503,0.00014179184,0.00026414296,0.000075339885,0.0007982936,0.0007309461,0.00019732941],"category_scores_gemma":[0.0006757211,0.00069661124,0.003422855,0.00033300673,0.00026693498,0.00012658695,0.00015001792,0.0010387338,0.000013953925],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00059620023,0.00029408932,0.00042808155,0.76083905,0.0024225593,0.000008093878,0.000015280706,1.1482704e-7,3.1975316e-7,3.962924e-7,0.0041808574,0.23121499],"study_design_scores_gemma":[0.0043061655,0.00053971953,0.00007367997,0.620988,0.023069283,0.0000045233755,0.0000029566522,0.0000113534115,0.0000015532452,2.9894036e-7,0.35040778,0.0005946839],"about_ca_topic_score_codex":0.00012192029,"about_ca_topic_score_gemma":0.000058926606,"teacher_disagreement_score":0.34622693,"about_ca_system_score_codex":0.001239896,"about_ca_system_score_gemma":0.0030111996,"threshold_uncertainty_score":0.9995485},"labels":[],"label_agreement":null},{"id":"W2594378124","doi":"10.1016/j.cllc.2017.02.003","title":"Long-term Outcomes of Induction Carboplatin and Gemcitabine Followed by Concurrent Radiotherapy With Low-dose Paclitaxel and Gemcitabine for Stage III Non–small-cell Lung Cancer","year":2017,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Gemcitabine; Medicine; Carboplatin; Regimen; Lung cancer; Internal medicine; Paclitaxel; Toxicity; Chemotherapy; Oncology; Radiation therapy; Induction chemotherapy; Stage (stratigraphy); Urology; Gastroenterology; Surgery; Cisplatin","score_opus":0.034101239382636865,"score_gpt":0.4044510390594963,"score_spread":0.37034979967685944,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2594378124","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96515316,0.02742312,0.00023136084,0.0027233562,0.0010288281,0.0028991327,0.00042952647,0.000030062689,0.000081471015],"genre_scores_gemma":[0.9784958,0.016602848,0.00032663296,0.00045436277,0.00044038193,0.0010964548,0.000060137063,0.000075604694,0.0024478293],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99767137,0.000046914414,0.0007883682,0.0007861108,0.00028331,0.00042391676],"domain_scores_gemma":[0.99767554,0.00035770584,0.00072375307,0.00066283724,0.00021878451,0.00036135325],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003720137,0.00041897013,0.0012697879,0.00006349628,0.00022461245,0.00007077265,0.00015058901,0.00022811576,0.000119067365],"category_scores_gemma":[0.000076664466,0.0002944305,0.00021506322,0.00006396958,0.00041192022,0.0001646819,0.00007555012,0.00028811532,2.3810183e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001367351,0.0006444251,0.9750991,0.0013914977,0.0013882791,0.000014980272,0.00028094096,0.0000057419034,0.00072073506,0.000017307913,0.003758465,0.01531116],"study_design_scores_gemma":[0.035322737,0.0013873397,0.9568498,0.0012032541,0.0018989143,0.0000030930198,0.000033848737,0.0009607459,0.0014069853,0.0000030361607,0.00055557495,0.0003746302],"about_ca_topic_score_codex":0.0010751686,"about_ca_topic_score_gemma":0.0012626986,"teacher_disagreement_score":0.033955384,"about_ca_system_score_codex":0.00035715234,"about_ca_system_score_gemma":0.0003323954,"threshold_uncertainty_score":0.99995077},"labels":[],"label_agreement":null},{"id":"W2599098340","doi":"10.1016/j.cllc.2017.03.010","title":"LUME-Meso: Design and Rationale of the Phase III Part of a Placebo-Controlled Study of Nintedanib and Pemetrexed/Cisplatin Followed by Maintenance Nintedanib in Patients With Unresectable Malignant Pleural Mesothelioma","year":2017,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Boehringer Ingelheim (Canada)","funders":"","keywords":"Nintedanib; Pemetrexed; Medicine; Bevacizumab; Oncology; Internal medicine; Mesothelioma; Clinical endpoint; Maintenance therapy; Vascular endothelial growth factor; Carboplatin; Interim analysis; Cisplatin; Surgery; Chemotherapy; Clinical trial; Pathology; Idiopathic pulmonary fibrosis","score_opus":0.024084200424865424,"score_gpt":0.34554553585664266,"score_spread":0.32146133543177724,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2599098340","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967922,0.00043583696,0.000038596583,0.00015966028,0.00007802489,0.0022629627,0.00013833106,0.0000037336667,0.000090678855],"genre_scores_gemma":[0.99894136,0.00007273477,0.00011648745,0.000065839355,0.000020880869,0.00012704439,0.000012985581,0.000014699662,0.0006279673],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998266,0.00016170995,0.00072515185,0.00028926745,0.000405133,0.00015274185],"domain_scores_gemma":[0.9984247,0.00042154614,0.0006259051,0.00032854982,0.00010401972,0.00009527672],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00048426428,0.00015250947,0.0006742615,0.000042878037,0.00008109521,0.000010138587,0.00014454863,0.000054809076,0.00009728174],"category_scores_gemma":[0.00048827744,0.000088802924,0.00008525122,0.00007628756,0.0003970917,0.00009255688,0.00009771046,0.00011643638,1.9726579e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.049973153,0.0023870608,0.9441754,0.000078306046,0.0002906536,0.0000027694434,0.00012955119,0.00004632181,0.00071689184,0.000011838745,0.0016125329,0.0005755031],"study_design_scores_gemma":[0.101736054,0.0025650922,0.89101446,0.0005846333,0.00045224052,7.153044e-7,0.00016919899,0.002761964,0.0005628382,0.000020375363,0.000029593411,0.00010281348],"about_ca_topic_score_codex":0.00022033742,"about_ca_topic_score_gemma":0.00011686596,"teacher_disagreement_score":0.05316094,"about_ca_system_score_codex":0.000040525287,"about_ca_system_score_gemma":0.00009938017,"threshold_uncertainty_score":0.3621278},"labels":[],"label_agreement":null},{"id":"W2623774916","doi":"10.1016/j.cllc.2017.05.018","title":"The Impact of Baseline Edmonton Symptom Assessment Scale Scores on Treatment and Survival in Patients With Advanced Non–small-cell Lung Cancer","year":2017,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Medicine; Hazard ratio; Confidence interval; Internal medicine; Lung cancer; Performance status; Univariate analysis; Cancer; Oncology; Multivariate analysis","score_opus":0.020224339236493256,"score_gpt":0.4164750863310177,"score_spread":0.39625074709452446,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2623774916","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9931316,0.0025299974,0.000005705009,0.00096263026,0.00046475735,0.0018541282,0.0001557474,0.000013962566,0.00088147237],"genre_scores_gemma":[0.9878387,0.01062204,0.00011205732,0.00009183963,0.0002376058,0.0006656324,0.000027081676,0.000041750594,0.00036332113],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979659,0.00010561974,0.0006135382,0.00059175014,0.00031867312,0.0004045606],"domain_scores_gemma":[0.9975577,0.00060163584,0.00048747731,0.0008888135,0.00019935501,0.00026503336],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040213822,0.0003542543,0.00082894834,0.000047447647,0.00023626375,0.000057108526,0.00017592825,0.000116036135,0.00006797751],"category_scores_gemma":[0.00005994045,0.0001759373,0.00023699197,0.000071375114,0.00023471203,0.00008807085,0.00007251485,0.00023702403,8.770037e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002438455,0.0020154314,0.9575998,0.00010238885,0.0006104486,0.000008530019,0.000075643475,0.00031722203,0.000010212045,0.0000052211985,0.00053810445,0.036278527],"study_design_scores_gemma":[0.017395567,0.004067583,0.97434884,0.0013309951,0.00062242814,1.952813e-7,0.000016845786,0.0017476148,0.00018221898,0.0000034655334,0.00009721814,0.00018700273],"about_ca_topic_score_codex":0.005133531,"about_ca_topic_score_gemma":0.0075081126,"teacher_disagreement_score":0.036091525,"about_ca_system_score_codex":0.0015512307,"about_ca_system_score_gemma":0.0007662301,"threshold_uncertainty_score":0.7760397},"labels":[],"label_agreement":null},{"id":"W2624631663","doi":"10.1016/j.cllc.2017.05.019","title":"An Evolving Algorithm to Select and Sequence Therapies in EGFR Mutation-positive NSCLC: A Strategic Approach","year":2017,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"National Institute for Health and Care Research","keywords":"Medicine; Epidermal growth factor receptor; Gefitinib; Oncology; Lung cancer; Targeted therapy; Mutation; Internal medicine; non-small cell lung cancer (NSCLC); Erlotinib; Cancer; Gene","score_opus":0.06694516579670678,"score_gpt":0.47560684700353717,"score_spread":0.4086616812068304,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2624631663","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98316467,0.0029470432,0.001913809,0.0026386168,0.00032055288,0.0014296889,0.000094097166,0.00005846832,0.007433054],"genre_scores_gemma":[0.98764646,0.00024013399,0.010348181,0.0008041852,0.00027913292,0.00024557742,0.000034485252,0.000021300371,0.00038051512],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988101,0.00006852514,0.0003012625,0.0004452481,0.00014726099,0.0002276122],"domain_scores_gemma":[0.9990352,0.00011708318,0.00011632201,0.0003495701,0.00016081608,0.00022102559],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026053604,0.00014457901,0.0003136694,0.00005821902,0.00022472058,0.00013726289,0.00011682185,0.000096142685,0.000046822734],"category_scores_gemma":[0.00009094485,0.00011543312,0.000053262633,0.00009171492,0.00014432,0.00026508776,0.000026247695,0.00021115954,0.0000034848545],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00037505222,0.0009234591,0.62239796,0.00013538255,0.0008211541,0.00021470981,0.0058444925,0.0001480177,0.00057531154,0.00096424395,0.0005053051,0.3670949],"study_design_scores_gemma":[0.0035794973,0.00084222585,0.95554066,0.00042142518,0.00038023753,0.000026242666,0.00082410354,0.037284605,0.00007383505,0.0006645265,0.00009919753,0.00026343955],"about_ca_topic_score_codex":0.0011227386,"about_ca_topic_score_gemma":0.00039835845,"teacher_disagreement_score":0.36683148,"about_ca_system_score_codex":0.00022260418,"about_ca_system_score_gemma":0.0004169056,"threshold_uncertainty_score":0.47072262},"labels":[],"label_agreement":null},{"id":"W2658185239","doi":"10.1016/j.cllc.2017.06.002","title":"Symptom and Quality of Life Improvement in LUX-Lung 8, an Open-Label Phase III Study of Second-Line Afatinib Versus Erlotinib in Patients With Advanced Squamous Cell Carcinoma of the Lung After First-Line Platinum-Based Chemotherapy","year":2017,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; Royal Victoria Hospital; Kingston General Hospital; McGill University Health Centre; Royal Victoria Regional Health Centre","funders":"National Institute for Health and Care Research; NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research","keywords":"Afatinib; Medicine; Erlotinib; Lung cancer; Internal medicine; Discontinuation; Adverse effect; Oncology; Quality of life (healthcare); Cancer; Epidermal growth factor receptor","score_opus":0.05280740285528082,"score_gpt":0.43782188862627236,"score_spread":0.3850144857709915,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2658185239","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99408954,0.00041073532,0.000007482569,0.00016805665,0.0002840313,0.0046159523,0.0002995995,0.000006630718,0.00011797915],"genre_scores_gemma":[0.99893695,0.000021419195,0.000181871,0.00022852642,0.00005164882,0.000421403,0.00003972342,0.000037747977,0.00008067995],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972423,0.00013389671,0.0014633372,0.0005350282,0.00037411583,0.00025136943],"domain_scores_gemma":[0.9969298,0.00037947058,0.0012467479,0.0009983312,0.00028192293,0.00016369161],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005143135,0.00026312348,0.0010088513,0.00007113344,0.00008801442,0.00001818713,0.00033741127,0.000113902315,0.00011323983],"category_scores_gemma":[0.00019909053,0.00017877808,0.00006488663,0.00015159226,0.0002288584,0.00018595942,0.00013817815,0.00025821698,8.080414e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.037168127,0.015214565,0.94193727,0.00049615686,0.00016608542,0.0000027096119,0.0012564093,0.00014953697,0.00011050143,0.0000027407955,0.000024027058,0.0034718784],"study_design_scores_gemma":[0.22847022,0.008853774,0.7597796,0.00026861147,0.00030155794,2.4325052e-8,0.00022727053,0.0014168465,0.0005307451,0.0000014837818,0.000006194282,0.00014371125],"about_ca_topic_score_codex":0.0018698741,"about_ca_topic_score_gemma":0.011204849,"teacher_disagreement_score":0.19130209,"about_ca_system_score_codex":0.00019683247,"about_ca_system_score_gemma":0.0005488868,"threshold_uncertainty_score":0.72903585},"labels":[],"label_agreement":null},{"id":"W2658764594","doi":"10.1016/j.cllc.2017.06.007","title":"Radical Treatment of Stage II Non–small-cell Lung Cancer With Nonsurgical Approaches: A Multi-institution Report of Outcomes","year":2017,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; BC Cancer Agency; University of Toronto; Princess Margaret Cancer Centre; University of Ottawa","funders":"","keywords":"Medicine; Odds ratio; Lung cancer; Confidence interval; Stage (stratigraphy); Chemoradiotherapy; Internal medicine; Comorbidity; Surgery; Multivariate analysis; Radiation therapy; Performance status; Cancer","score_opus":0.11650885357204215,"score_gpt":0.43154050372874553,"score_spread":0.31503165015670337,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2658764594","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98798513,0.0042072223,0.00038931,0.0023184011,0.00073162984,0.0021172687,0.00019963397,0.00003828999,0.0020131012],"genre_scores_gemma":[0.9860549,0.004138721,0.0024919966,0.00011071904,0.00032889834,0.00096824084,0.000037217116,0.000044740988,0.005824555],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970508,0.000062195744,0.0012276575,0.00079369283,0.00046974685,0.00039588776],"domain_scores_gemma":[0.9967301,0.00021350755,0.0011068637,0.001358113,0.00020885146,0.00038254625],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037439424,0.00039113985,0.0015652028,0.00006840516,0.00025057886,0.000021372129,0.00022063189,0.0002859462,0.00023882254],"category_scores_gemma":[0.00012152959,0.00024060064,0.00058600056,0.00008693277,0.00077546027,0.00009860424,0.00010492724,0.00023530629,0.0000018494683],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011113153,0.005857798,0.9825693,0.000680407,0.0018341783,0.0005629525,0.0002728163,0.00012260211,0.000033417924,0.000064789405,0.00046004687,0.0064304247],"study_design_scores_gemma":[0.025199799,0.0022812807,0.9534915,0.0013371772,0.0040559005,0.000032844193,0.000054788165,0.003891781,0.0034953628,0.0000014705471,0.0057996917,0.0003583655],"about_ca_topic_score_codex":0.00302491,"about_ca_topic_score_gemma":0.0012650107,"teacher_disagreement_score":0.029077714,"about_ca_system_score_codex":0.00079549453,"about_ca_system_score_gemma":0.0014585848,"threshold_uncertainty_score":0.9811409},"labels":[],"label_agreement":null},{"id":"W2735559606","doi":"10.1016/j.cllc.2017.06.021","title":"Impact of Pretreatment Interstitial Lung Disease on Radiation Pneumonitis and Survival in Patients Treated With Lung Stereotactic Body Radiation Therapy (SBRT)","year":2017,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Effects of Radiation Exposure","field":"Medicine","cited_by":79,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Interstitial lung disease; Common Terminology Criteria for Adverse Events; Confidence interval; Pneumonitis; Odds ratio; Univariate analysis; Radiology; Lung; Usual interstitial pneumonia; Hazard ratio; Internal medicine; Nuclear medicine; Radiation therapy; Multivariate analysis","score_opus":0.017265483080409032,"score_gpt":0.3926696811419582,"score_spread":0.3754041980615492,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2735559606","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99687004,0.0007439087,0.000005845301,0.00032708037,0.0003181894,0.0014498144,0.000098459765,0.000025192581,0.00016145846],"genre_scores_gemma":[0.99809545,0.0012810391,0.0000059299346,0.000081270424,0.00022568162,0.00008846604,0.000120694844,0.000034156357,0.000067313296],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998379,0.00021057532,0.0004791238,0.00039453892,0.0003172666,0.00021950815],"domain_scores_gemma":[0.9982153,0.0003822716,0.0005179169,0.00047801182,0.0001284065,0.00027809278],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024513676,0.00022785323,0.0004957506,0.00012658192,0.00009183562,0.000049300586,0.000094180854,0.000104724604,0.0000655387],"category_scores_gemma":[0.0004860661,0.00016511517,0.00014194335,0.00008152797,0.00011957485,0.00027301116,0.000020144722,0.00022652163,0.0000016835775],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007158986,0.00072721223,0.96847993,0.0000804912,0.00046601376,0.0000284053,0.000090478075,0.000048012917,0.000012290432,0.0000055704545,0.00024587943,0.02265674],"study_design_scores_gemma":[0.014014077,0.0035637082,0.9740746,0.0003689118,0.00029694152,6.765468e-7,0.0000020965042,0.007480511,0.000031182015,0.0000020160714,0.00001320913,0.0001520417],"about_ca_topic_score_codex":0.00044287537,"about_ca_topic_score_gemma":0.000045952183,"teacher_disagreement_score":0.022504698,"about_ca_system_score_codex":0.00071533024,"about_ca_system_score_gemma":0.00024376626,"threshold_uncertainty_score":0.6733201},"labels":[],"label_agreement":null},{"id":"W2753686261","doi":"10.1016/j.cllc.2017.08.002","title":"Survival Impact of Cardiac Dose Following Lung Stereotactic Body Radiotherapy","year":2017,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Lung cancer; Lung; Radiation therapy; Radiosurgery; Stereotactic radiotherapy; Radiology; Internal medicine; Oncology","score_opus":0.04554200722388401,"score_gpt":0.4745003899239481,"score_spread":0.4289583827000641,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2753686261","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9784004,0.013318241,0.000007927723,0.0011899011,0.0036602374,0.0008103935,0.00006647468,0.000040316976,0.0025061239],"genre_scores_gemma":[0.990534,0.0068570566,0.000103994076,0.00017438423,0.0013362415,0.000115024755,0.000012607522,0.000054353946,0.000812326],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99797976,0.00011786425,0.00065784313,0.0004894721,0.0003711716,0.0003838727],"domain_scores_gemma":[0.99743015,0.00043665527,0.0004417986,0.0012450916,0.00011154709,0.00033478343],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006143539,0.0002641551,0.0011626877,0.000047463036,0.00017833288,0.000064346816,0.00024188285,0.00017850054,0.0004028769],"category_scores_gemma":[0.00025257736,0.00018854304,0.001565985,0.00006450292,0.00015579337,0.00016875243,0.000069045556,0.00029305328,0.0000068553904],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006070378,0.0004140109,0.9751009,0.00012941152,0.0048801475,0.00004883247,0.00006927946,0.000004509231,0.00016726399,0.000022953296,0.0078598475,0.01069586],"study_design_scores_gemma":[0.004824866,0.0006811354,0.9895881,0.0005770312,0.0015672484,0.0000017490507,0.0000065013664,0.0004050013,0.00014018464,0.000009742208,0.002006337,0.00019213276],"about_ca_topic_score_codex":0.0015566114,"about_ca_topic_score_gemma":0.000048040205,"teacher_disagreement_score":0.014487224,"about_ca_system_score_codex":0.00085394445,"about_ca_system_score_gemma":0.00061993196,"threshold_uncertainty_score":0.7688562},"labels":[],"label_agreement":null},{"id":"W2792770181","doi":"10.1016/j.cllc.2018.03.004","title":"Update on International Cooperative Groups Studies in Thoracic Malignancies: The Emergence of Immunotherapy","year":2018,"lang":"en","type":"review","venue":"Clinical Lung Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"National Cancer Institute","keywords":"Medicine; Lung cancer; Immunotherapy; Cancer immunotherapy; Oncology; Intensive care medicine; Internal medicine; Cancer","score_opus":0.18685287426036798,"score_gpt":0.5488623498999278,"score_spread":0.36200947563955976,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2792770181","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00042767182,0.99251556,0.000008111189,0.000709961,0.0044348105,0.0012720799,0.00012383382,0.000017580218,0.0004903793],"genre_scores_gemma":[0.0002158039,0.9954991,0.00003633222,0.0014995752,0.0010798662,0.00043229386,0.000040688003,0.000047472513,0.001148915],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9967079,0.00041079076,0.0017306663,0.0005349624,0.0003672724,0.0002484092],"domain_scores_gemma":[0.99748856,0.00078754104,0.0007508515,0.00060261425,0.0003248839,0.000045542118],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001514867,0.00038076346,0.0018968068,0.0001310558,0.00006379957,0.000012781332,0.00050912396,0.0002887322,0.0010944346],"category_scores_gemma":[0.00029366394,0.00020473817,0.0008091982,0.00050007633,0.00096140715,0.000050446426,0.000091609094,0.00062992936,0.00002823983],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002193952,0.0002720377,0.0005234665,0.004324885,0.004406413,0.000018733448,0.00041186347,0.0000010009122,0.000003482079,0.000107529064,0.042701665,0.945035],"study_design_scores_gemma":[0.0009058051,0.00044858936,0.00028591507,0.045765568,0.0004889493,0.000008458385,0.00014043176,0.00001191162,0.000009188912,0.000017805894,0.9516848,0.00023261654],"about_ca_topic_score_codex":0.000031958356,"about_ca_topic_score_gemma":0.00007833019,"teacher_disagreement_score":0.94480234,"about_ca_system_score_codex":0.00027323485,"about_ca_system_score_gemma":0.00063318136,"threshold_uncertainty_score":0.9998187},"labels":[],"label_agreement":null},{"id":"W2793193850","doi":"10.1016/j.cllc.2018.02.001","title":"Multidisciplinary Clinics in Lung Cancer Care: A Systematic Review","year":2018,"lang":"en","type":"review","venue":"Clinical Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Lung cancer; Multidisciplinary approach; Cochrane Library; MEDLINE; Family medicine; Cancer; Intensive care medicine; Patient satisfaction; Systematic review; Retrospective cohort study; Meta-analysis; Internal medicine; Nursing","score_opus":0.0785871536455149,"score_gpt":0.5196003194022045,"score_spread":0.44101316575668964,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2793193850","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000006581597,0.98052526,0.0000016947196,0.00043769833,0.002599363,0.014214351,0.00023962307,0.00012247359,0.0018529714],"genre_scores_gemma":[0.000007637121,0.97585785,0.00011214133,0.0012235267,0.0018540272,0.0154187335,0.00016280203,0.00033337018,0.0050299144],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9917185,0.0007847683,0.004471826,0.0016728862,0.0006082643,0.0007437585],"domain_scores_gemma":[0.9941612,0.0013078211,0.0018207367,0.0018607808,0.000301822,0.0005476572],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0013466207,0.0010293858,0.009802968,0.00022299717,0.00008537473,0.00003356094,0.00051824347,0.00095215044,0.0012166436],"category_scores_gemma":[0.00072702725,0.0006826126,0.0025612866,0.0008048904,0.00024121595,0.000067057226,0.0003188626,0.0012250738,0.0002595778],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000028265587,0.00040745907,0.00979303,0.8984348,0.002036726,0.00017538392,0.00005199413,1.7358622e-7,8.5558266e-10,0.0000089001405,0.039150726,0.049912527],"study_design_scores_gemma":[0.0011607305,0.00018029237,0.00019029484,0.6782732,0.03268469,0.000015397085,0.0000067769065,0.00003209926,2.3503299e-8,0.0000011533546,0.28699324,0.00046209982],"about_ca_topic_score_codex":0.0001719837,"about_ca_topic_score_gemma":0.0005721276,"teacher_disagreement_score":0.2478425,"about_ca_system_score_codex":0.0034503608,"about_ca_system_score_gemma":0.0030854458,"threshold_uncertainty_score":0.9996964},"labels":[],"label_agreement":null},{"id":"W2794061572","doi":"10.1016/j.cllc.2018.03.009","title":"Afatinib as First-line Treatment of Older Patients With EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Subgroup Analyses of the LUX-Lung 3, LUX-Lung 6, and LUX-Lung 7 Trials","year":2018,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":63,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Genentech; Ariad Pharmaceuticals; AstraZeneca; Eli Lilly and Company","keywords":"Afatinib; Medicine; Lung cancer; Lung; Internal medicine; Oncology; Squamous-cell carcinoma of the lung; Erlotinib; Epidermal growth factor receptor; Cancer","score_opus":0.0457708610967405,"score_gpt":0.4460203423078012,"score_spread":0.4002494812110607,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2794061572","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9768361,0.012646886,0.00051242416,0.0010218129,0.0012585281,0.005307553,0.0009424391,0.00005074289,0.0014235267],"genre_scores_gemma":[0.9911213,0.003628108,0.00059434,0.0005462612,0.0009561,0.00087094,0.00027352676,0.0001057326,0.0019037233],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99512315,0.00039080018,0.0021317832,0.0010195028,0.00073071016,0.0006040696],"domain_scores_gemma":[0.9941978,0.0016241608,0.0017228666,0.00086277723,0.0011862713,0.0004061098],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005684334,0.0006623168,0.0020035566,0.00019552521,0.00037737572,0.000049202747,0.0002541055,0.00032587777,0.0007198806],"category_scores_gemma":[0.00033118812,0.00040242999,0.0006409596,0.0006770638,0.00068299385,0.0002105765,0.0001057207,0.00029347104,0.000004173538],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024666456,0.0025143623,0.9734918,0.0008384589,0.0062861606,0.000023160206,0.0033145298,0.0003886212,0.00021383054,0.00003245663,0.0039862613,0.0064437166],"study_design_scores_gemma":[0.039647713,0.004235163,0.9013645,0.0035940348,0.02820925,0.000007891779,0.00042071153,0.010152768,0.010882813,0.000027045495,0.00071591325,0.0007422218],"about_ca_topic_score_codex":0.0045259376,"about_ca_topic_score_gemma":0.0017106838,"teacher_disagreement_score":0.07212732,"about_ca_system_score_codex":0.00096033054,"about_ca_system_score_gemma":0.0013400742,"threshold_uncertainty_score":0.99984276},"labels":[],"label_agreement":null},{"id":"W2799769189","doi":"10.1016/j.cllc.2018.04.023","title":"Quality-adjusted Outcomes Stratified by Response in Patients With Advanced Non–Small-cell Lung Cancer Receiving First-line nab-Paclitaxel/Carboplatin or Paclitaxel/Carboplatin","year":2018,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Carboplatin; Internal medicine; Lung cancer; Paclitaxel; Clinical endpoint; Gastroenterology; Oncology; Cancer; Chemotherapy; Surgery; Randomized controlled trial; Cisplatin","score_opus":0.037175147913758796,"score_gpt":0.4235430040380626,"score_spread":0.3863678561243038,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2799769189","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9882997,0.001567246,0.00017032186,0.003167452,0.0012230854,0.0036010027,0.0006950867,0.00016728882,0.0011087671],"genre_scores_gemma":[0.9849749,0.00044002527,0.0019312892,0.0021344577,0.00044214743,0.0011405018,0.00024201407,0.00016138602,0.008533237],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99411285,0.0005285372,0.002154446,0.0013991012,0.0007968841,0.0010081579],"domain_scores_gemma":[0.99445605,0.0022633255,0.00087494816,0.0010831874,0.000714743,0.0006077281],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0012106787,0.0007505388,0.0016170499,0.00022542216,0.00030808084,0.000076772725,0.00031483884,0.0004815598,0.0010433438],"category_scores_gemma":[0.0013349805,0.0005317819,0.00029746047,0.00091979734,0.00036843683,0.00030979546,0.00011806617,0.00086840906,0.000019064431],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.022011232,0.0016072802,0.959945,0.0004165802,0.0008284638,0.0000369924,0.001244007,0.00014913917,0.00024145549,0.0000075750354,0.004838886,0.008673359],"study_design_scores_gemma":[0.03068243,0.0032431458,0.9590839,0.0015803365,0.0010635651,0.0000011670086,0.0003136477,0.0011983007,0.00028564266,0.000011248949,0.0017798563,0.0007567389],"about_ca_topic_score_codex":0.001831467,"about_ca_topic_score_gemma":0.00983206,"teacher_disagreement_score":0.008671197,"about_ca_system_score_codex":0.0012927806,"about_ca_system_score_gemma":0.0017067932,"threshold_uncertainty_score":0.9998698},"labels":[],"label_agreement":null},{"id":"W2800790347","doi":"10.1016/j.cllc.2018.04.001","title":"SUNSET: Stereotactic Radiation for Ultracentral Non–Small-Cell Lung Cancer—A Safety and Efficacy Trial","year":2018,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":109,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; Hôpital Notre-Dame; Cancer Care Ontario; Centre Hospitalier de l’Université de Montréal; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Lung cancer; Esophagus; Radiology; Mediastinum; Esophageal cancer; Radiation therapy; Stage (stratigraphy); Surgery; Oncology; Cancer; Internal medicine","score_opus":0.035272580195626346,"score_gpt":0.40953002950950756,"score_spread":0.3742574493138812,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2800790347","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97525454,0.008945896,0.0002645562,0.0049482347,0.0045295064,0.005113123,0.00020614505,0.00007230901,0.0006657013],"genre_scores_gemma":[0.97324646,0.01386387,0.00029685642,0.0021003818,0.007837103,0.00086345855,0.00007501098,0.00006832461,0.0016485491],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99764353,0.00008391594,0.00082682027,0.0007123703,0.00022390598,0.00050945877],"domain_scores_gemma":[0.9977003,0.0009859592,0.00031436447,0.00039178462,0.00019584599,0.0004117886],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047196515,0.00028574787,0.00072309276,0.00005260412,0.00018915973,0.000050485927,0.000104234445,0.00024284619,0.0004325983],"category_scores_gemma":[0.00021098008,0.00022906628,0.00030267084,0.00014374407,0.00017574655,0.0000934569,0.000033667857,0.00025833043,0.0000093914605],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09291908,0.0020625335,0.7354602,0.00094712176,0.0016423016,0.000019213716,0.0006515037,0.00001910177,0.00007918249,0.00006872301,0.060018253,0.106112756],"study_design_scores_gemma":[0.32126278,0.0062983977,0.555155,0.0012973476,0.006759923,0.000007410323,0.000044201242,0.008190831,0.0017961522,0.000018642055,0.09842759,0.00074175774],"about_ca_topic_score_codex":0.0003367142,"about_ca_topic_score_gemma":0.00039420652,"teacher_disagreement_score":0.22834368,"about_ca_system_score_codex":0.000692989,"about_ca_system_score_gemma":0.0006641813,"threshold_uncertainty_score":0.93410516},"labels":[],"label_agreement":null},{"id":"W2802496191","doi":"10.1016/j.cllc.2018.04.008","title":"Correlation of Neutrophil to Lymphocyte Ratio and Absolute Neutrophil Count With Outcomes With PD-1 Axis Inhibitors in Patients With Advanced Non–Small-Cell Lung Cancer","year":2018,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Inflammatory Biomarkers in Disease Prognosis","field":"Medicine","cited_by":144,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Lung Cancer Canada","keywords":"Medicine; Internal medicine; Lung cancer; Neutrophil to lymphocyte ratio; Absolute neutrophil count; Lymphocyte; Cancer; Oncology; Gastroenterology; Immunology; Chemotherapy; Neutropenia","score_opus":0.008905247391622071,"score_gpt":0.30355450861337774,"score_spread":0.29464926122175567,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2802496191","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9953576,0.0007135556,0.00015282816,0.00046198932,0.0004753573,0.0024992463,0.00006398765,0.00004472607,0.00023076124],"genre_scores_gemma":[0.99634093,0.00019484846,0.0013382668,0.0011271391,0.00025402755,0.00047878356,0.000022924763,0.00008145885,0.00016162136],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99732095,0.0000786257,0.0008803457,0.00073946855,0.0005380722,0.00044252173],"domain_scores_gemma":[0.99774957,0.00016016299,0.00048807205,0.00050888926,0.0007159436,0.00037734624],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002639655,0.00038822222,0.0008064623,0.00017165826,0.00009754044,0.00002396203,0.00014093476,0.00018824452,0.000069823174],"category_scores_gemma":[0.000060757713,0.000265026,0.0000817258,0.0004855152,0.00047004913,0.00019489341,0.000085475294,0.00026753184,0.0000035576095],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015404255,0.00034119352,0.97929174,0.00038939112,0.00031453976,0.00002427786,0.00030207515,0.0006267132,0.000056753404,0.0000045922875,0.00053531746,0.0027091305],"study_design_scores_gemma":[0.015445085,0.0021023052,0.976375,0.0016327135,0.0006847275,0.0000014198431,0.00004234914,0.002791818,0.00032252207,0.0000013233455,0.00023162185,0.0003691138],"about_ca_topic_score_codex":0.00025470648,"about_ca_topic_score_gemma":0.0010017816,"teacher_disagreement_score":0.002916761,"about_ca_system_score_codex":0.00054668315,"about_ca_system_score_gemma":0.0008907194,"threshold_uncertainty_score":0.9999802},"labels":[],"label_agreement":null},{"id":"W2804492207","doi":"10.1016/j.cllc.2018.05.002","title":"Rationale and Protocol for a Canadian Multicenter Phase II Randomized Trial Assessing Selective Metabolically Adaptive Radiation Dose Escalation in Locally Advanced Non–small-cell Lung Cancer (NCT02788461)","year":2018,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Cancer Care Ontario; Princess Margaret Cancer Centre; BC Cancer Agency; University of Toronto","funders":"","keywords":"Medicine; Lung cancer; Randomized controlled trial; Radiation therapy; Oncology; Population; Internal medicine; Nuclear medicine","score_opus":0.038362843716046424,"score_gpt":0.44552593973049626,"score_spread":0.40716309601444983,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2804492207","genre_codex":"protocol","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"protocol","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.4732382,0.0009912013,0.004430083,0.0050689518,0.0013588005,0.5135993,0.000234695,0.000071803726,0.0010070187],"genre_scores_gemma":[0.5012233,0.000154648,0.0032440564,0.0017439722,0.001577419,0.4915773,0.00006931248,0.000052439107,0.00035750467],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9969117,0.00029873697,0.0011790593,0.0008252296,0.0002745221,0.0005107626],"domain_scores_gemma":[0.9971324,0.00099776,0.00048242687,0.00024038018,0.0006771967,0.00046980256],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011039182,0.00034741903,0.0011418179,0.00019700016,0.00029169652,0.000072142975,0.0000887634,0.00027906892,0.00019485083],"category_scores_gemma":[0.0005878383,0.00027812668,0.00029833114,0.00030477054,0.00022010655,0.00029801906,0.000036490677,0.00032423213,0.0000017744595],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.88899374,0.002447056,0.026889922,0.00030531923,0.00082499476,0.000009593658,0.0008647572,0.00016340184,0.000118676726,0.00007887207,0.004061251,0.0752424],"study_design_scores_gemma":[0.8675656,0.0026148953,0.013302258,0.0008079436,0.0011874521,7.6392183e-7,0.000031545023,0.108750686,0.00064764376,0.000045531244,0.004734763,0.00031092824],"about_ca_topic_score_codex":0.008685909,"about_ca_topic_score_gemma":0.055294666,"teacher_disagreement_score":0.10858729,"about_ca_system_score_codex":0.0015361396,"about_ca_system_score_gemma":0.0033079467,"threshold_uncertainty_score":0.9999671},"labels":[],"label_agreement":null},{"id":"W2809572377","doi":"10.1016/j.cllc.2018.06.001","title":"Ultracentral Tumors Treated With Stereotactic Body Radiotherapy: Single-Institution Experience","year":2018,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Lung cancer; Lung; Radiosurgery; Radiation therapy; Cohort; Toxicity; Esophagus; Internal medicine; Radiology","score_opus":0.035240322004458244,"score_gpt":0.3937644911359875,"score_spread":0.35852416913152924,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2809572377","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99366415,0.001499342,0.00012308659,0.0012825859,0.00057661714,0.0007286304,0.000011934475,0.00012590036,0.0019877288],"genre_scores_gemma":[0.995015,0.000743679,0.00032035122,0.0015716648,0.0013424587,0.0002026381,0.000012160105,0.0000342798,0.0007577684],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983013,0.000059178383,0.00044455624,0.0005423058,0.0002720172,0.00038059495],"domain_scores_gemma":[0.99884874,0.00011449479,0.00015918778,0.00041074856,0.0001602359,0.00030658633],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001133277,0.00022691523,0.0004632796,0.000041938747,0.00011928884,0.000037635877,0.00008899326,0.00010979112,0.0007677422],"category_scores_gemma":[0.00005295951,0.00014998367,0.00013675565,0.00022463592,0.0005221257,0.00014291087,0.000012432823,0.00018534967,0.00002397264],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016020541,0.00093069347,0.9885194,0.00005298282,0.00041868238,0.00011968387,0.00029341306,0.0000026357143,0.00041165933,0.000056450062,0.0019066372,0.005685763],"study_design_scores_gemma":[0.00855469,0.005182427,0.9589619,0.0013534717,0.0007575204,0.000090612695,0.00006343215,0.00069521356,0.008173794,0.0000037295317,0.015797282,0.00036593806],"about_ca_topic_score_codex":0.0002376443,"about_ca_topic_score_gemma":0.00015798297,"teacher_disagreement_score":0.029557453,"about_ca_system_score_codex":0.00081323204,"about_ca_system_score_gemma":0.0003028186,"threshold_uncertainty_score":0.8406239},"labels":[],"label_agreement":null},{"id":"W2885210084","doi":"10.1016/j.cllc.2018.07.008","title":"Cell-Free DNA Next-Generation Sequencing Prediction of Response and Resistance to Third-Generation EGFR Inhibitor","year":2018,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":63,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Institute of Infection and Immunity; Clovis Oncology","keywords":"T790M; Liquid biopsy; Lung cancer; Medicine; Cancer research; KRAS; Cell-free fetal DNA; DNA sequencing; Resistance mutation; Oncology; Gene; Osimertinib; Exon; EGFR inhibitors; Internal medicine; Epidermal growth factor receptor; Gefitinib; Cancer; Polymerase chain reaction; Erlotinib; Biology; Genetics; Reverse transcriptase; Colorectal cancer","score_opus":0.0895180354257775,"score_gpt":0.3965163339387146,"score_spread":0.3069982985129371,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2885210084","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99041945,0.001514757,0.0009049629,0.0035407506,0.0012803592,0.0007433933,0.00012517562,0.000050552033,0.0014206115],"genre_scores_gemma":[0.98789614,0.00025279296,0.004038038,0.0012354405,0.0029707113,0.00012500223,0.000049582024,0.000023907856,0.0034083559],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99846977,0.00013537328,0.00058270904,0.0004015937,0.00024284708,0.0001676899],"domain_scores_gemma":[0.9987464,0.00013610742,0.00016368095,0.00039950284,0.0003656624,0.00018864872],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00057537144,0.00013199169,0.00027079228,0.000081979255,0.00014672466,0.000028577455,0.00006114053,0.00013935956,0.00006641916],"category_scores_gemma":[0.0005130312,0.0001135725,0.00007018286,0.00021038986,0.00013105264,0.00016315217,0.00004024666,0.000120638404,0.0000066768253],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031710025,0.00022843492,0.043667927,0.00017990274,0.0002352866,0.000009746641,0.0018568244,0.000039323804,0.6805011,0.0002502719,0.26609653,0.0037636503],"study_design_scores_gemma":[0.022035379,0.008432309,0.36434627,0.0022249182,0.0037568603,0.000020883635,0.0007037878,0.024016466,0.50493324,0.0003925288,0.06815369,0.0009836985],"about_ca_topic_score_codex":0.0000722589,"about_ca_topic_score_gemma":0.0005024044,"teacher_disagreement_score":0.32067832,"about_ca_system_score_codex":0.00042901767,"about_ca_system_score_gemma":0.0005553008,"threshold_uncertainty_score":0.46313524},"labels":[],"label_agreement":null},{"id":"W2893221436","doi":"10.1016/j.cllc.2018.09.005","title":"Efficacy of Nivolumab and Pembrolizumab in Patients With Advanced Non–Small-Cell Lung Cancer Needing Treatment Interruption Because of Adverse Events: A Retrospective Multicenter Analysis","year":2018,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":90,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Grand River Hospital; University of Victoria","funders":"AstraZeneca Canada","keywords":"Medicine; Nivolumab; Pembrolizumab; Internal medicine; Lung cancer; Adverse effect; Hazard ratio; Cohort; Common Terminology Criteria for Adverse Events; Proportional hazards model; Cancer; Oncology; Renal cell carcinoma; Immunotherapy","score_opus":0.019306177894472296,"score_gpt":0.3678977620764572,"score_spread":0.3485915841819849,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2893221436","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997382,0.00081993215,0.0000848502,0.000063972104,0.00026789404,0.0011997541,0.00007503321,0.00001308959,0.000093472845],"genre_scores_gemma":[0.9979605,0.0012044504,0.00028505462,0.00009594536,0.00011656775,0.000100741214,0.000024234883,0.000026914195,0.00018557752],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981286,0.000065801076,0.00081969006,0.0004874923,0.0002425653,0.00025583495],"domain_scores_gemma":[0.9985981,0.000107651205,0.0005180202,0.0003275719,0.00033836564,0.00011026879],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001868715,0.000231631,0.00083688524,0.00024716067,0.000036747908,0.0000026822104,0.00008467123,0.00013179895,0.00022295583],"category_scores_gemma":[0.000050714265,0.00017348255,0.00028010595,0.0006221086,0.00024709947,0.0001065308,0.000042689506,0.00016164975,4.6248294e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03545334,0.001206001,0.9507586,0.00014597569,0.0023680432,0.0000019508063,0.0012046086,0.00004372999,0.0005025252,4.4882051e-7,0.00002474026,0.008290068],"study_design_scores_gemma":[0.042543977,0.002822033,0.9465124,0.0010241716,0.0027342264,1.9303481e-7,0.00014811975,0.0031699156,0.0008498704,4.1732883e-7,0.00003185129,0.00016280824],"about_ca_topic_score_codex":0.0016000535,"about_ca_topic_score_gemma":0.0022907148,"teacher_disagreement_score":0.00812726,"about_ca_system_score_codex":0.00088954176,"about_ca_system_score_gemma":0.00018599632,"threshold_uncertainty_score":0.70744133},"labels":[],"label_agreement":null},{"id":"W2897305886","doi":"10.1016/j.cllc.2018.10.001","title":"LACE-Bio: Validation of Predictive and/or Prognostic Immunohistochemistry/Histochemistry-based Biomarkers in Resected Non–small-cell Lung Cancer","year":2018,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of New Brunswick; Princess Margaret Cancer Centre; University of Toronto; University Health Network; Queen's University","funders":"Canadian Cancer Society Research Institute; National Institutes of Health; Institut National Du Cancer; Sanofi; Texas Medical Board; Ligue Contre le Cancer; Foundation for the National Institutes of Health","keywords":"Immunohistochemistry; Medicine; Lung cancer; Oncology; Pathology; Internal medicine","score_opus":0.023872109312829584,"score_gpt":0.40891452944386075,"score_spread":0.3850424201310312,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2897305886","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98998594,0.0040703793,0.0002481911,0.0006210556,0.00042337726,0.0017274745,0.00019194793,0.000053701042,0.0026779163],"genre_scores_gemma":[0.9956914,0.00035591572,0.00072975556,0.00020621734,0.0003361177,0.00088716915,0.00014592789,0.00004131332,0.0016061922],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979935,0.00006161787,0.00078290154,0.0005915211,0.00024980385,0.0003205995],"domain_scores_gemma":[0.99820745,0.0003555003,0.00035954296,0.00040157005,0.00046816154,0.00020775721],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002785195,0.00024864916,0.0005179183,0.00009155565,0.00008865705,0.000014637851,0.00012546913,0.00026814587,0.00047519928],"category_scores_gemma":[0.00041212162,0.00020494149,0.00013037036,0.0004321267,0.00047027436,0.000058072423,0.000048612044,0.00027724786,0.0000018495062],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004976081,0.0009025004,0.9313981,0.0018236764,0.0010459595,0.000030426803,0.0005718237,0.000052750675,0.0492919,0.0000017335416,0.0077324356,0.0021726203],"study_design_scores_gemma":[0.038723156,0.0030671367,0.58378273,0.0085669365,0.008421621,0.000014396542,0.00046090275,0.03760144,0.31688482,0.000027142101,0.0013417216,0.001107996],"about_ca_topic_score_codex":0.00079939165,"about_ca_topic_score_gemma":0.00014565025,"teacher_disagreement_score":0.34761536,"about_ca_system_score_codex":0.00077553943,"about_ca_system_score_gemma":0.0019430862,"threshold_uncertainty_score":0.83572716},"labels":[],"label_agreement":null},{"id":"W2902933008","doi":"10.1016/j.cllc.2018.11.012","title":"Phase 1b/2 Randomized Study of MEDI-575 in Combination With Carboplatin Plus Paclitaxel Versus Carboplatin Plus Paclitaxel Alone in Adult Patients With Previously Untreated Advanced Non–Small-Cell Lung Cancer","year":2018,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"Eli Lilly Japan; Pfizer Japan; Genentech; MSD K.K.; Ono Pharmaceutical; Stiftelsen för Kunskaps- och Kompetensutveckling; Exelixis; Taiho Pharmaceutical; North Carolina GlaxoSmithKline Foundation; Novartis; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; Bayer Corporation; Takeda Pharmaceutical Company; AbbVie; MedImmune; Merck; GlaxoSmithKline; Celgene; Bayer","keywords":"Carboplatin; Paclitaxel; Medicine; Lung cancer; Oncology; Internal medicine; Chemotherapy; Cisplatin","score_opus":0.02561469216365942,"score_gpt":0.4055740958390569,"score_spread":0.3799594036753975,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2902933008","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9817011,0.00252698,0.000044531233,0.0004454444,0.0006946835,0.013575544,0.000118780285,0.00008143064,0.00081151497],"genre_scores_gemma":[0.993487,0.0012885879,0.00036185057,0.0001834594,0.00027857735,0.003790555,0.000106629705,0.00013241169,0.00037093312],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99276215,0.0009190505,0.0023084076,0.0013745646,0.0015253146,0.0011105316],"domain_scores_gemma":[0.9933907,0.002208231,0.0010757411,0.00093694124,0.0019181697,0.00047025262],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0017165487,0.00074863835,0.0032964326,0.00045639937,0.00013691805,0.00003155514,0.00037561328,0.00031772017,0.000117147865],"category_scores_gemma":[0.0019719566,0.0005306622,0.00021197855,0.0015169469,0.0009945256,0.0002569531,0.0002181926,0.0011513504,0.0000033963709],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4407849,0.007770297,0.5360853,0.00093382364,0.001522618,0.00010958427,0.008718594,0.00042197036,0.000042051215,0.000007130697,0.00042801816,0.0031756964],"study_design_scores_gemma":[0.8716496,0.015179989,0.08720984,0.0034428772,0.0017757359,8.154077e-7,0.0018411571,0.018031945,0.00022322718,0.0000054814,0.000018181758,0.0006211232],"about_ca_topic_score_codex":0.014611245,"about_ca_topic_score_gemma":0.07450001,"teacher_disagreement_score":0.4488755,"about_ca_system_score_codex":0.0025828641,"about_ca_system_score_gemma":0.0021305694,"threshold_uncertainty_score":0.9997145},"labels":[],"label_agreement":null},{"id":"W2904270864","doi":"10.1016/j.cllc.2018.12.009","title":"Effect of Coexisting KRAS and TP53 Mutations in Patients Treated With Chemotherapy for Non–small-cell Lung Cancer","year":2018,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"KRAS; Medicine; Internal medicine; Hazard ratio; Oncology; Lung cancer; Chemotherapy; Clinical endpoint; Confidence interval; Cancer; Gastroenterology; Clinical trial; Colorectal cancer","score_opus":0.019217476370916184,"score_gpt":0.4167759382705536,"score_spread":0.3975584618996374,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2904270864","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954271,0.00061097235,0.000106165666,0.0002611568,0.0001865304,0.0023911186,0.0001074812,0.000024288562,0.0008852017],"genre_scores_gemma":[0.99701995,0.00017474983,0.00057096,0.00036503267,0.00024656852,0.00075452967,0.00006719705,0.000041895295,0.0007591229],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987715,0.000050594284,0.00045174864,0.0003623955,0.00012533186,0.00023845793],"domain_scores_gemma":[0.99870795,0.0004950185,0.00020997004,0.00018217914,0.00027696055,0.000127903],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002119004,0.0001831315,0.00049883116,0.000071462266,0.000082035585,0.0000109156035,0.000051139836,0.00011010541,0.00008229316],"category_scores_gemma":[0.0000844924,0.00012723746,0.00008426636,0.00021939797,0.0001952207,0.00005044412,0.0000136660365,0.00012085482,7.995172e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018402785,0.00029097038,0.97762793,0.00048266782,0.0003697479,0.0000019790705,0.00040564424,0.00001106863,0.000073504685,0.000004067687,0.00079534535,0.018096805],"study_design_scores_gemma":[0.03568011,0.0060919835,0.94417304,0.0013196861,0.0025841093,9.0520274e-7,0.000035327885,0.005156931,0.0041556563,0.0000058177266,0.0005515757,0.00024484508],"about_ca_topic_score_codex":0.0006079496,"about_ca_topic_score_gemma":0.0005213689,"teacher_disagreement_score":0.033839833,"about_ca_system_score_codex":0.00020290469,"about_ca_system_score_gemma":0.00027251925,"threshold_uncertainty_score":0.5188593},"labels":[],"label_agreement":null},{"id":"W2905706267","doi":"10.1016/j.cllc.2018.12.010","title":"Financial Burden Among Patients With Lung Cancer in a Publically Funded Health Care System","year":2018,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":53,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Princess Margaret Cancer Centre; University Health Network","funders":"Cancer Care Ontario","keywords":"Medicine; Logistic regression; Lung cancer; Confidence interval; Odds ratio; Cohort; Medicaid; Health care; Quality of life (healthcare); Demography; Internal medicine; Finance; Emergency medicine; Family medicine; Nursing","score_opus":0.023660150016801777,"score_gpt":0.319641527852575,"score_spread":0.2959813778357732,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2905706267","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9648476,0.01181362,0.00058360316,0.0021794941,0.0039433097,0.0014746875,0.0012416105,0.00012333004,0.013792741],"genre_scores_gemma":[0.9935028,0.00062740286,0.0001777379,0.0019459929,0.0024840045,0.00034633008,0.00003345289,0.000078463454,0.0008038324],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.995901,0.000057504283,0.0019146209,0.001072603,0.00010484651,0.00094946055],"domain_scores_gemma":[0.9975434,0.00009833918,0.0011055534,0.00059116504,0.00028802353,0.00037352057],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000789238,0.00037071694,0.0012783142,0.00024384023,0.00022096784,0.00013852053,0.0005166702,0.00038402472,0.0007212864],"category_scores_gemma":[0.000262361,0.00037291422,0.00021865036,0.00047695194,0.000390807,0.0005779171,0.00013278447,0.0005632768,0.00008285669],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029979047,0.000079570375,0.9653654,0.00022274835,0.00008139263,0.0000026983466,0.00069726555,0.00007364282,3.858286e-8,0.008736225,0.014203924,0.010237269],"study_design_scores_gemma":[0.0034656378,0.00039085152,0.95733476,0.0005087074,0.000022335567,2.6150258e-7,0.000071474904,0.0020862112,9.472945e-7,0.0001598977,0.035408393,0.0005505126],"about_ca_topic_score_codex":0.0075038616,"about_ca_topic_score_gemma":0.014878289,"teacher_disagreement_score":0.028655179,"about_ca_system_score_codex":0.0021231265,"about_ca_system_score_gemma":0.0008551409,"threshold_uncertainty_score":0.99987227},"labels":[],"label_agreement":null},{"id":"W2907212631","doi":"10.1016/j.cllc.2018.12.022","title":"Afatinib With Pembrolizumab for Treatment of Patients With Locally Advanced/Metastatic Squamous Cell Carcinoma of the Lung: The LUX-Lung IO/KEYNOTE 497 Study Protocol","year":2019,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Boehringer Ingelheim (Canada)","funders":"Janssen Pharmaceuticals; Merck Sharp and Dohme; Genentech; Takeda Pharmaceutical Company; AbbVie; Celgene; Medtronic; Novartis; Sanofi; Merck; Eli Lilly and Company; Bristol-Myers Squibb; AstraZeneca; Roche; Astellas Pharma US; Boehringer Ingelheim; Amgen; Pfizer","keywords":"Medicine; Afatinib; Pembrolizumab; Squamous-cell carcinoma of the lung; Lung; Lung cancer; Oncology; Internal medicine; Basal cell; Cancer; Immunotherapy; Gefitinib; Epidermal growth factor receptor","score_opus":0.019693372578323994,"score_gpt":0.39662562323210593,"score_spread":0.37693225065378194,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2907212631","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.83660203,0.00026911835,0.00012202784,0.0001981955,0.00020330014,0.16177714,0.00018022166,0.000017048847,0.0006309197],"genre_scores_gemma":[0.91773516,0.0000059232966,0.00039111346,0.00014451962,0.00007493017,0.079836406,0.000024226634,0.000060671424,0.0017270667],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975958,0.00014297607,0.00085712713,0.0005258062,0.00053637876,0.0003419477],"domain_scores_gemma":[0.997102,0.00056816585,0.0007196841,0.0009334812,0.0005460144,0.00013060478],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001646551,0.00033846195,0.00082507305,0.000044209046,0.00013010469,0.000014286286,0.00022250041,0.00006606639,0.00011644674],"category_scores_gemma":[0.000046852547,0.00014387678,0.00026630049,0.0002753767,0.00024228211,0.00008206015,0.000044063898,0.00013734082,0.000001900333],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011017633,0.0054312646,0.97628826,0.00080908416,0.00072592485,0.0000042499173,0.0011359396,0.0008202141,0.0000076171086,0.000017808356,0.00051955186,0.0032224257],"study_design_scores_gemma":[0.08088655,0.024427345,0.8857549,0.00037066918,0.0043990747,0.0000017835524,0.0005644635,0.0014676165,0.00034484486,0.000010728529,0.0015300572,0.00024196974],"about_ca_topic_score_codex":0.00015235289,"about_ca_topic_score_gemma":0.00015315611,"teacher_disagreement_score":0.09053339,"about_ca_system_score_codex":0.00037528836,"about_ca_system_score_gemma":0.0011559618,"threshold_uncertainty_score":0.5867125},"labels":[],"label_agreement":null},{"id":"W2907628865","doi":"10.1016/j.cllc.2018.12.017","title":"Durable Clinical Response to Crizotinib in IRF2BP2-NTRK1 Non–small-cell Lung Cancer","year":2018,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Health Ontario","funders":"","keywords":"Trk receptor; Tropomyosin receptor kinase B; Tropomyosin receptor kinase A; Tropomyosin receptor kinase C; Receptor tyrosine kinase; Crizotinib; Cancer research; Tyrosine kinase; Neurotrophin; Lung cancer; Medicine; Low-affinity nerve growth factor receptor; Kinase; Internal medicine; Receptor; Biology; Cell biology; Platelet-derived growth factor receptor; Neurotrophic factors; Growth factor","score_opus":0.04866820201861862,"score_gpt":0.48360318254583984,"score_spread":0.43493498052722124,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2907628865","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9665751,0.00266409,0.00020089651,0.015734103,0.0044350983,0.002486891,0.00012877186,0.00012704071,0.0076480205],"genre_scores_gemma":[0.95441186,0.0015623856,0.0018873083,0.014044264,0.003654195,0.0010556026,0.000025887026,0.000117019554,0.0232415],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9953869,0.00041607267,0.001775141,0.0011713636,0.0003985718,0.0008519695],"domain_scores_gemma":[0.9961657,0.001237106,0.00029835931,0.00091289333,0.00048368797,0.0009022772],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0019527475,0.00039923884,0.0010805795,0.00020511531,0.00018398109,0.00005378302,0.0003171386,0.00044222688,0.0023105117],"category_scores_gemma":[0.0010980741,0.00033289517,0.00041526277,0.00073018414,0.00032440238,0.00012783225,0.00016433242,0.0007917586,0.00028229403],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00712733,0.0011012532,0.8440122,0.0001618853,0.00045163365,0.0001356759,0.00069134985,0.000045892157,0.00045897206,0.000018947616,0.13706093,0.008733945],"study_design_scores_gemma":[0.013073086,0.0018498648,0.88507736,0.0012271465,0.0014908836,0.00000766048,0.00016059066,0.0023243842,0.0005045184,0.000025968224,0.09370905,0.00054951885],"about_ca_topic_score_codex":0.0013298151,"about_ca_topic_score_gemma":0.0028617708,"teacher_disagreement_score":0.04335188,"about_ca_system_score_codex":0.0007962957,"about_ca_system_score_gemma":0.0025642188,"threshold_uncertainty_score":0.9999123},"labels":[],"label_agreement":null},{"id":"W2943846365","doi":"10.1016/j.cllc.2019.05.003","title":"Outcome Differences Between First- and Second-generation EGFR Inhibitors in Advanced EGFR Mutated NSCLC in a Large Population-based Cohort","year":2019,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; Kingston General Hospital; Princess Margaret Cancer Centre; University of Toronto","funders":"Pfizer Canada; Boehringer Ingelheim; British Microcirculation Society; Bayer; Boehringer Ingelheim España; AstraZeneca Canada; Roche; Genzyme; Eisai; Merck; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Hazard ratio; Oncology; Internal medicine; Lung cancer; Propensity score matching; Discontinuation; Cohort; Population; Proportional hazards model; Epidermal growth factor receptor; Cancer; Confidence interval","score_opus":0.030615193183594274,"score_gpt":0.4080269110230662,"score_spread":0.3774117178394719,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2943846365","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955235,0.0006991855,0.000021575039,0.001207293,0.0005887704,0.001493785,0.00009673671,0.000038096365,0.00033103945],"genre_scores_gemma":[0.9976158,0.00007316931,0.00014345872,0.0006933156,0.00023076068,0.00024168537,0.00036533925,0.000024397255,0.0006120625],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980728,0.00008240734,0.00086906645,0.0004946988,0.00020107492,0.00027994806],"domain_scores_gemma":[0.9990573,0.00034963223,0.00016371033,0.00022461807,0.000062005296,0.00014276344],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033019343,0.00018915467,0.00061575504,0.00015110585,0.00005386894,0.000022292405,0.000054982356,0.00018626239,0.00044092693],"category_scores_gemma":[0.00013693994,0.0001557031,0.00009014998,0.0002823123,0.000035903657,0.00013671808,0.000023398798,0.00029362724,0.000010770321],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009608671,0.00015985279,0.99642384,0.0001016469,0.00008305651,0.000007948068,0.00010773954,0.00014462843,0.000027254364,0.000020912335,0.00010931756,0.0027177029],"study_design_scores_gemma":[0.0070586735,0.0001830259,0.98725253,0.00031720218,0.0001687236,4.1391732e-7,0.000034136996,0.0044197245,0.000023379182,0.000022911441,0.0003476312,0.00017161788],"about_ca_topic_score_codex":0.00085743517,"about_ca_topic_score_gemma":0.010908372,"teacher_disagreement_score":0.010050937,"about_ca_system_score_codex":0.00046467377,"about_ca_system_score_gemma":0.00021082988,"threshold_uncertainty_score":0.63493884},"labels":[],"label_agreement":null},{"id":"W2979041297","doi":"10.1016/j.cllc.2019.09.007","title":"Phase II Study Evaluating the Mechanisms of Resistance on Tumor Tissue and Liquid Biopsy in Patients With EGFR-mutated Non-pretreated Advanced Lung Cancer Receiving Osimertinib Until and Beyond Radiologic Progression: The MELROSE Trial","year":2019,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Servier; Les Laboratories Pierre Fabre; Takeda Pharmaceutical Company; AbbVie; Roche; Novartis; Meso Scale Diagnostics; Sanofi; Merck; GlaxoSmithKline; Boehringer Ingelheim; Amgen; Pfizer; Canadian Asian Studies Association; AstraZeneca; Bristol-Myers Squibb; Bayer","keywords":"Medicine; Osimertinib; Lung cancer; Liquid biopsy; Biopsy; Acquired resistance; Cancer; Pathology; Oncology; Cancer research; Internal medicine; Adenocarcinoma; ROS1","score_opus":0.023275238700409616,"score_gpt":0.4492838678513752,"score_spread":0.4260086291509656,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2979041297","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9881952,0.0024062574,0.000010467226,0.00085495284,0.0005273883,0.0077620815,0.0000671251,0.000029756215,0.00014680868],"genre_scores_gemma":[0.99752575,0.00015434848,0.00026958977,0.00037549913,0.00009620873,0.0011079548,0.000026431271,0.000039743307,0.00040448306],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99732953,0.00035911374,0.00083513703,0.0006880189,0.00046135078,0.00032681972],"domain_scores_gemma":[0.99789584,0.000667361,0.0005725688,0.00049233343,0.00024902337,0.00012287691],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009426523,0.0003002478,0.00073416595,0.00006837536,0.00026358047,0.000024950896,0.00014706695,0.000100141784,0.00010114139],"category_scores_gemma":[0.00032387231,0.00014696084,0.0000608445,0.00044249455,0.00021750308,0.00010480453,0.00009276499,0.0003952189,6.2379615e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.38966945,0.008160853,0.53509986,0.0004324331,0.002000804,0.000055354998,0.006008149,0.0003140439,0.0032163763,0.000049331575,0.00035712944,0.054636195],"study_design_scores_gemma":[0.44327086,0.13008718,0.4077735,0.0049035503,0.0041339057,0.000005079855,0.0017881102,0.0048130597,0.0023292117,0.00007100473,0.00009661159,0.0007279441],"about_ca_topic_score_codex":0.00009013418,"about_ca_topic_score_gemma":0.00012890798,"teacher_disagreement_score":0.12732638,"about_ca_system_score_codex":0.00020844617,"about_ca_system_score_gemma":0.00035300825,"threshold_uncertainty_score":0.59928894},"labels":[],"label_agreement":null},{"id":"W2997563701","doi":"10.1016/j.cllc.2019.11.004","title":"Predictors of Survival Benefit From Immune Checkpoint Inhibitors in Patients With Advanced Non–small-cell Lung Cancer: A Systematic Review and Meta-analysis","year":2020,"lang":"en","type":"review","venue":"Clinical Lung Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Mount Sinai Hospital; Cancer Care Ontario; Western University","funders":"","keywords":"Medicine; Meta-analysis; Lung cancer; Oncology; Nivolumab; Internal medicine; Immune system; Cancer; Immunotherapy; Immunology","score_opus":0.04228492074617649,"score_gpt":0.3698276433116152,"score_spread":0.3275427225654387,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2997563701","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.001272849,0.98773026,0.000006537242,0.00021158122,0.00041373025,0.008921066,0.0013705703,0.00003160642,0.000041779353],"genre_scores_gemma":[0.00044564472,0.9959383,0.00009440428,0.0003803053,0.0001435895,0.002231533,0.00038296237,0.00011975126,0.00026353126],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99187946,0.00052071025,0.005215585,0.0012518074,0.0007061533,0.0004262567],"domain_scores_gemma":[0.99408424,0.0007667599,0.0033920375,0.0011303442,0.00030903012,0.00031761316],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.0012149919,0.00094064017,0.019166112,0.00026504605,0.000042946278,0.000023986302,0.00041650838,0.00050171,0.0005214786],"category_scores_gemma":[0.0002131846,0.00057571195,0.0045902,0.0017941209,0.00020081639,0.00008173291,0.0001693849,0.00095463684,0.0000018030184],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00055770803,0.00029565292,0.018884027,0.73007756,0.24109901,0.000011939109,0.000071493654,0.0000032834832,3.6289651e-7,2.6957971e-7,0.00010085612,0.008897842],"study_design_scores_gemma":[0.0028416368,0.00033794463,0.0031211567,0.17164475,0.81512,4.9516547e-7,0.000011421212,0.000020882491,0.0000019911147,2.6241693e-7,0.0063725132,0.00052699086],"about_ca_topic_score_codex":0.0012292347,"about_ca_topic_score_gemma":0.0006081946,"teacher_disagreement_score":0.574021,"about_ca_system_score_codex":0.00055895647,"about_ca_system_score_gemma":0.0009257005,"threshold_uncertainty_score":0.99966943},"labels":[],"label_agreement":null},{"id":"W2997646222","doi":"10.1016/j.cllc.2019.11.007","title":"Stereotactic Body Radiation Therapy for Extracranial Oligometastatic Non–small-cell Lung Cancer: A Systematic Review","year":2019,"lang":"en","type":"review","venue":"Clinical Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Randomized controlled trial; Lung cancer; Radiosurgery; Dose fractionation; Oncology; Radiation therapy; Quality of life (healthcare); Retrospective cohort study; MEDLINE; Internal medicine","score_opus":0.08089800982159952,"score_gpt":0.467511362536988,"score_spread":0.3866133527153885,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2997646222","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000031402327,0.9560988,0.00004786862,0.0005428762,0.0033547932,0.03908049,0.00058300694,0.00008209006,0.00017866088],"genre_scores_gemma":[0.00003324603,0.95748097,0.000115215305,0.0027860687,0.0017792885,0.034270495,0.00041325073,0.0002806325,0.0028408123],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9927173,0.00063036627,0.0037751107,0.0014859423,0.0006090657,0.0007821703],"domain_scores_gemma":[0.99178654,0.003078275,0.0027261004,0.0015656941,0.0003693157,0.00047407986],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001578029,0.0011240349,0.009826555,0.00020099047,0.000120340206,0.000093642,0.00047384566,0.0006126189,0.00046612098],"category_scores_gemma":[0.00039734165,0.0007471487,0.0033061674,0.000515254,0.00007098425,0.00011936334,0.00006759479,0.0008415878,0.00010037063],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009613608,0.0006272882,0.0008532619,0.82939816,0.005443634,0.000026866126,0.000026592328,4.4354863e-7,5.3805838e-8,0.000006114654,0.01603993,0.14748155],"study_design_scores_gemma":[0.0045967014,0.0006597578,0.00009402021,0.6654931,0.09091527,0.000021475322,0.000002135775,0.00023142213,4.9263514e-7,0.0000018663717,0.23736204,0.00062172645],"about_ca_topic_score_codex":0.00012141896,"about_ca_topic_score_gemma":0.000030185336,"teacher_disagreement_score":0.2213221,"about_ca_system_score_codex":0.002308935,"about_ca_system_score_gemma":0.0036067243,"threshold_uncertainty_score":0.99949795},"labels":[],"label_agreement":null},{"id":"W3006923011","doi":"10.1016/j.cllc.2020.02.013","title":"Effect of Hospitalization During First Chemotherapy and Performance Status on Small-cell Lung Cancer Outcomes","year":2020,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Research Institute in Oncology and Hematology; University of Manitoba; CancerCare Manitoba","funders":"Fondation de l’Hôpital Saint-Boniface; University of Manitoba; Manitoba Medical Service Foundation","keywords":"Medicine; Internal medicine; Lung cancer; Cohort; Performance status; Neutropenia; Chemotherapy; Retrospective cohort study; Cancer; Febrile neutropenia; Oncology","score_opus":0.024733776137534275,"score_gpt":0.40715397650250174,"score_spread":0.3824202003649675,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3006923011","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98470294,0.007985022,0.00001195565,0.005172181,0.00031660625,0.0012588114,0.00004422489,0.00006759818,0.0004406606],"genre_scores_gemma":[0.96481556,0.03264705,0.000034725184,0.0013225286,0.00042397078,0.00022936673,0.0000054261814,0.000049911905,0.00047144978],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980746,0.00008638384,0.00052757614,0.0005027364,0.00039054395,0.0004181477],"domain_scores_gemma":[0.99858445,0.00050467724,0.00019505696,0.00026116456,0.00013103135,0.00032363596],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031611466,0.00025614045,0.0007916942,0.000051953903,0.00011291865,0.000016240949,0.00011603333,0.0001207319,0.00020929641],"category_scores_gemma":[0.00040372583,0.00018559153,0.00016192129,0.00023475738,0.00019853195,0.000074940304,0.00010466581,0.00038532008,0.0000032953205],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002521136,0.00007283368,0.9809183,0.0052686264,0.00039099398,0.0000065738677,0.00050082826,0.00010522081,0.00015392531,0.00000237882,0.0019032778,0.0081559075],"study_design_scores_gemma":[0.007904558,0.0024509893,0.9738136,0.0008777279,0.00033557139,4.061793e-7,0.000017174241,0.0056225765,0.0077952323,4.7523378e-7,0.0009734884,0.00020819546],"about_ca_topic_score_codex":0.00012876221,"about_ca_topic_score_gemma":0.000041685067,"teacher_disagreement_score":0.02466203,"about_ca_system_score_codex":0.00027164395,"about_ca_system_score_gemma":0.00018437585,"threshold_uncertainty_score":0.7568203},"labels":[],"label_agreement":null},{"id":"W3010980640","doi":"10.1016/j.cllc.2020.03.006","title":"Immune-related Encephalitis in Two Patients Treated With Immune Checkpoint Inhibitor","year":2020,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bristol-Myers Squibb Canada; AstraZeneca France; Roche; Pfizer","keywords":"Medicine; Immune system; Atezolizumab; Immunosuppression; Lung cancer; Immune checkpoint; Ipilimumab; Immunotherapy; Cancer; Nivolumab; Immunology; Cetuximab; Oncology; Cancer research; Internal medicine; Colorectal cancer","score_opus":0.02314803481008118,"score_gpt":0.35463236200858134,"score_spread":0.3314843271985002,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3010980640","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98901105,0.0045226132,0.0000048326565,0.0037239504,0.00041454384,0.0008712948,0.000033695036,0.000097296004,0.0013207342],"genre_scores_gemma":[0.9957467,0.0010888086,0.00006351348,0.002026738,0.0002588635,0.00009825901,0.000078392404,0.00004668801,0.00059204176],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974083,0.000120659606,0.0013127816,0.0005112072,0.00028932464,0.00035773747],"domain_scores_gemma":[0.9989487,0.00011336842,0.00027430343,0.0003041683,0.00013206707,0.00022738983],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00032905515,0.00024572373,0.000698603,0.000056296016,0.000046322857,0.000018291994,0.00013856859,0.00015516646,0.0011097942],"category_scores_gemma":[0.00014949335,0.000183149,0.00029346542,0.0006088099,0.0002519761,0.00009611205,0.000049484108,0.00054425065,0.00002811962],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010140348,0.0004449872,0.9587919,0.00010635057,0.00043326252,0.00007427522,0.0003729433,0.0000071799277,0.004162245,0.0000068321942,0.00081099215,0.024648681],"study_design_scores_gemma":[0.028191822,0.0016069462,0.9589177,0.0010327675,0.00020940274,0.000004838267,0.00006454805,0.0005243888,0.0046935026,0.000004590848,0.0044166674,0.00033285224],"about_ca_topic_score_codex":0.0010662253,"about_ca_topic_score_gemma":0.00010771503,"teacher_disagreement_score":0.02431583,"about_ca_system_score_codex":0.00024799208,"about_ca_system_score_gemma":0.00026910417,"threshold_uncertainty_score":0.9998033},"labels":[],"label_agreement":null},{"id":"W3015653861","doi":"10.1016/j.cllc.2020.03.009","title":"Early Detection of Multiple Resistance Mechanisms by ctDNA Profiling in a Patient With EGFR-mutant Lung Adenocarcinoma Treated With Osimertinib","year":2020,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Health Ontario; University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"Geneseeq Technology","keywords":"Osimertinib; Medicine; Adenocarcinoma; Lung cancer; Mutant; Oncology; Profiling (computer programming); Acquired resistance; Internal medicine; Lung; Cancer research; Cancer; Gene; Genetics; Biology; ROS1","score_opus":0.019017340067786454,"score_gpt":0.3274518005291633,"score_spread":0.30843446046137685,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3015653861","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99249816,0.0021840478,0.002395814,0.0007609378,0.00007281295,0.0016703404,0.00010647994,0.00007076732,0.00024065886],"genre_scores_gemma":[0.9971444,0.000078468904,0.0015917149,0.0005106807,0.00006495646,0.00038628635,0.000038262548,0.000050026665,0.00013520384],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99810493,0.000077641766,0.0006662345,0.0005490317,0.0003184833,0.00028365236],"domain_scores_gemma":[0.99889237,0.00014351195,0.00030470535,0.00024242718,0.0001770679,0.00023989982],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000094551484,0.0002231901,0.00054315844,0.000052774965,0.000059418613,0.0000126651175,0.00007171389,0.000120926314,0.000036798516],"category_scores_gemma":[0.00008937303,0.00015338142,0.00008912061,0.00046801654,0.000095522715,0.0000941968,0.00002084712,0.00029392447,0.0000018415247],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011806263,0.00056954386,0.95485663,0.00040529072,0.00079850724,0.00021738393,0.0011670868,0.00011954015,0.025411977,0.00003064018,0.0002599249,0.004357217],"study_design_scores_gemma":[0.046003155,0.01493481,0.5662722,0.0039787586,0.004572373,0.000032096956,0.0012325317,0.024122864,0.33666638,0.00003121032,0.0009980274,0.001155617],"about_ca_topic_score_codex":0.00044687284,"about_ca_topic_score_gemma":0.00045291046,"teacher_disagreement_score":0.38858443,"about_ca_system_score_codex":0.0002891571,"about_ca_system_score_gemma":0.00029982856,"threshold_uncertainty_score":0.62547123},"labels":[],"label_agreement":null},{"id":"W3016429630","doi":"10.1016/j.cllc.2020.04.009","title":"Incidence and Mortality of Lung Cancer Among Never Smokers in Relationship to Secondhand Smoking: Findings From the PLCO Trial","year":2020,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Lung cancer; Hazard ratio; Chronic bronchitis; Confidence interval; Incidence (geometry); Internal medicine; Lung cancer screening; Proportional hazards model","score_opus":0.08453461208895334,"score_gpt":0.45741601521522296,"score_spread":0.3728814031262696,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3016429630","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98659694,0.0020531085,0.000039944338,0.008940413,0.0005639261,0.0013550981,0.00016077425,0.0000207777,0.00026899675],"genre_scores_gemma":[0.99391264,0.00025416238,0.0000678339,0.0047676293,0.00051306613,0.0002756763,0.000023093697,0.00001944519,0.00016648433],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982882,0.00010768381,0.00069556,0.0004445151,0.00026194923,0.00020208581],"domain_scores_gemma":[0.99827355,0.0009618934,0.0001716061,0.00025178265,0.00008400152,0.00025716424],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036240128,0.00015340486,0.00046280443,0.00003422671,0.00008112769,0.000023867276,0.0001213258,0.00015085282,0.0003974936],"category_scores_gemma":[0.00089519034,0.00010944742,0.00011911576,0.00034145656,0.00018081392,0.00016606697,0.000076065335,0.00041072455,0.0000012890484],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022477263,0.000055171084,0.98984516,0.00005284536,0.00034610348,0.000009079016,0.0020794752,0.00009528363,0.0000137779125,0.00005718749,0.00457798,0.0006202259],"study_design_scores_gemma":[0.014068053,0.00016329096,0.9825511,0.0003755252,0.00091882143,2.1406996e-7,0.00012023211,0.00092585024,0.000039768885,0.00005503226,0.0006650197,0.00011712037],"about_ca_topic_score_codex":0.005854398,"about_ca_topic_score_gemma":0.0030552596,"teacher_disagreement_score":0.011820327,"about_ca_system_score_codex":0.00021861395,"about_ca_system_score_gemma":0.00048030002,"threshold_uncertainty_score":0.88501376},"labels":[],"label_agreement":null},{"id":"W3027850675","doi":"10.1016/j.cllc.2020.05.015","title":"Combining EGFR and MET Inhibition With Crizotinib in EGFR-mutated Lung Adenocarcinoma Harboring MET Amplification: A Brief Report","year":2020,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Takeda Canada; Genentech; Meso Scale Diagnostics; Clovis Oncology; Chugai Pharmaceutical; Roche; Novartis; Amgen; Pfizer; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; AstraZeneca France; Takeda Pharmaceutical Company","keywords":"Crizotinib; Osimertinib; Medicine; Epidermal growth factor receptor; Lung cancer; Adenocarcinoma; Cancer research; Gefitinib; Tyrosine kinase; Oncology; Acquired resistance; Internal medicine; Erlotinib; Receptor; Cancer","score_opus":0.05111740777455702,"score_gpt":0.4146171040608322,"score_spread":0.36349969628627515,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3027850675","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.983928,0.0032360412,0.00072400266,0.008574137,0.00025633458,0.0011691716,0.00003846183,0.0001468356,0.0019270042],"genre_scores_gemma":[0.9943612,0.00023723785,0.0017216323,0.0025795696,0.00036230337,0.00028293955,0.00018125417,0.000048233556,0.00022563651],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99773765,0.000088492605,0.00086830923,0.00072840624,0.00028293388,0.00029419916],"domain_scores_gemma":[0.9986412,0.00021170171,0.00029774857,0.0003001594,0.00018278863,0.00036642252],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033821553,0.00022623317,0.00058749254,0.00007881758,0.00010299301,0.000051801635,0.00005862125,0.00013350001,0.00012728547],"category_scores_gemma":[0.0002928743,0.00018787292,0.000089980225,0.00048189546,0.00014665807,0.00019039073,0.000050159248,0.0004258116,0.000004440396],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006494393,0.00018854023,0.99114376,0.00023766022,0.00044162112,0.00083190884,0.0010262469,0.00005038691,0.00037143292,0.00045602824,0.0015733079,0.0030296787],"study_design_scores_gemma":[0.011629828,0.0011156453,0.97660536,0.0010499394,0.0017770426,0.0001823674,0.0005035157,0.0028884166,0.00055937306,0.000049033322,0.003260822,0.0003786591],"about_ca_topic_score_codex":0.00029457273,"about_ca_topic_score_gemma":0.00007603401,"teacher_disagreement_score":0.0145383915,"about_ca_system_score_codex":0.00027638944,"about_ca_system_score_gemma":0.0004897175,"threshold_uncertainty_score":0.76612353},"labels":[],"label_agreement":null},{"id":"W3036426983","doi":"10.1016/j.cllc.2020.06.015","title":"Duration of Targeted Therapy in Patients With Advanced Non–small-cell Lung Cancer Identified by Circulating Tumor DNA Analysis","year":2020,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Janssen Biotech; Guardant Health; Loxo Oncology; Bristol-Myers Squibb Canada; Genentech; Daiichi-Sankyo; LAM Therapeutics; National Institutes of Health; Seattle Genetics; Boehringer Ingelheim; NRG Oncology; F. Hoffmann-La Roche; International Studies Association; Novartis; National Cancer Institute; AbbVie; Merck; GlaxoSmithKline; Canadian Asian Studies Association; Bristol-Myers Squibb; AstraZeneca; Spectrum Pharmaceuticals; Pfizer","keywords":"Medicine; Lung cancer; Circulating tumor DNA; Oncology; Internal medicine; Cancer; Targeted therapy; Cancer research","score_opus":0.017585960567135774,"score_gpt":0.3654505714863328,"score_spread":0.347864610919197,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3036426983","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946602,0.002179891,0.00046665652,0.0006857272,0.00018576074,0.0014151236,0.00016242635,0.000034798275,0.00020939604],"genre_scores_gemma":[0.9970536,0.00033458465,0.00037686832,0.0013070905,0.00011249768,0.00029923389,0.00032502163,0.0000380166,0.00015308861],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978817,0.00007211059,0.00091838103,0.0005412801,0.0003264021,0.0002600998],"domain_scores_gemma":[0.99860996,0.00011224115,0.0005084152,0.00025989107,0.00030416978,0.0002053133],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013115455,0.00021718029,0.0007204362,0.000099112876,0.000058515132,0.00001762986,0.00010096478,0.00009095136,0.0003506188],"category_scores_gemma":[0.00007548557,0.00016798693,0.00021690883,0.0010099609,0.00006048198,0.00013292099,0.000022794615,0.00023165243,0.0000015242695],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00088708114,0.0004559088,0.98836774,0.00016009658,0.0016870844,0.000007440142,0.0006843218,0.0015907659,0.0017156244,0.0000014988209,0.0007720003,0.003670459],"study_design_scores_gemma":[0.011594728,0.00050312735,0.97067416,0.00021271726,0.0027118423,8.2866585e-8,0.00008889653,0.012077386,0.0018136929,0.0000017674428,0.00010616671,0.0002154068],"about_ca_topic_score_codex":0.00046084073,"about_ca_topic_score_gemma":0.0002707301,"teacher_disagreement_score":0.017693533,"about_ca_system_score_codex":0.0002554892,"about_ca_system_score_gemma":0.00042220688,"threshold_uncertainty_score":0.6850308},"labels":[],"label_agreement":null},{"id":"W3045949208","doi":"10.1016/j.cllc.2020.07.009","title":"Real-World Effectiveness of Nivolumab Monotherapy After Prior Systemic Therapy in Advanced Non–Small-Cell Lung Cancer in the United States","year":2020,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Novartis; AstraZeneca; Bristol-Myers Squibb Canada; Bristol-Myers Squibb","keywords":"Medicine; Nivolumab; Internal medicine; Lung cancer; Oncology; Confidence interval; Chemotherapy; Retrospective cohort study; Cancer; Performance status; Clinical trial; Immunotherapy","score_opus":0.025052380947219895,"score_gpt":0.3735398882047727,"score_spread":0.3484875072575528,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3045949208","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97699153,0.017655142,0.000045196037,0.0015969819,0.00041522578,0.003047739,0.000065465785,0.00003856739,0.00014415896],"genre_scores_gemma":[0.9446069,0.04969842,0.00004871458,0.0039449697,0.00022681561,0.0012520402,0.00002512713,0.000065066364,0.00013197593],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967675,0.0007346717,0.0011507239,0.0006080287,0.00031393525,0.00042513586],"domain_scores_gemma":[0.9978086,0.0011018484,0.0003366836,0.0004799286,0.00014965115,0.00012329203],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013000048,0.00033276563,0.0009772982,0.00019224145,0.000037834892,0.000020473051,0.0003384864,0.00019852674,0.00035540404],"category_scores_gemma":[0.000043195076,0.00023041076,0.00030627064,0.0013471397,0.00018410958,0.00007986806,0.00003433311,0.0006288981,0.0000022475572],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04830395,0.00043701587,0.9131427,0.0017552442,0.00035830477,0.000055962162,0.00334589,0.001127716,0.008254111,0.000003259219,0.00036481099,0.022851063],"study_design_scores_gemma":[0.025030162,0.0009941165,0.95481884,0.0034758612,0.00015022606,0.0000020829104,0.0005053075,0.0100623565,0.0028820012,0.000008377496,0.0016892987,0.0003813404],"about_ca_topic_score_codex":0.007083137,"about_ca_topic_score_gemma":0.002597879,"teacher_disagreement_score":0.041676197,"about_ca_system_score_codex":0.00047136733,"about_ca_system_score_gemma":0.000553893,"threshold_uncertainty_score":0.99952877},"labels":[],"label_agreement":null},{"id":"W3081032382","doi":"10.1016/j.cllc.2020.08.002","title":"Tocilizumab for COVID-19 Pneumonia in a Patient With Non–Small-cell Lung Cancer Treated With Chemoimmunotherapy","year":2020,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"COVID-19 and healthcare impacts","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bristol-Myers Squibb Canada; Astellas Pharma; Roche Italia; Bayer; Les Laboratories Pierre Fabre; Ipsen Biopharmaceuticals; Meso Scale Diagnostics; Amgen","keywords":"Medicine; Tocilizumab; Case fatality rate; Pneumonia; Chemoimmunotherapy; Internal medicine; Coronavirus disease 2019 (COVID-19); Lung cancer; Coronavirus; Disease; Cancer; Infectious disease (medical specialty); Epidemiology","score_opus":0.08262461788749009,"score_gpt":0.4470605545082073,"score_spread":0.3644359366207172,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3081032382","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93694186,0.0040238816,0.0007206219,0.053322818,0.0001465224,0.0043665455,0.00013002825,0.00012331318,0.0002243938],"genre_scores_gemma":[0.91511905,0.0016759327,0.00042176418,0.08043514,0.00043410083,0.0013777369,0.000037174097,0.00009485672,0.00040423308],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973968,0.000079189995,0.0008010635,0.0007760136,0.00032148635,0.000625426],"domain_scores_gemma":[0.9974788,0.00058855524,0.00028664563,0.00040381428,0.00022874784,0.0010134275],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00026076002,0.00035202943,0.0009409692,0.000076386306,0.00010117241,0.000026911834,0.00015800184,0.00025664677,0.00030087744],"category_scores_gemma":[0.00027216214,0.00024547547,0.00017177408,0.00050516665,0.0001294016,0.00006524997,0.000034093875,0.0005817835,0.0000034078118],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.030647224,0.0005653407,0.9272354,0.0038707484,0.00039072553,0.00032959622,0.0035015505,0.00063549355,0.0007101308,0.0000066686207,0.008935427,0.023171684],"study_design_scores_gemma":[0.13454276,0.029490268,0.5336195,0.005046437,0.0023589423,0.000063188214,0.0010125581,0.051554117,0.0025974747,0.00002046976,0.23732048,0.0023737566],"about_ca_topic_score_codex":0.0063669267,"about_ca_topic_score_gemma":0.005623256,"teacher_disagreement_score":0.39361587,"about_ca_system_score_codex":0.0012827339,"about_ca_system_score_gemma":0.0056090443,"threshold_uncertainty_score":0.99999976},"labels":[],"label_agreement":null},{"id":"W3087498123","doi":"10.1016/j.cllc.2020.09.007","title":"Nanoparticle Albumin-bound Paclitaxel Plus Carboplatin Induction Followed by Nanoparticle Albumin-bound Paclitaxel Maintenance in Squamous Non–Small-cell Lung Cancer (ABOUND.sqm): A Phase III Randomized Clinical Trial","year":2020,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Nanoparticle-Based Drug Delivery","field":"Materials Science","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Guardant Health; Roche Diagnostics; Bristol-Myers Squibb Canada; Genentech; AstraZeneca; Fundación Agencia Aragonesa para la Investigación y el Desarrollo; C17 Children's Cancer and Blood Disorders; Astellas Pharma; University of Texas Southwestern Medical Center; Merck Sharp and Dohme; Takeda Pharmaceuticals U.S.A.; Simmons College; AbbVie; University of Arizona Cancer Center; Alexion Pharmaceuticals; PharmaMar; Novartis; Celgene; Boehringer Ingelheim; Ariad Pharmaceuticals; Roche; Merck; Pfizer; Bristol-Myers Squibb; Eli Lilly and Company; Sarah Cannon Research Institute","keywords":"Medicine; Paclitaxel; Hazard ratio; Internal medicine; Clinical endpoint; Lung cancer; Carboplatin; Interim analysis; Gastroenterology; Randomized controlled trial; Progression-free survival; Confidence interval; Oncology; Cancer; Surgery; Chemotherapy","score_opus":0.04164487511171669,"score_gpt":0.36982539895188354,"score_spread":0.3281805238401668,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3087498123","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9733868,0.005627891,0.0004429005,0.0053034117,0.0075244214,0.0068184077,0.00039398784,0.00036195584,0.000140228],"genre_scores_gemma":[0.98817843,0.00069544924,0.00039324575,0.0042818,0.0023873607,0.0027348185,0.000045342407,0.00020953029,0.0010740007],"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98286796,0.003760138,0.0065771737,0.0029938372,0.0013659804,0.002434923],"domain_scores_gemma":[0.98838603,0.005891793,0.002051837,0.0014398987,0.0005294488,0.0017009627],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.010326281,0.0011439773,0.003861202,0.00016411649,0.00053824764,0.00059854734,0.0012829953,0.0009028262,0.0012729377],"category_scores_gemma":[0.0062449453,0.001047433,0.001264409,0.0014297449,0.0019026047,0.0009889953,0.0005400337,0.0016395831,0.0002468659],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.42817083,0.0035818925,0.007829233,0.0002990484,0.00026535138,0.00021915,0.0018227779,0.0009803529,0.52018917,0.000069593276,0.034923267,0.0016493198],"study_design_scores_gemma":[0.7368859,0.0017801523,0.00024228689,0.0003780266,0.0013492904,0.000006016799,0.0005222571,0.091938786,0.16364926,0.00011274788,0.0014861061,0.0016491687],"about_ca_topic_score_codex":0.0037466947,"about_ca_topic_score_gemma":0.00196731,"teacher_disagreement_score":0.35653993,"about_ca_system_score_codex":0.0012608794,"about_ca_system_score_gemma":0.0027133834,"threshold_uncertainty_score":0.99964005},"labels":[],"label_agreement":null},{"id":"W3093030175","doi":"10.1016/j.cllc.2020.09.013","title":"A Phase II Study of Telisotuzumab Vedotin in Patients With c–MET-positive Stage IV or Recurrent Squamous Cell Lung Cancer (LUNG-MAP Sub-study S1400K, NCT03574753)","year":2020,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":79,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Center for Advancing Translational Sciences; Bristol-Myers Squibb Canada; National Institutes of Health; Clovis Oncology; Exelixis; Eli Lilly and Company; AstraZeneca; Shire; F. Hoffmann-La Roche; Takeda Pharmaceuticals U.S.A.; Neos Therapeutics; Foundation for the National Institutes of Health; Spectrum Pharmaceuticals; Novartis; National Cancer Institute; AbbVie; Merck; University of Colorado; Boehringer Ingelheim","keywords":"Medicine; Lung cancer; Internal medicine; Stage (stratigraphy); Oncology; Lung; Gastroenterology","score_opus":0.03232496123790799,"score_gpt":0.4204253364912456,"score_spread":0.38810037525333757,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3093030175","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98730975,0.0022351933,0.000028669125,0.0005911804,0.0007892858,0.00805016,0.0006994648,0.00007534114,0.00022094302],"genre_scores_gemma":[0.9963714,0.00012731907,0.00007833023,0.00081374304,0.000359837,0.0013016864,0.00013536101,0.00009758574,0.0007147539],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9956341,0.00032097963,0.0014902551,0.0011573345,0.00082101685,0.00057633006],"domain_scores_gemma":[0.9973465,0.00037941913,0.0006283502,0.00057365466,0.0005320462,0.000539988],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00029358693,0.0005252517,0.0013443856,0.00015297373,0.0001817042,0.000029394258,0.00025286287,0.0001590327,0.00061382796],"category_scores_gemma":[0.00020105684,0.00036956504,0.00019869296,0.0007979174,0.00013782523,0.00017828422,0.00018770686,0.00073754945,0.000005739684],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017271515,0.044330478,0.9134901,0.000503256,0.001190462,0.00017771019,0.010145084,0.00023867749,0.0000141300525,0.0000022930706,0.0058358735,0.006800402],"study_design_scores_gemma":[0.18385772,0.10622749,0.6924773,0.0009244016,0.007132109,6.107192e-7,0.004307491,0.002456891,0.00021761666,0.0000010009494,0.0015415892,0.0008557735],"about_ca_topic_score_codex":0.0014843275,"about_ca_topic_score_gemma":0.0025555259,"teacher_disagreement_score":0.22101282,"about_ca_system_score_codex":0.0009833346,"about_ca_system_score_gemma":0.0014263731,"threshold_uncertainty_score":0.9998756},"labels":[],"label_agreement":null},{"id":"W3096564526","doi":"10.1016/j.cllc.2020.10.018","title":"Deep and Durable Response to Nivolumab and Temozolomide in Small-Cell Lung Cancer Associated With an Early Decrease in Myeloid-Derived Suppressor Cells","year":2020,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; Ohio State University Press; Bristol-Myers Squibb Canada; Bristol-Myers Squibb","keywords":"Nivolumab; Medicine; Temozolomide; Lung cancer; Oncology; Biomarker; Myeloid; Clinical trial; Cancer research; Internal medicine; Cancer; Immunotherapy; Chemotherapy; Biology","score_opus":0.03676326828345943,"score_gpt":0.3743898209165638,"score_spread":0.33762655263310437,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3096564526","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9825195,0.005672636,0.000017027523,0.00958595,0.00010117749,0.0018658265,0.00006844604,0.00006551144,0.00010394634],"genre_scores_gemma":[0.99201596,0.0023872452,0.00039885225,0.0037093398,0.00016990381,0.0005428233,0.00000804636,0.00007356913,0.0006942519],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996523,0.00063279545,0.0007183187,0.0010151414,0.0003583242,0.0007524023],"domain_scores_gemma":[0.99675065,0.0013019354,0.00015455222,0.0003393201,0.00020320273,0.0012503418],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011122605,0.0003325358,0.0009811062,0.00015673028,0.000096962605,0.00006469195,0.00019499563,0.00022721352,0.00013736142],"category_scores_gemma":[0.0024858708,0.00028041875,0.00006402868,0.0006285774,0.0003036334,0.00017562837,0.00024895644,0.0008324965,0.0000030030617],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02834299,0.00029144285,0.94931495,0.0003552911,0.00023309232,0.0004100221,0.0027015437,0.00017855472,0.015245091,0.0000012696004,0.0018743387,0.0010514006],"study_design_scores_gemma":[0.015038523,0.0020592122,0.9663466,0.0011080428,0.00027920792,0.000002059236,0.00038478267,0.010933556,0.003084644,0.000006484132,0.0003145004,0.00044236716],"about_ca_topic_score_codex":0.0043866592,"about_ca_topic_score_gemma":0.02021563,"teacher_disagreement_score":0.017031658,"about_ca_system_score_codex":0.00063243374,"about_ca_system_score_gemma":0.0009608315,"threshold_uncertainty_score":0.9999648},"labels":[],"label_agreement":null},{"id":"W3109841362","doi":"10.1016/j.cllc.2020.11.005","title":"Survival Trends of Metastatic Lung Cancer in California by Age at Diagnosis, Gender, Race/Ethnicity, and Histology, 1990-2014","year":2020,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Center for Chronic Disease Prevention and Health Promotion; Eurostars; University of California, San Francisco; Centers for Disease Control and Prevention; Comprehensive Cancer Center, University of California, Davis; Foundation Medicine; University of California; Cancer Registry of Greater California; University of Southern California; National Cancer Institute; Illinois Department of Public Health; Tempus; California Department of Public Health; Public Health Institute; Merck; Research and Development Corporation of Newfoundland and Labrador; Pfizer; Eli Lilly and Company","keywords":"Medicine; Lung cancer; Race (biology); Ethnic group; Histology; Oncology; Internal medicine; Gerontology; Demography","score_opus":0.06266566209702124,"score_gpt":0.4391715871590069,"score_spread":0.37650592506198566,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3109841362","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8430796,0.12977058,0.00014818874,0.019852214,0.0011767172,0.0011102569,0.0028270367,0.00008712326,0.001948232],"genre_scores_gemma":[0.9764524,0.018040786,0.00022722578,0.0029659949,0.00025785938,0.00050254643,0.00020656531,0.000052216175,0.0012943873],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99770755,0.00019572658,0.00087230565,0.0006006663,0.00027032942,0.00035341177],"domain_scores_gemma":[0.9984812,0.00052919384,0.0002744288,0.00024961718,0.00006618998,0.00039933517],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00028214324,0.0002560462,0.0010047104,0.00008283073,0.000065072374,0.0000091183465,0.00011655037,0.00015698707,0.0016645011],"category_scores_gemma":[0.00017932155,0.00021014536,0.00019572431,0.00030764184,0.00031935988,0.000059476348,0.00012049244,0.00035167462,0.0000063790235],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00038541318,0.00030917508,0.84915155,0.000413485,0.0007598978,0.00008093506,0.00052767247,0.000046098954,0.00014018762,0.00003379657,0.13721822,0.010933587],"study_design_scores_gemma":[0.017209388,0.00076955266,0.82513887,0.0004802071,0.0063463952,0.000011157411,0.00016237937,0.005276512,0.00037308256,0.000053123138,0.14350596,0.00067340035],"about_ca_topic_score_codex":0.0024340781,"about_ca_topic_score_gemma":0.0036827212,"teacher_disagreement_score":0.13337277,"about_ca_system_score_codex":0.0005032038,"about_ca_system_score_gemma":0.00029333393,"threshold_uncertainty_score":0.9992481},"labels":[],"label_agreement":null},{"id":"W3119577993","doi":"10.1016/j.cllc.2020.12.015","title":"Subtypes of EGFR- and HER2-Mutant Metastatic NSCLC Influence Response to Immune Checkpoint Inhibitors","year":2021,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":65,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Bristol-Myers Squibb Canada; Bayer; AstraZeneca; Amgen; Pfizer; Merck","keywords":"Medicine; Hazard ratio; Lung cancer; Internal medicine; Oncology; Exon; Confidence interval; Response Evaluation Criteria in Solid Tumors; Cancer research; Mutation; Population; Progressive disease; Chemotherapy; Biology; Genetics; Gene","score_opus":0.025623159091516502,"score_gpt":0.38673176705541334,"score_spread":0.3611086079638968,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3119577993","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97880024,0.0132265445,0.000022575743,0.00695555,0.0004545238,0.00036239467,0.000028811695,0.000023810782,0.00012557438],"genre_scores_gemma":[0.9941038,0.002212232,0.0006210767,0.002015052,0.000118961776,0.000041687985,0.0000041136236,0.000023689074,0.0008593953],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99797726,0.00022001873,0.00095666293,0.00037514287,0.0002469452,0.0002239567],"domain_scores_gemma":[0.9984061,0.0005719824,0.00018471782,0.00040251514,0.00024219207,0.00019248301],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013020498,0.0001533381,0.00057371886,0.000063261214,0.000041359996,0.000015620477,0.00008082822,0.00009385656,0.00033553506],"category_scores_gemma":[0.0012126495,0.00012545416,0.00022986968,0.00039211535,0.0002487563,0.000054731932,0.00008558321,0.00022937189,0.0000064467235],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.033584442,0.0003573903,0.100221165,0.00041489702,0.00078920776,0.0001737914,0.0006226467,0.000015140862,0.8225474,0.00001917195,0.0010419621,0.040212825],"study_design_scores_gemma":[0.005115726,0.0009860775,0.79646164,0.0016360194,0.00039874436,0.000053786203,0.0002768217,0.0000636107,0.17150491,0.000036506714,0.023196135,0.0002700464],"about_ca_topic_score_codex":0.0002456891,"about_ca_topic_score_gemma":0.00008618279,"teacher_disagreement_score":0.6962404,"about_ca_system_score_codex":0.00011657998,"about_ca_system_score_gemma":0.0006793964,"threshold_uncertainty_score":0.5115872},"labels":[],"label_agreement":null},{"id":"W3119896753","doi":"10.1016/j.cllc.2021.01.002","title":"Systemic Inflammatory Markers of Survival in Epidermal Growth Factor–Mutated Non–Small-Cell Lung Cancer: Single-Institution Analysis, Systematic Review, and Meta-analysis","year":2021,"lang":"en","type":"review","venue":"Clinical Lung Cancer","topic":"Inflammatory Biomarkers in Disease Prognosis","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ontario Institute for Cancer Research; Public Health Ontario; University of Toronto","funders":"Department of Medicine, University of Toronto; Canadian Cancer Society","keywords":"Medicine; Hazard ratio; Internal medicine; Oncology; Lung cancer; Proportional hazards model; Stage (stratigraphy); Lactate dehydrogenase; Survival analysis; Progression-free survival; Confidence interval; Biology; Overall survival","score_opus":0.0801614749059747,"score_gpt":0.4071722007273196,"score_spread":0.3270107258213449,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3119896753","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00090575457,0.98897606,0.0001198432,0.00008203802,0.0004563056,0.008374569,0.0008893234,0.000072844894,0.0001232857],"genre_scores_gemma":[0.00455637,0.99059004,0.0001096925,0.00024726737,0.00013712436,0.0034792756,0.000515576,0.00011650825,0.00024815297],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9838931,0.004316125,0.008186845,0.0018407693,0.001018244,0.00074493996],"domain_scores_gemma":[0.9895949,0.0021217372,0.004884455,0.0017368887,0.0010352277,0.00062682974],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":["metaepi_narrow","metaepi_broad"],"category_scores_codex":[0.0047110724,0.0013056776,0.026739137,0.0015316376,0.00009618174,0.000066248394,0.00060773414,0.0011109507,0.00064606],"category_scores_gemma":[0.001794137,0.0009902569,0.010854962,0.005148849,0.0004168407,0.00016057333,0.0003268405,0.0011886241,0.000004703449],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000046893365,0.00016031432,0.043314423,0.6235029,0.3322324,0.00018976591,0.000019067038,0.000016764774,5.255801e-7,0.0000034112143,0.00014892129,0.00036459233],"study_design_scores_gemma":[0.00065067806,0.000034915687,0.0012324156,0.1525425,0.843957,0.000014498019,0.00002357136,0.00055248756,0.0000025326185,2.5715224e-7,0.00028710198,0.000702004],"about_ca_topic_score_codex":0.00026271425,"about_ca_topic_score_gemma":0.00040466446,"teacher_disagreement_score":0.51172465,"about_ca_system_score_codex":0.0014233238,"about_ca_system_score_gemma":0.002638774,"threshold_uncertainty_score":0.9999695},"labels":[],"label_agreement":null},{"id":"W3120580407","doi":"10.1016/j.cllc.2021.01.001","title":"Phase 2 Study of Talazoparib in Patients With Homologous Recombination Repair–Deficient Squamous Cell Lung Cancer: Lung-MAP Substudy S1400G","year":2021,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; National Institutes of Health; Pfizer","keywords":"Medicine; Homologous recombination; Lung cancer; Cancer research; Lung; Homologous chromosome; Oncology; Internal medicine; DNA; Biology; Genetics","score_opus":0.026244174818530565,"score_gpt":0.40082861854724255,"score_spread":0.37458444372871197,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3120580407","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9883708,0.0056869215,0.000040093964,0.00045330802,0.0018874719,0.002886204,0.00011635447,0.00011896264,0.00043991936],"genre_scores_gemma":[0.9968655,0.00038958117,0.000107108855,0.00059992785,0.00021333211,0.00083246414,0.000113676346,0.00007309099,0.00080527813],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9954491,0.0004842902,0.0016455117,0.0010612244,0.0008443722,0.0005154616],"domain_scores_gemma":[0.99681795,0.00043603318,0.00066150405,0.0009021552,0.0009285003,0.00025385496],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008084322,0.00036505325,0.0011171749,0.00019034666,0.0001082842,0.000019942692,0.00019081174,0.00023955308,0.00078140455],"category_scores_gemma":[0.00019332269,0.00032582518,0.00024455128,0.00086774677,0.00018237693,0.00012917866,0.000099085664,0.00075152685,0.0000049857676],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034453946,0.02988156,0.95386577,0.00041901777,0.00027864656,0.0001462378,0.0011545136,0.0004353799,0.00006645667,0.000010235693,0.008452301,0.0018444762],"study_design_scores_gemma":[0.11535675,0.010096442,0.8643635,0.00095123466,0.0013632051,0.0000050779367,0.00083316583,0.0038804663,0.0014466941,0.000015710666,0.0010155123,0.0006722467],"about_ca_topic_score_codex":0.0005060324,"about_ca_topic_score_gemma":0.00085038296,"teacher_disagreement_score":0.11191136,"about_ca_system_score_codex":0.0011401577,"about_ca_system_score_gemma":0.0009835851,"threshold_uncertainty_score":0.99991935},"labels":[],"label_agreement":null},{"id":"W3127357052","doi":"10.1016/j.cllc.2021.01.014","title":"Outcomes of Patients With Interstitial Lung Disease Receiving Programmed Cell Death 1 Inhibitors: A Retrospective Case Series","year":2021,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Institutes of Health; National Cancer Institute; Scleroderma Foundation; National Heart, Lung, and Blood Institute; Francis Family Foundation","keywords":"Medicine; Pembrolizumab; Interstitial lung disease; Pneumonitis; Nivolumab; Lung cancer; Internal medicine; Respiratory failure; Retrospective cohort study; Cancer; Lung; Immunotherapy","score_opus":0.017857843154615218,"score_gpt":0.3471131015781794,"score_spread":0.3292552584235642,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3127357052","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99555886,0.001515245,0.000044481953,0.00083231984,0.00090023706,0.0006853249,0.00014635366,0.000047453665,0.00026972155],"genre_scores_gemma":[0.99747443,0.00026458307,0.00041670553,0.0005141842,0.0002832224,0.00009522317,0.00005171355,0.000034581706,0.0008653791],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982891,0.0000935193,0.0006171209,0.00043597395,0.00030281697,0.00026146744],"domain_scores_gemma":[0.998603,0.0001397316,0.00024537105,0.00035705068,0.0004143075,0.0002405686],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020131987,0.0001983247,0.0005552529,0.00004243404,0.00006897022,0.00002381693,0.00006305853,0.000103630904,0.00034196544],"category_scores_gemma":[0.00029164384,0.00014458569,0.00028878736,0.00024156387,0.0002409255,0.00012385602,0.00006377964,0.00027813044,8.656692e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008032505,0.0007056012,0.98319376,0.00031122108,0.0005276128,0.0008315381,0.00020224327,9.885619e-7,0.00003221331,0.0000061408864,0.0013190504,0.0048371404],"study_design_scores_gemma":[0.006646573,0.0006337935,0.9894745,0.00071154634,0.00064800965,0.00002771671,0.00014984612,0.000052930256,0.00043980186,0.000009409105,0.0009940102,0.00021190534],"about_ca_topic_score_codex":0.00013442498,"about_ca_topic_score_gemma":0.0003020096,"teacher_disagreement_score":0.0062807137,"about_ca_system_score_codex":0.00029929544,"about_ca_system_score_gemma":0.00055922515,"threshold_uncertainty_score":0.5896033},"labels":[],"label_agreement":null},{"id":"W3127862010","doi":"10.1016/j.cllc.2021.01.018","title":"Immunotherapy and Stereotactic Ablative Radiotherapy for Lung Cancer with Co-existing Interstitial Lung Disease: A Case Report","year":2021,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; University of Toronto","funders":"","keywords":"Medicine; Lung cancer; Interstitial lung disease; Pembrolizumab; Lung; Radiation therapy; Oncology; Internal medicine; Treatment of lung cancer; Cancer; Immunotherapy","score_opus":0.036928143805845616,"score_gpt":0.43253017683435396,"score_spread":0.3956020330285083,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3127862010","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8481728,0.12077758,0.015439649,0.0061168824,0.0028746694,0.0036746634,0.0014192122,0.00022405841,0.0013005179],"genre_scores_gemma":[0.98131156,0.0052314983,0.0014738496,0.0035661731,0.002745688,0.0009014327,0.00019256934,0.00015456109,0.0044226944],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99721026,0.00015240668,0.0008900744,0.00093098544,0.00031352,0.0005027642],"domain_scores_gemma":[0.9974952,0.00054703944,0.00038732673,0.0005182766,0.0004865566,0.000565646],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00040781588,0.0003813531,0.00084523304,0.00006753362,0.00028542572,0.00009784664,0.0000940972,0.00017100661,0.00066764036],"category_scores_gemma":[0.00026055373,0.00031345777,0.00040584212,0.0001829816,0.00035327938,0.00020946887,0.000045967674,0.00044881704,4.93529e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.099241026,0.0012788634,0.6382416,0.004735654,0.00911572,0.1957096,0.0013229656,0.00011584099,0.0011173658,0.0004746407,0.025395231,0.023251532],"study_design_scores_gemma":[0.07234573,0.01419147,0.13890734,0.03351868,0.022662789,0.082193375,0.0021377034,0.5116688,0.00084610796,0.00018751831,0.115195945,0.0061445446],"about_ca_topic_score_codex":0.00030797653,"about_ca_topic_score_gemma":0.000101179874,"teacher_disagreement_score":0.51155293,"about_ca_system_score_codex":0.00051374314,"about_ca_system_score_gemma":0.0013539701,"threshold_uncertainty_score":0.99993175},"labels":[],"label_agreement":null},{"id":"W3129762211","doi":"10.1016/j.cllc.2021.02.011","title":"Lung Resection Without Tissue Diagnosis: A Pragmatic Perspective on the Indeterminate Pulmonary Nodule","year":2021,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CancerCare Manitoba; Research Institute in Oncology and Hematology; University of Manitoba","funders":"University of Manitoba","keywords":"Medicine; Malignancy; Lung cancer; Radiology; Biopsy; Indeterminate; Nodule (geology); Cancer; Cohort; Lung; Surgery; Internal medicine","score_opus":0.03337536294622753,"score_gpt":0.4280829197358462,"score_spread":0.39470755678961866,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3129762211","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8446074,0.020539949,0.00003121082,0.10186142,0.0026126294,0.0025973304,0.000074754964,0.00016365395,0.027511623],"genre_scores_gemma":[0.9823628,0.0051659164,0.00008016166,0.0048345076,0.0012216556,0.0022132648,0.000018519188,0.000051086292,0.004052094],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976969,0.0003173587,0.00051864644,0.0007084262,0.0004199631,0.00033871757],"domain_scores_gemma":[0.99744755,0.0010979009,0.00018764462,0.00070620567,0.00035498568,0.00020570755],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00048655007,0.00024721536,0.0005307016,0.000049713428,0.00019291561,0.00005211139,0.00012342536,0.00018326854,0.0011963072],"category_scores_gemma":[0.0008526138,0.00015845476,0.00026175467,0.00031577155,0.00015238322,0.00008120274,0.00008783724,0.0006035413,0.00006963993],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008207887,0.002369318,0.9157067,0.00043062126,0.0012236156,0.00085598783,0.00062683196,0.000029151777,0.00006919871,0.0015415687,0.05216886,0.02415734],"study_design_scores_gemma":[0.0062711425,0.0022785887,0.9164594,0.007232314,0.003447037,0.00018147028,0.001402832,0.0047853407,0.009885952,0.0012512096,0.046046972,0.0007577538],"about_ca_topic_score_codex":0.00022434653,"about_ca_topic_score_gemma":0.00031260526,"teacher_disagreement_score":0.13775536,"about_ca_system_score_codex":0.0012656059,"about_ca_system_score_gemma":0.000470102,"threshold_uncertainty_score":0.99971676},"labels":[],"label_agreement":null},{"id":"W3131242205","doi":"10.1016/j.cllc.2021.02.010","title":"Patient-Reported Outcomes with Durvalumab With or Without Tremelimumab Versus Standard Chemotherapy as First-Line Treatment of Metastatic Non–Small-Cell Lung Cancer (MYSTIC)","year":2021,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Merck Sharp and Dohme; Bayer Fund; Ipsen Biopharmaceuticals; Merck KGaA; Prince of Songkla University; F. Hoffmann-La Roche; AbbVie; Meso Scale Diagnostics; Sanofi; Roche; EMD Serono; Novartis; MedImmune; GlaxoSmithKline; Eli Lilly and Company; Bristol-Myers Squibb; AstraZeneca; Boehringer Ingelheim; Amgen; Pfizer","keywords":"Durvalumab; Tremelimumab; Medicine; Hazard ratio; Internal medicine; Chemotherapy; Oncology; Lung cancer; Confidence interval; Cancer; Immunotherapy","score_opus":0.05276557928474587,"score_gpt":0.3996062283725302,"score_spread":0.34684064908778434,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3131242205","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98568696,0.007974422,0.00028425257,0.0022647423,0.0008546327,0.002083284,0.00017615713,0.00007805157,0.0005974791],"genre_scores_gemma":[0.97395134,0.014604227,0.0028086565,0.0014829198,0.00026175837,0.00070222904,0.00007713637,0.00016177191,0.005949968],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9963876,0.00011716679,0.0013507176,0.0008664551,0.0007440321,0.00053400436],"domain_scores_gemma":[0.99678606,0.00057375286,0.00078472425,0.000887191,0.00065412297,0.00031416808],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00024329733,0.00056939054,0.0018336963,0.00009005579,0.00012415378,0.000035079796,0.0001239104,0.00016775017,0.0024843898],"category_scores_gemma":[0.000095706084,0.0003277826,0.00044056866,0.00055959256,0.00033460298,0.000080881204,0.000028285289,0.00024843676,0.0000024911703],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.291817,0.0027528156,0.62128335,0.00083792565,0.013403982,0.0007855288,0.0013121016,0.00025087158,0.00043184933,0.00000223799,0.0010312495,0.066091046],"study_design_scores_gemma":[0.54599625,0.09862597,0.19003306,0.006980303,0.03157206,0.0003008816,0.0025447735,0.005264488,0.055162583,0.00001038129,0.060592175,0.0029170453],"about_ca_topic_score_codex":0.0016001461,"about_ca_topic_score_gemma":0.008021668,"teacher_disagreement_score":0.4312503,"about_ca_system_score_codex":0.00093587657,"about_ca_system_score_gemma":0.0038011796,"threshold_uncertainty_score":0.99991745},"labels":[],"label_agreement":null},{"id":"W3147484097","doi":"10.1016/j.cllc.2021.03.011","title":"Three Decades of Malignant Pleural Mesothelioma: An Academic Center Experience","year":2021,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Montfort Hospital; University of Ottawa; Ottawa Hospital","funders":"","keywords":"Medicine; Pemetrexed; Interquartile range; Mesothelioma; Hazard ratio; Cohort; Internal medicine; Retrospective cohort study; Lung cancer; Pleural disease; Surgery; Confidence interval; Chemotherapy; Lung; Respiratory disease; Cisplatin; Pathology","score_opus":0.07487553085075112,"score_gpt":0.45274479987201877,"score_spread":0.37786926902126766,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3147484097","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945307,0.0037705891,0.00005898066,0.0007822566,0.0002913621,0.00013553408,0.00009733287,0.000021735388,0.00031153276],"genre_scores_gemma":[0.9960405,0.0010517387,0.00038152956,0.0016040119,0.0003989751,0.00003621666,0.00005417087,0.000015544323,0.00041729864],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99874437,0.00003654584,0.00046015534,0.00031655727,0.00026878857,0.00017360093],"domain_scores_gemma":[0.99928683,0.00009465427,0.000092429604,0.0002495874,0.000044449404,0.00023203203],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00009539799,0.00010507426,0.0002702666,0.000021092741,0.00003281665,0.000004440223,0.00009949352,0.00010996764,0.0013912166],"category_scores_gemma":[0.00010234092,0.0000812428,0.00015617587,0.000099114106,0.0002242006,0.00009516137,0.000072671246,0.00018433653,0.000015716398],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00033758307,0.00033153972,0.99065655,0.00006054141,0.000053710784,0.000035436835,0.00006408123,0.0000062189238,0.0033119337,0.00011307782,0.001246886,0.003782436],"study_design_scores_gemma":[0.000987599,0.00012425033,0.99175435,0.0002146764,0.00011206899,0.000014239898,0.000075864846,0.00038681197,0.00397995,0.00011795774,0.0021336065,0.00009861571],"about_ca_topic_score_codex":0.000023848424,"about_ca_topic_score_gemma":0.00003262295,"teacher_disagreement_score":0.0036838204,"about_ca_system_score_codex":0.000050555813,"about_ca_system_score_gemma":0.00012229863,"threshold_uncertainty_score":0.9995217},"labels":[],"label_agreement":null},{"id":"W3166324988","doi":"10.1016/j.cllc.2021.05.009","title":"Durvalumab After Concurrent Chemoradiotherapy in Elderly Patients With Unresectable Stage III Non–Small–Cell Lung Cancer (PACIFIC)","year":2021,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre","funders":"Genentech; Daiichi-Sankyo; Merck KGaA; Moffitt Cancer Center; Takeda Pharmaceuticals U.S.A.; Spectrum Pharmaceuticals; Sanofi; Novartis; Merck; GlaxoSmithKline; Eli Lilly and Company; Bristol-Myers Squibb; AstraZeneca; Roche; Astellas Pharma US; Boehringer Ingelheim; Amgen; Pfizer","keywords":"Durvalumab; Medicine; Chemoradiotherapy; Stage (stratigraphy); Lung cancer; Oncology; Internal medicine; Cancer; Immunotherapy","score_opus":0.018877387211315665,"score_gpt":0.3471904455025281,"score_spread":0.32831305829121243,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3166324988","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9672751,0.026592389,0.00011877284,0.00104744,0.0016943461,0.0013781163,0.00017206567,0.000050016115,0.0016717827],"genre_scores_gemma":[0.9726806,0.008925749,0.00019802716,0.0026744294,0.0005894432,0.0007327486,0.00008162842,0.000102151986,0.014015169],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99679846,0.00014358667,0.0009645513,0.00089113635,0.00052907504,0.00067322294],"domain_scores_gemma":[0.9982782,0.00018104124,0.00027175175,0.0006329213,0.00035160506,0.00028446683],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00044921468,0.00039469043,0.0009814274,0.00009517416,0.00007594133,0.000067932895,0.000197141,0.00029065326,0.005227425],"category_scores_gemma":[0.00003388811,0.00031576617,0.00030280827,0.00059922744,0.00022097473,0.00013074777,0.000059480528,0.0007062276,0.000005948883],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00938936,0.0010410822,0.9519863,0.0005732392,0.00050939625,0.00013869582,0.0004249018,0.00002458332,0.00046067167,0.000002240373,0.0076685594,0.027780948],"study_design_scores_gemma":[0.052474413,0.0011754233,0.86959964,0.0022995912,0.0004634723,0.0000040954333,0.00023456835,0.0013863432,0.0027939244,0.0000019647023,0.068721004,0.0008455887],"about_ca_topic_score_codex":0.0009950176,"about_ca_topic_score_gemma":0.0024248166,"teacher_disagreement_score":0.08238671,"about_ca_system_score_codex":0.0007874605,"about_ca_system_score_gemma":0.0015862923,"threshold_uncertainty_score":0.9999294},"labels":[],"label_agreement":null},{"id":"W3184251505","doi":"10.1016/j.cllc.2021.07.002","title":"Safety and Clinical Activity of Atezolizumab Plus Ipilimumab in Locally Advanced or Metastatic Non–Small Cell Lung Cancer: Results From a Phase 1b Trial","year":2021,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"F. Hoffmann-La Roche; Roche","keywords":"Atezolizumab; Medicine; Ipilimumab; Internal medicine; Tolerability; Lung cancer; Adverse effect; Oncology; Population; Common Terminology Criteria for Adverse Events; Cancer; Nivolumab; Immunotherapy","score_opus":0.05774961993168776,"score_gpt":0.4387506707119048,"score_spread":0.38100105078021707,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3184251505","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98120165,0.0106182,0.00046647925,0.001534528,0.0022995966,0.0021454687,0.0012973632,0.00004065434,0.00039604362],"genre_scores_gemma":[0.9452883,0.048986245,0.0013615274,0.0012583046,0.0009029971,0.00018051495,0.00013631622,0.00007107502,0.0018147079],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9943099,0.00064832426,0.0028802895,0.0012052563,0.00042734505,0.0005288921],"domain_scores_gemma":[0.9943683,0.0032934987,0.0008770983,0.0008132337,0.0002706991,0.00037717246],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0017157076,0.00040302527,0.002074182,0.000089252535,0.00007449672,0.00002686781,0.00022001873,0.0003945803,0.0005020007],"category_scores_gemma":[0.001241159,0.00032309012,0.00059406256,0.0005518882,0.0004538926,0.00013658765,0.00015808838,0.0009762831,0.0000020457999],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.75424093,0.0034312776,0.0053568357,0.00036052504,0.0010305045,0.0003120193,0.00025574898,0.000043607215,0.0014633249,0.0000017579787,0.0009888354,0.23251462],"study_design_scores_gemma":[0.92360294,0.0050730756,0.03476788,0.0026128974,0.0022167347,0.000010999413,0.00020431068,0.017883534,0.0041194335,0.000017241533,0.008835979,0.00065496267],"about_ca_topic_score_codex":0.0027069561,"about_ca_topic_score_gemma":0.008422268,"teacher_disagreement_score":0.23185965,"about_ca_system_score_codex":0.0006121422,"about_ca_system_score_gemma":0.004781746,"threshold_uncertainty_score":0.9999221},"labels":[],"label_agreement":null},{"id":"W3187683534","doi":"10.1016/j.cllc.2021.08.003","title":"Treatment Patterns and Outcomes of Patients With Advanced Pleural Mesothelioma at an Academic Referral Centre","year":2021,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Oakville-Trafalgar Memorial Hospital; University Health Network; Princess Margaret Cancer Centre","funders":"Swiss Cancer Research Foundation","keywords":"Medicine; Systemic therapy; Cohort; Internal medicine; Referral; Retrospective cohort study; Mesothelioma; Clinical trial; Lung cancer; Pleural disease; Cancer registry; Cancer; Respiratory disease; Lung; Family medicine; Pathology","score_opus":0.03065030722444028,"score_gpt":0.3861032261572204,"score_spread":0.35545291893278014,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3187683534","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9979171,0.00061292085,0.0000011090167,0.0006380604,0.00010162108,0.00022292433,0.0004220911,0.0000143920615,0.00006974097],"genre_scores_gemma":[0.9968214,0.0007137733,0.000105230676,0.0005921275,0.00006662908,0.000017691864,0.0003413775,0.000016151811,0.0013255938],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990333,0.000040895975,0.00029980618,0.00028537752,0.00020152019,0.00013914745],"domain_scores_gemma":[0.9993946,0.00008527033,0.000093824456,0.00017663867,0.00003723159,0.0002124582],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000022322733,0.00012710562,0.00032316745,0.000015336189,0.000032776996,0.000002554105,0.000031389405,0.00006878659,0.00049099047],"category_scores_gemma":[0.000027595148,0.00008085009,0.000081244136,0.00003819132,0.00008902978,0.00006696761,0.000043023454,0.00008157017,0.000003333737],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012652222,0.0005096457,0.9872585,0.000047722486,0.00016110425,0.000013464146,0.000045469355,0.000007958519,0.00003778233,0.000006813213,0.00007350513,0.010572825],"study_design_scores_gemma":[0.0042410973,0.00058855076,0.9936887,0.000082550425,0.00031094215,0.0000014522611,0.000037081634,0.000050725546,0.0002487835,0.000005310587,0.00065101206,0.0000938121],"about_ca_topic_score_codex":0.000028138997,"about_ca_topic_score_gemma":0.0001066818,"teacher_disagreement_score":0.0104790125,"about_ca_system_score_codex":0.00014104614,"about_ca_system_score_gemma":0.00005388105,"threshold_uncertainty_score":0.5376001},"labels":[],"label_agreement":null},{"id":"W3194655971","doi":"10.1016/j.cllc.2021.08.001","title":"Neutrophil-to-lymphocyte ratio is correlated to driver gene mutations in surgically-resected non-small cell lung cancer and its post-operative evolution impacts outcomes","year":2021,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Inflammatory Biomarkers in Disease Prognosis","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Lung cancer; Internal medicine; Neutrophil to lymphocyte ratio; Gastroenterology; Transthyretin; Univariate analysis; Multivariate analysis; Adenocarcinoma; Clinical endpoint; Lymphocyte; Cancer; Oncology; Surgery","score_opus":0.01924254206241358,"score_gpt":0.3662186233797291,"score_spread":0.3469760813173155,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3194655971","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9852786,0.005386107,0.00009750169,0.0056539294,0.0009343078,0.0020498466,0.00034885202,0.000069688664,0.00018116541],"genre_scores_gemma":[0.9895812,0.0009928945,0.0005389008,0.0064808005,0.00024779706,0.0006044686,0.00010634338,0.00006145749,0.001386113],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99689364,0.00026071563,0.00102747,0.000885374,0.00037072028,0.000562103],"domain_scores_gemma":[0.99690396,0.00047329778,0.00018021915,0.00039887623,0.0011920489,0.0008516306],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00034852096,0.0003602396,0.00077290914,0.00022807205,0.00015385388,0.000061172104,0.00014594983,0.00034753708,0.0007686438],"category_scores_gemma":[0.0008324713,0.00032594186,0.00023100631,0.0008932489,0.00009409074,0.00015494114,0.00020574067,0.0004402055,0.000046902664],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015284439,0.00033570654,0.9671628,0.00022870128,0.0005061674,0.00043750074,0.0011713923,0.00074988254,0.023875717,0.000014599663,0.0033424739,0.00064661686],"study_design_scores_gemma":[0.0060126134,0.00017536132,0.96834946,0.00059678376,0.00062859437,0.00000839154,0.00009354527,0.015947018,0.0075687533,0.0000037431519,0.00022520652,0.0003905269],"about_ca_topic_score_codex":0.00035913178,"about_ca_topic_score_gemma":0.0011680219,"teacher_disagreement_score":0.016306965,"about_ca_system_score_codex":0.0011494794,"about_ca_system_score_gemma":0.0023633707,"threshold_uncertainty_score":0.99991924},"labels":[],"label_agreement":null},{"id":"W3203387497","doi":"10.1016/j.cllc.2021.09.006","title":"Longitudinal Assessment of Health Utility Scores, Symptoms and Toxicities in Patients with Small Cell Lung Cancer Using Real World Data","year":2021,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Internal medicine; Disease; Lung cancer; Depression (economics); Anxiety; Performance status; Medical record; Cohort; Cancer; Pathological; Chemotherapy; Psychiatry","score_opus":0.17221650362404584,"score_gpt":0.5071352465686404,"score_spread":0.33491874294459456,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3203387497","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9842635,0.012472729,0.00011051709,0.0010214386,0.0003158599,0.0009499187,0.00043841702,0.000021926993,0.00040569162],"genre_scores_gemma":[0.9908512,0.006218909,0.0018279032,0.00037325936,0.00021602432,0.000065161315,0.0001085406,0.000035184803,0.00030380773],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965589,0.00033597744,0.0009938414,0.0009004591,0.0006488041,0.0005619966],"domain_scores_gemma":[0.99763596,0.00043169237,0.00038776742,0.00088448357,0.0004026276,0.00025745638],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012454591,0.0002424011,0.0011207367,0.000117295334,0.000106530155,0.000027762002,0.00022135848,0.00006721408,0.00012302583],"category_scores_gemma":[0.00016455972,0.00019186943,0.00006722646,0.00053313904,0.00057270343,0.00014045346,0.0006727832,0.000617534,1.3270018e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005106226,0.00048603845,0.9865489,0.0017044266,0.0003544029,0.000021736418,0.00010159793,0.00003144054,0.0000045168963,0.000014413075,0.0013538791,0.008868024],"study_design_scores_gemma":[0.0040947697,0.00034709665,0.9868103,0.0022920375,0.00026027564,5.9865556e-7,0.0000672471,0.0056881364,0.000023578443,0.000004426387,0.00023779261,0.0001737014],"about_ca_topic_score_codex":0.010829166,"about_ca_topic_score_gemma":0.03795623,"teacher_disagreement_score":0.027127067,"about_ca_system_score_codex":0.0009193894,"about_ca_system_score_gemma":0.0038006778,"threshold_uncertainty_score":0.9957578},"labels":[],"label_agreement":null},{"id":"W3207399235","doi":"10.1016/j.cllc.2021.10.001","title":"Clinical Outcomes for Plasma-Based Comprehensive Genomic Profiling Versus Standard-of-Care Tissue Testing in Advanced Non–Small Cell Lung Cancer","year":2021,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Lung cancer; Genotyping; Internal medicine; Oncology; ROS1; Guideline; Prospective cohort study; Clinical trial; Biomarker; Cancer; Genotype; Pathology; Adenocarcinoma","score_opus":0.0745080612710012,"score_gpt":0.47380908286018025,"score_spread":0.3993010215891791,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3207399235","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9826998,0.00848364,0.00044944466,0.00066756696,0.0032280388,0.0029253073,0.0007170706,0.00006386767,0.0007652438],"genre_scores_gemma":[0.9421444,0.0007091617,0.053490162,0.0009072347,0.000616622,0.001186078,0.00025358965,0.00010788267,0.00058487646],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9966742,0.00012568673,0.0015514643,0.0008653491,0.00027206342,0.00051126495],"domain_scores_gemma":[0.9939755,0.0036491887,0.00049025804,0.00049917126,0.0011108795,0.00027497858],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000272561,0.0003414969,0.0014018426,0.00008989882,0.000114877,0.00002219542,0.0001561221,0.00028792128,0.00010763036],"category_scores_gemma":[0.000859966,0.00030417333,0.00045745634,0.00033884824,0.00014951141,0.00006662534,0.00008173197,0.0005100318,0.0000027834758],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0044179275,0.0003659037,0.94392335,0.00164347,0.0005757279,0.00007348487,0.00022821185,0.004115177,0.00050092995,0.000014894889,0.00036917016,0.043771755],"study_design_scores_gemma":[0.11231679,0.005517935,0.8083883,0.004380707,0.0070105614,0.0000034065008,0.0021402976,0.03223603,0.0138607705,0.00002491811,0.01292106,0.0011992314],"about_ca_topic_score_codex":0.00015253769,"about_ca_topic_score_gemma":0.0012464804,"teacher_disagreement_score":0.13553505,"about_ca_system_score_codex":0.00084098906,"about_ca_system_score_gemma":0.00431724,"threshold_uncertainty_score":0.99994105},"labels":[],"label_agreement":null},{"id":"W4220881379","doi":"10.1016/j.cllc.2022.03.002","title":"Safety of Tepotinib in Patients With MET Exon 14 Skipping NSCLC and Recommendations for Management","year":2022,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Cilag; National Cancer Institute; Chugai Pharmaceutical; EMD Serono; Samsung; Genentech; Ipsen; Ono Pharmaceutical; Servier; Les Laboratories Pierre Fabre; Taiho Pharmaceutical; Regeneron Pharmaceuticals; Teva Pharmaceutical Industries; Yuhan; Merck KGaA; Daiichi Sankyo Europe; Sanofi; Amgen; Pfizer; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Nausea; Vomiting; Hypoalbuminemia; Internal medicine; Pleural effusion; Adverse effect; Discontinuation; Gastroenterology; Tolerability; Creatinine; Diarrhea","score_opus":0.027452091176557177,"score_gpt":0.41042706575234256,"score_spread":0.3829749745757854,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220881379","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9813508,0.000976427,0.00080519967,0.0061239316,0.00092021085,0.0048630866,0.00069811643,0.000039199393,0.004223061],"genre_scores_gemma":[0.9920257,0.0002078171,0.0048242435,0.0008745496,0.000048708687,0.00085965724,0.0002509112,0.00001916553,0.00088930107],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990591,0.00004275812,0.0004040885,0.00023148581,0.00013633631,0.00012626301],"domain_scores_gemma":[0.9994341,0.0001655031,0.00013461141,0.00014728328,0.000059975908,0.00005849179],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024223271,0.00007460484,0.00024446854,0.000071046656,0.00008351249,0.000004030132,0.000041429423,0.000023262653,0.00019486278],"category_scores_gemma":[0.00002860894,0.00006256237,0.000052638363,0.0001623872,0.000038043054,0.000038542486,0.000056852692,0.00011314967,2.1114641e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013763596,0.0006844447,0.8613342,0.0001316188,0.0005433395,0.0000028265245,0.0002699771,0.00008500643,6.936784e-7,0.00061083236,0.0042434926,0.13071719],"study_design_scores_gemma":[0.014097735,0.0009836667,0.9413054,0.00024157108,0.0007142881,4.800605e-7,0.00028978576,0.00012435726,0.0000027480103,0.00006903679,0.042074498,0.0000964125],"about_ca_topic_score_codex":0.00003948902,"about_ca_topic_score_gemma":0.000040212904,"teacher_disagreement_score":0.13062078,"about_ca_system_score_codex":0.00019967319,"about_ca_system_score_gemma":0.00008468877,"threshold_uncertainty_score":0.25512195},"labels":[],"label_agreement":null},{"id":"W4232272905","doi":"10.1016/s1525-7304(11)70331-x","title":"2003 Highlights From: 10th World Conference on Lung Cancer Vancouver, British Columbia, Canada August 10-14, 2003","year":2003,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Lung cancer; Family medicine; Gerontology; Oncology","score_opus":0.031852679934469046,"score_gpt":0.3582101110860964,"score_spread":0.32635743115162735,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4232272905","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.35075775,0.06270716,0.00020982715,0.007789948,0.070291534,0.009582571,0.008924157,0.0006968972,0.48904017],"genre_scores_gemma":[0.2801837,0.004791544,0.00060017215,0.010162374,0.0013725939,0.0010093359,0.00025345891,0.00013141635,0.7014954],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9962981,0.00018436815,0.0009858427,0.0010642181,0.0007026329,0.0007648704],"domain_scores_gemma":[0.99674326,0.0002597517,0.0003396997,0.00067859906,0.0011946214,0.00078409485],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00020492118,0.00036234112,0.0009534248,0.00005267592,0.00032591267,0.00016802622,0.0002233426,0.00024962018,0.043882288],"category_scores_gemma":[0.00049445656,0.00042350838,0.00016291007,0.0009327419,0.00019673292,0.00014496705,0.000036905578,0.0005984125,0.000032685308],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000104857856,0.00030365828,0.19413324,0.00006381626,0.00079342356,0.00021702066,0.000024352337,0.00002215658,0.0000032157282,0.0001460357,0.79973596,0.0044522677],"study_design_scores_gemma":[0.0062685614,0.00018916964,0.101699755,0.0013551022,0.0017672342,0.000004860776,0.00003600048,0.00035692877,0.000056013054,0.00007726663,0.8875843,0.0006047601],"about_ca_topic_score_codex":0.9035236,"about_ca_topic_score_gemma":0.9968689,"teacher_disagreement_score":0.21245526,"about_ca_system_score_codex":0.0022060224,"about_ca_system_score_gemma":0.011345504,"threshold_uncertainty_score":0.99982166},"labels":[],"label_agreement":null},{"id":"W4255131969","doi":"10.1016/j.cllc.2014.09.003","title":"Weekly nab-Paclitaxel in Combination With Carboplatin as First-Line Therapy in Patients With Advanced Non–Small-Cell Lung Cancer: Analysis of Safety and Efficacy in Patients With Renal Impairment","year":2014,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Celgene","keywords":"Medicine; Internal medicine; Carboplatin; Tolerability; Lung cancer; Renal function; Urology; Gastroenterology; Creatinine; Kidney disease; Population; Oncology; Chemotherapy; Adverse effect","score_opus":0.007468378888666048,"score_gpt":0.3285392792150845,"score_spread":0.3210709003264185,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4255131969","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961505,0.00045098638,0.000084866835,0.00042382433,0.00006910235,0.0025247363,0.000079937105,0.000015004081,0.0002010305],"genre_scores_gemma":[0.99806,0.00057460426,0.00037937792,0.0002577883,0.000026312411,0.0002932064,0.00026444017,0.000040003695,0.00010425228],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99755573,0.00012139331,0.00090926234,0.0006229249,0.00044140496,0.00034929073],"domain_scores_gemma":[0.9983928,0.00031190005,0.0004626867,0.00036264438,0.00029598622,0.000173957],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031544812,0.00031002954,0.0009966444,0.00037428638,0.00005250704,0.00001288892,0.00009262554,0.00012978754,0.000051188992],"category_scores_gemma":[0.000049142305,0.00020567172,0.00008197949,0.0011513551,0.00012681972,0.00012485878,0.000029279787,0.00031834547,3.151887e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012215586,0.0039495374,0.95703334,0.00011669095,0.000918036,0.0000046061737,0.00078011357,0.010158837,0.0000017739202,0.0000069705343,0.000014649034,0.014799842],"study_design_scores_gemma":[0.06890602,0.0068964367,0.9163746,0.0010129338,0.0012421847,8.517887e-8,0.000040331608,0.0052187024,0.000016479014,0.0000029677572,0.00005646663,0.00023278146],"about_ca_topic_score_codex":0.0024734382,"about_ca_topic_score_gemma":0.011348729,"teacher_disagreement_score":0.056690432,"about_ca_system_score_codex":0.0006836432,"about_ca_system_score_gemma":0.00038731293,"threshold_uncertainty_score":0.83870494},"labels":[],"label_agreement":null},{"id":"W4280491580","doi":"10.1016/j.cllc.2022.05.004","title":"Neoadjuvant Prehabilitation Therapy for Locally Advanced Non–Small-Cell Lung Cancer: Optimizing Outcomes Throughout the Trajectory of Care","year":2022,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Cancer survivorship and care","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cégep de l'Outaouais; McGill University; McGill University Health Centre","funders":"","keywords":"Prehabilitation; Medicine; Neoadjuvant therapy; Lung cancer; Physical therapy; Oncology; Internal medicine; Cancer","score_opus":0.029155886877714966,"score_gpt":0.4066167116200266,"score_spread":0.37746082474231163,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4280491580","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91639596,0.06742956,0.0015583014,0.0037659195,0.004656507,0.004903801,0.00055385585,0.00009393149,0.0006421697],"genre_scores_gemma":[0.9860818,0.0035244494,0.0009800952,0.0035184044,0.00050037884,0.004396191,0.000074440984,0.00008724228,0.0008370118],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973796,0.00021867637,0.0009239011,0.0006052783,0.00046886015,0.00040366594],"domain_scores_gemma":[0.9971062,0.0012982837,0.0003976344,0.00064269104,0.00042002037,0.00013515857],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006712653,0.00028298062,0.0008434078,0.00005805359,0.00028498127,0.000015333317,0.0003543822,0.00013096009,0.00033040496],"category_scores_gemma":[0.00011764778,0.00020497214,0.0007531955,0.00027342953,0.00018184524,0.00007378341,0.000108745386,0.0005921267,4.3631297e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006537703,0.0005822256,0.7358471,0.0022715165,0.00076129363,0.0000064049227,0.02328338,0.023485776,0.0010700157,0.000064072505,0.005231566,0.20085897],"study_design_scores_gemma":[0.06515505,0.015030783,0.6036027,0.0025575182,0.0048251203,0.00000888522,0.08403947,0.039223384,0.007882105,0.00017054153,0.17471841,0.0027860035],"about_ca_topic_score_codex":0.0010652326,"about_ca_topic_score_gemma":0.0020057568,"teacher_disagreement_score":0.19807296,"about_ca_system_score_codex":0.0005753076,"about_ca_system_score_gemma":0.0012174873,"threshold_uncertainty_score":0.83585215},"labels":[],"label_agreement":null},{"id":"W4293538919","doi":"10.1016/j.cllc.2022.08.012","title":"Combination Intravenous Immune Globulin (IVIG) and High Dose Steroids for Treatment of Immune-Related Myelitis in a Non-Small Cell Lung Cancer Patient Treated With Pembrolizumab and Palliative Radiation Treatment: A Case Report","year":2022,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kingston Health Sciences Centre; Queen's University","funders":"","keywords":"Medicine; Myelitis; Immunosuppression; Pembrolizumab; Immune system; Radiation therapy; Lung cancer; Combination therapy; Immunology; Oncology; Internal medicine; Immunotherapy; Spinal cord","score_opus":0.017116082278763618,"score_gpt":0.3256398879880671,"score_spread":0.3085238057093035,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4293538919","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9740356,0.02005125,0.00003843502,0.0004803915,0.00018183918,0.0044308663,0.0007230502,0.000024518062,0.000034000004],"genre_scores_gemma":[0.9898784,0.005477164,0.00027545917,0.00004724244,0.000044206667,0.0032509072,0.0006215339,0.000048028545,0.00035702653],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973626,0.00022629747,0.0012424081,0.0006480425,0.0001981744,0.00032246622],"domain_scores_gemma":[0.99826175,0.00037603284,0.0007183353,0.00033768432,0.00013814005,0.00016803978],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00026440388,0.0003521834,0.0010355178,0.00013516941,0.00017390585,0.000017511571,0.000036782967,0.00012264775,0.000094136325],"category_scores_gemma":[0.000028883234,0.00026594038,0.00018893006,0.0002685948,0.000118729964,0.00005423493,0.0000390116,0.00012897908,1.610644e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013991852,0.009185101,0.5739341,0.00056354975,0.0034212465,0.014224308,0.0076469295,0.0009439491,0.0002165878,0.000055811117,0.000046654255,0.37576994],"study_design_scores_gemma":[0.113077134,0.042278532,0.814098,0.00051112415,0.0054466794,0.0017688178,0.0009250091,0.01905044,0.0018624632,0.00004289857,0.00038204095,0.0005568817],"about_ca_topic_score_codex":0.013471875,"about_ca_topic_score_gemma":0.0009405118,"teacher_disagreement_score":0.37521306,"about_ca_system_score_codex":0.0016371281,"about_ca_system_score_gemma":0.00037226226,"threshold_uncertainty_score":0.99997926},"labels":[],"label_agreement":null},{"id":"W4297178813","doi":"10.1016/j.cllc.2022.09.007","title":"Real-World Treatment Sequencing, Toxicities, Health Utilities, and Survival Outcomes in Patients with Advanced ALK-Rearranged Non-Small-Cell Lung Cancer","year":2022,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Takeda (Canada); University Health Network","funders":"Takeda Canada; Swiss Cancer Research Foundation","keywords":"Medicine; Lung cancer; Oncology; Internal medicine; Crizotinib; Cancer","score_opus":0.03495241721016053,"score_gpt":0.40106089194501493,"score_spread":0.3661084747348544,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4297178813","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9854905,0.004063973,0.000006920794,0.0017997605,0.00096577394,0.0028253738,0.0008062192,0.00007792331,0.003963583],"genre_scores_gemma":[0.978321,0.0032379306,0.00041854347,0.0018418732,0.00015700464,0.0022231955,0.00029487116,0.00008423496,0.013421302],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99713534,0.00020902428,0.00083403004,0.0007574323,0.00045184052,0.0006123357],"domain_scores_gemma":[0.9984398,0.00029185612,0.0003269709,0.00045329967,0.00010814361,0.00037991893],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003055302,0.00038656336,0.0011047,0.00017003379,0.0003160735,0.000023857849,0.00011395546,0.00007005214,0.00055241067],"category_scores_gemma":[0.000020755224,0.0002931014,0.00015245024,0.0003623497,0.00012917584,0.000100478515,0.00008871484,0.0004137071,9.793897e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00096340966,0.00074669666,0.98412067,0.00022067287,0.0005745097,0.000025867079,0.0016849384,0.00033916588,0.0000030622289,0.000030872077,0.0012456372,0.010044497],"study_design_scores_gemma":[0.020512199,0.0023793143,0.967801,0.00031136037,0.00065934676,9.0179407e-7,0.00095890684,0.0005422315,0.000013901642,0.000008964021,0.0064604706,0.00035143798],"about_ca_topic_score_codex":0.027750859,"about_ca_topic_score_gemma":0.034669165,"teacher_disagreement_score":0.019548789,"about_ca_system_score_codex":0.0064714057,"about_ca_system_score_gemma":0.0034023481,"threshold_uncertainty_score":0.99995214},"labels":[],"label_agreement":null},{"id":"W4310725957","doi":"10.1016/j.cllc.2022.11.009","title":"27-gene Immuno-Oncology (IO) Score is Associated With Efficacy of Checkpoint Immunotherapy in Advanced NSCLC: A Retrospective BC Cancer Study","year":2022,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Lung cancer; Internal medicine; Oncology; Cancer; Pembrolizumab; Cohort; Immunotherapy; Nivolumab; Retrospective cohort study; Progression-free survival; PD-L1; Overall survival","score_opus":0.03495201550638214,"score_gpt":0.4031342660278066,"score_spread":0.36818225052142445,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310725957","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9805698,0.012635017,0.000006384944,0.0017827158,0.0013585964,0.0028146645,0.00018059257,0.000066578315,0.00058565073],"genre_scores_gemma":[0.9920201,0.003025562,0.0000646849,0.0020223982,0.00018357528,0.0011480906,0.000035729867,0.00009068842,0.0014091848],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9958085,0.0005256772,0.0015350208,0.0008643641,0.0007093321,0.00055710657],"domain_scores_gemma":[0.99751997,0.00042641058,0.0008956856,0.0007306484,0.00030599552,0.00012130072],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001699545,0.0003760485,0.0015432033,0.00020130815,0.0001694189,0.000012179265,0.00037027575,0.00020646877,0.0034024888],"category_scores_gemma":[0.00020286691,0.00031526643,0.0004383667,0.0012847491,0.0003839935,0.00008399561,0.00015227727,0.0010831396,0.0000018141768],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.059063144,0.0055858735,0.87558913,0.00003670019,0.003244885,0.00011927644,0.0039731576,0.000119026794,0.01270403,0.0000041143953,0.0015568727,0.038003787],"study_design_scores_gemma":[0.047692288,0.009270397,0.9346491,0.00046807315,0.00038555288,0.000011013137,0.0012854835,0.00011190729,0.001571898,0.0000141086875,0.0041325404,0.0004076246],"about_ca_topic_score_codex":0.0026432471,"about_ca_topic_score_gemma":0.0020061508,"teacher_disagreement_score":0.059059985,"about_ca_system_score_codex":0.0033142944,"about_ca_system_score_gemma":0.0017733438,"threshold_uncertainty_score":0.99992996},"labels":[],"label_agreement":null},{"id":"W4312208458","doi":"10.1016/j.cllc.2022.12.009","title":"Prevalence and Predictability of Occult Satellite Nodules in Clinical Stage Ia Non-small Cell Lung Cancer following Lobectomy","year":2022,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"National Center for Advancing Translational Sciences; Georgia Clinical and Translational Science Alliance; American College of Surgeons; National Institutes of Health; American Cancer Society","keywords":"Medicine; Stage (stratigraphy); Adenocarcinoma; Lung cancer; Nodule (geology); Occult; Radiology; Solitary pulmonary nodule; Lymphovascular invasion; Lymph node; Cancer; Internal medicine; Lung; Oncology; Pathology; Metastasis","score_opus":0.02973051381325117,"score_gpt":0.40461349498390053,"score_spread":0.3748829811706494,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4312208458","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95061976,0.043869376,0.000012386878,0.0008816809,0.0015310709,0.0019345814,0.00036917956,0.00004482728,0.0007371377],"genre_scores_gemma":[0.9724003,0.024059713,0.0003136539,0.0008200075,0.00037345788,0.0010497276,0.000024181076,0.00004780783,0.0009111246],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99546295,0.00044706368,0.001883996,0.0011460359,0.00054516067,0.00051480177],"domain_scores_gemma":[0.9970885,0.0012126177,0.00048191077,0.00072462676,0.000121172234,0.0003711517],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002144711,0.00033568323,0.0012100152,0.00008968838,0.00011989655,0.000019169353,0.00026071584,0.00020794405,0.000767823],"category_scores_gemma":[0.00023611829,0.000290257,0.00058504735,0.00035101114,0.0002656289,0.00009885293,0.00037767363,0.00094997615,0.0000018317158],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000735398,0.0015454048,0.9868552,0.0023090872,0.00039966454,0.0000865643,0.00030864164,0.00011881832,0.000029090465,0.000011248828,0.0015344595,0.0060664276],"study_design_scores_gemma":[0.0072218794,0.00071709557,0.98349106,0.0010455007,0.0011350871,0.0000017633822,0.00008936632,0.0018037474,0.00015600969,0.000007161633,0.004059914,0.0002714148],"about_ca_topic_score_codex":0.001540278,"about_ca_topic_score_gemma":0.0010340401,"teacher_disagreement_score":0.021780567,"about_ca_system_score_codex":0.0008240249,"about_ca_system_score_gemma":0.0009663044,"threshold_uncertainty_score":0.99995494},"labels":[],"label_agreement":null},{"id":"W4317548432","doi":"10.1016/j.cllc.2022.12.014","title":"Lung Immune Therapy Evaluation (LITE) Risk, a Novel Prognostic Model for Patients With Advanced Non-Small Cell Lung Cancer Treated With Immune Checkpoint Blockade","year":2023,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Health Services; Foothills Medical Centre; Alberta Cancer Foundation; University of Calgary","funders":"","keywords":"Medicine; Internal medicine; Cohort; Oncology; Proportional hazards model; Lung cancer; Framingham Risk Score; non-small cell lung cancer (NSCLC); Atezolizumab; Cancer; Nivolumab; Immunotherapy; Disease","score_opus":0.035899805712855636,"score_gpt":0.36607902581447854,"score_spread":0.33017922010162293,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4317548432","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9742953,0.011380514,0.0031838266,0.0006017645,0.00057659094,0.009236044,0.00038487665,0.00022309207,0.00011797288],"genre_scores_gemma":[0.98045987,0.007969065,0.0016413558,0.00032682525,0.00036559734,0.006693626,0.00054954813,0.00021501852,0.0017790926],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.995834,0.00012448044,0.0013570593,0.0010662077,0.00078374654,0.00083452824],"domain_scores_gemma":[0.99647784,0.0005245022,0.00088190427,0.0007892205,0.0010804607,0.00024608008],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013791845,0.00059886836,0.0010712589,0.00018101513,0.0002822197,0.000051298797,0.0002748487,0.00032624157,0.00016818139],"category_scores_gemma":[0.00018126608,0.00041274293,0.0004751695,0.00093715836,0.00022775243,0.00016560465,0.00005445196,0.0005998026,0.0000035379705],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.049747985,0.0018942594,0.85593456,0.0007679906,0.0027420102,0.0000057683114,0.001044743,0.010366907,0.01022459,0.0000012554378,0.0006310581,0.066638865],"study_design_scores_gemma":[0.0457264,0.0017164499,0.4613525,0.0014551511,0.0018563474,9.048111e-7,0.000067451394,0.48468864,0.0021928416,0.000004246959,0.00039455164,0.00054451876],"about_ca_topic_score_codex":0.0006674652,"about_ca_topic_score_gemma":0.00026458548,"teacher_disagreement_score":0.47432175,"about_ca_system_score_codex":0.00073836447,"about_ca_system_score_gemma":0.0014528418,"threshold_uncertainty_score":0.99983245},"labels":[],"label_agreement":null},{"id":"W4319461436","doi":"10.1016/j.cllc.2023.01.009","title":"A Multicenter Retrospective Chart Review of Clinical Outcomes Among Patients With KRAS G12C Mutant Non–Small Cell Lung Cancer","year":2023,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Kingston Health Sciences Centre; Princess Margaret Cancer Centre","funders":"National Cancer Institute; Genentech; Helsinn; Eisai; National Comprehensive Cancer Network; Apollomics; BeiGene; Sanofi; Daiichi-Sankyo; Amgen; Pfizer; EMD Serono; Mersana Therapeutics; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Lung cancer; KRAS; Retrospective cohort study; Oncology; Internal medicine; Cancer","score_opus":0.03211703283370258,"score_gpt":0.439156164387392,"score_spread":0.4070391315536894,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4319461436","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98362565,0.0057858373,0.000026067692,0.0017751835,0.002185875,0.003899262,0.0004917617,0.00013184686,0.0020784924],"genre_scores_gemma":[0.9515986,0.036255762,0.0002972353,0.004761337,0.00063759484,0.0011054474,0.00021127374,0.000113262104,0.0050194864],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99597204,0.0001581136,0.0018613258,0.00086793146,0.00061277545,0.00052782166],"domain_scores_gemma":[0.9966675,0.00053540803,0.00085178594,0.0007045938,0.0007977286,0.00044297028],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00074338005,0.0003925786,0.0017536172,0.00010012938,0.00009907053,0.000015391823,0.00020349477,0.00023473136,0.00090101577],"category_scores_gemma":[0.00052642036,0.0002551094,0.0007026513,0.0005759014,0.0003028343,0.00012232804,0.00011629996,0.00061999355,0.00003972674],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00035731238,0.0008987728,0.97349465,0.0029917175,0.0015801905,0.00003797045,0.0001805618,0.0000064323012,0.0000021312965,0.0000049242535,0.01808108,0.0023642802],"study_design_scores_gemma":[0.009414587,0.00053037616,0.9729557,0.010060173,0.003909441,3.4852988e-7,0.000037281552,0.000564111,0.000023378592,0.0000028459503,0.0022243017,0.00027742214],"about_ca_topic_score_codex":0.0006364279,"about_ca_topic_score_gemma":0.0004974632,"teacher_disagreement_score":0.032027073,"about_ca_system_score_codex":0.00038608868,"about_ca_system_score_gemma":0.00082872156,"threshold_uncertainty_score":0.9999901},"labels":[],"label_agreement":null},{"id":"W4319758837","doi":"10.1016/j.cllc.2023.02.003","title":"Brief Report: Clinical Outcomes Using Plasma-Based Molecular Profiling to Guide Treatment Decisions in Patients With Advanced NSCLC and Limited Access to Broad Tissue Testing","year":2023,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Liquid biopsy; Precision medicine; ROS1; Targeted therapy; Genotyping; Oncology; Profiling (computer programming); Biopsy; Companion diagnostic; Internal medicine; Bioinformatics; Intensive care medicine; Pathology; Cancer; Gene; Adenocarcinoma; Genotype","score_opus":0.09745426049707119,"score_gpt":0.5102924480330977,"score_spread":0.4128381875360265,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4319758837","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9930951,0.00009866521,0.0008006407,0.0020566548,0.00044530557,0.0030748746,0.00007224786,0.0001343426,0.00022216693],"genre_scores_gemma":[0.9517958,0.00005290724,0.042984724,0.0038359214,0.0001411225,0.00047344013,0.0001604965,0.000094355586,0.00046119757],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99673414,0.00009843717,0.0013667904,0.00094640435,0.00038980652,0.00046442528],"domain_scores_gemma":[0.9966663,0.0015338312,0.0002591549,0.0005769897,0.00036577182,0.00059791416],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041828802,0.00030645943,0.00083165086,0.00025445368,0.00012423248,0.00006239774,0.00012749134,0.0001465262,0.000013580997],"category_scores_gemma":[0.00396149,0.00022271722,0.0001253711,0.0011254521,0.00007263447,0.00012078382,0.00012605079,0.00020772534,0.000008339935],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00069122564,0.0004707661,0.8765866,0.000019356708,0.00023939152,0.00043565064,0.0000503073,0.0062255845,0.00004364884,0.0000022354752,0.00029201002,0.1149432],"study_design_scores_gemma":[0.009937861,0.001733913,0.9803079,0.00096002634,0.00063592853,0.0000045999113,0.000022743741,0.0033700864,0.00022001966,0.0000057864795,0.0025277059,0.00027345124],"about_ca_topic_score_codex":0.0006275775,"about_ca_topic_score_gemma":0.0003508568,"teacher_disagreement_score":0.11466975,"about_ca_system_score_codex":0.00055309193,"about_ca_system_score_gemma":0.0009346673,"threshold_uncertainty_score":0.90821445},"labels":[],"label_agreement":null},{"id":"W4362671306","doi":"10.1016/j.cllc.2023.03.015","title":"A rare case of false negative ROS1 fusion in metastatic pulmonary adenocarcinoma: Case report and lessons learned","year":2023,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Medical Imaging and Pathology Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; McGill University Health Centre; University of Ottawa","funders":"","keywords":"Medicine; ROS1; Adenocarcinoma; Lung cancer; Pulmonary adenocarcinoma; Oncology; Radiology; Internal medicine; Cancer","score_opus":0.17408252988308429,"score_gpt":0.49464819567056867,"score_spread":0.32056566578748436,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362671306","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9837953,0.0056765815,0.000016557742,0.009462079,0.00030603076,0.00036215963,0.00004997355,0.00005134834,0.00027996697],"genre_scores_gemma":[0.99573946,0.001807716,0.00029643116,0.00049217546,0.00012164171,0.0000821485,0.000018502,0.00001808901,0.0014238065],"study_design_codex":"case_report","study_design_gemma":"observational","domain_scores_codex":[0.99810857,0.0002662859,0.0007602938,0.00046489912,0.00014639217,0.00025357385],"domain_scores_gemma":[0.9974585,0.0017481132,0.00019203339,0.00028807233,0.00010556773,0.00020766663],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013527418,0.00014266813,0.0006898782,0.00012136742,0.000083365805,0.000004130608,0.0000374561,0.000110096385,0.000056025492],"category_scores_gemma":[0.0047358447,0.00010971389,0.00010539985,0.00039183756,0.0005694038,0.000036569807,0.00013963225,0.0005026235,0.000005398862],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017793586,0.00010470529,0.36494505,0.00027887142,0.00008016467,0.61891824,0.0006128514,0.00000326686,0.00004682231,0.000009468857,0.002248658,0.012573958],"study_design_scores_gemma":[0.005898194,0.00055611524,0.62103057,0.0015743446,0.0014668728,0.3526915,0.0057307133,0.009181771,0.00012419005,0.00085579033,0.00049760356,0.00039232674],"about_ca_topic_score_codex":0.00084963493,"about_ca_topic_score_gemma":0.0006682889,"teacher_disagreement_score":0.26622674,"about_ca_system_score_codex":0.00003297023,"about_ca_system_score_gemma":0.00020640083,"threshold_uncertainty_score":0.5669591},"labels":[],"label_agreement":null},{"id":"W4365148130","doi":"10.1016/j.cllc.2023.04.001","title":"The 8th Edition TNM Stage Reclassification of T4 Non-Small Cell Lung Cancer: A Granular Examination of Short and Long-Term Outcomes","year":2023,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; Montreal General Hospital; Ottawa Hospital; McGill University","funders":"","keywords":"Medicine; Lymphovascular invasion; Internal medicine; Pneumonectomy; Stage (stratigraphy); Perioperative; Oncology; Multivariate analysis; Lung cancer; Cohort; Univariate analysis; Proportional hazards model; Retrospective cohort study; Cancer; Metastasis; Surgery","score_opus":0.059204944660306624,"score_gpt":0.40590201980295715,"score_spread":0.3466970751426505,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4365148130","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9904795,0.0047671236,0.0000994008,0.0020417112,0.0010220878,0.0011796048,0.00012652915,0.000039809842,0.0002442198],"genre_scores_gemma":[0.9685556,0.029020771,0.000036336776,0.0001483267,0.0003220572,0.0005634468,0.00010314077,0.000027850287,0.0012224392],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981922,0.00010042,0.0007601611,0.0003874108,0.0003363037,0.00022352487],"domain_scores_gemma":[0.9982033,0.00069759355,0.00032507858,0.00041599767,0.00023928139,0.00011879755],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007910505,0.00017089036,0.00050330843,0.000079489786,0.0000966872,0.000016084607,0.00010691803,0.00014879905,0.00006568096],"category_scores_gemma":[0.00010363492,0.000115252864,0.00018343634,0.00027098553,0.00018829656,0.00006855968,0.000050895116,0.00018462903,0.0000018700691],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000114470764,0.0002394031,0.9668062,0.000889811,0.00023433208,0.0000067638302,0.00016995864,0.000016944377,0.00029315054,0.000049113056,0.002741407,0.028438495],"study_design_scores_gemma":[0.0017141285,0.0002405747,0.991583,0.0006212659,0.0007959168,4.2113814e-7,0.000053350115,0.00197125,0.0024526378,0.0000086730915,0.00045093938,0.0001078361],"about_ca_topic_score_codex":0.00015169282,"about_ca_topic_score_gemma":0.00039291443,"teacher_disagreement_score":0.02833066,"about_ca_system_score_codex":0.0002746264,"about_ca_system_score_gemma":0.00022921037,"threshold_uncertainty_score":0.46998754},"labels":[],"label_agreement":null},{"id":"W4381056888","doi":"10.1016/j.cllc.2023.06.002","title":"Association of Molecular Profiles and Mutational Status With Distinct Histological Lung Adenocarcinoma Subtypes. An Analysis of the LACE-Bio Data","year":2023,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; Queen's University","funders":"Upstate Cancer Center; National Cancer Institute; State University of New York Upstate Medical University; National Institutes of Health; U.S. Department of Health and Human Services","keywords":"Medicine; Hazard ratio; Internal medicine; Lung cancer; Oncology; Adenocarcinoma; Stage (stratigraphy); Proportional hazards model; Survival analysis; Log-rank test; Cancer; Confidence interval; Biology","score_opus":0.044265411069385724,"score_gpt":0.3938889351135902,"score_spread":0.3496235240442045,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4381056888","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944299,0.0021773062,0.000022548104,0.0021929252,0.00010027412,0.00038136446,0.0005903544,0.00002022137,0.000085107014],"genre_scores_gemma":[0.9984403,0.00037194559,0.00013241965,0.00014040574,0.000055373523,0.000053867476,0.0005978947,0.000010978269,0.0001967713],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99852484,0.00013088863,0.0004131424,0.00038413715,0.00037937553,0.00016763323],"domain_scores_gemma":[0.9984219,0.00046684788,0.00034681763,0.00049322407,0.00016934428,0.00010187205],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042268794,0.00010361907,0.00047271897,0.00006415637,0.000040601426,0.000007365454,0.00012722469,0.00009660742,0.000109933906],"category_scores_gemma":[0.00034638864,0.000060142036,0.000112095775,0.00057219906,0.00016118228,0.00004925246,0.000103084996,0.00012857081,6.028845e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022059931,0.00020354168,0.9936218,0.00010282338,0.0025541226,0.000016660164,0.00006338586,0.000113740774,0.000018500328,0.00010650458,0.0021790792,0.0007992118],"study_design_scores_gemma":[0.0011387964,0.00021199897,0.9794682,0.000088774614,0.00801513,7.481567e-7,0.000034875746,0.010695541,0.00011045406,0.000016380138,0.00015268708,0.00006636671],"about_ca_topic_score_codex":0.00032920102,"about_ca_topic_score_gemma":0.00065741455,"teacher_disagreement_score":0.014153583,"about_ca_system_score_codex":0.00027834342,"about_ca_system_score_gemma":0.00031134448,"threshold_uncertainty_score":0.2452521},"labels":[],"label_agreement":null},{"id":"W4385989042","doi":"10.1016/j.cllc.2023.08.013","title":"Patient-Provider Discussion About Lung Cancer Screening by Race and Ethnicity: Implications for Equitable Uptake of Lung Cancer Screening","year":2023,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"National Cancer Institute; National Institutes of Health","keywords":"Medicine; Ethnic group; Lung cancer; Lung cancer screening; Demography; Population; Health equity; National Health Interview Survey; Race (biology); Health Information National Trends Survey; Family medicine; Gerontology; Health care; Public health; Environmental health; Health information; Internal medicine; Pathology","score_opus":0.06364927794912452,"score_gpt":0.4444849408526525,"score_spread":0.380835662903528,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385989042","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7047126,0.18000922,0.007875279,0.08975053,0.0028107127,0.00863613,0.005237001,0.00053383247,0.00043463986],"genre_scores_gemma":[0.9050254,0.06469844,0.0036983388,0.0048164483,0.0018222827,0.011929779,0.0006623662,0.00032163132,0.0070252907],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9961179,0.00009292438,0.0013318731,0.0010932764,0.0004395249,0.00092450075],"domain_scores_gemma":[0.9971591,0.00079268584,0.00048414222,0.0006481884,0.0004167372,0.0004991364],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006695192,0.00043101623,0.0011121955,0.00013291762,0.0004144088,0.000057776902,0.00019517023,0.0003225783,0.00030745583],"category_scores_gemma":[0.0003110428,0.00030349253,0.00041850188,0.00063776417,0.0002283332,0.00025396547,0.0002915505,0.00044369986,0.0000016830284],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00048082927,0.00019294415,0.6255536,0.0008948621,0.0009516371,0.0000030356262,0.00032928176,0.0003951897,0.0005270534,0.000062044615,0.19068682,0.17992271],"study_design_scores_gemma":[0.011338665,0.0006818712,0.8305771,0.0083781425,0.0049646636,0.0000038379508,0.0003455878,0.04714072,0.0015718652,0.00006885825,0.094010286,0.0009183967],"about_ca_topic_score_codex":0.0019821909,"about_ca_topic_score_gemma":0.0007598373,"teacher_disagreement_score":0.20502351,"about_ca_system_score_codex":0.0005220521,"about_ca_system_score_gemma":0.00055026216,"threshold_uncertainty_score":0.9999417},"labels":[],"label_agreement":null},{"id":"W4387746099","doi":"10.1016/j.cllc.2023.10.006","title":"Clinical, Genomic, and Transcriptomic Featurses of Lung Adenocarcinoma With Uncommon EGFR Mutation","year":2023,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Aging","funders":"","keywords":"Medicine; Adenocarcinoma; Hazard ratio; Oncology; Transcriptome; Epidermal growth factor receptor; Lung cancer; Internal medicine; Mutation; Proportional hazards model; Cancer; Gene; Confidence interval; Biology; Genetics; Gene expression","score_opus":0.04045872465736925,"score_gpt":0.4408475566299222,"score_spread":0.4003888319725529,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387746099","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9882811,0.006553261,0.00006469659,0.002317087,0.00067065493,0.00083418534,0.00008397381,0.00010789927,0.0010871702],"genre_scores_gemma":[0.9930765,0.0033728643,0.00050079514,0.00061517267,0.00037270912,0.00011156591,0.00010128954,0.000044448927,0.0018046635],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982342,0.00009530461,0.0007593399,0.00045938854,0.00020315778,0.0002485818],"domain_scores_gemma":[0.9986486,0.00044935726,0.0002209454,0.0003161282,0.0001387201,0.00022627952],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037279533,0.00018137126,0.00061840576,0.00009938469,0.00008250432,0.00001678802,0.00008042005,0.00016568122,0.00013228755],"category_scores_gemma":[0.00007327347,0.00013300251,0.0001861992,0.00030424423,0.00030967474,0.0000855265,0.000026955538,0.00028083223,0.000011110837],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007044957,0.00017928521,0.96936196,0.00025879845,0.00085916906,0.000058891044,0.00032614902,0.000033285884,0.000111781585,0.000087978246,0.009750232,0.018267948],"study_design_scores_gemma":[0.005435837,0.00077509216,0.98737514,0.00034306064,0.0020295146,0.000015825004,0.00016965787,0.0014600625,0.00006443632,0.000047223697,0.0021343518,0.000149816],"about_ca_topic_score_codex":0.00020216993,"about_ca_topic_score_gemma":0.00022960723,"teacher_disagreement_score":0.018118132,"about_ca_system_score_codex":0.0001265703,"about_ca_system_score_gemma":0.00045666125,"threshold_uncertainty_score":0.54236853},"labels":[],"label_agreement":null},{"id":"W4387844353","doi":"10.1016/j.cllc.2023.10.008","title":"A Brief Report on the Patterns of Mediastinal Nodal Failure in Resectable Stage IB-IIIA NSCLC Treated With Neoadjuvant Immunotherapy Combinations, a Secondary Analysis of a Prospective Trial","year":2023,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"National Cancer Institute","keywords":"Medicine; Mediastinal lymph node; Neoadjuvant therapy; Lung cancer; Stage (stratigraphy); NODAL; Pneumonectomy; Oncology; Primary tumor; Pathological; Radiology; Internal medicine; Surgery; Cancer; Metastasis; Breast cancer","score_opus":0.02976366767990048,"score_gpt":0.3846218119986783,"score_spread":0.3548581443187778,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387844353","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9940675,0.0002728813,0.000010778964,0.0027650935,0.00013282246,0.0019154329,0.00032747615,0.00003483313,0.00047316277],"genre_scores_gemma":[0.99710405,0.0005311726,0.000023517392,0.00020175333,0.00010311982,0.0009200842,0.00016502445,0.000028977749,0.0009223296],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974416,0.0001949128,0.0010427955,0.00052340096,0.00053095684,0.00026637188],"domain_scores_gemma":[0.99730897,0.0011430442,0.0005477706,0.0006379426,0.00027473076,0.00008754326],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010277645,0.00020120281,0.0010348571,0.00031678542,0.000052985117,0.000012733862,0.00012807385,0.000117319374,0.0006629598],"category_scores_gemma":[0.00029491025,0.00011787126,0.00036085202,0.0016209088,0.0001722661,0.00004787311,0.00003775569,0.00039855513,0.0000014740565],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.025905648,0.0015872575,0.9643069,0.00009116328,0.0042716255,0.00031553925,0.00042118863,0.00009119029,0.000032033717,0.00016122972,0.0011177864,0.0016984304],"study_design_scores_gemma":[0.05210734,0.0033925266,0.9403618,0.0007879584,0.0015100237,0.0000038769585,0.00021146305,0.0007442006,0.00044314182,0.000016191094,0.000302217,0.00011923583],"about_ca_topic_score_codex":0.0030104208,"about_ca_topic_score_gemma":0.0048603974,"teacher_disagreement_score":0.026201691,"about_ca_system_score_codex":0.0003533433,"about_ca_system_score_gemma":0.0007057933,"threshold_uncertainty_score":0.7258945},"labels":[],"label_agreement":null},{"id":"W4388461185","doi":"10.1016/j.cllc.2023.11.003","title":"Lack of Association Between Immunotherapy and Improvement of Survival for Non-small Cell Lung Cancer Patients With Hemodialysis: A Nationwide Retrospective Cohort Study","year":2023,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Daiichi Sankyo Europe; Novo Nordisk Pharma; Bayer Yakuhin; Eli Lilly Japan; Novartis Pharma; Daiichi Sankyo Company; Shionogi; Eli Lilly and Company; Ono Pharmaceutical; Astellas Pharma; Eisai; Novo Nordisk; Daiichi-Sankyo; JCR Pharmaceuticals; Nipro; Chugai Pharmaceutical; Mitsubishi Tanabe Pharma Corporation; Mallinckrodt Pharmaceuticals; Kissei; Asahi Kasei Pharma Corporation; Boehringer Ingelheim Japan; Taiho Pharmaceutical; Kyorin Pharmaceutical; Pfizer; Nippon Shinyaku; Bristol-Myers Squibb; AstraZeneca; Torii Pharmaceutical","keywords":"Medicine; Lung cancer; Retrospective cohort study; Internal medicine; Oncology; Hemodialysis; Immunotherapy; Cohort; Proportional hazards model; Cohort study; Cancer; Intensive care medicine","score_opus":0.02647111851505887,"score_gpt":0.36919193737432016,"score_spread":0.3427208188592613,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388461185","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99490196,0.00039341408,0.000088136505,0.00024429135,0.00041896105,0.0034734257,0.00037174896,0.000024808858,0.000083278996],"genre_scores_gemma":[0.9970066,0.0011379084,0.00005951191,0.0001326742,0.0002321789,0.0005937752,0.00007420174,0.000036534657,0.0007266006],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979309,0.00006864382,0.00086575904,0.000405474,0.00049455994,0.00023468249],"domain_scores_gemma":[0.99769413,0.0004989792,0.0007773719,0.00024112951,0.0007247409,0.000063622196],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014925573,0.00017389002,0.00087615364,0.0001077876,0.000060821018,0.000010775475,0.00009275633,0.00014017009,0.000045641544],"category_scores_gemma":[0.00010817766,0.00013813666,0.0001963532,0.00045937154,0.00007358256,0.000051579063,0.000032113232,0.00015988754,2.6501624e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026424935,0.0005635459,0.9874682,0.0002458998,0.003598259,2.696955e-7,0.00048060855,0.0000069867615,0.0007314645,6.352885e-7,0.0007215118,0.003540145],"study_design_scores_gemma":[0.014119905,0.0018548465,0.9806448,0.00018328734,0.0013033377,1.022854e-8,0.00012578827,0.0002499491,0.0012702079,0.00000662258,0.00009322781,0.000147992],"about_ca_topic_score_codex":0.000986503,"about_ca_topic_score_gemma":0.0005124107,"teacher_disagreement_score":0.011477413,"about_ca_system_score_codex":0.00050855736,"about_ca_system_score_gemma":0.0002973981,"threshold_uncertainty_score":0.5633049},"labels":[],"label_agreement":null},{"id":"W4389218966","doi":"10.1016/j.cllc.2023.11.013","title":"Detection of Circulating Tumor DNA After Stereotactic Ablative Radiotherapy in Patients With Unbiopsied Lung Tumors (SABR-DETECT)","year":2023,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; London Health Sciences Centre; Sunnybrook Health Science Centre; Western University","funders":"","keywords":"SABR volatility model; Medicine; Malignancy; Ablative case; Lung cancer; Cohort; Radiology; Biopsy; Radiation therapy; Liquid biopsy; Cancer; Stage (stratigraphy); Oncology; Internal medicine; Surgery","score_opus":0.009783436021709141,"score_gpt":0.3067070037666224,"score_spread":0.29692356774491324,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389218966","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99818164,0.0006714577,0.00021486374,0.000031291667,0.00033505762,0.00044386258,0.000058062862,0.000014587607,0.000049191767],"genre_scores_gemma":[0.9989835,0.00024487905,0.000086462234,0.00022956239,0.0002249011,0.000110817986,0.0000307661,0.000042218588,0.000046907884],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985808,0.00007668318,0.0005063828,0.00042112987,0.00014506732,0.00026990747],"domain_scores_gemma":[0.99914455,0.00012695002,0.0002434568,0.00028663676,0.00011548833,0.00008289261],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024230931,0.00016719592,0.0002953874,0.00007371305,0.000034228553,0.000015408732,0.00011016945,0.000115257215,0.000027102711],"category_scores_gemma":[0.00018865883,0.00015224874,0.00010655422,0.00028892496,0.00010402616,0.00000694653,0.00006144909,0.00016070563,0.0000016851375],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015317182,0.000087352004,0.98007584,0.000072888935,0.00018695838,0.0000118742355,0.00008634916,0.000830229,0.012463774,0.0000021061658,0.00013128687,0.0045196014],"study_design_scores_gemma":[0.0026421302,0.00054274965,0.98586965,0.00012974256,0.000049526236,8.446966e-7,0.000021047697,0.0019822118,0.00819177,0.000014299888,0.00031114137,0.0002448648],"about_ca_topic_score_codex":0.00008474615,"about_ca_topic_score_gemma":0.00033761887,"teacher_disagreement_score":0.0057938094,"about_ca_system_score_codex":0.00010699303,"about_ca_system_score_gemma":0.00015526402,"threshold_uncertainty_score":0.62085235},"labels":[],"label_agreement":null},{"id":"W4389430282","doi":"10.1016/j.cllc.2023.12.001","title":"Brief Report: Updated Efficacy and Safety Data From an Integrated Analysis of Entrectinib in Locally Advanced/Metastatic ROS1 Fusion-Positive Non–Small-Cell Lung Cancer","year":2023,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"Manchester Biomedical Research Centre; National Institutes of Health; National Cancer Institute; National Institute for Health and Care Research; F. Hoffmann-La Roche","keywords":"Medicine; ROS1; Internal medicine; Lung cancer; Oncology; Adverse effect; Population; Cancer; Clinical trial; Gastroenterology; Adenocarcinoma","score_opus":0.03765262139459042,"score_gpt":0.44138423347119976,"score_spread":0.40373161207660935,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389430282","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9884164,0.0029151377,0.0009100349,0.0009946162,0.0005788705,0.0015902995,0.0041075987,0.000100285564,0.00038676907],"genre_scores_gemma":[0.97173816,0.0059524695,0.001548802,0.0008407202,0.00017913179,0.00020271583,0.017707268,0.00007124753,0.0017594988],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963719,0.0002106898,0.0014934029,0.0011948964,0.00033156353,0.0003975512],"domain_scores_gemma":[0.9967418,0.00090166344,0.0005525966,0.0011097094,0.0003446156,0.00034966768],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00062620733,0.00031775443,0.001234724,0.0003499846,0.00009402208,0.000030914212,0.00026179006,0.00016411355,0.00085761974],"category_scores_gemma":[0.00040024795,0.00026007133,0.00017041173,0.0023757648,0.00017855856,0.00020794403,0.00022529047,0.000439238,0.0000046727246],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031450714,0.0014745335,0.90881026,0.00017036477,0.008799221,0.00089162635,0.001334331,0.0063503715,0.0006339531,0.0000058102078,0.0059405193,0.062443923],"study_design_scores_gemma":[0.009246849,0.00027000761,0.8439706,0.00082749315,0.014620098,0.000003963669,0.0004175582,0.12865984,0.00018661277,0.000008970454,0.0014909387,0.00029706344],"about_ca_topic_score_codex":0.008841691,"about_ca_topic_score_gemma":0.013629363,"teacher_disagreement_score":0.12230948,"about_ca_system_score_codex":0.00032814746,"about_ca_system_score_gemma":0.0011448016,"threshold_uncertainty_score":0.99998516},"labels":[],"label_agreement":null},{"id":"W4389955555","doi":"10.1016/j.cllc.2023.12.005","title":"Transitioning to Neoadjuvant Therapy for Resectable Non-Small Cell Lung Cancer: Trends and Surgical Outcomes in a Regionalized Pulmonary Oncology Network","year":2023,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; McGill University; McGill University Health Centre","funders":"","keywords":"Medicine; Neoadjuvant therapy; Lung cancer; Oncology; Internal medicine; Proportional hazards model; Radiation therapy; Cohort; Stage (stratigraphy); Surgery; Cancer; Breast cancer","score_opus":0.05391070537303225,"score_gpt":0.4376664856493412,"score_spread":0.38375578027630897,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389955555","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9272032,0.017944073,0.000048380287,0.049486298,0.0012780431,0.0022023679,0.00010442269,0.000116125615,0.0016171176],"genre_scores_gemma":[0.923009,0.051429152,0.0009969793,0.0057903985,0.0020357177,0.007996411,0.00017842047,0.00011355671,0.008450357],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99743736,0.00013460322,0.00077411457,0.0007631444,0.00021435485,0.00067639997],"domain_scores_gemma":[0.9975778,0.0015311054,0.00013353144,0.00029036895,0.00009737132,0.00036985817],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00080091425,0.00027669512,0.0011134725,0.0001718617,0.00013335096,0.00002364508,0.00011214235,0.00027389202,0.00021306233],"category_scores_gemma":[0.00003481794,0.00021382287,0.00033412603,0.0006658595,0.00008265121,0.000050808507,0.0000533201,0.00032708878,0.0000037670131],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00400872,0.0006020108,0.87347656,0.0002074533,0.0003505165,0.00038156228,0.0003029585,0.0009592624,0.000019843756,0.000043354543,0.05035283,0.06929493],"study_design_scores_gemma":[0.02524243,0.0018822968,0.8071075,0.0013467047,0.0005365977,0.00001753251,0.00005969383,0.016716696,0.000056546898,0.000099068326,0.14648709,0.00044780737],"about_ca_topic_score_codex":0.0010166535,"about_ca_topic_score_gemma":0.0015650954,"teacher_disagreement_score":0.09613426,"about_ca_system_score_codex":0.0006077648,"about_ca_system_score_gemma":0.00053411874,"threshold_uncertainty_score":0.87194437},"labels":[],"label_agreement":null},{"id":"W4394676583","doi":"10.1016/j.cllc.2024.04.003","title":"Brief Report: Impact of Anti-Cancer Treatments on Outcomes of COVID-19 in Patients With Thoracic Cancers: A CCC19 Registry Analysis","year":2024,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"COVID-19 and healthcare impacts","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"National Center for Advancing Translational Sciences; National Cancer Institute; National Institutes of Health; University of Minnesota; Vanderbilt Institute for Clinical and Translational Research; Vanderbilt University Medical Center; Vanderbilt University; International Association for the Study of Lung Cancer","keywords":"Medicine; Interquartile range; Lung cancer; Cancer; Internal medicine; Cancer registry; Chemotherapy; Oncology","score_opus":0.09097972502493502,"score_gpt":0.5590113706944905,"score_spread":0.46803164566955546,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394676583","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99377316,0.0019044168,0.000043394517,0.0023599716,0.0002920028,0.00082148134,0.000629773,0.000048545087,0.00012722467],"genre_scores_gemma":[0.9960631,0.0011388281,0.000046563466,0.0015538853,0.00012693672,0.00007536078,0.000104072504,0.00003736675,0.00085384696],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99681884,0.00013345994,0.00133987,0.0007011677,0.00061872817,0.0003879291],"domain_scores_gemma":[0.99705243,0.0007637932,0.00058816525,0.00080788624,0.00022716755,0.00056054164],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006113239,0.00029294455,0.0015633036,0.00046293737,0.00003225021,0.000015264059,0.00012698272,0.00023216967,0.00047609888],"category_scores_gemma":[0.0011324654,0.00018767125,0.0007119945,0.0014783554,0.0002081013,0.000093322466,0.00003535751,0.0004276411,0.000001696841],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025608658,0.0006301882,0.9799043,0.0011787532,0.004880034,0.00023747091,0.00022828554,0.001308248,0.0000073383535,0.0000055620176,0.0016814119,0.007377566],"study_design_scores_gemma":[0.0031112842,0.0013967099,0.9904359,0.0010573079,0.0027567516,0.000001841371,0.000017566568,0.0004702663,0.00003859824,0.00000899216,0.00053462625,0.0001701777],"about_ca_topic_score_codex":0.032163996,"about_ca_topic_score_gemma":0.0039145406,"teacher_disagreement_score":0.028249454,"about_ca_system_score_codex":0.0029937741,"about_ca_system_score_gemma":0.0072833714,"threshold_uncertainty_score":0.9983444},"labels":[],"label_agreement":null},{"id":"W4394989656","doi":"10.1016/j.cllc.2024.04.011","title":"Immediate Versus Deferred Systemic Therapy in Patients With Mesothelioma","year":2024,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Oakville-Trafalgar Memorial Hospital; University Health Network","funders":"Swiss Cancer Research Foundation","keywords":"Medicine; Mesothelioma; Systemic therapy; Lung cancer; Internal medicine; Intensive care medicine; Oncology; Cancer; Pathology","score_opus":0.028112548610917023,"score_gpt":0.37298119246088435,"score_spread":0.34486864384996735,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394989656","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99098086,0.006858461,0.0000031945494,0.0003056183,0.0008769551,0.00041278906,0.00006191833,0.000050565166,0.00044966117],"genre_scores_gemma":[0.9978842,0.00093316607,0.000021892836,0.00037339362,0.00029184483,0.00008328711,0.00007115945,0.000024879597,0.0003161507],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990101,0.0000342806,0.0002853858,0.00027492532,0.00024258767,0.00015276286],"domain_scores_gemma":[0.999501,0.00018099463,0.00003149128,0.00014319403,0.000018273426,0.00012504416],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009517202,0.000111070505,0.00021294695,0.00005245147,0.000016721884,0.000012635741,0.00004973843,0.000067836445,0.0003417325],"category_scores_gemma":[0.000028123035,0.00007189745,0.00009132911,0.0001481476,0.00007500676,0.000058223177,0.000016679662,0.00014977327,0.00007852724],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0058458294,0.00024646072,0.9764452,0.00010530396,0.00016240288,0.000025947142,0.000025453939,0.000016153672,0.000013391855,0.000021518646,0.0014363823,0.015655963],"study_design_scores_gemma":[0.005791835,0.0006705615,0.99106085,0.00056669745,0.000104289145,7.2849826e-7,0.000009573698,0.00027517983,0.000012334934,0.000011133101,0.0013971592,0.000099635065],"about_ca_topic_score_codex":0.000023347533,"about_ca_topic_score_gemma":0.0000097029415,"teacher_disagreement_score":0.015556328,"about_ca_system_score_codex":0.0001660453,"about_ca_system_score_gemma":0.00011223901,"threshold_uncertainty_score":0.3741731},"labels":[],"label_agreement":null},{"id":"W4399881578","doi":"10.1016/j.cllc.2024.06.007","title":"MDT-BRIDGE: Neoadjuvant Durvalumab Plus Chemotherapy Followed by Either Surgery and Adjuvant Durvalumab or Chemoradiotherapy and Consolidation Durvalumab in Resectable or Borderline-resectable Stage IIB–IIIB NSCLC","year":2024,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"AstraZeneca","keywords":"Durvalumab; Medicine; Chemoimmunotherapy; Chemoradiotherapy; Chemotherapy; Oncology; Neoadjuvant therapy; Gemcitabine; Internal medicine; Stage (stratigraphy); Surgery; Cancer; Immunotherapy; Breast cancer; Nivolumab; Cyclophosphamide","score_opus":0.047810905458119946,"score_gpt":0.4172892982631643,"score_spread":0.36947839280504435,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399881578","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8983244,0.086157694,0.000107702544,0.009986379,0.001504412,0.0027959412,0.00033486087,0.00026987953,0.0005187333],"genre_scores_gemma":[0.8595356,0.11170606,0.0003686521,0.003197647,0.00097618584,0.0011449379,0.0001954384,0.00028154676,0.022593979],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9947829,0.00033869367,0.0015912373,0.0016451668,0.00067027204,0.0009716913],"domain_scores_gemma":[0.99604315,0.00215542,0.0002945733,0.0007748974,0.00018567017,0.00054626685],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0018050328,0.0007063469,0.0020954672,0.00028350716,0.00019011092,0.0002760792,0.0001793998,0.0004915572,0.0026279204],"category_scores_gemma":[0.0005041817,0.00049628085,0.0003274468,0.00082220434,0.000404893,0.00039982487,0.000097408345,0.0007724111,0.00001661998],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.038925346,0.0022035472,0.37917805,0.0034887241,0.0029327741,0.0017654226,0.0016880699,0.000060491704,0.0012048336,0.000090375856,0.3486034,0.21985897],"study_design_scores_gemma":[0.12767103,0.007944006,0.2879624,0.016804209,0.0028578106,0.0005076697,0.0007406707,0.06653862,0.007571186,0.0001184622,0.4772142,0.0040697325],"about_ca_topic_score_codex":0.0032594197,"about_ca_topic_score_gemma":0.0030153051,"teacher_disagreement_score":0.21578924,"about_ca_system_score_codex":0.0013289077,"about_ca_system_score_gemma":0.0024409564,"threshold_uncertainty_score":0.9997489},"labels":[],"label_agreement":null},{"id":"W4402666045","doi":"10.1016/j.cllc.2024.09.003","title":"A Phase II Study of Neoadjuvant Opnurasib KRAS G12C Inhibitor in Patients With Surgically Resectable Non-Small Cell Lung Cancer (CCTG IND.242A): A Substudy of the IND.242 Platform Master Protocol","year":2024,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"CancerCare Manitoba; Institut universitaire de cardiologie et de pneumologie de Québec; Ottawa Hospital; Princess Margaret Cancer Centre; Kingston Health Sciences Centre; Centre Hospitalier de l’Université de Montréal; Juravinski Cancer Centre; McGill University Health Centre","funders":"Canadian Cancer Society Research Institute; Novartis Pharmaceuticals Canada; Novartis","keywords":"Medicine; Lung cancer; Master regulator; Internal medicine; Phases of clinical research; Oncology; KRAS; Cancer; Chemotherapy","score_opus":0.033905800890108716,"score_gpt":0.4154961196874887,"score_spread":0.38159031879738,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402666045","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9273911,0.00042707022,0.000008079756,0.00021135646,0.00060695794,0.070353225,0.00018569324,0.000034823966,0.00078168215],"genre_scores_gemma":[0.94814694,0.000026453847,0.000054493135,0.00013807455,0.00022791067,0.049757034,0.00002020656,0.00007525611,0.0015536281],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9962053,0.00012538383,0.0015905873,0.00078467204,0.0007795793,0.0005145141],"domain_scores_gemma":[0.9978731,0.00028534932,0.0004764544,0.0007018905,0.00043070273,0.00023245298],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005096785,0.00041291266,0.0010493017,0.00020001014,0.00012977293,0.000037275855,0.000296451,0.00021873007,0.00037295348],"category_scores_gemma":[0.000060065373,0.00023450688,0.00024970586,0.0009674041,0.00019253186,0.00019801338,0.00023740146,0.0007710889,0.0000019694528],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005641335,0.01642537,0.964915,0.0011093325,0.0009877982,0.000057955644,0.004422175,0.00009977065,0.000052270705,0.0000072390353,0.0018427381,0.0044390494],"study_design_scores_gemma":[0.106421374,0.021762902,0.85590947,0.0067305486,0.0028370086,0.0000022840152,0.0010592663,0.0012870323,0.0010610486,0.000015105659,0.0023610257,0.00055291306],"about_ca_topic_score_codex":0.0018081075,"about_ca_topic_score_gemma":0.0037037951,"teacher_disagreement_score":0.10900547,"about_ca_system_score_codex":0.0005747322,"about_ca_system_score_gemma":0.0020059245,"threshold_uncertainty_score":0.9562913},"labels":[],"label_agreement":null},{"id":"W4403465646","doi":"10.1016/j.cllc.2024.10.003","title":"Perioperative Outcomes of Neoadjuvant Therapy in Resectable Lung Cancer Patients With Endobronchial Disease in the Era of Personalized Medicine","year":2024,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Tracheal and airway disorders","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre; Montreal General Hospital","funders":"","keywords":"Medicine; Perioperative; Lung cancer; Neoadjuvant therapy; Disease; Cancer; Oncology; Internal medicine; Intensive care medicine; Surgery","score_opus":0.026442071578248075,"score_gpt":0.40385842739214856,"score_spread":0.3774163558139005,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403465646","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95846224,0.030303763,0.0000051691845,0.009414347,0.00032105224,0.0010398543,0.00009565437,0.000013296612,0.0003446406],"genre_scores_gemma":[0.99397707,0.004204703,0.000019260407,0.0010341263,0.00016436772,0.00023126566,0.000022958484,0.000021452186,0.00032477613],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981157,0.0001794674,0.0006811197,0.0003381778,0.0004475529,0.00023798035],"domain_scores_gemma":[0.9989563,0.0005098188,0.000102381186,0.00020949947,0.00011351148,0.00010849183],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043176505,0.00018001423,0.0006930693,0.00007211314,0.00002627465,0.0000065016548,0.00013702981,0.000071654365,0.00067837595],"category_scores_gemma":[0.00019245737,0.00008647151,0.00013905541,0.0003842923,0.000430909,0.00007539783,0.000019613299,0.00057094207,4.4564868e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034038343,0.0005789882,0.9811058,0.00033656764,0.00015264122,0.000017676082,0.0041523217,0.00007403508,0.00002608667,0.00015800376,0.00068833586,0.009305734],"study_design_scores_gemma":[0.009375238,0.0007863886,0.9848958,0.0017574496,0.00015969286,1.5372308e-7,0.00038557738,0.0016224748,0.000011485644,0.00002195523,0.00088019704,0.00010358468],"about_ca_topic_score_codex":0.0026068746,"about_ca_topic_score_gemma":0.001991169,"teacher_disagreement_score":0.03551487,"about_ca_system_score_codex":0.000096052114,"about_ca_system_score_gemma":0.00059496483,"threshold_uncertainty_score":0.7427741},"labels":[],"label_agreement":null},{"id":"W4403824763","doi":"10.1016/j.cllc.2024.10.009","title":"A Poor Prognostic ALK Phenotype: A Review of Molecular Markers of Poor Prognosis in ALK Rearranged Nonsmall Cell Lung Cancer","year":2024,"lang":"en","type":"review","venue":"Clinical Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital du Sacré-Cœur de Montréal; Princess Margaret Cancer Centre; University Health Network; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Lung cancer; Phenotype; Crizotinib; Oncology; Pathology; Internal medicine; Cancer research; Gene; Genetics; Biology","score_opus":0.04387556233235692,"score_gpt":0.4588760357133568,"score_spread":0.4150004733809999,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403824763","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000109554676,0.9832599,0.000006132007,0.0011968842,0.0009639875,0.009215771,0.0007932377,0.00005753441,0.00439699],"genre_scores_gemma":[0.0006688101,0.98967177,0.00051044533,0.0008441875,0.0003209793,0.006009551,0.00029395724,0.0002012607,0.0014790521],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99413776,0.00044694575,0.0030611854,0.0011371927,0.00064975617,0.0005671714],"domain_scores_gemma":[0.99671257,0.000616239,0.0012521697,0.000651646,0.00043234738,0.0003350428],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00092657376,0.0007531871,0.004597361,0.00032636346,0.000031489788,0.000017072984,0.00036367757,0.0005787327,0.000722487],"category_scores_gemma":[0.00059826014,0.0005405397,0.001819126,0.0013681384,0.00024171018,0.00006035033,0.00015278888,0.0010671166,0.000019054369],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016277716,0.000804074,0.00334392,0.58102864,0.0039625526,0.00022465478,0.000057547797,0.0000010596607,0.000005385693,0.000020368487,0.028129194,0.38225982],"study_design_scores_gemma":[0.0016374604,0.00041175904,0.00024616052,0.5318953,0.059736997,0.000011364459,0.000010794065,0.000066243374,0.000008590436,0.0000054438233,0.40551463,0.000455291],"about_ca_topic_score_codex":0.00063370453,"about_ca_topic_score_gemma":0.00018384872,"teacher_disagreement_score":0.38180453,"about_ca_system_score_codex":0.00082522613,"about_ca_system_score_gemma":0.0051452927,"threshold_uncertainty_score":0.9997046},"labels":[],"label_agreement":null},{"id":"W4406413355","doi":"10.1016/j.cllc.2025.01.006","title":"Immunotherapy for Early-Stage Non–Small Cell Lung Cancer: A Practical Guide of Current Controversies","year":2025,"lang":"en","type":"review","venue":"Clinical Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Ottawa Hospital; Foothills Medical Centre; University of Manitoba; CancerCare Manitoba; University of Ottawa","funders":"","keywords":"Medicine; Stage (stratigraphy); Lung cancer; Current (fluid); Oncology; Immunotherapy; Intensive care medicine; Cancer; Internal medicine; Medical physics","score_opus":0.08856486698412494,"score_gpt":0.5215169780719962,"score_spread":0.43295211108787124,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406413355","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000050766586,0.983801,0.0004198935,0.000829404,0.0040327557,0.007838811,0.0017770167,0.000053589254,0.0011967295],"genre_scores_gemma":[0.000022341213,0.9810837,0.00066996284,0.0006728987,0.0014858148,0.00658055,0.00016605637,0.00011950924,0.009199186],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9950595,0.00022058372,0.0024949268,0.0011426248,0.00041726642,0.0006651363],"domain_scores_gemma":[0.9906693,0.0059804283,0.0015110724,0.0010210999,0.0004956338,0.00032246317],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00072091416,0.00078229356,0.0049084476,0.00017875676,0.000098100776,0.000043340813,0.0003440784,0.00066060334,0.00043890512],"category_scores_gemma":[0.0006076249,0.00057823164,0.002840192,0.00032240193,0.0002151284,0.00007112677,0.00014495765,0.0009494744,0.0000067466362],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006692598,0.0013829395,0.0149124665,0.12825015,0.0045625316,0.000025967083,0.000055796034,0.0000021317996,2.6169025e-7,0.00014464349,0.21124218,0.6387517],"study_design_scores_gemma":[0.0062191267,0.0005785911,0.00033590515,0.066865526,0.016760424,0.0000020868142,0.00000818449,0.000067244364,0.000010241467,0.000005017747,0.90871155,0.00043612358],"about_ca_topic_score_codex":0.00059773156,"about_ca_topic_score_gemma":0.0001473759,"teacher_disagreement_score":0.69746935,"about_ca_system_score_codex":0.0017276044,"about_ca_system_score_gemma":0.007880671,"threshold_uncertainty_score":0.9996669},"labels":[],"label_agreement":null},{"id":"W4406943114","doi":"10.1016/j.cllc.2025.01.011","title":"Efficacy and Safety of Atezolizumab in Chinese Patients With Advanced Thymic Carcinoma: A Multicenter, Single-Arm Phase 2 Study","year":2025,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Myasthenia Gravis and Thymoma","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"F. Hoffmann-La Roche; Roche Canada","keywords":"Medicine; Atezolizumab; Internal medicine; Adverse effect; Clinical endpoint; Thymic carcinoma; Phases of clinical research; Carcinoma; Oncology; Toxicity; Gastroenterology; Surgery; Cancer; Clinical trial; Chemotherapy; Immunotherapy; Pembrolizumab","score_opus":0.015002351373619539,"score_gpt":0.38976841873497026,"score_spread":0.3747660673613507,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406943114","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99627554,0.0011064021,0.000012987302,0.00017477977,0.00024962402,0.0018136017,0.000027867978,0.000018049152,0.00032111778],"genre_scores_gemma":[0.99936026,0.00008910098,0.00010328753,0.00019430659,0.000045120993,0.000051776362,0.000015946693,0.000018287388,0.00012192346],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99836,0.00009189756,0.0007413449,0.00041226574,0.00018351054,0.00021099202],"domain_scores_gemma":[0.99896777,0.0002857261,0.00016036676,0.00033881026,0.00012922043,0.00011808402],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019920415,0.00018414433,0.0006766466,0.00009788135,0.000033615594,0.0000066702273,0.000087732624,0.0000740317,0.000044509732],"category_scores_gemma":[0.00025754154,0.00012291402,0.00006955963,0.00029993802,0.00012561759,0.000047050577,0.000077045675,0.00026217234,7.7139225e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020787708,0.012707912,0.92115366,0.0001459771,0.00013344755,0.00002303943,0.00031357913,0.0000054366533,0.000039485174,0.000008876257,0.000028440189,0.044652406],"study_design_scores_gemma":[0.091934346,0.004108477,0.9024307,0.0005500395,0.00021397241,4.891163e-7,0.000063105304,0.00038378563,0.000016942795,0.000006415853,0.00018821914,0.0001035123],"about_ca_topic_score_codex":0.000105123996,"about_ca_topic_score_gemma":0.00018524281,"teacher_disagreement_score":0.07114664,"about_ca_system_score_codex":0.00009395428,"about_ca_system_score_gemma":0.000121103156,"threshold_uncertainty_score":0.5012288},"labels":[],"label_agreement":null},{"id":"W4407576352","doi":"10.1016/j.cllc.2025.02.007","title":"Brief Report: Real-World Clinical Utility of Next-Generation Sequencing of Circulating Tumor DNA for Patients With Advanced Lung Squamous Cell Carcinoma (SQUIN)","year":2025,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Instituto de Salud Carlos III; Ministry of Health","keywords":"Medicine; Lung cancer; DNA sequencing; Basal cell; Oncology; Lung; Internal medicine; Squamous-cell carcinoma of the lung; Carcinoma; Cancer research; Circulating tumor DNA; DNA; Pathology; Cancer; Genetics; Biology","score_opus":0.03964681026597641,"score_gpt":0.3595522546330487,"score_spread":0.31990544436707224,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407576352","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99379265,0.000925771,0.0022907294,0.000039789258,0.0009463671,0.0008539367,0.0001944745,0.000008102795,0.00094820006],"genre_scores_gemma":[0.9968388,0.00015960913,0.001626979,0.00028858712,0.00044125706,0.00008413919,0.00030450575,0.000028589257,0.0002275347],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972413,0.00009699188,0.0015703914,0.0006770179,0.00015542876,0.00025885357],"domain_scores_gemma":[0.99736756,0.00041490683,0.000875926,0.00062739145,0.0006100046,0.00010423921],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00070916326,0.00019303999,0.000538286,0.00004365829,0.000072142975,0.000015081149,0.00017938671,0.00017325574,0.000011833611],"category_scores_gemma":[0.0011831148,0.00018496373,0.0002876637,0.0001580674,0.00018816574,0.000008067786,0.000118054304,0.00015879533,8.173278e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007240849,0.0002784051,0.9754064,0.00036956565,0.00007209105,0.0000045173597,0.000016253933,0.00051573943,0.0141886175,0.00008076842,0.001670654,0.0066728904],"study_design_scores_gemma":[0.007995601,0.0015876573,0.88237995,0.00024406881,0.0006327292,0.0000015676414,0.000049627448,0.025820823,0.07748435,0.00006968378,0.0031597093,0.0005742217],"about_ca_topic_score_codex":0.0003258252,"about_ca_topic_score_gemma":0.0012193569,"teacher_disagreement_score":0.093026444,"about_ca_system_score_codex":0.00008657856,"about_ca_system_score_gemma":0.0011103143,"threshold_uncertainty_score":0.7542602},"labels":[],"label_agreement":null},{"id":"W4408605892","doi":"10.1016/j.cllc.2025.03.003","title":"Systematic Review for the Follow-up of Curatively Treated Patients With Lung Cancer","year":2025,"lang":"en","type":"review","venue":"Clinical Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Windsor Regional Hospital; Western University; Ottawa Hospital; Health Sciences Centre; Juravinski Cancer Centre; Sunnybrook Health Science Centre; McMaster University; St. Joseph’s Healthcare Hamilton","funders":"Ontario Ministry of Health and Long-Term Care; Cancer Care Ontario","keywords":"Medicine; Lung cancer; Oncology; Internal medicine; Intensive care medicine","score_opus":0.05301872819949766,"score_gpt":0.4923063349317381,"score_spread":0.43928760673224043,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408605892","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000002855222,0.97266537,0.000071958486,0.000359381,0.0010284114,0.023739286,0.0016644913,0.00003816975,0.0004300908],"genre_scores_gemma":[0.00001324101,0.9686528,0.000056847693,0.00075303944,0.00020814793,0.019353375,0.00046599936,0.00006609806,0.01043044],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9961081,0.00028435673,0.0022320098,0.0006416211,0.00040499336,0.00032888327],"domain_scores_gemma":[0.9934883,0.0029329932,0.0016770429,0.0008500983,0.0008988682,0.00015267615],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00043939243,0.000571706,0.0051955925,0.00009183167,0.00013795584,0.000018769993,0.00031442483,0.00027882945,0.00018304691],"category_scores_gemma":[0.00091139856,0.00025890963,0.0014852918,0.00064552657,0.0001545026,0.00006033879,0.00005317407,0.00038797862,0.0000027783205],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000111972106,0.00019787876,0.0017021844,0.8980549,0.011506597,0.0000019876409,0.000029110604,5.1225385e-7,2.045751e-9,0.0000434642,0.023270337,0.06508105],"study_design_scores_gemma":[0.0027367123,0.00021887117,0.00017452784,0.7433583,0.14989431,8.7269206e-7,0.0000054399034,0.000019590667,8.0538875e-8,0.0000012261883,0.10337488,0.00021514873],"about_ca_topic_score_codex":0.00013777796,"about_ca_topic_score_gemma":0.000122413,"teacher_disagreement_score":0.15469657,"about_ca_system_score_codex":0.0006728818,"about_ca_system_score_gemma":0.003005492,"threshold_uncertainty_score":0.9999863},"labels":[],"label_agreement":null},{"id":"W4409260804","doi":"10.1016/j.cllc.2025.04.001","title":"Real-World Creatinine-Based Estimates of Acute and Chronic Kidney Dysfunction in Patients with Advanced ALK-Rearranged Non-Small-Cell Lung Cancer Receiving Tyrosine Kinase Inhibitors","year":2025,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Chemotherapy-induced organ toxicity mitigation","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Takeda (Canada); Centre Hospitalier de l’Université de Montréal; University Health Network","funders":"University Health Network","keywords":"Medicine; Lung cancer; Creatinine; Internal medicine; Tyrosine kinase; Oncology; Lung; Anaplastic lymphoma kinase; Cancer; Crizotinib; Cancer research; Receptor","score_opus":0.009388244117177437,"score_gpt":0.3259740877169874,"score_spread":0.31658584359980996,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409260804","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947413,0.0007998404,0.0002272682,0.0016378064,0.0004723403,0.0014706603,0.00006462919,0.00006913497,0.00051697926],"genre_scores_gemma":[0.9953477,0.00087038113,0.001786295,0.00094007957,0.0002082509,0.00019014852,0.00013216231,0.00006504929,0.00045995633],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99784356,0.000071681,0.0008634397,0.0006163434,0.00026882597,0.0003361656],"domain_scores_gemma":[0.99835134,0.0003504487,0.00040753072,0.00038072222,0.00028393167,0.00022601099],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00030391768,0.00030703854,0.000748163,0.00026436694,0.00007075463,0.000018634048,0.00009161875,0.000210915,0.0001376723],"category_scores_gemma":[0.0002446777,0.00026822422,0.000099877536,0.00081793504,0.00018600303,0.00014891643,0.000041439453,0.00048211162,6.701421e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022496055,0.0004028799,0.93782073,0.0010658486,0.00023426139,0.0000041265457,0.00009537519,0.00019294195,0.043257315,0.000002190099,0.0014446464,0.013230075],"study_design_scores_gemma":[0.019459454,0.00060389657,0.7766519,0.00680125,0.0008358009,1.5748262e-7,0.000011352423,0.0077350903,0.18753444,0.000005802993,0.00009838302,0.00026247973],"about_ca_topic_score_codex":0.0007414753,"about_ca_topic_score_gemma":0.0014449944,"teacher_disagreement_score":0.16116884,"about_ca_system_score_codex":0.0008827922,"about_ca_system_score_gemma":0.0012534322,"threshold_uncertainty_score":0.999977},"labels":[],"label_agreement":null},{"id":"W4410712044","doi":"10.1016/j.cllc.2025.05.011","title":"Baseline Characteristics of Participants and Pulmonary Nodules in the Watch the Spot Trial: A Pragmatic Trial of Less versus More Intensive Strategies for Active Surveillance of Patients With Small Pulmonary Nodules","year":2025,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Michigan State Horticultural Society; Mailman School of Public Health, Columbia University; Fundacja na rzecz Nauki Polskiej; American College of Radiology; American College of Chest Physicians; Canada Research Coordinating Committee; Mining History Association; American Thoracic Society; Boston University; University of Pennsylvania; National Cancer Institute; Cleveland Clinic Foundation; Patient-Centered Outcomes Research Institute; American Cancer Society","keywords":"Medicine; Lung cancer screening; Baseline (sea); Lung cancer; Internal medicine; Radiology; Intensive care medicine; Emergency medicine","score_opus":0.06467884625987014,"score_gpt":0.3946738112295906,"score_spread":0.3299949649697205,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410712044","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99229157,0.0005282346,0.000028688713,0.0024179926,0.0005205856,0.0036007036,0.0005565101,0.0000056436065,0.000050065824],"genre_scores_gemma":[0.99776584,0.0009396208,0.000078311874,0.00018507482,0.00014376813,0.00075011,0.00010078894,0.000015403537,0.000021105307],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9979445,0.0002761253,0.001005983,0.00031727046,0.00024121214,0.00021495654],"domain_scores_gemma":[0.9937493,0.0045150043,0.0006056828,0.00040990952,0.0006742812,0.000045821645],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00083942246,0.00019021082,0.0009382462,0.000041500683,0.000037001966,0.000010074028,0.00015734634,0.00010203054,0.0000050957665],"category_scores_gemma":[0.0012896704,0.000096420845,0.00015350882,0.00020207207,0.0004424342,0.0000485041,0.000053607462,0.00019045945,6.126509e-8],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6237469,0.0035132063,0.3441099,0.0012792704,0.0007966897,0.000010313827,0.0006367711,0.000014791819,0.000012219076,0.00023180555,0.00018316299,0.025465036],"study_design_scores_gemma":[0.1358605,0.0037108597,0.8545784,0.0014122823,0.0011283068,3.8003716e-7,0.0021115253,0.00075835263,0.000122403,0.00009797985,0.0001023493,0.00011666769],"about_ca_topic_score_codex":0.00026762852,"about_ca_topic_score_gemma":0.00045629885,"teacher_disagreement_score":0.5104685,"about_ca_system_score_codex":0.00007310354,"about_ca_system_score_gemma":0.00030909036,"threshold_uncertainty_score":0.3931928},"labels":[],"label_agreement":null},{"id":"W4410845417","doi":"10.1016/j.cllc.2025.05.006","title":"KRAS ctDNA Detection in Patients With Resectable Lung Adenocarcinoma","year":2025,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"Fondation de l'Hôpital Général de Montréal; Fonds de Recherche du Québec - Santé; American Society on Aging; American Surgical Association Foundation","keywords":"Medicine; KRAS; Adenocarcinoma; Internal medicine; Stage (stratigraphy); Liquid biopsy; Oncology; Clinical trial; Biopsy; Gastroenterology; Cancer; Colorectal cancer","score_opus":0.013075088355639933,"score_gpt":0.3976272195076861,"score_spread":0.3845521311520462,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410845417","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98744714,0.0027121995,0.00025404306,0.0009556132,0.00077831064,0.001094862,0.000017578319,0.000056769233,0.006683503],"genre_scores_gemma":[0.9937891,0.00013744473,0.00014225258,0.0009006296,0.00014420247,0.00023884584,0.00002872308,0.000019149165,0.00459965],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99872863,0.000053055483,0.00040298823,0.00038093774,0.00018364089,0.00025074003],"domain_scores_gemma":[0.99924004,0.0001290912,0.00007984874,0.00029128022,0.00015443128,0.00010531692],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014427517,0.00013448659,0.00032148094,0.00012735307,0.00007737754,0.000016865048,0.00006370709,0.00012480372,0.00015911396],"category_scores_gemma":[0.00008520332,0.00010001217,0.00007916276,0.00045810064,0.000064836684,0.00009130607,0.000023526727,0.00029340337,0.000007179375],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009532124,0.00034600883,0.9800365,0.00010323224,0.0002915447,0.000009074407,0.0000600235,0.000022649576,0.000005543518,0.000058710826,0.0031263262,0.014987161],"study_design_scores_gemma":[0.0075194673,0.0003591461,0.9879816,0.00045973263,0.00058368803,4.220767e-7,0.000022050952,0.0004883747,0.00010345424,0.000056310844,0.0023241516,0.00010157089],"about_ca_topic_score_codex":0.00036724002,"about_ca_topic_score_gemma":0.0010951667,"teacher_disagreement_score":0.01488559,"about_ca_system_score_codex":0.00053234457,"about_ca_system_score_gemma":0.0005014392,"threshold_uncertainty_score":0.40783778},"labels":[],"label_agreement":null},{"id":"W4411011492","doi":"10.1016/j.cllc.2025.05.009","title":"Evaluating Diagnostic and Treatment Timelines for ALK-Positive NSCLC Patients: Results From a Global Registry","year":2025,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Crizotinib; Timeline; Lung cancer; Internal medicine; Oncology; Intensive care medicine","score_opus":0.052301883469510736,"score_gpt":0.5085346421026976,"score_spread":0.45623275863318685,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411011492","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96575266,0.008437083,0.00050280883,0.00863316,0.0015631898,0.0034316108,0.005862908,0.0000838296,0.0057327566],"genre_scores_gemma":[0.9823592,0.0014875508,0.0046478445,0.0028403758,0.00096321787,0.001215731,0.0015629756,0.000024282728,0.0048988746],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984923,0.000058112888,0.0005817103,0.0005351998,0.00013292488,0.00019976524],"domain_scores_gemma":[0.9964874,0.0026332184,0.00016531414,0.00028059212,0.0002953083,0.00013817327],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001430599,0.00017780422,0.00040253787,0.000021793232,0.00012431925,0.000026898317,0.000048353206,0.00012336783,0.000022870909],"category_scores_gemma":[0.0027457767,0.00013193207,0.00015191302,0.00011849146,0.000097873926,0.00004625277,0.000033560256,0.00007473155,0.0000032938622],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029617888,0.0008544636,0.53881556,0.00005266206,0.0017557318,0.000009511283,0.00019011486,0.0000308296,0.0000059121303,0.00012853285,0.020865204,0.43432972],"study_design_scores_gemma":[0.036767572,0.0020589288,0.9363987,0.0017437582,0.0062309355,8.0962343e-7,0.00008589015,0.003797732,0.00005844995,0.00068171875,0.0119484095,0.0002271259],"about_ca_topic_score_codex":0.0009713514,"about_ca_topic_score_gemma":0.00029461953,"teacher_disagreement_score":0.4341026,"about_ca_system_score_codex":0.00060779596,"about_ca_system_score_gemma":0.0005886851,"threshold_uncertainty_score":0.5380034},"labels":[],"label_agreement":null},{"id":"W4412868826","doi":"10.1016/j.cllc.2025.07.004","title":"Factors Associated With Local Control and Toxicity of Hypofractionated Radiotherapy for Early and Late-Stage Ultracentral Lung Tumors","year":2025,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"University of Sadat City; National Cancer Institute; Canadian Health Libraries Association; Children's Hospital Los Angeles; Burroughs Wellcome Fund","keywords":"Medicine; Pneumonitis; Toxicity; Radiation therapy; Lung cancer; Proportional hazards model; Retrospective cohort study; Lung; Internal medicine; Radiology; Oncology","score_opus":0.02743192409449264,"score_gpt":0.37527696509368796,"score_spread":0.34784504099919533,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412868826","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99194664,0.0038670688,0.0010252423,0.0014552937,0.00021964496,0.0011662908,0.00022085891,0.000035464785,0.000063479696],"genre_scores_gemma":[0.9974506,0.0008296283,0.000046470355,0.0008481581,0.000054653356,0.0001195377,0.000023950872,0.00001947538,0.00060751755],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987925,0.000058858433,0.0004273061,0.0003499376,0.00013996978,0.00023139981],"domain_scores_gemma":[0.9980454,0.0013272425,0.0001906915,0.00013526047,0.00014670716,0.00015471829],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021701174,0.0001800372,0.0006614637,0.00004746724,0.0000674417,0.000016114094,0.000037881397,0.00015379165,0.000043902786],"category_scores_gemma":[0.00017830363,0.00012201049,0.00011609902,0.0001261356,0.0002539311,0.000076121665,0.000008336151,0.00018093131,4.5084636e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014775981,0.00039075513,0.992011,0.00018094295,0.0018779982,0.0000044020067,0.00006513742,0.000080058104,0.00020517215,0.000092232294,0.0007363495,0.00287833],"study_design_scores_gemma":[0.012945601,0.0007447065,0.9765983,0.0006518226,0.0008624281,2.4470316e-7,0.000025124706,0.006391541,0.0012004904,0.000011629367,0.00044902493,0.00011905659],"about_ca_topic_score_codex":0.0001785428,"about_ca_topic_score_gemma":0.00012600068,"teacher_disagreement_score":0.015412695,"about_ca_system_score_codex":0.00035164642,"about_ca_system_score_gemma":0.0002466205,"threshold_uncertainty_score":0.49754432},"labels":[],"label_agreement":null},{"id":"W4413161315","doi":"10.1016/j.cllc.2025.08.006","title":"The Changing Landscape of Lung Cancer Resection Outcomes Over the Past two Decades","year":2025,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institut universitaire de cardiologie et de pneumologie de Québec","funders":"Fonds de Recherche du Québec - Santé; Institut universitaire de cardiologie et de pneumologie de Québec, Université Laval; Université Laval","keywords":"Medicine; Lung cancer; Resection; Intensive care medicine; General surgery; Oncology; Surgery","score_opus":0.026387292732446624,"score_gpt":0.4468284189242515,"score_spread":0.4204411261918049,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413161315","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9103134,0.042043075,0.00004452485,0.038964454,0.0039070556,0.0011746711,0.000038717124,0.000056275458,0.0034578035],"genre_scores_gemma":[0.97893363,0.011595607,0.000014707413,0.002820331,0.00095093396,0.00068897195,0.0000052040973,0.000021112546,0.0049695116],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983466,0.00011040636,0.00057373533,0.00033742463,0.0002903902,0.0003413975],"domain_scores_gemma":[0.9976118,0.0014399131,0.0002038392,0.00051181036,0.00015331239,0.000079329184],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006840681,0.00017557794,0.0004436586,0.00007559155,0.00029247664,0.000036381036,0.00018356594,0.00010251285,0.00021100113],"category_scores_gemma":[0.0001817144,0.00008368228,0.0003253155,0.0004378988,0.00018077604,0.00004612474,0.00010883822,0.00033273853,0.000002226176],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029403713,0.00011122059,0.92768264,0.00016465758,0.0010276051,0.0000028409186,0.0001271144,0.00004621833,0.000004930465,0.0006255057,0.057684835,0.012228411],"study_design_scores_gemma":[0.002953378,0.00009064051,0.97063917,0.0009711619,0.0011879416,7.883024e-7,0.0001095375,0.0017795799,0.00017844795,0.00007124778,0.021918412,0.00009966796],"about_ca_topic_score_codex":0.00060102495,"about_ca_topic_score_gemma":0.0017614712,"teacher_disagreement_score":0.0686202,"about_ca_system_score_codex":0.0003301402,"about_ca_system_score_gemma":0.0003121872,"threshold_uncertainty_score":0.34124643},"labels":[],"label_agreement":null},{"id":"W4415451907","doi":"10.1016/j.cllc.2025.10.018","title":"Savolitinib Plus Osimertinib in Epidermal Growth Factor Receptor-Mutated, MET-Amplified Advanced Non-Small Cell Lung Cancer: A Randomized Phase II trial","year":2025,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"AstraZeneca","keywords":"Osimertinib; Lung cancer; Epidermal growth factor receptor; Placebo; Biomarker; Epidermal growth factor","score_opus":0.034201739119460645,"score_gpt":0.4352266216902665,"score_spread":0.4010248825708058,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415451907","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95348024,0.017385129,0.0012021151,0.00446932,0.006057872,0.011345398,0.0006174467,0.000224311,0.005218141],"genre_scores_gemma":[0.9701954,0.005066997,0.0014559124,0.0038251816,0.0012056124,0.006776501,0.0003323937,0.00010542603,0.011036588],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9943456,0.00053980097,0.0025483812,0.001228614,0.0004015615,0.0009360438],"domain_scores_gemma":[0.9954295,0.0023500782,0.00066786027,0.0006312433,0.0004060878,0.00051521655],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0009865458,0.0006261774,0.0027277938,0.0003266732,0.00027211063,0.000051119958,0.00031182193,0.00046113497,0.0013115149],"category_scores_gemma":[0.0013057056,0.0005058021,0.00095862965,0.00080453313,0.00030884932,0.00019081244,0.00015589136,0.0009464483,0.00001594407],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.90206075,0.0047104987,0.02794349,0.0011232445,0.0037783433,0.00010529149,0.0018713529,0.0003116752,0.0007132998,0.00039712666,0.020531632,0.036453288],"study_design_scores_gemma":[0.9794508,0.0011834613,0.001602479,0.0014154476,0.0036602602,0.0000015051523,0.00016273142,0.0043233735,0.002080235,0.00011645205,0.005434125,0.00056910684],"about_ca_topic_score_codex":0.0018424495,"about_ca_topic_score_gemma":0.00031309755,"teacher_disagreement_score":0.07739007,"about_ca_system_score_codex":0.0013895486,"about_ca_system_score_gemma":0.0038561362,"threshold_uncertainty_score":0.99973935},"labels":[],"label_agreement":null},{"id":"W4416185269","doi":"10.1016/j.cllc.2025.11.004","title":"Response to the letter to the Editor on “The Changing Landscape of Lung Cancer Resection Outcomes Over the Past Two Decades”","year":2025,"lang":"en","type":"letter","venue":"Clinical Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Institut universitaire de cardiologie et de pneumologie de Québec","funders":"","keywords":"Letter to the editor; Lung cancer; Resection; MEDLINE; Pneumonectomy","score_opus":0.029820641690574374,"score_gpt":0.41264450310951795,"score_spread":0.3828238614189436,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416185269","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.023746349,0.002224603,0.000021183265,0.9469721,0.022745438,0.0035280832,0.00036126017,0.00004393676,0.00035707533],"genre_scores_gemma":[0.022856843,0.0007049845,0.000008657541,0.86186314,0.093703195,0.004524895,0.00002927243,0.00008680659,0.016222237],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99514997,0.0010587774,0.00097416725,0.0009072826,0.0011511187,0.0007587045],"domain_scores_gemma":[0.98869014,0.008534286,0.00041488244,0.0019469096,0.00027772086,0.0001360574],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0027478265,0.0005598434,0.000956571,0.00021830597,0.0004903868,0.000108871754,0.0008907595,0.0005245872,0.000697978],"category_scores_gemma":[0.0009669013,0.0002129003,0.0007759663,0.0008221112,0.00018405916,0.000038378144,0.00036244577,0.0027460698,0.000043521268],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018210359,0.00007412287,0.08828089,0.00016379004,0.0013188396,0.00002636046,0.00052939315,0.00014250372,0.0000020078578,0.0000119251445,0.9063742,0.0012549355],"study_design_scores_gemma":[0.0013268164,0.00029726542,0.08358274,0.0022471673,0.0015199084,0.0000015045662,0.0000463686,0.00013246071,0.000033820827,0.000004187528,0.910574,0.00023376568],"about_ca_topic_score_codex":0.0007768239,"about_ca_topic_score_gemma":0.001332115,"teacher_disagreement_score":0.085108966,"about_ca_system_score_codex":0.000986975,"about_ca_system_score_gemma":0.000590535,"threshold_uncertainty_score":0.99955463},"labels":[],"label_agreement":null},{"id":"W4417526956","doi":"10.1016/j.cllc.2025.12.005","title":"Patient-Relevant Outcomes From the Phase III MARIPOSA-2 Trial: Amivantamab-Chemotherapy Versus Chemotherapy in EGFR-Mutant Advanced Non-Small-Cell Lung Cancer Following Disease Progression on Osimertinib","year":2025,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Cancer Foundation","funders":"Janssen Research and Development; Johnson and Johnson","keywords":"Chemotherapy; Lung cancer; Osimertinib; Phases of clinical research; Pemetrexed; Disease; Adenocarcinoma","score_opus":0.025086633603350963,"score_gpt":0.4423766151278952,"score_spread":0.4172899815245443,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417526956","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9621586,0.00964982,0.00008064175,0.015078091,0.005678899,0.0061594504,0.00020272154,0.00011786662,0.0008738908],"genre_scores_gemma":[0.97888786,0.004407803,0.0003180017,0.011951086,0.0004650042,0.0025532446,0.00015185564,0.00010103347,0.0011641297],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9963021,0.00018767905,0.0013409696,0.0010308808,0.0005179916,0.0006203494],"domain_scores_gemma":[0.99666756,0.0014733189,0.00043918128,0.00090290693,0.000112066205,0.00040493952],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003127819,0.0005431957,0.0010913954,0.00011739713,0.00025221088,0.00006467797,0.0002966022,0.0002337037,0.0004283606],"category_scores_gemma":[0.00028236973,0.00034372573,0.00070992217,0.00048035756,0.00011160397,0.00012299573,0.00007726947,0.0006449127,0.0000060561483],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.23989655,0.006312909,0.3987968,0.00016513486,0.0033293278,0.00016204735,0.0012327154,0.00014888366,0.00066012796,0.00003350301,0.0071869995,0.342075],"study_design_scores_gemma":[0.8092586,0.002945868,0.14603455,0.0060420325,0.0053561516,2.4293996e-7,0.0005252308,0.007118514,0.0027077517,0.00012381174,0.018924113,0.00096313097],"about_ca_topic_score_codex":0.0006885766,"about_ca_topic_score_gemma":0.0002834872,"teacher_disagreement_score":0.56936204,"about_ca_system_score_codex":0.001013817,"about_ca_system_score_gemma":0.0016831895,"threshold_uncertainty_score":0.9999015},"labels":[],"label_agreement":null}]}